0001493152-24-008850.txt : 20240305 0001493152-24-008850.hdr.sgml : 20240305 20240305160537 ACCESSION NUMBER: 0001493152-24-008850 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 91 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240305 DATE AS OF CHANGE: 20240305 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InspireMD, Inc. CENTRAL INDEX KEY: 0001433607 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 262123838 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35731 FILM NUMBER: 24720269 BUSINESS ADDRESS: STREET 1: 4 MENORAT HAMAOR ST. CITY: TEL AVIV STATE: L3 ZIP: 6744832 BUSINESS PHONE: (888) 776-6804 MAIL ADDRESS: STREET 1: 4 MENORAT HAMAOR ST. CITY: TEL AVIV STATE: L3 ZIP: 6744832 FORMER COMPANY: FORMER CONFORMED NAME: Saguaro Resources, Inc. DATE OF NAME CHANGE: 20080428 10-K 1 form10-k.htm
false FY 0001433607 http://fasb.org/us-gaap/2023#AccountsPayableOtherCurrent http://fasb.org/us-gaap/2023#AccountsPayableOtherCurrent 0001433607 2023-01-01 2023-12-31 0001433607 2023-06-30 0001433607 2024-03-05 0001433607 2023-12-31 0001433607 2022-12-31 0001433607 us-gaap:SeriesCPreferredStockMember 2023-12-31 0001433607 us-gaap:SeriesCPreferredStockMember 2022-12-31 0001433607 2022-01-01 2022-12-31 0001433607 us-gaap:CommonStockMember 2021-12-31 0001433607 us-gaap:PreferredStockMember NSPR:SeriesCConvertiblePreferredStockMember 2021-12-31 0001433607 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001433607 us-gaap:RetainedEarningsMember 2021-12-31 0001433607 2021-12-31 0001433607 us-gaap:CommonStockMember 2022-12-31 0001433607 us-gaap:PreferredStockMember NSPR:SeriesCConvertiblePreferredStockMember 2022-12-31 0001433607 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001433607 us-gaap:RetainedEarningsMember 2022-12-31 0001433607 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001433607 us-gaap:PreferredStockMember NSPR:SeriesCConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001433607 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001433607 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001433607 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001433607 us-gaap:PreferredStockMember NSPR:SeriesCConvertiblePreferredStockMember 2023-01-01 2023-12-31 0001433607 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001433607 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001433607 us-gaap:CommonStockMember 2023-12-31 0001433607 us-gaap:PreferredStockMember NSPR:SeriesCConvertiblePreferredStockMember 2023-12-31 0001433607 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001433607 us-gaap:RetainedEarningsMember 2023-12-31 0001433607 NSPR:RussiaAndBelarusMember us-gaap:SalesMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0001433607 NSPR:RussiaAndBelarusMember us-gaap:SalesMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0001433607 us-gaap:SeriesCPreferredStockMember 2023-01-01 2023-12-31 0001433607 us-gaap:SeriesCPreferredStockMember 2022-01-01 2022-12-31 0001433607 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001433607 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2023-12-31 0001433607 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2023-12-31 0001433607 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2023-12-31 0001433607 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001433607 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001433607 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001433607 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001433607 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001433607 us-gaap:ComputerEquipmentMember 2023-12-31 0001433607 us-gaap:ComputerEquipmentMember 2022-12-31 0001433607 NSPR:OfficeFurnitureAndEquipmentMember 2023-12-31 0001433607 NSPR:OfficeFurnitureAndEquipmentMember 2022-12-31 0001433607 us-gaap:MachineryAndEquipmentMember 2023-12-31 0001433607 us-gaap:MachineryAndEquipmentMember 2022-12-31 0001433607 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001433607 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001433607 NSPR:SeveranceTypeOneMember 2023-01-01 2023-12-31 0001433607 NSPR:SeveranceTypeOneMember 2022-01-01 2022-12-31 0001433607 NSPR:SeveranceTypeTwoMember 2023-01-01 2023-12-31 0001433607 NSPR:SeveranceTypeTwoMember 2022-01-01 2022-12-31 0001433607 2021-02-03 0001433607 2021-02-03 2021-02-03 0001433607 us-gaap:PrivatePlacementMember 2023-05-12 2023-05-12 0001433607 us-gaap:PrivatePlacementMember NSPR:PreFundedWarrantsMember 2023-05-12 0001433607 us-gaap:PrivatePlacementMember us-gaap:WarrantMember 2023-05-12 0001433607 us-gaap:PrivatePlacementMember NSPR:SeriesHWarrantsMember 2023-05-12 0001433607 us-gaap:PrivatePlacementMember NSPR:SeriesIWarrantsMember 2023-05-12 0001433607 us-gaap:PrivatePlacementMember NSPR:SeriesJWarrantsMember 2023-05-12 0001433607 us-gaap:PrivatePlacementMember NSPR:SeriesKWarrantsMember 2023-05-12 0001433607 NSPR:PreFundedWarrantsMember 2023-05-12 0001433607 us-gaap:WarrantMember 2023-05-12 0001433607 us-gaap:WarrantMember 2023-12-31 0001433607 NSPR:PreFundedWarrantsMember 2023-12-31 0001433607 us-gaap:SeriesCPreferredStockMember 2023-05-12 0001433607 us-gaap:SeriesCPreferredStockMember 2023-05-16 0001433607 NSPR:AtTheMarketOfferingMember us-gaap:WarrantMember 2023-12-31 0001433607 NSPR:PreferredStockBlankCheckMember 2023-12-31 0001433607 us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0001433607 us-gaap:RestrictedStockMember 2023-12-31 0001433607 us-gaap:EmployeeStockOptionMember NSPR:EmployeesAndDirectorsMember 2023-01-01 2023-12-31 0001433607 us-gaap:EmployeeStockOptionMember NSPR:EmployeesAndDirectorsMember 2022-01-01 2022-12-31 0001433607 us-gaap:EmployeeStockOptionMember NSPR:ConsultantMember 2023-01-01 2023-12-31 0001433607 us-gaap:EmployeeStockOptionMember NSPR:ConsultantMember 2022-01-01 2022-12-31 0001433607 us-gaap:RestrictedStockMember NSPR:ConsultantMember 2023-01-01 2023-12-31 0001433607 us-gaap:RestrictedStockMember NSPR:ConsultantMember 2022-01-01 2022-12-31 0001433607 us-gaap:RestrictedStockUnitsRSUMember NSPR:ConsultantMember 2023-01-01 2023-12-31 0001433607 NSPR:EmployeeAndNonEmployeeStockOptionMember 2023-12-31 0001433607 NSPR:EmployeeAndNonEmployeeStockOptionMember 2023-01-01 2023-12-31 0001433607 NSPR:SeriesEWarrantsMember 2023-12-31 0001433607 NSPR:SeriesFWarrantsMember 2023-12-31 0001433607 NSPR:SeriesGWarrantsMember 2023-12-31 0001433607 NSPR:SeriesHWarrantsMember 2023-12-31 0001433607 NSPR:SeriesIWarrantsMember 2023-12-31 0001433607 NSPR:SeriesJWarrantsMember 2023-12-31 0001433607 NSPR:SeriesKWarrantsMember 2023-12-31 0001433607 NSPR:UnderwriterWarrantsMember 2023-12-31 0001433607 NSPR:EmployeeMember 2022-12-31 0001433607 NSPR:EmployeeMember 2021-12-31 0001433607 NSPR:EmployeeMember 2023-01-01 2023-12-31 0001433607 NSPR:EmployeeMember 2022-01-01 2022-12-31 0001433607 NSPR:EmployeeMember 2023-12-31 0001433607 NSPR:NonEmployeeMember 2022-12-31 0001433607 NSPR:NonEmployeeMember 2021-12-31 0001433607 NSPR:NonEmployeeMember 2023-01-01 2023-12-31 0001433607 NSPR:NonEmployeeMember 2022-01-01 2022-12-31 0001433607 NSPR:NonEmployeeMember 2023-12-31 0001433607 NSPR:EmployeeMember us-gaap:RestrictedStockMember 2022-12-31 0001433607 NSPR:EmployeeMember us-gaap:RestrictedStockMember 2021-12-31 0001433607 NSPR:EmployeeMember us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0001433607 NSPR:EmployeeMember us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001433607 NSPR:EmployeeMember us-gaap:RestrictedStockMember 2023-12-31 0001433607 NSPR:EmployeeMember us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001433607 NSPR:EmployeeMember us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001433607 NSPR:EmployeeMember us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001433607 NSPR:EmployeeMember us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001433607 NSPR:EmployeeMember us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001433607 NSPR:ExercisePriceOneMember 2023-01-01 2023-12-31 0001433607 NSPR:ExercisePriceOneMember 2023-12-31 0001433607 NSPR:ExercisePriceTwoMember 2023-01-01 2023-12-31 0001433607 NSPR:ExercisePriceTwoMember 2023-12-31 0001433607 NSPR:ExercisePriceThreeMember 2023-01-01 2023-12-31 0001433607 NSPR:ExercisePriceThreeMember 2023-12-31 0001433607 NSPR:ExercisePriceFourMember 2023-01-01 2023-12-31 0001433607 NSPR:ExercisePriceFourMember 2023-12-31 0001433607 srt:MinimumMember 2023-01-01 2023-12-31 0001433607 srt:MaximumMember 2023-01-01 2023-12-31 0001433607 srt:MinimumMember 2022-01-01 2022-12-31 0001433607 srt:MaximumMember 2022-01-01 2022-12-31 0001433607 us-gaap:CostOfSalesMember 2023-01-01 2023-12-31 0001433607 us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0001433607 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0001433607 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001433607 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-12-31 0001433607 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-12-31 0001433607 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0001433607 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001433607 srt:DirectorMember 2023-01-01 2023-12-31 0001433607 srt:DirectorMember 2022-01-01 2022-12-31 0001433607 NSPR:ConsultancyAgreementMember 2023-09-15 2023-09-15 0001433607 us-gaap:RelatedPartyMember 2023-01-01 2023-12-31 0001433607 NSPR:NonEmployeeDirectorsMember 2023-01-01 2023-12-31 0001433607 NSPR:TwoThousandTwentyOneEquityIncentivePlanMember 2023-12-31 0001433607 NSPR:TwoThousandTwentyOneEquityIncentivePlanMember 2023-01-01 2023-12-31 0001433607 us-gaap:SubsequentEventMember 2024-01-01 2024-01-01 0001433607 us-gaap:IsraelTaxAuthorityMember 2023-01-01 2023-12-31 0001433607 NSPR:GermanyMember 2023-01-01 2023-12-31 0001433607 2016-12-29 2016-12-29 0001433607 2017-12-31 0001433607 NSPR:ArisingBeforeJanuaryOneTwoThousandAndEighteenMember 2023-01-01 2023-12-31 0001433607 NSPR:LimitedMember 2023-12-31 0001433607 us-gaap:IsraelTaxAuthorityMember 2023-12-31 0001433607 srt:ParentCompanyMember 2023-01-01 2023-12-31 0001433607 srt:ParentCompanyMember 2022-01-01 2022-12-31 0001433607 srt:SubsidiariesMember 2023-01-01 2023-12-31 0001433607 srt:SubsidiariesMember 2022-01-01 2022-12-31 0001433607 country:US us-gaap:EarliestTaxYearMember 2023-01-01 2023-12-31 0001433607 country:US us-gaap:LatestTaxYearMember 2023-01-01 2023-12-31 0001433607 country:IL us-gaap:EarliestTaxYearMember 2023-01-01 2023-12-31 0001433607 country:IL us-gaap:LatestTaxYearMember 2023-01-01 2023-12-31 0001433607 country:DE us-gaap:EarliestTaxYearMember 2023-01-01 2023-12-31 0001433607 country:DE us-gaap:LatestTaxYearMember 2023-01-01 2023-12-31 0001433607 country:IT 2023-01-01 2023-12-31 0001433607 country:IT 2022-01-01 2022-12-31 0001433607 country:DE 2023-01-01 2023-12-31 0001433607 country:DE 2022-01-01 2022-12-31 0001433607 country:RU 2023-01-01 2023-12-31 0001433607 country:RU 2022-01-01 2022-12-31 0001433607 NSPR:OtherCountriesMember 2023-01-01 2023-12-31 0001433607 NSPR:OtherCountriesMember 2022-01-01 2022-12-31 0001433607 NSPR:CGuardEPSMember 2023-01-01 2023-12-31 0001433607 NSPR:CGuardEPSMember 2022-01-01 2022-12-31 0001433607 NSPR:MGuardPrimeEPSMember 2023-01-01 2023-12-31 0001433607 NSPR:MGuardPrimeEPSMember 2022-01-01 2022-12-31 0001433607 NSPR:CustomerAMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001433607 NSPR:CustomerAMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001433607 NSPR:CustomerBMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001433607 NSPR:CustomerBMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:EUR NSPR:segment

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

 

FORM 10-K

 

(Mark One)

 

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2023

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

COMMISSION FILE NUMBER: 001-35731

 

InspireMD, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   26-2123838

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification Number)

 

4 Menorat Hamaor St.

Tel Aviv, Israel

   6744832
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (888) 776-6804

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   NSPR   Nasdaq Capital Market

 

Securities registered pursuant to Section 12(g) of the Act: none

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
   
Non-accelerated filer ☒ Smaller reporting company ☒
   
  Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act) Yes ☐ No ☒

 

The aggregate market value of the voting and non-voting stock held by non-affiliates of the registrant as of June 30, 2023, based on the price at which the common equity was last sold on such date, was $46,130,594. For purposes of this computation only, all officers, directors and 10% or greater stockholders of the registrant are deemed to be affiliates.

 

Indicate the number of shares outstanding of each of the registrant’s classes of common stock as of the latest practicable date.

 

Class   Outstanding at March 5, 2024
Common Stock, $0.0001 par value   23,456,590

 

Documents incorporated by reference:

 

Portions of the Registrant’s definitive proxy statement for its 2024 Annual Meeting of Stockholders, which the Registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after December 31, 2023, are incorporated by reference into Part III of this Annual Report on Form 10-K.

 

 

 

 
 

 

TABLE OF CONTENTS

 

    Page
  Cautionary Note Regarding Forward-Looking Statements  
  PART I 5
Item 1. Business. 5
Item 1A. Risk Factors. 29
Item 1B. Unresolved Staff Comments. 57
Item 1C. Cybersecurity. 57
Item 2. Properties. 58
Item 3. Legal Proceedings. 58
Item 4. Mine Safety Disclosures. 58
     
  PART II 58
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. 58
Item 6. [Reserved] 59
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations. 59
Item 7A. Quantitative and Qualitative Disclosures About Market Risk. 66
Item 8. Financial Statements and Supplementary Data. 66
Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure. 66
Item 9A. Controls and Procedures. 66
Item 9B. Other Information. 67
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 67
     
  PART III 67
Item 10. Directors, Executive Officers and Corporate Governance. 67
Item 11. Executive Compensation. 67
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. 67
Item 13. Certain Relationships and Related Transactions, and Director Independence. 68
Item 14. Principal Accounting Fees and Services. 68
     
  PART IV 68
Item 15. Exhibits and Financial Statement Schedules. 68

 

-2-
 

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Annual Report on Form 10-K contains “forward-looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment and regulation, including, revenue growth. Words such as “may,” “will,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, as well as statements in future tense, identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and will probably not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information we have when those statements are made or our management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to:

 

  ● our history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives;
     
  ● our need to raise additional capital to meet our business requirements in the future and such capital raising may be costly or difficult to obtain and could dilute out stockholders’ ownership interests;
     
  ● market acceptance of our products;
     
  ● an inability to secure and maintain regulatory approvals for the sale of our products;
     
  ● negative clinical trial results or lengthy product delays in key markets;
     
  ● our ability to maintain compliance with the Nasdaq listing standards;
     
  ● our ability to generate revenues from our products and obtain and maintain regulatory approvals for our products;
     
  ● our ability to adequately protect our intellectual property;
     
  ● our dependence on a single manufacturing facility and our ability to comply with stringent manufacturing quality standards and to increase production as necessary;
     
  ● the risk that the data collected from our current and planned clinical trials may not be sufficient to demonstrate that our technology is an attractive alternative to other procedures and products;
     
  ● intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do;
     
  ● entry of new competitors and products and potential technological obsolescence of our products;
     
  ● inability to carry out research, development and commercialization plans;
     
  ● loss of a key customer or supplier;
     
  ● technical problems with our research and products and potential product liability claims;
     
  ● product malfunctions;
     
  ● price increases for supplies and components;

 

-3-
 

 

  ● insufficient or inadequate reimbursement by governmental and other third-party payers for our products;
     
  ● our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful;
     
  ● adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions;
     
  ● the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction;
     
 

●

 

 security, political and economic instability in the Middle East that could harm our business, including due to the current war between Israel and Hamas; and
     
  ● current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk

 

The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with that may cause our actual results to differ from those anticipated in our forward-looking statements. You should review carefully the risks and uncertainties described under the heading “Item 1A. Risk Factors” in this Annual Report on Form 10-K for a discussion of these and other risks that relate to our business and investing in shares of our common stock. Moreover, new risks regularly emerge, and it is not possible for our management to predict or articulate all the risks we face, nor can we assess the impact of all risks on our business or the extent to which any risk, or combination of risks, may cause actual results to differ from those contained in any forward-looking statements. All forward-looking statements included in this Annual Report are based on information available to us on the date of this Annual Report. Except to the extent required by applicable laws or rules, we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained above and throughout this Annual Report.

 

The forward-looking statements contained in this Annual Report on Form 10-K are expressly qualified in their entirety by this cautionary statement. We do not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

 

All information in this Annual Report on Form 10-K relating to shares or price per share reflects the 1-for-15 reverse stock split effected by us on April 26, 2021.

 

-4-
 

 

PART I

 

In this Annual Report on Form 10-K, unless the context requires otherwise, the terms “we,” “our,” “us,” or “the Company” refer to InspireMD, Inc., a Delaware corporation, and its subsidiaries, including InspireMD Ltd., taken as a whole.

 

Item 1. Business.

 

Overview

 

We are a medical device company focusing on the development and commercialization of our proprietary MicroNet™ stent platform for the treatment of carotid artery disease and other vascular disease. A stent is an expandable “scaffold-like” device, usually constructed of a metallic material, that is inserted into the lumen of the artery to create patency and revascularization of blood flow. MicroNet, a micron mesh sleeve, is attached over a stent to provide embolic protection both during and after stenting procedures.

 

Our CGuard™ carotid embolic prevention system (“CGuard EPS”) combines MicroNet and a unique self-expandable nitinol stent in a single device for use in carotid artery revascularization. Our CGuard EPS originally received CE mark approval under Medical Device Directive 93/42/EEC (“MDD”) in the European Union (“EU”) in March 2013 and was fully launched in Europe in September 2015. Subsequently, we launched CGuard EPS in over 30 countries and on February 3, 2021, we executed a distribution agreement with Chinese partners for the purpose of expanding our presence in the Asian markets. In January 2024, we received CE mark recertification under the EU’s Medical Device Regulation regulatory framework. Currently, we are seeking strategic partners for a potential launch of CGuard EPS in Japan and other Asian countries.

 

On September 8, 2020, we received approval from the U.S. Food and Drug Administration (“FDA”) of our Investigation Device Exemption (“IDE”), thereby allowing us to proceed with a pivotal study of our CGuard™ Carotid Stent System, C-GUARDIANS, for prevention of stroke in patients in the United States. C-GUARDIANS is a prospective, multicenter, single-arm, pivotal study to evaluate the safety and efficacy of the CGuard™ Carotid Stent System when used to treat symptomatic and asymptomatic carotid artery stenosis in patients undergoing carotid artery stenting (“CAS”). The study, which completed enrollment in June 2023, enrolled 316 patients across 24 trial sites in the U.S. and Europe and from April 2023 included deployment of the CGuard stent using CGuard Prime, our next generation CAS stent platform.

 

The primary endpoint is a composite of: (1) incidence of major adverse events including Death (all-cause mortality), any Stroke, and Myocardial Infarction (DSMI) through 30-days post index procedure, or (2) ipsilateral stroke from day 31 to day 365 post-procedure. All events are adjudicated by an independent clinical events committee. The composite index will be compared to a performance goal based on the observed rate of the two components of the primary endpoint from previous pivotal stent trials which are considered industry standard. The performance goal will be considered met if the upper bound of the two-sided 95% confidence interval calculated from the observed primary endpoint rate is < 11.6% and the p-value is less than 0.025.

 

In November 2023, we announced positive 30-day follow up results from the C-GUARDIANS trial in which stenting with the CGuard Carotid Stent System in patients with carotid artery stenosis and at high risk for carotid endarterectomy had a DSMI rate of 0.95%, measured from the date of the procedure through 30 days follow-up post-procedure. We anticipate reporting primary endpoint results from the C-GUARDIANS trial mid 2024 that may support the submission of a premarket approval, or PMA, application in the third quarter of 2024 with a view to potential FDA approval of the CGuard Prime stent system in the first half of 2025.

 

We continue to invest in current and future potential new indications, products and manufacturing enhancements for CGuard that are expected to reduce cost of goods and/or provide the best-in-class performing delivery systems, such as CGuard Prime. In furtherance of our strategy that focuses on establishing the CGuard Carotid Stent System as a viable alternative to vascular surgery, we are developing a new transcarotid artery revascularization (TCAR) system, SwitchGuard™ neuroprotection system (“SwitchGuard NPS”), for transcarotid access and neuro protection. In addition, we intend to explore new indications for CGuard to leverage the advantages of stent design and mesh protection, well suited in labels such as acute stroke with tandem lesions.

 

-5-
 

 

We consider our current addressable market for our CGuard Carotid Stent System and SwitchGuard NPS to be both symptomatic and asymptomatic individuals with diagnosed high-grade carotid artery stenosis for whom intervention is preferable to medical (drug) therapy. This group includes not only carotid artery stenting patients but also individuals undergoing carotid endarterectomy, as the two approaches compete for the same patient population. Assuming full penetration of the intervention caseload by CGuard, we estimate that the addressable market for CGuard Carotid Stent System and SwitchGuard NPS is approximately $1.3 billion (source: Health Research International Personal Medical Systems, Inc. September 13, 2021 Results of Update Report on Global Carotid Stenting Procedures and Markets by Major Geography and Addressable Markets and internal estimates). According to this same report and internal estimates, assuming full penetration of treatment for all individuals diagnosed with high-grade carotid artery stenosis, we estimate the total available market for CGuard Carotid Stent System and SwitchGuard NPS to be approximately $9.3 billion, which may grow over time if expanded treatment options such as CGuard Carotid Stent System and SwitchGuard NPS lead to increased patient screening for carotid artery disease.

 

In October 2023, the Centers for Medicare and Medicaid Service (“CMS”) issued its final National Coverage Determination (“NCD”), expanding coverage of CAS to include both asymptomatic and standard risk patients, significantly expanding the U.S. CAS addressable market.

 

Our mission is to offer a comprehensive set of delivery solutions (TCAR and Transfemoral) in order to deliver best in class results through patient outcomes by way of stent performance with CGuard Carotid Stent System and SwitchGuard NPS.

 

We were organized in the State of Delaware on February 29, 2008.

 

Private Placement

 

On May 12, 2023, we entered into a securities purchase agreement (the “Purchase Agreement”) pursuant to which we agreed to sell and issue in a private placement (the “Private Placement Offering”) an aggregate of 10,266,270 shares (the “Private Placement Shares”) of our common stock, pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 15,561,894 shares of common stock and warrants to purchase up to an aggregate of 51,656,328 shares of common stock, consisting of Series H warrants to purchase up to 12,914,086 shares of common stock (the “Series H Warrants”), Series I warrants to purchase up to 12,914,078 shares of common stock (the “Series I Warrants”), Series J warrants to purchase up to 12,914,086 shares of Common Stock (the “Series J Warrants”) and Series K warrants to purchase up to 12,914,086 shares of common stock (the “Series K Warrants” and together with the Series H Warrants, Series I Warrants and Series J Warrants, the “Warrants”), at an offering price of $1.6327 per Private Placement Share and associated Warrants and an offering price of $1.6326 per Pre-Funded Warrant and associated Warrants.

 

The Pre-Funded Warrants will be immediately exercisable at an exercise price of $0.0001 per share and will not expire until exercised in full. The Warrants will be immediately exercisable upon issuance at an exercise price of $1.3827 per share, subject to adjustment as set forth therein. The Warrants have a term of the earlier of (i) five years from the date of issuance and (ii) (A) in the case of the Series H Warrants, 20 trading days following the Company’s public release of primary and secondary end points related to one year follow up study results from the Company’s C-GUARDIANS pivotal trial, (B) in the case of the Series I Warrants, 20 trading days following the Company’s announcement of receipt of Premarket Approval from the Food and Drug Administration (“FDA”) for the CGuard Prime Carotid Stent System (135 cm), (C) in the case of the Series J Warrants, 20 trading days following the Company’s announcement of receipt of FDA approval for the SwitchGuard and CGuard Prime 80 and (D) in the case on the Series K Warrants, 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of the CGuard Carotid Stent System in the United States begins.

 

The Warrants may be exercised on a cashless basis if there is no effective registration statement registering the shares underlying the Warrants. Under the terms of the Pre-Funded Warrants and Warrants, certain of the selling stockholders may not exercise the Pre-Funded Warrants or Warrants to the extent such exercise would cause such selling stockholder, together with its affiliates and attribution parties, to beneficially own a number of shares of common stock which would exceed 4.99% or 9.99% of our then outstanding common stock following such exercise, excluding for purposes of such determination common stock issuable upon exercise of the Pre-Funded Warrants or Warrants which have not been exercised. The Warrants may be exercised into pre-funded warrants if the selling stockholder is unable to exercise the Warrant due to the foregoing beneficial ownership limitation or at the selling shareholder’s election.

 

In connection with the Purchase Agreement, we entered into a registration rights agreement (the “Registration Rights Agreement”). Pursuant to the Registration Rights Agreement, we were required to file a resale registration statement (the “Registration Statement”) with the SEC to register for resale the Private Placement Shares and the shares of common stock issuable upon exercise of the Pre-Funded Warrants and Warrants, within 20 days of the signing date of the Purchase Agreement (the “Signing Date”), and to have such Registration Statement declared effective within 45 days after the Signing Date in the event the Registration Statement is not reviewed by the SEC, or 90 days of the Signing Date in the event the Registration Statement is reviewed by the SEC. We were obligated to pay certain liquidated damages if we fail to file the Registration Statement when required, fails to cause the Registration Statement to be declared effective by the SEC when required, of if we fail to maintain the effectiveness of the Registration Statement. The Registration Statement was subsequently filed on May 23, 2023 and declared effective on June 1, 2023. We paid LifeSci Capital LLC, a placement fee equal to 5.6% of the aggregate gross proceeds from the closing of the Private Placement Offering, or approximately $2.4 million, and legal expenses of $41,600. In addition, we paid Piper Sandler & Co. a financial advisory fee of $1.5 million, AGP/Alliance Global Partners a financial advisory fee of $250,000 and lead investor counsel expenses of $125,000.

 

-6-
 

 

Our Industry

 

Carotid

 

Carotid arteries are located on each side of the neck and provide the primary blood supply to the brain. Carotid artery disease, also called carotid artery stenosis, is a type of atherosclerosis (hardening of the arteries) that is one of the major risk factors for ischemic stroke. In carotid artery disease, plaque accumulates in the artery walls, narrowing the artery and disrupting the blood supply to the brain. This disruption in blood supply, together with plaque debris breaking off the artery walls and traveling to the brain, are the primary causes of stroke. According to the World Health Organization (https://www.who.int/cardiovascular_diseases/resources/atlas/en/) every year, 15 million people worldwide suffer a stroke, and nearly six million die and another five million are left permanently disabled. According to the same source, stroke is the second leading cause of disability, after dementia.

 

In 2022, 3.0 million people between the age of 50 and 89 years old were estimated to be diagnosed with high grade carotid artery disease, of which, approximately 394,000 of those diagnosed required intervention for carotid artery disease (according to the Health Research International Personal Medical Systems, Inc. September 13, 2021 Results of Update Report on Global Carotid Stenting Procedures and Markets by Major Geography and Addressable Markets). There are three current intervention treatments used for carotid artery disease. The first is a carotid endarterectomy where a surgeon accesses the blocked carotid artery though an incision in the neck, and then surgically removes the plaque. The second is transcarotid artery revascularization where a surgeon accesses the blocked carotid artery though an incision in the neck, and then places a stent to open the artery and prevent embolization while combining high-rate blood flow reversal to protect the brain. The third is carotid artery stenting, which is a minimally invasive endovascular treatment for carotid artery disease and an alternative to carotid endarterectomy. Endovascular techniques using stents and carotid embolic prevention system protect against plaque and debris traveling downstream, blocking off the vessel and disrupting blood flow. We believe that the use of a stent with an embolic protection system should increase the number of patients being treated since it would avoid the need for complex surgery.

 

Our Products

 

MicroNet Mesh Platform Technology

 

MicroNet is our proprietary circular knitted mesh which wraps around a stent to protect patients from plaque debris flowing downstream upon deployment. MicroNet is made of a single fiber from a biocompatible polymer widely used in medical implantations. The size, or aperture, of the current MicroNet ‘pore’ is only 150-180 microns in order to maximize protection against the potentially dangerous plaque and thrombus. The MicroNet mesh is the core technology around which we have developed products for specific applications.

 

CGuard – Carotid Artery Applications

 

Our CGuard EPS combines our MicroNet mesh and a self-expandable nitinol stent (a stent that expands without balloon dilation pressure or need of an inflation balloon) in a single device for use in carotid artery applications. MicroNet is placed over and attached to an open cell nitinol metal stent platform which is designed to trap debris and emboli that can dislodge from the diseased carotid artery and potentially travel to the brain and cause a stroke. This danger is one of the greatest limitations of carotid artery stenting with conventional carotid stents and stenting methods. The CGuard EPS technology is a highly flexible stent system that conforms to the carotid anatomy.

 

We believe that our CGuard EPS design provides advantages over existing therapies in treating carotid artery stenosis, such as conventional carotid stenting and surgical endarterectomy, given the superior embolic protection characteristics provided by the MicroNet. We believe the MicroNet will provide acute embolic protection at the time of the procedure, but more importantly, we believe that CGuard EPS will provide post-procedure protection against embolic dislodgement, which can occur up to 48 hours post-procedure. It is in this post-procedure time frame that embolization is the source of post-procedural strokes in the brain. Schofer, et al. (“Late cerebral embolization after emboli-protected carotid artery stenting assessed by sequential diffusion-weighted magnetic resonance imaging,” Journal of American College of Cardiology Cardiovascular Interventions, Volume 1, 2008) have shown that the majority of the incidents of embolic showers associated with carotid stenting occur post-procedure.

 

-7-
 

 

Our CGuard EPS originally received CE mark approval in the EU in March 2013 and was fully launched in Europe in September 2015. Subsequently, we launched CGuard EPS in 30 plus countries and on February 3, 2021, we executed a distribution agreement with Chinese partners for the purpose of expanding our presence in China.

 

On September 8, 2020, we received approval from the FDA of our IDE, thereby allowing us to proceed with a pivotal study of our CGuard™ Carotid Stent System, C-GUARDIANS, for prevention of stroke in patients in the United States. C-GUARDIANS is a prospective, multicenter, single-arm, pivotal study to evaluate the safety and efficacy of the CGuard™ Carotid Stent System when used to treat symptomatic and asymptomatic carotid artery stenosis in patients undergoing carotid artery stenting. The study, which completed enrollment in June 2023, enrolled 316 patients across 24 trial sites in the U.S. and Europe and from April 2023 included deployment of the CGuard stent using CGuard Prime, our next generation CAS stent platform.

 

The primary endpoint is a composite of: (1) incidence of major adverse events including Death (all-cause mortality), any Stroke, and Myocardial Infarction (DSMI) through 30-days post index procedure, or (2) ipsilateral stroke from day 31 to day 365 post-procedure. All events are adjudicated by an independent clinical events committee.The composite index will be compared to a performance goal based on the observed rate of the two components of the primary endpoint from previous pivotal stent trials which are considered industry standard. The performance goal will be considered met if the upper bound of the two-sided 95% confidence interval calculated from the observed primary endpoint rate is < 11.6% and the p-value is less than 0.025.

 

In November 2023, we announced positive 30-day follow up results from the C-GUARDIANS trial in which stenting with the CGuard Carotid Stent System in patients with carotid artery stenosis and at high risk for carotid endarterectomy had a DSMI rate of 0.95%, measured from the date of the procedure through 30 days follow-up post-procedure. We anticipate reporting primary endpoint results from the C-GUARDIANS trial in mid 2024 that may support the submission of a PMA application in the third quarter of 2024 with a view to potential FDA approval of the CGuard Prime stent system in the first half of 2025.

 

CGuard Prime Stent System

 

The CGuard Prime stent system is a mesh-covered self-expanding carotid stent that is loaded into a transfemoral rapid exchange (Rx) delivery system that we are developing and that is subject to regulatory approval.

 

The CGuard Prime Carotid Stent is a self-expanding nitinol stent covered with a MicroNet bio-stable sleeve woven from a single strand of 23 μm Polyethylene Terephthalate (PET). The MicroNet sleeve is designed to trap and seal thrombus and plaque against the vessel wall, providing continuous embolic prevention. The CGuard Prime Carotid Stent is available in diameters ranging from 6.0mm to 10mm and in lengths of 20, 30, 40 and 60mm. The CGuard Prime delivery system is a rapid exchange (Rx), delivery system with a 6Fr profile that can accommodate all stent sizes from 6mm to 10mm. The CGuard Prime is available in two lengths: 80 cm and 135 cm.

 

CGuard Prime advances the first generation CGuard transfemoral delivery system with new handle design for deployment accuracy, new catheter design for more flexible navigation of tortuous anatomy especially in acute revascularize settings as well as two lengths, 135cm and 80cm for booth transfemoral and transcarotid access. From April 2023, the C-GUARDIANS trial included deployment of the CGuard stent using CGuard Prime.

 

Switchguard NPS

 

SwitchGuard NPS is a Class IIa, non-invasive transcarotid artery revascularization (TCAR) device that we are developing and that is subject to regulatory approval that is composed of medical grade tubing with male Luer lock connectors at each end and an in-line 200-micron blood filter. The device is intended as an external arterial-venous (A-V) shunt, allowing arterial blood to flow into the venous system, while filtering particulate before returning blood to the patient on the venous side.

 

The SwitchGuard arterio-venous extension line with filter is intended for flow circuit and particle removal when connecting arterial and/or venous introducers during interventional procedures.

 

SwitchGuard is being developed to answer a need of flow reversal for cerebral protection in coronary artery stenting (“CAS”) since symptomatic distal embolization, caused by the release of material (thrombotic, necrotic, or atherosclerotic) from the site of the lesion during the intervention, is the most frequent and important complication of CAS. Reversing blood flow has been shown to reduce stroke risk during carotid artery procedures.

 

-8-
 

 

Physicians frequently use extension lines constructed from blood filter transfusion sets during interventional procedures for the purpose of A-V shunting.

 

We expect to submit an IDE to the FDA for the C-GUARDIANS II clinical trial during the second half of 2024, which, if approved, would allow us to initiate a clinical trial to support the clearance of the SwitchGuard NPS coupled with CGuard Prime. In February 2024, we appointed the principal investigators for the C-GUARDIANS II clinical trial of SwitchGuard NPS.

 

Acute Stroke with Tandem Lesions

 

It is estimated that 20-30% of acute ischemic strokes are caused by large vessel occlusion involve tandem lesions- high grade stenosis/occlusion of the internal carotid artery plus thrombotic occlusion of an intracranial vessel. Currently there is no indicated use of CAS for these lesions during stroke treatment when the placement of an embolic protection device is not possible. We believe CGuard Prime is optimally suited for intervention in this acute setting by way for design (flexible / low metal structure) as well as MicroNet mesh offering embolic protection both during and post procedural implantation. Our goal is to develop CGuard Prime to mitigate strokes in this acute setting.

 

In November 2023, we announced a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The study is expected to enroll 15 acute stroke patients across three U.S. sites to explore the safety and feasibility. of using CGuard Prime to treat acute ischemic stroke patients with tandem lesions.

 

MGuard Prime

 

We historically developed and sold the MGuard Prime embolic protection system (“MGuard Prime EPS”) which was marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions. Over the past years there has been a shift in industry preferences towards drug eluting stents. As a result of declining sales and utilization of the MGuard Prime EPS, which was largely driven by the predominant industry preferences favoring drug-eluting stents, during the second quarter of 2022 we ceased sales of MGuard Prime EPS following a phase out period.

 

Completed Clinical Trials for CGuard EPS

 

CARENET

 

The CARENET trial was the first multi-center study of CGuard EPS following the receipt of CE mark of this device in March 2013. The CARENET trial was designed to evaluate feasibility and safety of CGuard EPS in treatment of carotid lesions in consecutive patients suitable for CASin a multi-operator, real-life setting. The acute, 30-day, magnetic resonance imaging (“MRI”), ultrasound and six-month clinical event results were presented at the LINC conference in Leipzig, Germany in February, 2015. In the third quarter of 2015, the results of the CGuard CARENET trial were published in the Journal of the American College of Cardiology. In November 2015, positive twelve-month follow-up data from the CGuard CARENET trial was presented at the 42nd Annual Symposium on Vascular and Endovascular Issues, documenting the benefits of the CGuard MicroNet technology as well as the patency benefits (maintaining the artery open) of the internal and external carotid arteries at twelve months. In September 2022, the results of the CGuard CARENET trial five year follow up were published in the Journal of the American College of Cardiology: Cardiovascular Interventions Vol. 15, No 18, 2022 September 26, 2022:1883-1891. There was no ipsilateral stroke or ipsilateral stroke-related death which occurred throughout the five years. In addition, no stent restenosis or external carotid artery occlusion occurred in CARENET by 5 years, indicating normal healing and uncompromised side-branch patency.

 

MACCE (myocardial infarction (“MI”), stroke or death) rate was 0.0% at 30 days. At six months, there was one death, which was not device or procedure-related but did result in a MACCE rate of 3.6% at six months. At twelve months there were two additional deaths, which were not device or procedure-related resulting in a MACCE rate of 10.7% at one year.

 

-9-
 

 

  

30 days

(n=30)

  

6 months

(n=28)

  

12 months

(n=28)

 
MACCE (MI, stroke, death)   (0) 0.0%   (1) 3.6%   (3) 10.7%
MI   (0) 0.0%   (0) 0.0%   (0) 0.0%
stroke   (0) 0.0%   (0) 0.0%   (0) 0.0%
death   (0) 0.0%   (1) 3.6%   (3) 10.7%

 

CAS carries the risk of cerebral embolization during and following the procedure, leading to life-threatening complications, mainly cerebral ischemic events. Diffusion-weighted magnetic resonance imaging (DW-MRI) is a sensitive tool used to identify cerebral emboli during CAS by measuring “lesions” within the brain which are areas that are ischemic and do not receive oxygenated blood due to cerebral emboli. In the CARENET trial, 37.0% of patients treated with CGuard EPS had new ischemic lesions at 48 hours after the procedure, with an average volume of 0.039 cm3. Of these lesions, there was only one that remained at 30 days following the procedure and all others had resolved. Complete details appear in the following table. Where there is a second number shown below after a ± symbol, it indicates the potential error in the measurement.

 

  

48 hours

n=27

  

30 days

n=26

 
Subjects with new Acute Ischemic Lesions (“AIL”)   10    1 
Incidence of new lesions   37.0%   4.0%
Total number new AIL   83    1 
Avg. number new AIL per patient   3.19 ± 10.33    0.04 ± 0.20 
Average lesion volume (cm3)   0.039 ± 0.08    0.08 ± 0.00 
Maximum lesion volume (cm3)   0.445    0.116 
Permanent AIL at 30 days   —    1 

 

The healing process of the tissue and in-stent restenosis can be measured by a non-invasive form of ultrasound called duplex ultrasound. This type of ultrasound measures the velocity of the blood that flows within the carotid arteries, which increases exponentially as the lumen of the internal carotid artery narrows and the percent stenosis increases. One of the measurements is called PSV (peak systolic volume) and is known to be highly correlated to the degree of in-stent restenosis; PSV values higher than 300 cm/sec are indicative of >70% stenosis, while PSV values lower than 104 cm/sec are indicative of <30% restenosis and healthy healing. In the CARENET trial, duplex ultrasound measurements done at 30 days, 6 months and 12 months following the stenting procedure all attest to healthy normal healing without restenosis concerns, as the PSV values were 60.96 cm/sec ± 22.31, 85.24 cm/sec ± 39.56, and 90.22 cm/sec ± 37.72 respectively. The internal carotid artery was patent in all patients (100%).

 

The conclusions of the CARENET trial were:

 

  ● The CARENET trial demonstrated safety of the CGuard EPS stent, with a 30 day MACCE rate of 0%.
     
  ● Incidence of new ipsilateral lesions (percent of patients with new lesions on the ipsilateral side (same side where the stent was employed)) at 48 hours was reduced by almost half compared to published data, and volume was reduced almost tenfold.
     
  ● All but one lesion had resolved completely by 30 days.
     
  ● Twelve-month data showed no stroke or stroke-related deaths, and no cardiac adverse events.
     
  ● Five-year data showed no ipsilateral stroke or ipsilateral stroke-related deaths, and no stent restenosis or external carotid artery occlusion occurred in CARENET by 5 years, indicating normal healing and uncompromised side-branch patency.
     
  ● CGuard EPS offers enhanced benefits for patients undergoing CAS with unprecedented safety.

 

-10-
 

 

Physician-Sponsored Clinical Trials for CGuard—PARADIGM-101 and PARADIGM -500 Studies

 

PARADIGM-101 (Prospective evaluation of All-comer peRcutaneous cArotiD revascularization In symptomatic and increased-risk asymptomatic carotid artery stenosis, using CGuard™ Mesh-covered embolic prevention stent system-101) was an investigator-led, single center study with the objective of evaluating feasibility and outcome of routine use of CGuard EPS in 101 consecutive unselected all-comer patients referred for carotid revascularization, initiated in 2015. In May 2016, the 30-day results were presented at the EuroPCR 2016 Late-Breaking Clinical Trial Session in Paris, and in the Journal of EuroIntervention. In Dec 2020, the 12 month results were presented in the Official Journal of the EuroPCR and the European Association of Percutaneous Coronary Interventions, EuroIntervention 2020;16:e950-e952. DOI: 10.4244/EIJ-D-19-01014) Key findings from the PARADIGM-101 study and the follow-up data are as follows.

 

  ● CGuard EPS delivery success was 99.1%. The clinical evaluation also found no device foreshortening or elongation;
     
  ● Angiographic diameter stenosis or vessel narrowing was reduced from 83±9% to only 6.7±5% (p<0.001);
     
  ● Periprocedural death/major stroke/ myocardial infarction (“MI”) rates were 0%;
   
  ● Between 30 days and 12 months, there were no strokes or stroke-related deaths. There were four non -device related deaths (heart failure exacerbation, urosepsis, pulmonary embolism and microcellular pulmonary cancer).

 

The results of the PARADIGM-101 study demonstrated that CGuard EPS can safely be used in a high risk, all-comer population of patients with carotid artery stenosis and indicated that routine use of CGuard EPS may prevent cerebral events, such as strokes, by holding plaque against the vessel wall, preventing emboli from being released into the blood stream. The PARADIGM-101 study found that CGuard EPS is applicable in up to 90% of all-comer patients with carotid stenosis.

 

PARADIGM-101 was subsequently increased to include 500 consecutive patients with symptomatic or increased stroke risk asymptomatic atherosclerotic carotid stenosis patients. The new study is known as PARADIGM -500. In June 2022, the 1-year results were presented at the EuroPCR in Leipzig, Germany.

 

Key findings from the PARADIGM-500 study are as follows.

 

  ● 30 Day Death/Stroke rate of 0.75%; 30-day death/stroke/myocardial infarction rate of 0.94%;
     
  ● 12-month freedom from ipsilateral stroke, in stent restenosis and target lesion revascularization rate of 99.6%.

 

Clinical Results and Mechanical Properties of the Carotid CGUARD Double-Layered Embolic Prevention Stent Study

 

“Clinical Results and Mechanical Properties of the Carotid CGUARD Double-Layered Embolic Prevention Stent Study” was an investigator-led, prospective single-center study which evaluated CGuard EPS in 30 consecutive patients with internal carotid artery stenosis disease with the objective of reporting early clinical outcomes with a novel MicroNet covered stent for the internal carotid artery and the in vitro investigation of the device’s mechanical properties. In October 2016, the 30-day positive results were published online-ahead-of-print in the Journal of Endovascular Therapy.

 

Key findings from the study are as follows:

 

  ● 100% success in implanting CGuard EPS without residual stenosis;

 

-11-
 

 

  ● No peri- or post-procedural complications;
     
  ● No deaths, major adverse events, minor or major strokes, or new neurologic symptoms during the six months following the procedure;
     
  ● Modified Rankin Scale improved for the symptomatic patients from 1.56 prior to the procedure to 0 afterwards;
     
  ● All vessels treated with CGuard EPS remained patent (open) at six months; and
     
  ● DW-MRI performed in 19 of 30 patients found no new ipsilateral lesions after 30 days and after six months compared with the baseline DW-MRI studies.

 

Additionally, based on engineering evaluations, the study concluded that CGuard EPS provides a high radial force and strong support in stenotic lesions. The stent is easy to use and safe to implant because it does not foreshorten and its structure adapts well to changes in diameter and direction of tortuous vascular anatomies. The MicroNet mesh of CGuard did not cause any changes to specific mechanical parameters of the underlying stent.

 

Safety and Efficacy of the New Micromesh-Covered Stent CGuard in Patients Undergoing Carotid Artery Stenting: Early Experience From a Single Center

 

“Safety and Efficacy of the New Micromesh-Covered Stent CGuard in Patients Undergoing Carotid Artery Stenting: Early Experience From a Single Center” was an investigator-led, single-center study which evaluated CGuard EPS in 82 consecutive patients. The aim of the study was to evaluate the safety (technical success) and efficacy (clinical success) of the CGuard stent system – a new nitinol stent covered by a closed-cell polyethylene and terephthalate mesh designed to prevent embolic events. In 2017, the 30-day positive results were published online-ahead-of-print in the European Journal of Vascular and Endovascular Surgery (2017), https://doi.org/10.1016/j.ejvs.2017.09.015.

 

Key findings from the study are as follows:

 

  ● 100% success in implanting CGuard EPS;
     
  ● One case of acute stent thrombosis occurred within 4 hours of the procedure:
     
  ● One minor stroke was recorded within the peri-operative period following the acute stent thrombosis, mentioned above;
     
  ● No new adverse neurological events were recorded at the post-operative period.
     
  ● DW-MRI was performed to assess the occurrence of new ischaemic brain lesions from the target vessel following placement of the CGuard stent peri- (48-72 hours) and post-operatively (30 days) in 21 and 11 patients, respectively. Five of 21 patients (23.8%) had new ischaemic brain lesions peri-operatively (48-72 hours) on the ipsilateral side, for a total number of 30 lesions, with an average lesion volume of 0.039 +/- 0.025 cm3. Four patients (19.1%) had new ischaemic brain lesions on the contralateral side, for a total number of nine lesions, with an average lesion volume of 0.019 +/- 0.011 cm3 (range 0.016-0.034 cm3). At the postoperative period, spontaneous resolution was noted in all the lesions recorded in the peri-operative period in the 11 patients participating. Only one symptomatic patient had two new ischaemic brain lesions (1 ipsilateral and 1 contralateral).

 

-12-
 

 

CGUARD Mesh-Covered Stent in Real World: The IRON-Guard Registry

 

“CGUARD Mesh-Covered Stent in Real World: The IRON-Guard Registry using CGuard EPS” was a physician initiated prospective multi-center registry that included 200 patients from 12 medical centers in Italy. The objective of the study was to report 30-day outcomes (including MACCE) in a prospective series of patients who were treated with CGuard EPS between April 2015 and June 2016. In January 2017, 30-day results were presented at the Leipzig Interventional Course (LINC) 2017 and published in the Journal of EuroIntervention in May 2017. The 12-month follow-up was published in the Journal of EuroIntevention in October 2018.

 

Key 30-day results presented were:

 

  ● 100% success in implanting CGuard EPS;
     
  ● No MI, major stroke or death at 30 days;
     
  ● There were two transient ischemic attacks and five periprocedural minor strokes, including one thrombosis solved by surgery.
     
  ● Total elimination of post-procedural neurologic complications by 30 days;
     
  ● DW-MRI performed pre-procedure and between 24- and 72-hours post-procedure in 61 patients, indicated that 12 patients had new micro emboli (19%).
     
  ● At 12-month, there were no new major neurological adverse events, thrombosis or external carotid occlusion recorded;
     
  ● One myocardial infarction occurred at 12 months.

 

Initial Clinical Study of the New CGuard EPS MicroNet Covered Carotid Stent: “One Size Fits All”

 

“Initial Clinical Study of the New CGuard EPS MicroNet Covered Carotid Stent: ‘One Size Fits All’” was an investigator-led, single-center study, which evaluated CGuard EPS in 30 consecutive patients with symptomatic stenosis of the internal carotid artery with the objective of evaluating the CGuard EPS MicroNet covered stent for its ability to adjust to different vessel diameters. The results of the study were published in the Journal of Endovascular Therapy in May 2019. The conclusion of the study as reported was that CGuard EPS has high conformability combined with an almost equivalent outward radial force at expansion diameters ranging from 5.5 to 9.0 mm. The first clinical results demonstrate the “One Size Fits All” stent can be implanted in internal carotid arteries with reference diameters within this range.

 

-13-
 

 

Key findings from the study were as follows:

 

  ● 100% technical success in implanting CGuard EPS;
     
  ● No neurological events within 30 days;
     
  ● The chronic outward force normalized by stent length demonstrated a near-equivalent radial force outcome; and
     
  ● The stent displayed only a minor difference between the minimal radial force at 9.0 mm (0.195 N/mm) and the maximal radial force at 5.5 mm (0.330 N/mm).

 

Preliminary Results from a Prospective Real-World Multicenter Clinical Practice of Carotid Artery Stenting Using the CGuard Embolic Prevention System: The IRONGUARD 2 Study

 

“Preliminary Results From a Prospective Real-World Multicenter Clinical Practice of Carotid Artery Stenting Using the CGuard Embolic Prevention System: The IRONGUARD 2 Study” is a physician initiated prospective multi-center registry enrolling 733 patients from 20 medical centers in Italy, from January 2017 to June 2019. The objective of the study is to evaluate periprocedural (24 hours), post-procedural (up to 30 days), and 12-month outcomes in a largest, prospective, multicenter series of patients submitted for protected carotid artery stenting with the CGuard Embolic Prevention System. The 24-hour, 30-day and 12-month preliminary results (data available on 726 patients out of the 733 treated) were presented at the Leipzig Interventional Course (LINC) in January 2021. The study’s preliminary results from the IRONGUAURD 2 study suggested in a real-world evaluation of carotid artery stenting, CGuard EPS can be safely used for treatment of extracranial carotid artery stenosis, allowing a low rate of post procedural adverse events by 12 months.

 

Key findings from the study are as follows:

 

  ● 100% procedural success in implanting CGuard EPS;
     
  ● 1 death from hemorrhagic stroke (patient was admitted for immediate treatment of CAS due to stroke), 2 minor strokes, 6 TIAs and one nonfatal AMI at 24 hours;
     
  ● 1 minor stroke, 2 TIAs, three AMIs, no deaths and no stent thrombosis/occlusions between 24 hours and 30 days; and
     
  ● 1 minor stroke, 4 TIAs, 2 AMIs and 8 deaths (the 2 mentioned AMIs, 4 malignancies, 1 suicide and 1 undefined complication in Guillain-Barré Syndrome) between 30 days and 1 year.

 

Thirty-Day Results of the Novel CGuard-Covered Stent in Patients Undergoing Carotid Artery Stenting

 

“Thirty-Day Results of the Novel CGuard-Covered Stent in Patients Undergoing Carotid Artery Stenting” was an investigator-led, prospective single-center study which evaluated CGuard EPS in 103 patients that underwent carotid artery stenting procedures. The aim of the study was to provide early-term evaluation, safety, and efficacy of the novel CGuard micromesh self-expanding stent with embolic protection system (EPS). In April 2021, the 30-day positive results were published in the Journal of Endovascular Therapy, DOI: 10.1177/15266028211007466.

 

Key findings from the study are as follows:

 

  ● 100% technical success was achieved in all patients:
     
  ● No major adverse events (death, stroke, or myocardial infarction) at 30 days.

 

-14-
 

 

The SIBERIA Trial for Carotid Artery Stenosis: A Randomized Controlled Trial of Conventional Versus Micronet™-Covered Stent Use in Percutaneous Neuroprotected Carotid Artery Revascularization: Peri-procedural and 30-day Diffusion-Weighted Magnetic Resonance Imaging and Clinical Outcomes (RCT trial)

 

“The SIBERIA Trial for Carotid Artery Stenosis: A Randomized Controlled Trial of Conventional Versus Micronet™-Covered Stent Use in Percutaneous Neuroprotected Carotid Artery Revascularization: Peri-procedural and 30-day Diffusion-Weighted Magnetic Resonance Imaging and Clinical Outcomes” was an investigator-initiated randomized clinical trial, single-center study, which evaluated one hundred patients who qualified for carotid revascularization with high risk for surgery and were randomized 1:1 to either CGuard EPS or AcculinkTM. The primary endpoints were incidence and volume of new cerebral embolic post-procedural lesions (24-48 hours) as determined by diffusion weighted magnetic resonance imaging (DW-MRI). The principal secondary endpoints included incidence of periprocedural or postprocedural stroke, myocardial infarction and death at 30 days. The 30-day results of the study were presented in a late-breaking session at the EuroPCR in June 2020 and published (Randomized Controlled Trial of Conventional Versus MicroNet-Covered Stent in Carotid Artery Revascularization, JACC Cardiovascular Interventions, Vol. 14, November 21, 2021). The conclusion of the study was that the CGuard™ Micronet™-covered stent use in consecutive unselected patients subjected to neuroprotected carotid artery stenting was associated with a greater than three-fold reduction in the procedure-generated mean cerebral lesion volume, and with zero post-procedural cerebral embolisms observed. The MicroNet covered stent significantly reduced periprocedural and abolished post procedural cerebral embolism in relation to a conventional carotid stent. This is consistent with the MicroNet covered stent’s sustained embolism prevention, translating into cerebral protection not only during but after carotid artery stenting. The incidence of restenosis and vessel occlusion according to the ICA (internal carotid artery) ultrasound and the incidence of strokes, myocardial infarctions or deaths between the study arms at 365 days were presented at the LINC conference in Leipzig, Germany in June, 2022. The 12-month outcomes demonstrated a significantly higher prevalence of the combined endpoint of death, stroke or myocardial infarctions and in-stent restenosis and vessel occlusion rate in the first generation (single layer) carotid stent, AcculinkTM, versus the MicroNet-Covered Stent, CGuard™.

 

Key findings from the study are as follows:

 

  ● Peri Procedure, the CGuard™ arm was observed to have a 57% reduction in new cerebral lesion average volume per patient (171 mm3 vs. 73 mm3), a statistically significant improvement (p=0.017) and 222 mm3 vs. 84 mm3 (p=0.038);
     
  ● Post Procedure (24-48 hours), the CGuard™ arm was observed to have a 78% reduction in the average volume of new cerebral lesions (157 mm3 vs. 700 mm3), a statistically significant improvement (p=0.007);
     
  ● At 30 days, DW-MRI showed zero new cerebral lessons in the CGuard™ arm versus six in the Acculink™ arm (p=0.03);
     
  ● At 30 days, there were zero strokes, myocardial infarctions or deaths in the CGuard arm and two events the Acculink™ arm (two strokes);

 

  ● At 365 there were zero cases of restenosis and vessel occlusion in the CGuard™ arm versus 3 cases of restenosis and 1 case of vessel occlusion in the Acculink™ arm;
     
  ● At 365 days, there were one event in the CGuard arm (one death) and five events the Acculink™ arm (two strokes, two deaths and one myocardial infarction).

 

On-going and Planned Clinical Trials

 

C-GUARDIANS

 

C-GUARDIANS is a prospective, multicenter, single-arm, pivotal study to evaluate the safety and efficacy of the CGuard Carotid Stent System when used to treat symptomatic and asymptomatic carotid artery stenosis in patients undergoing carotid artery stenting.

 

The study completed enrollment in June 2023. The primary endpoint is a composite of: (1) incidence of major adverse events including Death (all-cause mortality), any Stroke, and Myocardial Infarction (DSMI) through 30-days post index procedure, or (2) ipsilateral stroke from day 31 to day 365 post-procedure. All events are adjudicated by an independent clinical events committee. The composite index will be compared to a performance goal based on the observed rate of the two components of the primary endpoint from previous pivotal stent trials which are considered industry standard. The performance goal will be considered met if the upper bound of the two-sided 95% confidence interval calculated from the observed primary endpoint rate is < 11.6% and the p-value is less than 0.025.

 

-15-
 

 

From July 2021 to June 2023, 316 patients were prospectively enrolled at 24 sites in the US and the EU and from April 2023 included deployment of the CGuard stent using CGuard Prime, our next generation CAS stent platform. All CAS procedures were performed utilizing the CGuard MicroNetTM mesh covered stent and cleared intra-procedural cerebral protection distal embolic filters or proximal embolic protection with flow cessation, or both. At 30 days, the hierarchical DSMI rate was 0.95% in the intent to treat (ITT) analysis and 0.63% in the per- protocol (PP) analysis. Three patients experienced major adverse cardiovascular events by 30-days: one patient who did not take dual antiplatelet therapy (protocol violation) had a major stroke and died and two other patients had a stroke. There was no myocardial infarction (MI). These results support a potential “neuroprotective” effect of the CGuard stent from the procedure to 30 days follow-up.

 

We expect the primary endpoint at 1-year will be analyzed during the third quarter of 2024 when the last patient enrolled reaches 1-year of follow-up. We anticipate reporting primary endpoint results from the C-GUARDIANS trial in mid 2024 that may support the submission of a PMA application in the third quarter of 2024 with a view to potential FDA approval of the CGuard Prime stent system in the first half of 2025.

 

Early Feasibility Study of CGuard EPS for Acute Stroke Patients with Tandem Lesions

 

In November 2023, we announced the entry into a strategic agreement with the Jacobs Institute at the State University of New York at Buffalo to execute an early feasibility study of CGuard EPS for the treatment of acute stroke patients with tandem lesions. The study, a prospective, single center, single-arm, open label, non-blinded study is expected to enroll 15 acute stroke patients across three U.S. sites to assess the safety and feasibility .of using CGuard EPS to treat acute ischemic stroke patients with tandem lesions. of Dr. Adnan Siddiqui, Vice-Chairman and Professor of Neurosurgery at the State University of New York at Buffalo, CEO of the Jacobs Institute, is the Principal Investigator for the study. First patient enrollment is expected in the second quarter of 2024.

 

C-GUARDIANS II for SwitchGuard NPS

 

The SwitchGuard™ NPS is designed to allow the treating physician to reverse cerebral blood flow during a TCAR procedure. SwitchGuard™ is intended to prevent embolic debris generated during the procedure from traveling to the brain, passing the blood through the filter housed within the SwitchGuard™ before returning it to the patient to minimize blood loss.

 

We plan to submit an IDE to the FDA in the second half of 2024 for C-GUARDIANS II, a multicenter, single-arm, pivotal study to evaluate the safety and efficacy of the SwitchGuard NPS for providing cerebral embolic protection during carotid artery stenting via the Transcarotid Artery Revascularization (TCAR) approach. We appointed Patrick Geraghty, M.D., professor of surgery and radiology, section of vascular surgery at Washington University School of Medicine in St. Louis, MO, and Patrick Muck, M.D., program director and chief of vascular surgery at Good Samaritan Hospital in Cincinnati, OH, to act as lead principal investigators for the trial.

 

Additionally, William Gray, M.D., system chief of the cardiovascular division at Main Line Health in Wynnewood, PA and professor of medicine at Thomas Jefferson University in Philadelphia, PA, will act as a strategic advisor to the Company.

 

Future Clinical Trials

 

Pre and post-marketing clinical trials (outside the United States) could be conducted to further evaluate the safety and efficacy of CGuard EPS in specific indications.

 

Growth Strategy

 

Our primary business objective is to utilize our proprietary MicroNet technology and products to become the industry standard for the treatment of carotid disease and prevention of stroke and to provide a superior solution to the common acute problems caused by current stenting procedures, such as restenosis, embolic showers and late thrombosis. We are pursuing the following business strategies to achieve this objective.

 

● Widen the adoption of CGuard. We are seeking to expand the population of CGuard patients in those countries in which CGuard is commercially available. In particular, our focus is on establishing CGuard as a viable alternative (in appropriate cases) to carotid endarterectomy and the use of conventional carotid stents within the applicable medical communities. We intend to accomplish this goal by continuing to publish and present our clinical data, supporting investigator-initiated clinical registries and exploring the addition of additional devices to our portfolio, including the SwithchGuard NPS for use in TCAR cases. We have partnered and will continue to seek out partnerships with organizations focused on the treatment of stroke. We will also continue to engage advisory boards and to develop a network of key opinion leaders to assist us in our efforts to widen the adoption of CGuard. We aim to be the only company focusing on both the surgeons and interventionalists who perform both CAS and TCAR procedures.

 

-16-
 

 

● Portfolio expansion and pipeline development We plan to continue to invest in advancing our portfolio with new delivery system alternatives to facilitate the use of CGuard and SwitchGuard by all physicians. We believe our delivery systems, if approved, will enable all endovascular access points including accessory devices for trans carotid artery revascularization.
   
● Grow our presence in existing and new markets for CGuard EPS. We have launched CGuard EPS in most European and Latin American countries through a comprehensive distributor sales organizations network. We are continuing to focus on larger growing markets through this network by supporting our distributors with robust marketing and clinical education programs. We plan to continue to evaluate the transition to a direct selling model in certain currently served distributor markets, increasing our control on the market and gross profit margins. We are pursuing additional product registrations and distribution contracts with local distributors in other countries in Europe, Asia and Latin America. In February 2021, we executed a distribution agreement with Chinese partners for the purpose of expanding our presence in China. Currently, we are seeking strategic partners for a potential launch of CGuard EPS in Japan and other Asian countries. In addition, we plan to commercialize in the United States through a direct sales organization upon potential PMA approval of CGuard Prime.

 

● CMS approval of National Coverage Determination (NCD) – On October 11 2023, CMS issued an NCD covering the use of carotid stents (both CAS and TCAR) for the treatment of both symptomatic and asymptomatic patients either at high- or standard-surgical risk. This decision significantly increases the available market to endovascular procedures. Previously, only symptomatic patients at high-risk to surgery were covered through the CMS coverage, NCA - Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with Stenting (CAG-00085R8) - Tracking Sheet (cms.gov)

 

● Continue to leverage our MicroNet technology to develop additional applications for interventional cardiologists and vascular surgeons. In addition to the applications described above, we believe that we will eventually be able to utilize our proprietary MicroNet technology to address imminent market needs for new product innovations to significantly improve patient care. We continue to broadly develop and protect intellectual property using our mesh technology. Examples of some areas include peripheral vascular disease and neurovascular disease.
   
● Establish relationships with collaborative and development partners to fully develop and market our existing and future products. We are seeking strategic partners for collaborative research, development, marketing, distribution, or other agreements, which could assist with our development and commercialization efforts for CGuard and other potential products that are based on our MicroNet technology.

 

Competition

 

The markets in which we compete are highly competitive, subject to change and impacted by new product introductions and other activities of industry participants.

 

-17-
 

 

Carotid

 

With respect to competition for our carotid embolic prevention system, CGuard EPS, the manufacturers of products used in connection with CAS procedures in the United States, including a number of large companies, including Abbott Laboratories, Boston Scientific Corporation, Medtronic and Cordis Corporation. In Europe, in addition to the above-mentioned manufacturers, Terumo Medical Corporation also participates in the market for products used in connection with CAS procedures. As we develop and seek regulatory approval in the United States and Europe for our new TCAR neuroprotection system SwitchGuard, and continue to seek greater market share for CGuard, we expect to compete with Silk Road Medical in the total carotid artery revascularization market that comprises CAS, TCAR and carotid endarterectomy (“CEA”).

 

Many of these companies are larger companies or divisions of publicly-traded companies that have certain competitive advantages, including greater capital resources, larger customer bases, broader product lines, larger sales forces, greater marketing and management resources, larger research and development staffs and larger facilities than ours and have established reputations, relationships with our target customers and worldwide distribution methods that are more effective than ours. However, while there are currently many market participants in the U.S. carotid stent market, we believe that the European market is somewhat more fragmented for CAS products, and, in our opinion, smaller competitors may be able to gain market share with greater flexibility and more efficiently than in the United States.

 

We believe the principal competitive factors in our market include the following:

 

  ● Strength of clinical evidence- patient outcomes and adverse event rates;
  ● Scale and effectiveness of commercialization efforts/organizations
  ● Acceptance by treating physicians and referral sources;
  ● Physician learning curve;
  ● Ease-of-use and reliability;
  ● Economic benefits and cost savings;
 

●

●

Availability of reimbursement; and

Patient experience

 

Sales and Marketing

 

Sales and Marketing

 

Based on the positive CGuard EPS clinical data, we initiated the commercial launch of CGuard EPS in CE marked countries in early 2015. In September 2015, we announced full market launch of CGuard EPS in Europe. Since 2017 we have focused on sales of our products through local distribution partners and our own internal sales initiatives to gain greater reach into all the relevant clinical specialties and to expand our geographic coverage. Our current strategy seeks to broaden our sales efforts to increase CGuard EPS penetration within the community of interventionalists. In parallel, we aim at transitioning vascular surgeons from carotid endarterectomy procedures to carotid stenting with CGuard and accessory devices, which we believe can greatly expand our customer base. We have focused and we plan to continue to focus our marketing efforts primarily on key growth markets and to evaluate opportunities in new territories as they become available. In addition, we are using international trade shows and industry conferences to gain market exposure and brand recognition. We continue to work with leading physicians to enhance our marketing efforts and are developing relationships with new key opinion leaders to champion our technology and work with us in clinical studies.

 

Product Positioning

 

We believe that CGuard has potential to become the standard of care in treading carotid artery disease. It is a second-generation stent with positive patient outcomes demonstrating significant reduction in post-procedural neurological events.

 

Additionally, we intend to continue to evaluate potential product and manufacturing enhancements for CGuard expected to reduce cost of goods or provide the best-in-class performing delivery system and accessory solutions. We believe these improvements may allow us to reduce cost of goods and increase penetration in our existing geographies and better position us for entry into new markets.

 

-18-
 

 

Insurance Reimbursement

 

While most countries have established reimbursement codes for stenting procedures, certain countries may require additional clinical data before recognizing coverage and/or to obtain a certain level of reimbursement for one or more of our products. In these situations, we intend to complete the required clinical studies to obtain reimbursement approval in countries where it makes economic sense to do so.

 

In October 2023, CMS issued its final National Coverage Determination (“NCD”), expanding coverage of CAS to include both asymptomatic and standard risk patients, significantly expanding the U.S. CAS addressable market.

 

Intellectual Property

 

Patents

 

We have 59 issued patents, including 19 patents issued in the U.S., and 26 pending patent applications, 7 of which are pending in the United States. Many of these patents and applications cover aspects of our CGuard and MGuard technology. Patents outside the U.S. have been filed in Canada, China, Europe, Israel, India, Japan, Australia, and South Africa. The patents and applications fall into a number of patent families, as listed below:

 

Base Title of Patent Family  

Pending patent

applications

(Countries)

  

Issued patents

(Country and Patent No.)

   Issue Date
Bifurcated Stent Assemblies      

US 8,961,586

China ZL200780046676.2

  

02/24/2015

9/26/2012

Deformable Tip for Stent Delivery and Methods of Use      

US 10,258,491

Israel 260,945

  

4/16/2019

07/01/2020

Handle for Two-Stage Deployment of a Stent  

US (cont)

EP

CN

JP

IN

  

US 11,844,893

 

  

12/12/2023

 

Shunts with Blood-Flow Indicators

 

  

US (cont)

EP

CN

JP (allowed)

JP (divisional)

  

US 11,844,893

 

  

12/19/2023

 

    IN        
    HK        
Device for Shunting Blood Between the Arterial and Venous Systems  

US

EP

CN

JP

IN

        
    HK        
Devices for shunting blood  

US

PCT

        
             
In Vivo Filter Assembly       US 9,132,261   09/15/2015
             
Knitted Stent Jackets      

Canada 2,666,728

Canada 2,887,189

China ZL200780046697.4

China ZL201210320950.3

EP 2076212

Germany, France, & UK

US 10,137,015

India 323792

  

6/23/2015

5/1/2018

10/10/2012

12/2/2015

3/29/2017

 

11/27/2018

10/28/2019

 

 

-19-
 

 

 

Optimized Stent Jacket

   US (cont)  

Canada  2,670,724

Canada 3,013,758

China ZL201210454357.8

China ZL200780043259.2

India 297,257

Israel 230,922

US 9,132,003

US 9,526,644

US 9,782,281

US 10,070,976

US 10,406,006

US 10,406,008

US 11,051,959

 

EP 2088962

(BE, CH, DE, FR, UK, IT, IE, LX, NL)

EP3292837

(UK, DE, FR, IE)

 

 

 

12/11/2018

09/14/2021

12/09/2015

01/02/2013

05/30/2018

10/01/2020

09/15/2015

10/10/2017

12/27/2016

09/11/2018

09/10/2019

09/10/2019

07/06/2021

 

10/11/2017

 

11/09/2022

 

Stent Apparatuses for Treatment Via Body Lumens and Methods of Use   EPO  

South Africa 2007/10751

Canada 2,609,687

Canada 2,843,097

EP 1885281

(CH, DE, FR, GB, IE, IT)

US 10,932,926

US 10,058,440

US 10,070,977

  

10/27/2010

4/22/2014

10/27/2015

2/13/2019

 

03/02/2021

8/28/2018

9/11/2018

Stent Thermoforming Apparatus and Methods      

JP 6553178

US 9,527,234

US 10,376,393

 

  

7/12/2019

12/27/2016

8/13/2019

 

Methods or using a self-adjusting stent assembly and kits including the same  

US (cont)

EP

IN

CN (div)

  

US 11,684,498

China ZL 2019800679437

 

  

06/27/2023

05/03/2022

Intravascular sheath

   US (provisional)        

 

The patents and patent applications listed above cover various aspects of our products, specifically focusing on the mesh sleeve covering our stents, as well as methods for production and delivery mechanisms of the stents. We believe that our patents, in particular those covering the use of a knitted micron-level mesh sleeve over a stent for various indications, as well as our pending patent applications (if issued as patents with claims substantially in their present form), create a significant barrier against other companies seeking to use similar technology. We believe these patents and patent applications collectively cover all our existing products and may be useful in protecting our future technological developments. We intend to aggressively continue patenting new technologies and to actively pursue any infringement of our key patents.

 

-20-
 

 

Trade Secrets

 

We also rely on trade secret protection to protect our interests in proprietary know-how and/or for processes for which patents are difficult to obtain or enforce. As part of our trade secret policy, we rely on non-disclosure and confidentiality agreements with employees, consultants and other parties to protect trade secrets and other proprietary technology.

 

Trademarks

 

We have registered or applied to register the following trademarks, which we use in connection with our products:

 

  ● InspireMD® (US, European Union, and UK)
  ● MGuard® (European Union, and UK)
  ● CGuard® (US, European Union, and UK)
  ● MGuard Prime® (European Union, and UK)
  ● NGuard® (European Union and UK)
  ● PVGuard® (European Union, and UK)
  ● Micronet® (US)
  ● (MNP Micronet Protection logo) (European Union and UK)
  ● Carenet®)European Union and UK)
  ● SmartFit™ (US, UK, EP and CN)
  ● SmartFit Logo (EP, UK, CN)
  ● CGuard Prime (EP, UK, US, CN, JP)
  ● SwitchGuard (EP, UK, US, JP)
  ● True North Medical (EP, UK)
  ● MicroMesh logo (EP, UK)
  ● Micronet logo (updated version) (US, EP, UK, JP)

 

The trademarks are renewable indefinitely, so long as we continue using the marks and make the appropriate filings when required. We also use and may have common-law rights to various trademarks, trade names, and service marks.

 

Government Regulation

 

The manufacture and sale of our products are subject to regulation by numerous governmental authorities, principally the European Union CE mark and other corresponding foreign agencies.

 

Sales of medical devices outside the United States are subject to foreign regulatory requirements that vary widely from country to country. These laws and regulations range from simple product registration requirements in some countries to complex approval process, clinical trials and production controls in others. As a result, the processes and time periods required to obtain foreign marketing approval may be longer or shorter than those necessary to obtain FDA market authorization. These differences may affect the timeliness of international market introduction of our products. For the European Union nations, medical devices must obtain a CE mark before they may be placed on the market. In order to obtain and maintain the CE mark, we must comply with EU law on medical devices, which, until May 26, 2021 was governed by the MDD, by presenting comprehensive technical files for our products demonstrating safety and efficacy of the product to be placed on the market and passing initial and annual quality management system audit as per ISO 13485 standard by a European Notified Body. We have obtained ISO 13485 quality system certification and CGuard EPS that we currently distribute into the European Union, displays the required CE mark. In order to maintain certification, we are required to pass an annual surveillance audit conducted by Notified Body auditors. The European Union replaced the MDD with the new MDR regulation. The MDR entered into force after a transitional period of three years and a one year extension of that transition period due to the COVID-19 pandemic on May 26, 2021 and which changes several aspects of the regulatory framework in the European Union. Manufacturers had the duration of the transition period to update their technical documentation and processes to meet the new requirements in order to obtain a CE Mark. In January 2024, we received CE mark recertification of CGuard EPS under the MDR.

 

-21-
 

 

We have or had regulatory approval and made sales of CGuard EPS either through distributors pursuant to distribution agreements or directly, in the countries listed in the table below. While each of the European Union member countries accepts the CE mark as its sole requirement for marketing approval, some of these countries still require us to take additional steps in order to gain reimbursement rights for our products. Furthermore, while we believe that certain of the below-listed countries that are not members of the European Union and accept the CE mark as a primary requirement for marketing approval, each such country requires additional regulatory requirements for final marketing approval of our products. Furthermore, we are currently targeting additional countries in Europe, Asia, and Latin America; however, even if all governmental regulatory requirements are satisfied in each such country, we anticipate that obtaining marketing approval in each country could take as few as three months or as many as twelve months or more, due to the nature of the approval process in each individual country, including typical wait times for application processing and review, as discussed in greater detail below.

 

Please refer to the table below setting forth the approvals and sales made for CGuard EPS on a country-by-country basis

 

Approvals and Sales of CGuard EPS on a Country-by-Country Basis*

 

Countries 

CGuard EPS

Approval

  

CGuard EPS

Sales

 
Argentina   Y    Y 
Australia   Y    Y 
Austria   Y    Y 
Belarus   Y    Y 
Belgium   Y    Y 
Brazil   Y    Y 
Bulgaria   N    N 
Chile   Y    Y 
Colombia   Y    Y 
Croatia   Y    N 
Cyprus   Y    Y 
Czech Republic   Y    Y 
Denmark   Y    N 
Dominican Republic   N    N 
Ecuador   Y    N 
Estonia   Y    Y 
Finland   Y    Y 
France   Y    Y 
Germany   Y    Y 
Greece   Y    Y 
Netherlands   Y    Y 
Hong Kong   N    N 
Hungary   Y    N 
Iceland   Y    N 
India   Y    Y 
Ireland   Y    N 
Israel   Y    Y 
Italy   Y    Y 
Kazakhstan   Y    Y 
Latvia   Y    Y 
Lithuania   Y    Y 
Liechtenstein   Y    N 
Luxembourg   Y    N 
Malaysia   N    N 
Malta   Y    N 
Mexico   Y    Y 
Moldova   Y    Y 
Montenegro   N    N 
New Zealand   Y    N 
Norway   Y    N 

 

-22-
 

 

Peru     Y       Y  
Poland     Y       Y  
Portugal     Y       Y  
Romania     Y       Y  
Russia     Y       Y  
Saudi Arabia     N       N  
Serbia     Y       Y  
Slovakia     N       N  
Slovenia     Y       Y  
South Africa     Y       Y  
Spain     Y       Y  
Sweden     Y       Y  
Switzerland     Y       Y  
Turkey     N       N  
Taiwan     Y       Y  
Venezuela     N       N  
Vietnam     Y       Y  
Ukraine     Y       Y  
United Kingdom     Y       Y  
United States     N       Y (1)

 

  (1) Refers to CGuard units used in our ongoing FDA trial.

 

FDA Government Regulation of Medical Devices for Human Subjects

 

Many of our activities are subject to regulatory oversight by the FDA under provisions of the Federal Food, Drug, and Cosmetic Act and regulations thereunder, including regulations governing the development, marketing, labeling, promotion, manufacturing, and export of medical devices.

 

FDA Approval/Clearance Requirements

 

In the United States, most Class II or III medical devices must be cleared or approved by the FDA prior to commercialization. Unless an exemption applies, each medical device that is marketed in the United States must receive either 510(k) clearance or PMA. Medical devices that are class II devices receive 510(k) clearance are “cleared” by the FDA to market, distribute, and sell in the United States. Medical devices that are class III devices obtain a premarket approval by the FDA are “approved” to market, distribute, and sell in the United States, after FDA performs an on-site audit at the company premises.

 

Class I devices are those for which safety and effectiveness can be assured by adherence to the FDA’s general regulatory controls for medical devices, or the General Controls, which include compliance with the applicable portions of the FDA’s quality system regulations, facility registration and product listing, reporting of adverse medical events, and appropriate, truthful and non-misleading labeling, advertising, and promotional materials. Some Class I devices also require premarket clearance by the FDA through the 510(k) process described below.

 

Class II devices are required to file a Premarket review of 510(k) application that may also require General Controls, and any other special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. Pursuant to the Medical Device User Fee and Modernization Act of 2002 (MDUFMA), as of October 2002, unless a specific exemption applies, 510(k) submissions are subject to user fees. Certain Class II devices are exempt from this premarket review process.

 

-23-
 

 

Class III includes devices with the greatest risk. Devices in this class must demonstrate safety and efficacy requirements. In addition, Class III devices cannot generally be marketed until they receive a premarket approval. The safety and effectiveness of Class III devices cannot be assured solely by the General Controls and the other requirements described above. These devices require formal clinical studies to demonstrate safety and effectiveness. Under MDUFMA, PMAs (and supplemental PMAs) are subject to significantly higher user fees than 510(k) applications, and they also require considerably more time and resources.

 

The FDA decides whether a device line must undergo either the 510(k) clearance or premarket approval based on statutory criteria that utilize a risk-based classification system. Premarket approval is the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of Class III medical devices and, in many cases, Class II medical devices. Class III devices are those that support or sustain human life, are of substantial importance in preventing impairment of human health, or which present a potential, unreasonable risk of illness or injury. The FDA uses these criteria to decide whether a premarket approval or a 510(k) is appropriate, including the level of risk that the agency perceives is associated with the device and a determination by the agency of whether the product is a type of device that is similar to devices that are already legally marketed. Devices deemed to pose relatively less risk are placed in either Class I or II. In many cases, the FDA requires the manufacturer to submit a 510(k) requesting clearance (also referred to as a premarket notification), unless an exemption applies. The 510(k) must demonstrate that the manufacturer’s proposed device is “substantially equivalent” in intended use and in safety and effectiveness to a legally marketed predicate device. A “predicate device” is a pre-existing medical device to which equivalence can be drawn, generally by a Class II device that was in commercial distribution before May 28, 1976, for which the FDA has not yet called for submission of a PMA. A product that lacks a predicate device will default to a Class III device, although a company may seek to submit a De Novo classification request, rather than a PMA. The De Novo request allows a regulatory pathway to classify novel medical devices and FDA will determine which category is appropriate for that device and for which general controls alone, or general and special controls, provide reasonable occurrence of safety and effectiveness for the intended use, but for which there is no legally marketed predicate device.

 

Premarket Approval Pathway

 

Our CGuard Carotid Stent System is classified as a Class III medical device (considered a PMA) by the FDA. Class III medical devices are generally the highest risk devices and are therefore subject to more rigorous regulatory requirements by the FDA, since the FDA process of premarket approval involves scientific and regulatory review to evaluate the safety and effectiveness of Class III medical devices for the purpose(s) intended. The FDA will either approve or deny a premarket approval application and we cannot market a device until the FDA approves a premarket approval application.

 

A PMA must be supported by extensive data including, but not limited to, analytical, preclinical, clinical trials, manufacturing, statutory preapproval inspections, and labeling to demonstrate to the FDA’s satisfaction the safety and effectiveness of the device is safe and effective for its intended use. Before a premarket approval application is submitted, a manufacturer must generally apply for an Investigational Device Exemption (IDE) to conduct clinical trials. If the device presents a “significant risk,” as defined by the FDA, to human health, the FDA requires the device sponsor to file an IDE application with the FDA and obtain IDE approval prior to initiation of broader human clinical trials.

 

The IDE application must be supported by appropriate data, such as analytical, animal and laboratory testing results, manufacturing information, and an Investigational Review Board (IRB) approved protocol showing that it is safe to test the device in humans and that the testing protocol is scientifically sound, as well as ensuring patient informed consent is obtained.

 

A clinical trial may be suspended by either the FDA or the IRB at any time for various reasons, including a belief that the risks to the study participants outweigh the benefits of participation in the study. Even if a study is completed, clinical testing results may not demonstrate the safety and efficacy of the device, or they may be equivocal or otherwise insufficient to obtain approval of the product being tested. After the clinical trials have been completed, if at all, and the clinical trial data and results are collected and organized, a manufacturer may complete a premarket approval application.

 

-24-
 

 

Following the IDE, a PMA application must be prepared and after a PMA is sufficiently complete, then the FDA will accept the application and begin an in-depth review of the submitted information. By statute, the FDA has 180 days to review the “accepted application,” although, generally, review of the application can take between one and three years, but it may take significantly longer. During this review period, the FDA may request additional information or clarification of information already provided. Also, during the review period, an advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. The preapproval inspections conducted by the FDA include an evaluation of the manufacturing facility to ensure compliance with the Quality Systems Regulations, as well as inspections of the clinical trial sites by the Bioresearch Monitoring group to evaluate compliance with good clinical practice and human subject protections. New premarket approval applications or premarket approval supplements are required for modifications that affect the safety or effectiveness of the device, including, for example, certain types of modifications to the device’s indication for use, manufacturing process, labeling and design. Significant changes to an approved premarket approval require a 180-day supplement, whereas less substantive changes may utilize a 30-day notice, or a 135-day supplement. Premarket approval supplements often require submission of the same type of information as a premarket approval application, except that the supplement is limited to information needed to support any changes from the device covered by the original premarket approval application, and it may not require as extensive clinical data or the convening of an advisory panel.

 

510(k) Clearance Pathway

 

We do not currently market, distribute, or sell any products that have market clearance by the FDA under its 510(k) process. If, in the future, we develop products where 510(k) clearance is required, we would be required to submit a 510(k) demonstrating that such proposed devices are substantially equivalent to a respective previously cleared 510(k) device or a device that was in commercial distribution before May 28, 1976, for which the FDA has not yet called for the submission of 510(k). The FDA’s 510(k) clearance pathway usually takes from three to twelve months but could take longer. In some cases, the FDA may require additional information, including clinical data, to make a determination regarding substantial equivalence.

 

If a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a new or major change in its intended use, will require a new 510(k) clearance or, depending on the modification, a premarket approval. The FDA requires each device manufacturer to determine whether the proposed change requires submission of a new 510(k) or a premarket approval, but the FDA can review any such decision and can disagree with a manufacturer’s determination. If the FDA disagrees with a manufacturer’s determination, the FDA can require the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance or premarket approval of the modified device is obtained.

 

Pervasive and Continuing FDA Regulation

 

A host of regulatory requirements apply to our approved devices, including the quality system regulation (which requires manufacturers to follow elaborate design, testing, control, documentation and other quality assurance procedures), the Medical Device Reporting regulations (which require that manufacturers report to the FDA specified types of adverse events involving their products), labeling regulations, and the FDA’s general prohibition against promoting products for unapproved or “off-label” uses. Class II devices also can have special controls such as performance standards, post-market surveillance, patient registries, and certain FDA guidelines do apply to Class I devices.

 

A noncomprehensive list of the regulatory requirements that apply to our approved products classified as medical devices include:

 

  ● product listing and establishment registration, which helps facilitate FDA inspections and other regulatory action;
     
  ● Quality Systems Regulations, which requires manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the development and manufacturing process;

 

-25-
 

 

  ● labeling regulations and FDA prohibitions against the promotion of products for uncleared, unapproved or off-label use or indication;
     
  ● clearance of product modifications that could significantly affect safety or efficacy or that would constitute a major change in intended use of one of our cleared devices (if obtained);
     
  ● approval of product modifications that affect the safety or effectiveness of one of our cleared devices (if obtained);
     
  ● medical device reporting regulations, which require that manufacturers comply with FDA requirements to report if their device may have caused or contributed to a death or serious injury, or has malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction of the device or a similar device were to recur;
     
  ● post-approval restrictions or conditions, including post-approval study commitments;
     
  ● post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device;
     
  ● the FDA’s recall authority, whereby it can ask, or under certain conditions order, device manufacturers to recall from the market a product that is in violation of governing laws and regulations;
     
  ● regulations pertaining to voluntary recalls; and,
     
  ● notices of corrections or removals.

 

At this time, we have not registered as an establishment with the FDA. If we are approved or cleared to manufacture, prepare, or process a device in the United States, we and any third-party manufacturers that we may use will be required to register our establishments with the FDA. In addition, we and our manufacturing facilities will be subject to FDA inspections for compliance with the FDA’s Quality System Regulation. Additionally, some of our subcontractors may also be subject to FDA announced and unannounced inspections for compliance with the FDA’s Quality System Regulation and assurances that the Company is marketing appropriately the indications for use of the product. These regulations will require that we manufacture our products and maintain our documents in a prescribed manner with respect to design, manufacturing, testing and quality control activities and ensure that marketing materials and promotion are in compliance. As a medical device manufacturer, we will further be required to comply with FDA requirements regarding the reporting of adverse events associated with the use of our medical devices, as well as product malfunctions that would likely cause or contribute to death or serious injury if the malfunction were to recur. FDA regulations also govern product labeling and prohibit a manufacturer from marketing a medical device for unapproved applications.

 

U.S. Healthcare Laws and Regulations

 

In addition to the FDA regulations, there are a variety of other healthcare laws and regulations to which we may be subject if any of our products are marketed, sold, distributed, and/or utilized in the United States. In the United States, we may be subject to the oversight of FDA, Office of the Inspector General within the Department of Health and Human Services (OIG), the Center for Medicare and Medicaid Services (CMS), the Department of Justice (DOJ), in addition to others. We supply products that may be reimbursed by federally funded programs such as Medicare. As a result, our activities may be subject to regulation by CMS and potential enforcement by CMS, OIG and DOJ. Of specific note are federal and state fraud and abuse laws, which prohibit the payment or receipt of kickbacks, bribes or other remuneration, including the offer or solicitation of such payment, intended to induce or reward the purchase, recommendation or generation of business involving healthcare products any item or service payable by a health-care program. Other provisions of federal and state laws prohibit presenting, or causing to be presented, to third party payors (including, government programs, such as Medicare and Medicaid) for reimbursement, claims that are false or fraudulent, or which are for items or services that were not provided as claimed. In addition, other healthcare laws and regulations may apply, such as transparency and reporting requirements and privacy and security requirements. Violations of these laws can lead to civil and criminal penalties, including exclusion from participation in federal and state healthcare programs, any of which could have a material adverse effect on our business. These laws are potentially applicable to manufacturers of products regulated by the FDA as medical devices, such as us, and hospitals, physicians and other institutional or individual providers that may refer or purchase such products. The healthcare laws that may be applicable to our business or operations include, but are not limited to:

 

  ● The federal Anti-Kickback Statute, which prohibits a person from knowingly and willfully offering, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, in return for or to induce referring or recommending an individual to another person to receive items or services or to purchase, lease, order, or arrange for any good, facility, item or service payable in whole or in part under a Federal health care program;

 

-26-
 

 

  ● Federal false claims laws and civil monetary penalty laws, including the False Claims Act, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other government healthcare programs that are false or fraudulent, or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. The False Claims Act imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal health care program, knowingly makes, uses or causes to be made or used, a false record or statement material to a false or fraudulent claim, or knowingly makes a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. The federal Civil Monetary Penalties Law prohibits, among other things, the offering or transferring of remuneration to a Medicare or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary’s selection of a particular supplier of Medicare or Medicaid payable items or services;
     
  ● The federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which includes provisions that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, and for knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services;
     
  ● HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and its implementing regulations, including privacy protection that impose obligations and requirements on healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform certain services for them that involve the use or disclosure of individually identifiable health information, with respect to safeguarding the privacy and security of certain individually identifiable health information;
     
  ● The federal transparency requirements under the Affordable Care Act, including the provision commonly referred to as the Open Payments Act or Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid or Children’s Health Insurance Program to report annually to Centers for Medicare and Medicaid Services, or CMS, information related to payments and other transfers of value to physicians and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members; and
     
  ● Analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may be broader in scope and apply to referrals and items or services reimbursed by both governmental and non-governmental third-party payors, including private insurers, many of which differ from each other in significant ways and often are not preempted by federal law, thus complicating compliance efforts.

 

Customers

 

Our customer base is varied. We currently have distribution agreements for our CE mark-approved CGuard EPS with medical product distributors based in Europe, the Middle East, Asia Pacific and Latin America. We are currently in discussions with additional distribution companies in Europe, Asia, and Latin America.

 

-27-
 

 

Our distribution agreements stipulate that, while we shall assist in training by providing training materials, marketing guidance, marketing materials, and technical guidance, each distributor will be responsible for carrying out local registration, sales and marketing activities. In addition, in most cases, all sales costs, including sales representatives, incentive programs, and other marketing activities, will be borne by the distributor. Under current agreements, distributors purchase stents from us at a fixed price. Our current agreements with distributors are generally for a term of two to three years.

 

On February 3, 2021, we entered into a Distribution Agreement with three China-based partners, pursuant to which the Chinese partners will be responsible for conducting the necessary registration trials for commercial approval of our products in China, followed by an exclusive distribution right to sell our products in China. Under the Distribution Agreement, the China-based partners will be subject to minimum purchase obligations.

 

Manufacturing and Suppliers

 

The polymer fiber for MicroNet is supplied by Biogeneral, Inc., a San Diego, California-based specialty polymer manufacturer for medical and engineering applications.

 

Our catheter supplier for CGuard EPS supplies us with catheters that help create the base for our CGuard EPS stents. Our agreement with the supplier may be terminated by us upon eight months’ notice. On September 17, 2019, we amended the agreement with the supplier so that we are responsible for purchasing and handling inventory of components used in the manufacturing of CGuard EPS catheters, and they are responsible for the manufacturing process.

 

Our catheter supplier for CGuard Prime supplies us with catheters that help create the base for our CGuard Prime stent system. Our agreement with the supplier which may be terminated by us upon 9 months’ notice, calls for non-binding minimum orders.

 

We manufacture our CGuard EPS and our CGuard Prime at our own facility. The self-expanding bare-metal stents for our CGuard EPS and our CGuard Prime are being manufactured and supplied by a third-party. Our agreement with the supplier for the production of electro polished L605 bare-metal stents for CGuard EPS and CGuard Prime is priced on a per-stent basis, subject to the quantity of stents ordered. The complete assembly process for CGuard EPS and CGuard Prime, including knitting and securing the sleeved to the stent and the crimping of the sleeved stent in to a delivery catheter, is done at our Israel manufacturing site. Once CGuard EPS and CGuard Prime have been assembled, they are sent for sterilization in a third-party facility in Israel, and then back to our facility for final packaging and distribution.

 

A CGuard EPS and CGuard Prime consists of a CGuard stent and the delivery system. Each CGuard stent is manufactured from two main components, a self-expending nickel-titanium stent and the mesh polymer. This material is readily available and we acquire it in the open market. The mesh is made from polyethylene terephthalate (polyester). We have patent rights that cover the proposed CGuard stent with mesh. During 2022 our mesh supplier informed us that it will not be able to supply the polymer fiber in the future due to issues with raw materials, therefore we purchased inventory which should be sufficient to support our production needs until the end of 2026. We are currently testing a different source of PET showing equivalent mechanical properties of the original raw material. BioGeneral will produce the fiber from the new PET: samples were already produced for preliminary R&D testing. Complete validation process will take up to 18 months. The delivery system for CGuard is made out of polymer tubes we acquire from an original equipment manufacturer. In the event that our supplier can no longer supply this material, we would need to qualify another supplier, which could take up to a year. In addition, in order to retain the approval of the CE mark, we are required to perform periodic audits of the quality control systems of our key suppliers in order to ensure that their products meet our predetermined specifications.

 

-28-
 

 

Human Capital Management

 

As of December 31, 2023, we had 66 employees, 65 full-time and 1 part-time, consisting of 5 in executive management, 6 in research and development, 10 in quality assurance and compliance, 5 in finance and accounting, 26 in operations/production, 11 in sales, marketing and clinical, and 3 in all other miscellaneous roles, Human resources, and administration. Except for 5 of our employees in Europe, our employees are not party to any collective bargaining agreements. We do not expect the collective bargaining agreements to which our employees are party to have a material effect on our business or results of operations. We also employ 2 independent contractors in Poland and 1 in Brazil.

 

We believe that our future success will depend, in part, on our continued ability to attract, hire and retain qualified personnel. In particular, we depend on the skills, experience and performance of our senior management and research personnel. We compete for qualified personnel with other medical device, biotechnology, pharmaceutical and healthcare companies, as well as universities and non-profit research institutions.

 

We provide competitive compensation and benefits programs to help meet the needs of our employees. In addition to salaries, these programs (which vary by country/region and employment classification) include incentive compensation plan, pension, healthcare and insurance benefits, paid time off, family leave, and on-site services, among others. We also use targeted equity-based grants with vesting conditions to facilitate retention of personnel, particularly for our key employees.

 

We consider our relations with our employees to be good.

 

Item 1A. Risk Factors.

 

There are numerous and varied risks, known and unknown, that may prevent us from achieving our goals. You should carefully consider the risks described below and the other information included in this Annual Report on Form 10-K, including the consolidated financial statements and related notes. If any of the following risks, or any other risks not described below, actually occur, it is likely that our business, financial condition, and/or operating results could be materially adversely affected. The risks and uncertainties described below include forward-looking statements and our actual results may differ from those discussed in these forward-looking statements.

 

Summary Risk Factors

 

Our business is subject to numerous risks and uncertainties, including those highlighted in the section titled “Risk Factors” immediately following this prospectus summary. These risks include, among others, the following:

 

  ● we have a history of net losses and may experience future losses;
     
  ● our history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives,
     
  ● we will need to raise additional capital to meet our business requirements in the future, and such capital raising may be costly or difficult to obtain and could dilute our stockholders’ ownership interests;
     
  ● we may become subject to claims by much larger and better capitalized competitors enforcing their intellectual property rights against us or seeking to invalidate our intellectual property or our rights thereto;
     
  ● completing clinical trials for CGuard Carotid Stent System and SwitchGuard NPS in the United States require meeting a number of regulatory requirements and must be conducted in compliance with the FDA’s IDE regulations. Failure to maintain compliance with IDE regulations could have a material adverse effect on our business;
     
  ● clinical trials necessary to support a pre-market approval application will be lengthy and expensive and will require the enrollment of a large number of patients, and suitable patients may be difficult to identify and recruit. Any such delay or failure of clinical trials could prevent us from commercializing our stent products, which would materially and adversely affect our results of operations and the value of our business;

 

-29-
 

 

  ● the results of our clinical trials may be insufficient to obtain regulatory approval for our products;
     
  ● our products may in the future be subject to product notifications, recalls, or voluntary market withdrawals that could harm our reputation, business and financial results;
     
  ● we may be subject, directly or indirectly, to applicable U.S. federal and state anti-kickback, false claims laws, physician payment transparency laws, fraud and abuse laws or similar healthcare and security laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings;
     
  ● we may be exposed to product liability claims and insurance may not be sufficient to cover these claims;
     
  ● even if one or more of our products are approved by the FDA, we may fail to obtain an adequate level of reimbursement for our products by third party payors, such that there may be no commercially viable markets for our products or the markets may be much smaller than expected;
     
  ● in the United States and European Union, our business could be significantly and adversely affected by healthcare reform initiatives and/or other legislation or judicial interpretations of existing or future healthcare laws and/or regulations;
     
  ● if we are unable to obtain and maintain intellectual property protection covering our products, others may be able to make, use or sell our products, which would adversely affect our revenue;

 

  ● we are an international business, and we are exposed to various global and local risks that could have a material adverse effect on our financial condition and results of operations venue;
     
  ● our business, operating results and growth rates may be adversely affected by current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk;
     
  ● there are inherent limitations in all control systems, and misstatements due to error or fraud may occur and not be detected;
     
  ● we anticipate being subject to fluctuations in currency exchange rates because we expect a substantial portion of our revenues will be generated in Euros and U.S. dollars, while a significant portion of our expenses will be incurred in New Israeli Shekels;
     
  ● if there are significant shifts in the political, economic and military conditions in Israel and its neighbours, it could have a material adverse effect on our business relationships and profitability;
     
  ● it may be difficult for investors in the United States to enforce any judgments obtained against us or some of our directors or officers;
     
  ● the market prices of our common stock and our publicly traded warrants are subject to fluctuation and have been and may continue to be volatile, which could result in substantial losses for investors; and
     
  ●

our common stock could be delisted from the Nasdaq Stock Market if we fail to meet its continued listing requirements, including requirements with respect to the market value of publicly-held-shares, market value of listed shares, minimum bid price per share, and minimum stockholder’s equity, among others, and requirements relating to board and committee independence.

 

-30-
 

 

Risks Related to Our Financial Condition

 

We have a history of net losses and may experience future losses.

 

We have yet to establish any history of profitable operations. We reported a net loss of $19.9 million for the fiscal year ended December 31, 2023, and had a net loss of approximately $18.5 million during the fiscal year ended December 31, 2022. As of December 31, 2023, we had an accumulated deficit of $222 million. We expect to incur additional operating losses for the foreseeable future. There can be no assurance that we will be able to achieve sufficient revenues throughout the year or be profitable in the future.

 

We will need to raise additional capital to meet our business requirements in the future, and such capital raising may be costly or difficult to obtain and could dilute our stockholders’ ownership interests.

 

In order for us to pursue our business objectives without materially curtailing our operations, we will need to raise additional capital, which additional capital may not be available on reasonable terms or at all. For instance, we will need to raise additional funds to accomplish the following:

 

  ● furthering our efforts to ultimately seek the FDA approval for commercial sales of CGuard EPS and Switchguard NPS in the United States;
     
  ● development of our current and future products, including CGuard EPS and SwitchGuard NPS enhancements;
     
  ● pursuing growth opportunities, including more rapid expansion and funding regional distribution systems;
     
  ● making capital improvements to improve our infrastructure;
     
  ● hiring and retaining qualified management and key employees;
     
  ● responding to competitive pressures;
     
  ● complying with regulatory requirements such as licensing and registration; and
     
  ● maintaining compliance with applicable laws.

 

In May 2023, we issued four series of Warrants that expire upon the earlier of five years and 20 trading days following the occurrence of certain milestones specific to each series. If the Warrants are exercised in cash in full, this would result in $71.4 million of gross proceeds. There can be no assurance that we will achieve any of the milestones set forth in the Warrants or that the Warrants will be exercised in cash in full.

 

Any additional capital raised through the sale of equity or equity-backed securities may dilute our stockholders’ ownership percentages and could also result in a decrease in the market value of our equity securities.

 

The terms of any securities issued by us in future capital transactions may be more favorable to new investors, and may include preferences, superior voting rights and the issuance of warrants or other derivative securities, which may have a further dilutive effect on the holders of any of our securities then outstanding.

 

In addition, we may incur substantial costs in pursuing future capital financing, including investment banking fees, legal fees, accounting fees, securities law compliance fees, printing and distribution expenses and other costs. We may also be required to recognize non-cash expenses in connection with certain securities we issue, such as convertible notes and warrants, which may adversely impact our financial condition.

 

-31-
 

 

Risk Related to Commercialization of Our Products

 

While we derive most of our revenue from the sale of CGuard EPS in CE marked countries, our ability to generate significant revenues and achieve profitability depends, among other things, on our ability to receive FDA approval of CGuard Prime and SwitchGuard and other products we may develop. If we fail to obtain FDA approval for CGuard Prime, SwitchGuard or any other products we may develop, our results of operations and the value of our business would be materially and adversely affected.

 

We derive most of our revenue from sales of our CGuard EPS in CE marked countries and certain other select jurisdictions. We have not received approvals in the United States and certain other jurisdictions for CGuard Prime and have not received any approvals for SwitchGuard and there can be no assurance that we will be able to receive regulatory approvals to commence marketing and sales for our products in any jusrisdiction where we are seeking approvals. Our ability to generate significant revenues and achieve profitability depends on our ability to successfully obtain required regulatory approvals in the U.S. as well as to demonstrate sufficient clinical evidence and manufacture commercial quantities of our CGuard Prime, SwitchGuard and any other products we may develop at an acceptable cost. In addition, there may be insufficient demand for CGuard Prime, SwitchGuard and any other products we develop. If we fail to generate sufficient revenues from these products, our results of operations and the value of our business and securities would be materially and adversely affected.

 

The future success of our business cannot be determined at this time, and we do not anticipate generating significant revenues from product sales for the foreseeable future. In addition, we have no experience in commercializing our CGuard Prime or any other product we develop on a mass scale and face a number of challenges with respect to our commercialization efforts, including, among others, that:

 

  ● we may not have adequate financial or other resources to demonstrate adequate clinical results, attain required regulatory approvals and licensures, and begin the commercialization efforts for our CGuard Prime, SwitchGuard or any other product we develop in our target markets;
     
  ● we may fail to obtain or maintain required regulatory approvals and licensures for our CGuard Prime, SwitchGuard or any other product we develop in our target markets or may face adverse regulatory or legal actions relating to our products even if regulatory approval is obtained;
     
  ● we may not demonstrate adequate clinical safety and clinical effectiveness results from our CGuard Prime, SwitchGuard or any other product we develop to support regulatory body approval or market acceptance and adoption;
     
  ● We may not be able to scale up the manufacture of our CGuard Prime, SwitchGuard or any other product we develop to commercial quantities at an adequate quality or at an acceptable cost;
     
  ● we may not be able to establish adequate sales, marketing and distribution channels;
     
  ● healthcare professionals and patients may not accept our CGuard Prime, SwitchGuard or any other product we develop;
     
  ● other technological challenges may reduce the demand for our CGuard Prime, SwitchGuard or any other product we develop;
     
  ● new alliances between existing market participants and the entrance of new market participants may interfere with our market penetration efforts;
     
  ● government and private third-party payors may not agree to provide coding, coverage and payment adequate to reimburse healthcare providers and patients for any or all of the purchase price of CGuard Prime, SwitchGuard or any other product we develop which may adversely affect healthcare providers’ and patients’ willingness to purchase our C-Scan system;

 

-32-
 

 

  ● uncertainty as to market demand may result in inefficient pricing of our CGuard Prime, SwitchGuard or any other product we develop;
     
  ● we may not be able to adequately protect our intellectual property or may face third-party claims of intellectual property infringement; and
     
  ● we are dependent upon the results of ongoing clinical studies relating to our CGuard Prime and the products of our competitors.

 

If we are unable to meet any one or more of these challenges successfully, our ability to effectively commercialize CGuard Prime, SwitchGuard or any other product we develop could be limited, which in turn could have a material adverse effect on our business, financial condition and results of operations.

 

Although we completed the enrollment in our C-GUARDIANS trial of the CGuard Carotid Stent System, the outcome of the study is inherently uncertain.

 

In June 2023, we completed enrollment in the C-GUARDIANS trial. We anticipate reporting primary endpoint results from the C-GUARDIANS trial in mid 2024 that may support the submission of a PMA application in the third quarter of 2024 with a view to potential FDA approval of the CGuard Prime stent system in the first half of 2025. Although we reported positive 30-day follow-up data in November 2023, there can be no assurance that the primary endpoint results will be sufficient to support a PMA application or FDA approval, Clinical failure can occur at any stage of clinical development. Our clinical trials have been conducted under differing protocols, while using specific inclusion criteria and we cannot assure you that its actual clinical performances will be satisfactory to support proposed indications and regulatory approvals and clinical acceptance and adoption, or that its use will not result in unanticipated complications. Furthermore, the results of our clinical trials are subject to human analyses and interpretation of the data accumulated, which could be affected by various errors due to, among others, lack of sufficient clinical experience with CGuard EPS, SwitchGuard or any other product we develop, assumptions used in the statistical analysis of results, and interpretation errors in the analysis of the clinical trials results. Failure can occur at any time during the clinical trial process. If CGuard EPS, SwitchGuard or any other product we develop does not function as expected over time, we may not achieve regulatory clearances, and may not be widely adopted by healthcare providers and patients.

 

We plan on self-commercializing CGuard Prime in the U.S. if we receive FDA approval and historically have no experience selling, marketing or distributing products in the U.S.

 

We plan on self-commercializing CGuard Prime in the U.S., subject to receipt of FDA approval. As part of our plan, we intend to build out manufacturing, sales, marketing and distribution capabilities. Historically we have not had experience in manufacturing, selling, marketing or distributing products in the U.S. To be able to commercialize CGuard Prime upon approval, if at all, we must either develop internal manufacturing, sales, marketing and distribution capabilities, which is expensive and time-consuming, or enter into arrangements with third parties to perform these services.

 

There are risks involved with establishing our own manufacturing, sales, marketing and distribution capabilities. We must commit significant financial and managerial resources to develop a manufacturing facility and marketing and sales force with technical expertise and with supporting distribution capabilities. Factors that may inhibit our efforts to commercialize our products directly and without strategic partners include:

 

● our inability to recruit and retain adequate numbers of effective manufacturing, sales and marketing personnel;
   
● the inability of sales personnel to obtain access to or persuade physicians to use our stents;

 

-33-
 

 

● the inability to price our products at a sufficient price point to ensure an adequate and attractive level of profitability;
   
● the difficulty of obtaining reimbursement from governmental and commercial payers;
   
● the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and
   
● unforeseen costs and expenses associated with creating and sustaining an independent manufacturing, sales and marketing organization.

 

We may not be successful in recruiting the manufacturing, sales and marketing personnel necessary to sell CGuard Prime upon approval, if at all, and, even if we do build a sales force, we may not be successful in marketing CGuard Prime, which would have a material adverse effect on our business, financial condition and results of operations.

 

If we are unable to establish our own manufacturing, sales, marketing and distribution capabilities or enter into successful arrangements with third parties to perform these services, any future product revenues and our profitability, may be materially adversely affected.

 

Physicians may not widely adopt our products unless they determine, based on experience, long-term clinical data and published peer reviewed journal articles, among other standard-of-care considerations, that the use of our stents provides a safe and effective alternative to other existing treatments for coronary artery disease and carotid artery disease.

 

We believe that physicians will not widely adopt our products unless they determine, based on experience, long-term clinical data, published peer reviewed journal articles and payor coverage policies, among other factors, that the use of our products provide a safe and effective alternative to other existing treatments for the conditions we are seeking to address.

 

If we fail to demonstrate safety and efficacy that is at least comparable to existing and future therapies available on the market, our ability to successfully market our products will be significantly limited. Even if the data collected from clinical studies or clinical experience indicate positive results, each physician’s actual experience with our products will vary. Clinical trials conducted with our products may involve procedures performed by physicians who are technically proficient and are high-volume stent users of such products. Consequently, both short-term and long-term results reported in these clinical trials may be significantly more favorable than typical results of practicing physicians, which could negatively affect rates of adoptions of our products. We also believe that published peer-reviewed journal articles and recommendations and support by influential physicians regarding our products will be important for market acceptance and adoption, and we cannot assure you that we will receive these recommendations and support, or that supportive articles will be published.

 

If our manufacturing facilities are unable to provide an adequate supply of products, our growth could be limited and our business could be harmed.

 

We currently manufacture CGuard at our facility in Tel Aviv, Israel. If there were a disruption to our existing manufacturing facility, we would have no other means of manufacturing CGuard until we were able to restore the manufacturing capability at our facility or develop alternative manufacturing facilities. If we were unable to produce sufficient quantities of CGuard, SwitchGuard or any other product we develop to meet market demand or for use in our current and planned clinical trials, or if our manufacturing process yields substandard stents, our development and commercialization efforts would be delayed.

 

-34-
 

 

To manufacture CGuard, SwitchGuard and any other product we develop in quantities to meet anticipated market demand if we were to receive FDA approval, we will need to increase manufacturing capacity, which will involve significant challenges. In addition, the development of U.S. commercial-scale, regulation-compliant manufacturing capabilities will require us to invest substantial additional funds and hire and retain the technical personnel who have the necessary manufacturing experience. We may not successfully complete any required increase to existing manufacturing processes in a timely manner, or at all.

 

Additionally, any damage to or destruction of our Tel Aviv facility or its equipment, prolonged power outage or contamination at our facility would significantly impair our ability to produce CGuard.

 

Finally, the production of our stents must occur in a highly controlled, clean environment to minimize particles and other yield and quality-limiting contaminants. In spite of stringent quality controls, weaknesses in process control or minute impurities in materials may cause a substantial percentage of defective products in a lot. If we are unable to maintain stringent quality controls, or if contamination problems arise, our clinical development and commercialization efforts could be delayed, which would harm our business and results of operations.

 

CGuard is a complex medical deice that requires training for qualified personal.

 

CGuard and SwitchGuard are complex medical devices that requires training for qualified personal, including physicians. Although our distributors will be required to ensure that CGuard and SwitchGuard is prescribed only by trained clinicians, the potential for misuse of CGuard and SwitchGuard still exists due to its complexity. Such misuse could result in adverse medical consequences for patients that could damage our reputation, subject us to costly product liability litigation and otherwise have a material adverse effect on our business, financial condition and results of operations.

 

We operate in an intensely competitive and rapidly changing business environment, and there is a substantial risk our products could become obsolete or uncompetitive.

 

The medical device market is highly competitive. We compete with many medical device companies globally in connection with our current products and products under development. We face intense competition from numerous pharmaceutical and biotechnology companies in the therapeutics area, as well as competition from academic institutions, government agencies and research institutions. Abbott Laboratories, Boston Scientific Corporation, Medtronic, Cordis Corporation and Terumo Medical Corporation produce a polytetrafluoroethylene mesh-covered stent and a double layer metal stent, respectively As we develop and seek regulatory approval in the United States and Europe for our new TCAR neuroprotection system SwitchGuard and continue to seek greater market share for CGuard, we expect to compete with Silk Road Medical in the total carotid artery revascularization market that comprises CAS, TCAR and CEA. Most of our current and potential competitors, including but not limited to those listed above, have, and will continue to have, substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do. There can be no assurance that we will have sufficient resources to successfully commercialize our products, if and when they are approved for sale. The worldwide market for stent products is characterized by intensive development efforts and rapidly advancing technology. For example, during the second quarter of 2022 we ceased sales of our MGuard Prime EPS following a phase out period due to a shift in industry preferences. Our future success will depend largely upon our ability to anticipate and keep pace with those developments and advances. Current or future competitors could develop alternative technologies, products or materials that are more effective, easier to use or more economical than what we or any potential licensee develop. If our technologies or products become obsolete or uncompetitive, our related product sales and licensing revenue would decrease. This would have a material adverse effect on our business, financial condition and results of operations.

 

-35-
 

 

We may become subject to claims by much larger and better capitalized competitors enforcing their intellectual property rights against us or seeking to invalidate our intellectual property or our rights thereto.

 

Based on the prolific litigation that has occurred in the stent industry and the fact that we may pose a competitive threat to some large and well-capitalized companies that own or control patents relating to stents and their use, manufacture and delivery, we believe that it is possible that one or more third parties will assert a patent infringement claim against the manufacture, use or sale of our stents based on one or more of these patents. These companies also own patents relating to the use of drugs to treat restenosis, stent architecture, catheters to deliver stents, and stent manufacturing and coating processes and compositions, as well as general delivery mechanism patents like rapid exchange, which might be alleged to cover one or more of our products. In addition, it is possible that a lawsuit of which we are not aware asserting patent infringement, misappropriation of intellectual property, or related claims may have already been filed against us. As the number of competitors in the stent market grows and as the geographies in which we commercially market grow in number and scope, the possibility of patent infringement by us, and/or a patent infringement or misappropriation claim against us, increases.

 

Our competitors have maintained their positions in the market by, among other things, establishing intellectual property rights relating to their products and enforcing these rights aggressively against their competitors and new entrants into the market. All the major companies in the field of stents and related markets, including Boston Scientific, C.R. Bard, Inc., W.L. Gore & Associates and Medtronic, have been repeatedly involved in patent litigation relating to stents since at least 1997. The field of stents and related markets have experienced rapid technological change and obsolescence in the past, and our competitors have strong incentives to stop or delay the introduction of new products and technologies. We may pose a competitive threat to many of the companies in these markets. Accordingly, these companies will have a strong incentive to take steps, through patent litigation or otherwise, to prevent us from distributing our products. Such litigation or claims would divert attention and resources away from the development and/or commercialization of our products and could result in an adverse court judgment that would make it impossible or impractical to sell our products in one or more territories.

 

If we fail to maintain or establish satisfactory agreements or arrangements with suppliers or if we experience an interruption of the supply of materials from suppliers, we may not be able to obtain materials that are necessary to develop our products.

 

We depend on outside suppliers for certain raw materials. These raw materials or components may not always be available at our standards or on acceptable terms, if at all, and we may be unable to locate alternative suppliers or produce necessary materials or components on our own.

 

Some of the components of our products are currently provided by only one vendor, or a single-source supplier. We may have difficulty obtaining similar components from other suppliers that are acceptable to the FDA or foreign regulatory authorities if it becomes necessary. During 2022, our mesh supplier informed us that it will not be able to supply the polymer fiber in the future due to issues with raw materials, therefore we purchased inventory which should be sufficient to support our production needs until the middle of 2028. We are currently testing a different source of PET showing equivalent mechanical properties of the original raw material however there can be no assurance that the alternative source will result in successful validation and if we are unable to timely source an alternative supplier this could result regulatory delays and the interruption of our manufacturing and delivery of stents for an extended period of time which would delay completion of our clinical trials or commercialization of our products.

 

In addition, we will be required to obtain prior regulatory approval from the FDA or foreign regulatory authorities to use different suppliers or components that may not be as safe or as effective. As a result, regulatory approval of our products may not be received on a timely basis or at all.

 

Finally, we rely on a third-party vendor to perform the sterilization process. A third-party vendor’s failure to properly sterilize a component may cause delays or disruptions in our manufacturing process.

 

If there is a renewed outbreak of the COVID-19 pandemic, it may have a significant adverse effect on our business.

 

In the past, we were impacted by the COVID-19 pandemic, which has caused interruptions or delays of our business plan. If there is a renewed outbreak of COVID-19 it may result in restrictions and safety measures that could cause fluctuations in sales of our products, ability to manufacture, as well as potential disruptions to our supply chain.

 

-36-
 

 

In addition, if there is a renewed outbreak of COVID-19, this may cause disruptions that could have a material adverse impact on our FDA clinical trial plans and timelines, including:

 

  ● Delays in receiving authorizations from local regulatory authorities, ethics committees and institutional review boards to initiate planned clinical trials;
     
  ● Delays or difficulties in enrolling patients in our clinical trials;
     
  ● Delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;
     
  ● Delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including interruptions in global shipping that may affect the transport of clinical trial materials;
     
  ● Changes in local regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;
     
  ● Diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;
     
  ● Diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;
     
  ● Interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others, or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the integrity of clinical trial data;
     
  ● Risk that participants enrolled in our clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events;
     
  ● Delays in necessary interactions with local regulators, ethics committees and other third parties and contractors due to limitations in employee resources or forced furlough of government employees;
     
  ● Limitations in employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; and
     
  ● Refusal of the FDA to accept data from clinical trials in affected geographies.

 

Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the delay or denial of regulatory approvals or clearances of our product.

 

The extent to which any future outbreak of COVID-19 will impact our results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the virus.

 

Increasing inflation could adversely affect our business, financial condition, results of operations or cash flows.

 

Inflation and some of the measures taken by or that may be taken by the governments in countries where we operate in an attempt to curb inflation may have negative effects on the economies of those countries generally. If the United States or other countries where we operate experience substantial inflation in the future, our business may be adversely affected. This could have a material adverse impact on our business, financial condition, results of operations or cash flows.

 

-37-
 

 

Risks Related to our Clinical Trials and Regulatory Matters

 

Completing clinical trials for CGuard, SwitchGuard or any other product we develop in the United States require meeting a number of regulatory requirements and must be conducted in compliance with the FDA’s IDE regulations. Failure to maintain compliance with IDE regulations could have a material adverse effect on our business.

 

Clinical trials involve use of a medical device on human subjects under the supervision of qualified investigators in accordance with current Good Clinical Practices, including the requirement that all research subjects provide informed consent for their participation in the clinical study. The FDA classifies medical device candidates into “significant risk” and “non-significant risk” devices. Significant risk devices present a potential for serious risk to the health, safety, or welfare of a subject. Examples may include implants, devices that support or sustain human life, and devices that are substantially important in diagnosing, curing, mitigating, or treating disease or in preventing impairment to human health. If a medical device candidate presents a significant risk, an IDE application must be submitted and approved prior to commencing any human clinical trials in the United States in connection with such device.

 

In addition to our IDE approval, we must apply for and obtain IRB approval in connection with each clinical site before commencing any study activities. A written protocol with predefined end points, an appropriate sample size, and pre-determined patient inclusion and exclusion criteria, is also required before we may initiate or conduct the trial.

 

Importantly, the C-GUARDIANS trial and any others that we are conducting or may conduct in the future, must be conducted in accordance with the FDA’s IDE regulations, which, among other things, establish requirements for investigational device labeling, prohibit pre-approval promotion of a device candidate, and specify recordkeeping, reporting, and monitoring responsibilities of study sponsors and study investigators.

 

We may not be able to obtain IRB approval to undertake clinical trials in the United States for any products we intend to market in the United States in the future. If we do obtain such approvals, we may not be able to conduct studies which comply with the IDE and other regulations governing clinical investigations or the data from any such trials may not support clearance or approval of the investigational device. Failure to obtain such approvals or to comply with such regulations could have a material adverse effect on our business, financial condition and results of operations.

 

Relatedly, certainty that clinical trials must meet FDA requirements, including desired endpoints, produce meaningful or useful data, and be free of unexpected adverse effects, or that the FDA will accept the validity of foreign clinical study data, as applicable, cannot be guaranteed, and such uncertainty could preclude or delay regulatory approvals and commercialization, resulting in significant financial costs and reduced revenue. Moreover, the timing of the commencement, continuation, and completion of any future clinical trial may be subject to significant delays attributable to various causes, including, but not limited to, scheduling conflicts with participating clinicians and clinical institutions, difficulties in identifying and enrolling patients who meet trial eligibility criteria, failure of patients to complete the clinical trial, delay in or failure to meet regulatory and/or IRB requirements to conduct a clinical trial at a one or more prospective sites, and shortages of supply in the investigational device.

 

-38-
 

 

Clinical trials necessary to support a PMA application are lengthy and expensive and require the enrollment of a large number of patients, and suitable patients may be difficult to identify and recruit. Any such delay or failure of clinical trials could prevent us from commercializing our stent products, which would materially and adversely affect our results of operations and the value of our business.

 

Clinical trials necessary to support a pre-market approval application to the FDA for our products, including CGuard, SwitchGuard and any other product we develop stent are expensive and require the enrollment of a large number of patients, and suitable patients may be difficult to identify and recruit, which may cause a delay in the development and commercialization of our products. Patient enrollment in clinical trials and the ability to successfully complete patient follow-up depends on many factors, including the size of the patient population, the nature of the trial protocol, the proximity of patients to clinical sites, the eligibility criteria for the clinical trial and patient compliance. For example, patients may be discouraged from enrolling in our clinical trials if the trial protocol requires them to undergo extensive post-treatment procedures or follow-up to assess the safety and efficacy of our products, or they may be persuaded to participate in contemporaneous clinical trials of competitive products. In addition, patients participating in our clinical trials may die before completion of the trial or suffer adverse medical events unrelated to or related to our products. Delays in patient enrollment or failure of patients to continue to participate in a clinical trial, including during a follow-up period, may cause an increase in costs and delays or result in the failure of the clinical trial.

 

In addition, the length of time required to complete clinical trials for pharmaceutical and medical device products varies substantially according to the degree of regulation and the type, complexity, novelty and intended use of a product, and can continue for several years and cost millions of dollars. The commencement and completion of clinical trials for our products under development may be delayed by many factors, including governmental or regulatory delays and changes in regulatory requirements, policy and guidelines or our inability or the inability of any potential licensee to manufacture or obtain from third parties materials sufficient for use in preclinical studies and clinical trials.

 

The results of our C-GUARDIANS trial as well as any other clinical trials may be insufficient to obtain regulatory approval for our products.

 

We will only receive regulatory approval to commercialize CGuard Prime, SwitchGuard or any other product we develop if we can demonstrate to the satisfaction of the FDA or the applicable foreign regulatory agency, in well designed and conducted clinical trials, that the product is safe and effective. If we are unable to demonstrate that a product is safe and effective in advanced clinical trials involving large numbers of patients, we will be unable to submit the necessary application to receive regulatory approval to commercialize the product. We face risks that:

 

  ● the product may not prove to be safe or effective;
     
  ● the product’s benefits may not outweigh its risks;
     
  ● the results from advanced clinical trials may not confirm the positive results from pre-clinical studies and early clinical trials;
     
  ● the FDA or comparable foreign regulatory authorities may interpret data from pre-clinical and clinical testing in different ways than us; and
     
  ● the FDA or other regulatory agencies may require additional or expanded trials and data.

 

Patients may discontinue their participation in our clinical studies, which may negatively impact the results of these studies and extend the timeline for completion of our development programs.

 

Clinical trials for our products require sufficient patient enrollment. We may not be able to enroll a sufficient number of patients in a timely or cost-effective manner. Patients enrolled in our clinical studies may discontinue their participation at any time during the study as a result of a number of factors, including withdrawing their consent or experiencing adverse clinical events, which may or may not be judged to be related to our products under evaluation. If a large number of patients in a study discontinue their participation in the study, the results from that study may not be positive or may not support a filing for regulatory approval of the product.

 

In addition, the time required to complete clinical trials is dependent upon, among other factors, the rate of patient enrollment. Patient enrollment is a function of many factors, including the following:

 

  ● the size of the patient population;
     
  ● the nature of the clinical protocol requirements;
     
  ● the availability of other treatments or marketed therapies (whether approved or experimental);

 

-39-
 

 

  ● our ability to recruit and manage clinical centers and associated trials;
     
  ● the proximity of patients to clinical sites; and
     
  ● the patient eligibility criteria for the study.

 

Even if CGuard Prime, SwitchGuard or any other product we develop receives marketing approval, we or others may later discover that the product is less effective than previously believed or causes undesirable side effects that were not previously identified, which could compromise our ability or that of any collaborators to market the product, and could cause regulatory authorities to take certain regulatory actions.

 

It is possible that our clinical trials may indicate an apparent positive effect of a product that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. For example, we, or others, may discover that our products are less safe and effective than previously believed. If, we, or others, discover that a product is less effective than previously believed or causes undesirable side effects that were not previously identified, any of the following adverse events could occur:

 

  ● regulatory authorities may withdraw their approval of the product or seize the product;
  ● we, or any of our collaborators, may be required to recall the product, change the way the product is administered or conduct additional clinical trials;
  ● additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the particular product;
  ● we, or any of our collaborators, may be subject to fines, injunctions or the imposition of civil or criminal penalties;
  ● regulatory authorities may require the addition of labeling statements, such as a “black box” warning or a contraindication including with the product;
  ● we, or any of our collaborators, may be required to create a Medication Guide outlining the risks of the previously unidentified side effects for distribution to patients;
  ● we could be sued and held liable for harm caused to patients;
  ● physicians and patients may stop using our product; and
  ● our reputation may suffer.

 

Any of these events could harm our business and operations and could negatively impact our stock price.

 

Our products may in the future be subject to product notifications, recalls, or voluntary market withdrawals that could harm our reputation, business and financial results.

 

After regulatory approval has been obtained for medical device products, the product and the manufacturer are subject to continual review, including the review of adverse events and clinical results that are reported after our products are made available to patients, and there can be no assurance that such approval will not be withdrawn or restricted. Regulators may also subject approvals to restrictions or conditions or impose post-approval obligations on the holders of these approvals, and the regulatory status of such products may be jeopardized if such obligations are not fulfilled. If post-approval studies are required, such studies may involve significant time and expense.

 

The manufacturing and marketing of medical devices involves an inherent risk that our products may prove to be defective and cause a health risk even after regulatory clearances have been obtained. Medical devices may also be modified after regulatory clearance is obtained to such an extent that additional regulatory clearance is necessary before the device can be further marketed. In these events, we may voluntarily implement a recall or market withdrawal or may be required to do so by a regulatory authority.

 

 -40- 

 

 

In the European Economic Area, we must comply with the EU Medical Device Vigilance System. Under this system, manufacturers are required to take Field Safety Corrective Actions (“FSCAs”) to reduce a risk of death or serious deterioration in the state of health associated with the use of a medical device that is already placed on the market. A FSCA may include the recall, modification, exchange, destruction or retrofitting of the device. FSCAs must be communicated by the manufacturer or its legal representative to its customers and/or to the end users of the device through Field Safety Notices.

 

Any adverse event involving our products could result in other future voluntary corrective actions, such as recalls or customer notifications, or agency action, such as inspection or enforcement action. Adverse events have been reported to us in the past, and we cannot guarantee that they will not occur in the future. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, would require the dedication of our time and capital, distract management from operating our business and could harm our reputation and financial results.

 

We have only limited experience in regulatory affairs, which may affect our ability, or the time required, to navigate complex regulatory requirements and obtain necessary regulatory approvals, if such approvals are received at all. Regulatory delays or denials may increase our costs, cause us to lose revenue and materially and adversely affect our results of operations and the value of our business.

 

Because long-term success measures have not been completely validated for our products, especially CGuard, SwitchGuard and any other product we may develop, regulatory agencies may take a significant amount of time in evaluating product approval applications. Treatments may exhibit a favorable measure using one metric and an unfavorable measure using another metric. Any change in accepted metrics may result in reconfiguration of, and delays in, our clinical trials. Additionally, we have only limited experience in filing and prosecuting the applications necessary to gain regulatory approvals, and our clinical, regulatory and quality assurance personnel are currently composed of only ten employees. As a result, we may experience delays in connection with obtaining regulatory approvals for our products.

 

In addition, the products we and any potential licensees license, develop, manufacture and market are subject to complex regulatory requirements, particularly in the United States, Europe and Asia, which can be costly and time-consuming. There can be no assurance that such approvals will be granted on a timely basis, if at all. Furthermore, there can be no assurance of continued compliance with all regulatory requirements necessary for the manufacture, marketing and sale of the products we will offer in each market where such products are expected to be sold, or that products we have commercialized will continue to comply with applicable regulatory requirements. If a government regulatory agency were to conclude that we were not in compliance with applicable laws or regulations, the agency could institute proceedings to detain or seize our products, issue a recall, impose operating restrictions, enjoin future violations and assess civil and criminal penalties against us, our officers or employees and could recommend criminal prosecution. Furthermore, regulators may proceed to ban, or request the recall, repair, replacement or refund of the cost of, any device manufactured or sold by us. Furthermore, there can be no assurance that all necessary regulatory approvals will be obtained for the manufacture, marketing and sale in any market of any new product developed or that any potential licensee will develop using our licensed technology.

 

Even if our products are approved by regulatory authorities, if we or our suppliers fail to comply with ongoing regulatory requirements, or if we experience unanticipated problems with our products, these products could be subject to restrictions or withdrawal from the market.

 

Any regulatory approvals that we receive for our products will require surveillance to monitor the safety and efficacy of the product and may require us to conduct post-approval clinical studies. In addition, if a regulatory authority approves our products, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our products will be subject to extensive and ongoing regulatory requirements.

 

 -41- 

 

 

Moreover, if we obtain regulatory approval for any of our products, we will only be permitted to market our products for the indication approved by the regulatory authority, and such approval may involve limitations on the indicated uses or promotional claims we may make for our products. In addition, later discovery of previously unknown problems with our products, including adverse events of unanticipated severity or frequency, or with our suppliers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:

 

  ● restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market, or voluntary or mandatory product recalls;
     
  ● fines, warning letters, or untitled letters;
     
  ● holds on clinical trials;
     
  ● refusal by the regulatory authority to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;
     
  ● product seizure or detention, or refusal to permit the import or export of our products; and
     
  ● injunctions, the imposition of civil penalties or criminal prosecution.

 

The FDA also requires that our sales and marketing efforts, as well as promotions, be consistent with various laws and regulations. Approved medical device promotions must be consistent with and not contrary to labeling, balanced, truthful and not false or misleading, adequately substantiated (when required), and include adequate directions for use. In addition to the requirements applicable to approved products, we may also be subject to enforcement action in connection with any promotion of an investigational new device. A sponsor or investigator, or any person acting on behalf of a sponsor or investigator, may not represent in a promotional context that an investigational new device is safe or effective for the purposes for which it is under investigation or otherwise promote the device.

 

If the FDA investigates our marketing and promotional materials or other communications and finds that any of our investigational devices, or future commercial products, if any, are being marketed or promoted in violation of the applicable regulatory restrictions, we could be subject to the enforcement actions listed above, among others. Any enforcement action (or related lawsuit, which could follow such action) brought against us in connection with alleged violations of applicable device promotion requirements, or prohibitions, could harm our business and our reputation, as well as the reputation of any devices that may be approved for marketing in the U.S. in the future.

 

The applicable regulatory authorities’ policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our products. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.

 

Failure to obtain regulatory approval in foreign jurisdictions will prevent us from marketing our products in such jurisdictions.

 

We market CGuard EPS in certain international markets. In order to market any our products in other foreign jurisdictions, we must obtain separate regulatory approvals from the appropriate governing body in each applicable country. The approval processes vary among countries and can involve additional testing, and the time required to obtain approval may differ from that required to obtain CE mark or FDA approval. Foreign regulatory approval processes may include all of the risks associated with obtaining CE mark or FDA approval in addition to other risks. We may not obtain foreign regulatory approvals on a timely basis, if at all. CE mark approval or any future FDA approval does not ensure approval by regulatory authorities in other countries. We may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products in certain markets.

 

 -42- 

 

 

We are, or may be, subject to federal, state and foreign healthcare laws and regulations and implementation of or changes to such healthcare laws and regulations could adversely affect our business and results of operations.

 

In both the United States and certain foreign jurisdictions, there are laws and regulations specific to the healthcare industry which may affect all aspects of our business, including development, testing, marketing, sales, pricing, and reimbursement. Additionally, there have been a number of legislative and regulatory proposals in recent years to change the healthcare system in ways that could impact our ability to sell our products. If we are found to be in violation of any of these laws or any other federal or state regulations, we may be subject to administrative, civil and/or criminal penalties, damages, fines, individual imprisonment, exclusion from federal healthcare programs and the restructuring of our operations. Any of these could have a material adverse effect on our business and financial results. Since many of these laws have not been fully interpreted by the courts, there is an increased risk that we may be found in violation of one or more of their provisions. Any action against us for violation of these laws, even if we ultimately are successful in our defense, will cause us to incur significant legal expenses and divert our management’s attention away from the operation of our business.

 

We may be subject, directly or indirectly, to applicable U.S. federal and state anti-kickback, false claims laws, physician payment transparency laws, fraud and abuse laws or similar healthcare and security laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.

 

Healthcare providers, physicians and others will play a primary role in the recommendation, ordering and utilization of any products for which we obtain regulatory approval. If we obtain U.S. Food & Drug Administration approval for any of our products and begin commercializing those products in the United States, our operations may be subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal False Claims Act, and physician payment sunshine laws and regulations. These laws may impact, among other things, our potential sales, marketing and education programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include:

 

● the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs;

 

● federal civil and criminal false claims laws and civil monetary penalty laws, including the False Claims Act, which may be pursued through civil whistleblower or qui tam actions, impose criminal and civil penalties against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval from Medicare, Medicaid or other third-party payors that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;

 

● federal criminal statutes created through the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;

 

● HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and their respective implementing regulations, which imposes requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information;

 

● the federal transparency requirements under The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act, enacted into law in the United States in March 2010 (known collectively as the “Affordable Care Act”), including the provision commonly referred to as the Physician Payments Sunshine Act, which requires manufacturers of drugs, biologics, devices and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program to report annually to the U.S. Department of Health and Human Services information related to payments or other transfers of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and

 

 -43- 

 

 

● state and federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.

 

Additionally, we may be subject to state and non-U.S. equivalents of each of the healthcare laws described above, among others, some of which may be broader in scope and may apply regardless of the payor. Many U.S. states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare services reimbursed by any source, not just governmental payors, including private insurers. Several states impose marketing restrictions or require medical device companies to make marketing or price disclosures to the state. There are ambiguities as to what is required to comply with these state requirements, and if we fail to comply with an applicable state law requirement, we could be subject to penalties.

 

Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our future business activities could be subject to challenge under one or more of such laws. In addition, healthcare reform legislation has strengthened these laws. For example, the Affordable Care Act, among other things, amended the intent requirement of the federal Anti-Kickback and criminal healthcare fraud statutes. As a result of such amendment, a person or entity no longer needs to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation. Moreover, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.

 

Violations of fraud and abuse laws may be punishable by criminal and/or civil sanctions, including penalties, fines and/or exclusion or suspension from federal and state healthcare programs such as Medicare and Medicaid and debarment from contracting with the U.S. government. In addition, private individuals have the ability to bring actions on behalf of the U.S. government under the False Claims Act as well, as under the false claim laws of several states.

 

Efforts to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our existing or future business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. Any such actions instituted against us could have a significant adverse impact on our business, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Even if we are successful in defending against such actions, we may nonetheless be subject to substantial costs, reputational harm and adverse effects on our ability to operate our business. In addition, the approval and commercialization of any of our products outside the United States will also likely subject us to non-U.S. equivalents of the healthcare laws mentioned above, among other non-U.S. laws.

 

If any of our employees, agents, or the physicians or other providers or entities with whom we expect to do business are found to have violated applicable laws, we may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs, or, if we are not subject to such actions, we may suffer reputational harm for conducting business with persons or entities found, or accused of being, in violation of such laws. Any such events could adversely affect our ability to operate our business and our results of operations.

 

 -44- 

 

 

We may be exposed to product liability claims and insurance may not be sufficient to cover these claims.

 

We may be exposed to product liability claims based on the use of any of our products, or products incorporating our licensed technology, in the market or clinical trials. We may also be exposed to product liability claims based on the sale of any products under development following the receipt of regulatory approval. Product liability claims could be asserted directly by consumers, health-care providers or others. We have obtained product liability insurance coverage; however, such insurance may not provide full coverage for our future clinical trials, products to be sold, and other aspects of our business. Insurance coverage is becoming increasingly expensive, and we may not be able to maintain current coverage or expand our insurance coverage to include future clinical trials or the sale of new products or existing products in new territories, at a reasonable cost or in sufficient amounts to protect against losses due to product liability or at all. A successful product liability claim, or series of claims brought against us could result in judgments, fines, damages and liabilities that could have a material adverse effect on our business, financial condition and results of operations. We may incur significant expense investigating and defending these claims, even if they do not result in liability. Moreover, even if no judgments, fines, damages or liabilities are imposed on us, our reputation could suffer, which could have a material adverse effect on our business, financial condition and results of operations.

 

Even if one or more of our products are approved by the FDA, we may fail to obtain an adequate level of reimbursement for our products by third party payors, such that there may be no commercially viable markets for our products, or the markets, may be much smaller than expected.

 

The availability and levels of reimbursement by governmental and other third-party payors affect the market for our products. The efficacy, safety, performance and cost-effectiveness of our products and of any competing products are factors that may impact the availability and level of reimbursement. Reimbursement and healthcare payment systems in international markets vary significantly by country and include both government sponsored healthcare and private insurance. To obtain reimbursement or pricing approval in some countries, we may be required to produce clinical data, which may involve one or more clinical trials that compares the cost-effectiveness of our products to other available therapies. We may not obtain international reimbursement or pricing approvals in a timely manner, if at all. Our failure to receive international reimbursement or pricing approvals would negatively impact market acceptance of our products in the international markets in which those approvals are sought.

 

We believe that future reimbursement may be subject to increased restrictions both in the U.S. and in international markets. There is increasing pressure by governments worldwide to contain healthcare costs by limiting both the coverage and the level of reimbursement for therapeutic products and by refusing, in some cases, to provide any coverage for products that have not been approved by the relevant regulatory agency. Future legislation, regulation or reimbursement policies of third party payors may adversely affect the demand for our products and limit our ability to sell our products on a profitable basis. In addition, third party payors continually attempt to contain or reduce the costs of healthcare by challenging the prices charged for healthcare products and services. If reimbursement for our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, market acceptance of our products would be impaired, and future revenues, if any, would be adversely affected.

 

In the United States and European Union, our business could be significantly and adversely affected by healthcare reform initiatives and/or other legislation or judicial interpretations of existing or future healthcare laws and/or regulations.

 

The Affordable Care Act, signed into law in the United States in March 2010, contains certain provisions which can be modified through the regulatory process and for which it is unclear what the full impact and changes will be under the law.

 

The law also focuses on a number of provisions aimed at improving quality, broadening access to health insurance, enhancing remedies for fraud and abuse, adding transparency requirements, and decreasing healthcare costs, among others. Uncertainties remain regarding what negative unintended consequences these provisions will have on patient access to new technologies, pricing and the market for our products, and the healthcare industry in general. The Affordable Care Act includes provisions affecting the Medicare program, such as value-based payment programs, increased funding of comparative effectiveness research, reduced hospital payments for avoidable readmissions and hospital acquired conditions, and pilot programs to evaluate alternative payment methodologies that promote care coordination (such as bundled physician and hospital payments). Additionally, the provisions include a reduction in the annual rate of inflation for hospitals which started in 2011 and the establishment of an independent payment advisory board to recommend ways of reducing the rate of growth in Medicare spending. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.

 

 -45- 

 

 

Since its enactment, there have been judicial and Congressional challenges to certain aspects of the Affordable Care Act, to modify, repeal or otherwise invalidate all, or certain provisions of, the Affordable Care Act. Following the enactment of the Tax Act, on December 14, 2018 in a case in the United States District Court for the Northern District of Texas, a federal judge ruled that the individual mandate imposed by the Affordable Care Act is unconstitutional and inseverable from the other provisions of the Affordable Care Act and, therefore, the remaining provisions of the Affordable Care Act are invalid. On November 10, 2020, the United States Supreme Court heard arguments on whether the Affordable Care Act is constitutional, in whole or in part, and determined that the case lacked standing. The regulatory process of implementation of the Affordable Care Act will remain ongoing and may also increase our regulatory burdens and operating costs. Litigation and legislation related to the Affordable Care Act are likely to continue, with unpredictable and uncertain results. We cannot predict with certainty what affect further changes to the Affordable Care Act, and other similar health care laws that are enacted, would have on our business.

 

In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. These changes included aggregate reductions to Medicare payments to providers of up to two percent per fiscal year, which will remain in effect through 2027 unless additional Congressional action is taken. It is unclear what impact new quality and payment programs may have on our business, financial condition, results of operations or cash flows. Individual states in the United States have also become increasingly aggressive in passing legislation and implementing regulations designed to control product pricing, including price or patient reimbursement constraints, and discounts, and require marketing cost disclosure and transparency measures. We believe that additional state and federal health care reform measures may be adopted in the future that could have a material adverse effect on our industry generally and on our customers. Any changes in, or uncertainty with respect to, future reimbursement rates could impact our customers’ demand for our products, which in turn could have a material adverse effect on our business, financial condition, results of operations, or cash flows. Further, the federal, state and local governments, Medicare, Medicaid, managed care organizations, and foreign governments have in the past considered, are currently considering, and may in the future consider healthcare policies and proposals intended to curb rising healthcare costs, including those that could significantly affect both private and public reimbursement for healthcare services. Future significant changes in the healthcare systems in the United States or other countries, including changes intended to reduce expenditures along with uncertainty about whether and how changes may be implemented, could have a negative impact on the demand for our products. We are unable to predict with certainty whether other healthcare policies, including policies stemming from legislation or regulations affecting our business, may be proposed or enacted in the future; what effect such policies would have on our business; or the effect ongoing uncertainty about these matters will have on our customers’ purchasing decisions.

 

We cannot predict the impact that such actions against the Affordable Care Act and other laws enacted after its enactment will have on our business, and there is uncertainty as to what healthcare programs and regulations may be implemented or changed at the federal and/or state level in the United States, or the effect of any future legislation or regulation. Furthermore, we cannot predict what actions the Biden administration will implement in connection with laws impacting us. However, it is possible that such initiatives could have an adverse effect on our ability to obtain approval and/or successfully commercialize products in the United States in the future. For example, any changes that reduce, or impede the ability to obtain, reimbursement for the type of products we intend to commercialize in the United States (or our products more specifically, if approved) or reduce medical procedure volumes could adversely affect our business plan to introduce our products in the United States.

 

In May 2017, the European parliament and the council of the European Union approved the MDR which has replaced the existing medical device directives (93/42/EEC). The regulations entered into full application in May 26, 2021. The MDR provided a transitional period for placing on the market or putting into service of medical devices, which period was further extended on March 20. 2023, but such transitional provisions are not relevant to our products where already certified under the The MDR imposes stricter requirements on medical device manufacturers and strengthens the supervising competences of the competent authorities of European Union member states, the notified bodies and the authorized representatives. If we fail to comply with the modified regulation and requirements, it can adversely affect our business, operating results and prospects. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of future products.

 

 -46- 

 

 

Risk Factors Related to Our Intellectual Property

 

If we are unable to obtain and maintain intellectual property protection covering our products, others may be able to make, use or sell our products, which would adversely affect our revenue.

 

Our ability to protect our products from unauthorized or infringing use by third parties depends substantially on our ability to obtain and maintain valid and enforceable patents. Similarly, the ability to protect our trademark rights might be important to prevent third party counterfeiters from selling poor quality goods using our designated trademarks, and trade names. Due to evolving legal standards relating to the patentability, validity and enforceability of patents covering medical devices and pharmaceutical inventions and the scope of claims made under these patents, our ability to enforce patents is uncertain and involves complex legal and factual questions. Accordingly, rights under any of our pending patent applications and patents may not provide us with commercially meaningful protection for our products or may not afford a commercial advantage against our competitors or their competitive products or processes. In addition, patents may not be issued from any pending or future patent applications owned by or licensed to us, and moreover, patents that may be issued to us now or in the future may later be found invalid or unenforceable. Further, even if valid and enforceable, our patents may not be sufficiently broad to prevent others from marketing products like ours, despite our patent rights.

 

The validity of our patent claims depends, in part, on whether prior art references exist that describe or render obvious our inventions as of the filing date of our patent applications. We may not have identified all prior art, such as U.S. and foreign patents or published applications or published scientific literature, that could adversely affect the patentability of our issued patents and pending patent applications. For example, some material references may be in a foreign language and may not be uncovered during examination of our patent applications. Additionally, patent applications in the United States are maintained in confidence for up to 18 months after their filing. In some cases, however, patent applications remain confidential in the U.S. Patent and Trademark Office for the entire time prior to issuance as a U.S. patent. Patent applications filed in countries outside the U.S. are not typically published until at least 18 months from their first filing date. Similarly, publication of discoveries in the scientific or patent literature often lags behind actual discoveries. Therefore, we cannot be certain that we were the first to invent, or the first to file patent applications relating to, our stent technologies and related surgical technologies that we are developing. Third parties may initiate adversarial proceedings, known as an inter-partes review (IPR) in the U.S. Patent and Trademark Office to challenge the validity of our patent claims in the United States. It is possible that we may be unsuccessful in the proceedings, resulting in a loss of some portion or all of our patent rights in the United States.

 

In addition, statutory differences in patentable subject matter among jurisdictions may limit the protection we can obtain on certain of the technologies we develop. The laws of some foreign jurisdictions do not offer the same protection to, or may make it more difficult to effect the enforcement of, proprietary rights as in the United States. This risk may be exacerbated if we move our manufacturing to certain countries in Asia. If we encounter such difficulties or are otherwise precluded from effectively protecting our intellectual property rights in any foreign jurisdictions, our business prospects could be substantially harmed.

 

Our initiation of litigation to enforce our patent rights may prompt adversaries in such litigation to challenge the validity, scope, ownership, or enforceability of our patents. Third parties can sometimes bring challenges against a patent holder to resolve these issues, as well. If a court decides that any such patents are not valid, not enforceable, not wholly owned by us, or are of a limited scope, we may not have the right to stop others from using our inventions. Also, even if our patent rights are determined by a court to be valid and enforceable, they may not be sufficiently broad to prevent others from marketing products similar to ours or designing around our patents, despite our patent rights, nor do they provide us with freedom to operate unimpeded by the patent and other intellectual property rights of others that may cover our products. We may be forced into litigation to uphold the validity of the claims in our patent portfolio, as well as our ownership rights to such intellectual property, and litigation is often an uncertain and costly process.

 

We may not be able to protect our trade secrets adequately. Although we rely on non-disclosure and confidentiality agreements with employees, consultants and other parties to protect, in part, trade secrets and other proprietary technology, these agreements may be breached and we may not have adequate remedies for such breach. Moreover, others may independently develop equivalent proprietary information, and third parties may otherwise gain access to our trade secrets and proprietary knowledge. Any disclosure of confidential data into the public domain or to third parties could allow competitors to learn our trade secrets and use the information in competition against us.

 

 -47- 

 

 

Intellectual property rights of third parties could adversely affect our ability to commercialize our products and services, and we might be required to litigate or obtain licenses from third parties in order to develop or market our products. Such litigation or licenses could be costly or not available on commercially reasonable terms.

 

It is inherently difficult to conclusively assess our freedom to operate without infringing on third-party rights. Our competitive position may be adversely affected if existing patents or patents resulting from patent applications issued to third parties or other third-party intellectual property rights are held to cover our products or services or elements thereof, or our manufacturing or uses relevant to our development plans. In such cases, we may not be in a position to develop or commercialize products or services unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned or enter into a license agreement with the intellectual property right holder, if available on commercially reasonable terms. There may also be pending patent applications that if they result in issued patents, could be alleged to be infringed by our new products or services. If such an infringement claim should be brought and be successful, we may be required to pay substantial damages, be forced to abandon our new products or services or seek a license from any patent holders. No assurances can be given that a license will be available on commercially reasonable terms, if at all.

 

It is also possible that we have failed to identify relevant third-party patents or applications. For example, certain U.S. patent applications that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our new products or services could have been filed by others without our knowledge. Additionally, pending patent applications can, subject to certain limitations, be later amended in a manner that could cover our services, our new products or the use of our new products. Third-party intellectual property right holders may also actively bring infringement claims against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in pursuing the development of and/or marketing our new products or services. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing our new products or services that are held to be infringing. We might, if possible, also be forced to redesign our new products so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.

 

Patent policy and rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any issued patents.

 

Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of any patents that may issue from our patent applications or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. We therefore cannot be certain that we were the first to file the invention claimed in our owned and licensed patent or pending applications, or that we or our licensor were the first to file for patent protection of such inventions. Assuming all other requirements for patentability are met, in the United States prior to March 15, 2013, the first to make the claimed invention without undue delay in filing, is entitled to the patent, while generally outside the United States, the first to file a patent application is entitled to the patent. After March 15, 2013, under the Leahy-Smith America Invents Act, or the Leahy-Smith Act, enacted on September 16, 2011, the United States has moved to a first to file system. The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications are prosecuted and also affect patent litigation. In general, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any issued patents, all of which could have a material adverse effect on our business and financial condition.

 

 -48- 

 

 

We may be involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming, and unsuccessful.

 

Competitors may infringe our intellectual property. If we were to initiate legal proceedings against a third-party to enforce a patent covering one of our products or services, the defendant could counterclaim that the patent covering our product is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the United States Patent and Trademark Office, or USPTO, or made a misleading statement, during prosecution. Under the Leahy-Smith Act, the validity of U.S. patents may also be challenged in post-grant and inter partes review proceedings before the USPTO. The outcome following legal assertions of invalidity and unenforceability is unpredictable.

 

Derivation and interference proceedings initiated by third parties or brought by us may be necessary to determine the priority and ownership of inventions and/or their scope with respect to our patent or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our new products or services to market.

 

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our shares of common stock.

 

Risks Related to Our Business Operations

 

We face risks associated with litigation and claims.

 

We have in the past and may, in the future, be involved in one or more lawsuits, claims or other proceedings. These suits could concern issues including contract disputes, employment actions, employee benefits, taxes, environmental, health and safety, fraud and abuse, personal injury and product liability matters.

 

Our business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber-security.

 

In the ordinary course of our business, we collect and store sensitive data, including intellectual property, research data, our proprietary business information and that of our suppliers, technical information about our products, clinical trial plans and employee records. Similarly, our third-party providers possess certain of our sensitive data and confidential information. The secure maintenance of this information is critical to our operations and business strategy. Despite the implementation of security measures, our internal computer systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses, malware, ransomware, cyber fraud, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. Any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, encrypted, lost or stolen. Any such access, inappropriate disclosure of confidential or proprietary information or other loss of information, including our data being breached at third-party providers, could result in legal claims or proceedings, liability or financial loss under laws that protect the privacy of personal information, disruption of our operations or our product development programs and damage to our reputation, which could adversely affect our business. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.

 

 -49- 

 

 

The loss of key members of our senior management team or our inability to attract and retain highly skilled scientists and laboratory and field personnel could adversely affect our business.

 

We depend on the skills, experience and performance of our senior management and research personnel. The efforts of each of these persons will be critical to us as we continue to further develop our products, increase sales and broaden our product offerings. If we were to lose one or more of these key employees, we may experience difficulties in competing effectively, developing our technologies and implementing our business strategies. Our research and development programs and commercial laboratory operations depend on our ability to attract and retain highly skilled scientists and technicians. We may not be able to attract or retain qualified scientists and technicians in the future due to the intense competition for qualified personnel among life science businesses. There can be no assurance that we will be able to attract and retain necessary personnel on acceptable terms given the intense competition among medical device, biotechnology, pharmaceutical and healthcare companies, universities and non-profit research institutions for experienced management, scientists, researchers, sales and marketing and manufacturing personnel. If we are unable to attract, retain and motivate our key personnel to accomplish our business objectives, we may experience constraints that will adversely affect our ability to support our operations, and our results of operations may be materially and adversely affected.

 

We are an international business, and we are exposed to various global and local risks that could have a material adverse effect on our financial condition and results of operations.

 

We operate globally and develop and market products in multiple countries. Consequently, we face complex legal and regulatory requirements in multiple jurisdictions, which may expose us to certain financial and other risks. In addition, we are subject to global events beyond our control, including war, public health crises, such as pandemics and epidemics, trade disputes and other international events. Any of these changes could have a material adverse effect on our reputation, business, financial condition or results of operations.

 

For example, in the past we have been impacted by the COVID-19 pandemic which has caused interruptions or delays of our business plan. If there is a renewed outbreak of COVID-19 it may result in restrictions and safety measures that could cause fluctuations in sales of our products, ability to manufacture, as well as potential disruptions to our supply chain.

 

International sales and operations are subject to a variety of risks, including:

 

  ● foreign currency exchange rate fluctuations;
     
  ● greater difficulty in staffing and managing foreign operations;
     
  ● greater risk of uncollectible accounts;
     
  ● longer collection cycles;
     
  ● logistical and communications challenges;
     
  ● potential adverse changes in laws and regulatory practices, including export license requirements, trade barriers, tariffs and tax laws;

 

  ● changes in labor conditions;
     
  ● burdens and costs of compliance with a variety of foreign laws;
     
  ● political and economic instability;
     
  ● the escalation of hostilities in Israel, which could impair our ability to manufacture our products;

 

 -50- 

 

 

  ● increases in duties and taxation;
     
  ● foreign tax laws and potential increased costs associated with overlapping tax structures;
     
  ● greater difficulty in protecting intellectual property;
     
  ● the risk of third party disputes over ownership of intellectual property and infringement of third party intellectual property by our products; and
     
  ● general economic and political conditions in these foreign markets.

 

International markets are also affected by economic pressure to contain reimbursement levels and healthcare costs. Profitability from international operations may be limited by risks and uncertainties related to regional economic conditions, regulatory and reimbursement approvals, competing products, infrastructure development, intellectual property rights protection and our ability to implement our overall business strategy. We expect these risks will increase as we pursue our strategy to expand operations into new geographic markets. We may not succeed in developing and implementing effective policies and strategies in each location where we conduct business. Any failure to do so may harm our business, results of operations and financial condition.

 

Environmental, social and corporate governance (ESG) issues, including those related to climate change and sustainability, may have an adverse effect on our business, financial condition and results of operations and damage our reputation.

 

There is an increasing focus from certain investors, customers, consumers, employees and other stakeholders concerning ESG matters. Additionally, public interest and legislative pressure related to public companies’ ESG practices continue to grow. If our ESG practices fail to meet regulatory requirements or investor, customer, consumer, employee or other shareholders’ evolving expectations and standards for responsible corporate citizenship in areas including environmental stewardship, support for local communities, board of director and employee diversity, human capital management, employee health and safety practices, product quality, supply chain management, corporate governance and transparency, our reputation, brand and employee retention may be negatively impacted, and our customers and suppliers may be unwilling to continue to do business with us.

 

Customers, consumers, investors and other shareholders are increasingly focusing on environmental issues, including climate change, energy and water use, plastic waste and other sustainability concerns. Concern over climate change may result in new or increased legal and regulatory requirements to reduce or mitigate impacts to the environment. Changing customer and consumer preferences or increased regulatory requirements may result in increased demands or requirements regarding plastics and packaging materials, including single-use and non-recyclable plastic products and packaging, other components of our products and their environmental impact on sustainability, or increased customer and consumer concerns or perceptions (whether accurate or inaccurate) regarding the effects of substances present in certain of our products. Complying with these demands or requirements could cause us to incur additional manufacturing, operating or product development costs.

 

If we do not adapt to or comply with new regulations, including the SEC’s published proposed rules that would require companies to provide significantly expanded climate-related disclosures in their periodic reporting, which may require us to incur significant additional costs to comply and impose increased oversight obligations on our management and board of directors, or fail to meet evolving investor, industry or stakeholder expectations and concerns regarding ESG issues, investors may reconsider their capital investment in our Company, we may become subject to penalties, and customers and consumers may choose to stop purchasing our products, if approved for commercialization, which could have a material adverse effect on our reputation, business or financial condition.

 

 -51- 

 

 

Our business, operating results and growth rates may be adversely affected by current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk.

 

Our business depends on the economic health of the global economies. If the conditions in the global economies remain uncertain or continue to be volatile, or if they deteriorate, including as a result of the impact of military conflict, such as the war between Israel and Hamas and Russia and Ukraine, terrorism or other geopolitical events, our business, operating results and financial condition may be materially adversely affected. Economic weakness, inflation and increases in interest rates, limited availability of credit, liquidity shortages and constrained capital spending have at times in the past resulted, and may in the future result, in challenging and delayed sales cycles, slower adoption of new technologies and increased price competition, and could negatively affect our ability to forecast future periods, which could result in an inability to satisfy demand for our products and a loss of market share.

 

In addition, increases in inflation raise our costs for commodities, labor, materials and services and other costs required to grow and operate our business, and failure to secure these on reasonable terms may adversely impact our financial condition. Additionally, increases in inflation, along with the uncertainties surrounding any resurgence of COVID-19, geopolitical developments and global supply chain disruptions, have caused, and may in the future cause, global economic uncertainty and uncertainty about the interest rate environment, which may make it more difficult, costly or dilutive for us to secure additional financing. A failure to adequately respond to these risks could have a material adverse impact on our financial condition, results of operations or cash flows.

 

There can be no assurance that future credit and financial market instability and a deterioration in confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, liquidity shortages, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, or if adverse developments are experienced by financial institutions, it may cause short-term liquidity risk and also make any necessary debt or equity financing more difficult, more costly, more onerous with respect to financial and operating covenants and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to alter our operating plans. In addition, there is a risk that one or more of our service providers, financial institutions, manufacturers, suppliers and other partners may be adversely affected by the foregoing risks, which could directly affect our ability to attain our operating goals on schedule and on budget.

 

We are subject to financial reporting and other requirements that place significant demands on our resources.

 

We are subject to reporting and other obligations under the Securities Exchange Act of 1934, as amended, including the requirements of Section 404 of the Sarbanes-Oxley Act of 2002. Section 404 requires us to conduct an annual management assessment of the effectiveness of our internal controls over financial reporting. These reporting and other obligations place significant demands on our management, administrative, operational, internal audit and accounting resources. Any failure to maintain effective internal controls could have a material adverse effect on our business, operating results and stock price. Moreover, effective internal control is necessary for us to provide reliable financial reports and prevent fraud. If we cannot provide reliable financial reports or prevent fraud, we may not be able to manage our business as effectively as we would if an effective control environment existed, and our business and reputation with investors may be harmed.

 

There are inherent limitations in all control systems, and misstatements due to error or fraud may occur and not be detected.

 

The ongoing internal control provisions of Section 404 of the Sarbanes-Oxley Act of 2002 require us to identify material weaknesses in internal control over financial reporting, which is a process to provide reasonable assurance regarding the reliability of financial reporting for external purposes in accordance with accounting principles generally accepted in the United States. Our management, including our chief executive officer and chief financial officer, does not expect that our internal controls and disclosure controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. In addition, the design of a control system must reflect the fact that there are resource constraints, and the benefit of controls must be relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, in our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple errors or mistakes. Further, controls can be circumvented by individual acts of some persons, by collusion of two or more persons, or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, a control may be inadequate because of changes in conditions, such as growth of the company or increased transaction volume, or the degree of compliance with the policies or procedures may deteriorate. Because of inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

 

 -52- 

 

 

In addition, discovery and disclosure of a material weakness, by definition, could have a material adverse impact on our financial statements. Such an occurrence could discourage certain customers or suppliers from doing business with us and adversely affect how our stock trades. This could in turn negatively affect our ability to access equity markets for capital.

 

Risks Related to Operating in Israel

 

We anticipate being subject to fluctuations in currency exchange rates because we expect a substantial portion of our revenues will be generated in Euros and U.S. dollars, while a significant portion of our expenses will be incurred in New Israeli Shekels.

 

We expect a substantial portion of our revenues will be generated in U.S. dollars and Euros, while a significant portion of our expenses, principally salaries and related personnel expenses, is paid in New Israeli Shekels, or NIS. As a result, we are exposed to the risk that the rate of inflation in Israel will exceed the rate of devaluation of the NIS in relation to the Euro or the U.S. dollar, or that the timing of this devaluation will lag behind inflation in Israel. Because inflation has the effect of increasing the dollar and Euro costs of our operations, it would therefore have an adverse effect on our dollar-measured results of operations. The value of the NIS, against the Euro, the U.S. dollar, and other currencies may fluctuate and is affected by, among other things, changes in Israel’s political and economic conditions. Any significant revaluation of the NIS may materially and adversely affect our cash flows, revenues and financial condition. Fluctuations in the NIS exchange rate, or even the appearance of instability in such exchange rate, could adversely affect our ability to operate our business.

 

If there are significant shifts in the political, economic and military conditions in Israel and its neighbors, it could have a material adverse effect on our business relationships and profitability.

 

Our executive office, sole manufacturing facility and certain of our key personnel are located in Israel. Our business is directly affected by the political, economic and military conditions in Israel and its neighbors. Since the establishment of the State of Israel in 1948, a number of armed conflicts have occurred between Israel and its Arab neighbors.

 

In October 2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel’s border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in extensive deaths, injuries and kidnapping of civilians and soldiers. Following the attack, Israel’s security cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. In addition, since the commencement of these events, there have been continued hostilities along Israel’s northern border with Lebanon (with the Hezbollah terror organization) and southern border (with the Houthi movement in Yemen, as described below). It is possible that hostilities with Hezbollah in Lebanon will escalate, and that other terrorist organizations, including Palestinian military organizations in the West Bank as well as other hostile countries, such as Iran, will join the hostilities. Such clashes may escalate in the future into a greater regional conflict.

 

In connection with the Israeli security cabinet’s declaration of war against Hamas and possible hostilities with other organizations, several hundred thousand Israeli military reservists were drafted to perform immediate military service, including five full time employees in Israel of ours. Although many of such military reservists have since been released, including all our employees, they may be called up for additional reserve duty, depending on developments in the war in Gaza and along Israel’s other borders. Military service call ups that result in absences of personnel from us for an extended period of time may materially and adversely affect our business, prospects, financial condition and results of operations. As of the date hereof, we currently have 56 full-time employees located in Israel.

 

 -53- 

 

 

Since the war broke out on October 7, 2023, our operations have not been adversely affected by this situation, and we have not experienced disruptions to our clinical studies. None of the clinical sites currently participating in our clinical studies are located in Israel however we currently manufacture our CGuard at our facility in Tel Aviv, Israel. If there were a disruption to our existing manufacturing facility or our ability to procure raw materials and ship our products, we would have no other means of manufacturing and distributing CGuard until we were able to restore the manufacturing and distribution capability at our facility or develop alternative manufacturing facilities and distribution capabilities.

 

The intensity and duration of Israel’s current war against Hamas is difficult to predict at this stage, as are such war’s economic implications on the Company’s business and operations and on Israel’s economy in general. If the war extends for a long period of time or expands to other fronts, such as Lebanon, Syria and the West Bank, our operations may be adversely affected.

 

Our commercial insurance does not cover losses that may occur as a result of events associated with war and terrorism. Although the Israeli government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot assure you that this government coverage will be maintained or that it will sufficiently cover our potential damages. Any losses or damages incurred by us could have a material adverse effect on our business. Any armed conflicts or political instability in the region would likely negatively affect business conditions and could harm our results of operations.

 

The continued political instability and hostilities between Israel and its neighbors and any future armed conflict, terrorist activity or political instability in the region could adversely affect our operations in Israel and adversely affect the market price of our shares of common stock. In addition, several organizations and countries may restrict doing business with Israel and Israeli companies have been and are today subjected to economic boycotts. The interruption or curtailment of trade between Israel and its present trading partners could adversely affect our business, financial condition and results of operations.

 

Finally, political conditions within Israel may affect our operations. Israel has held five general elections between 2019 and 2022, and prior to October 2023, the Israeli government pursued extensive changes to Israel’s judicial system, which sparked extensive political debate and unrest. To date, these initiatives have been substantially put on hold. Actual or perceived political instability in Israel or any negative changes in the political environment, may individually or in the aggregate adversely affect the Israeli economy and, in turn, our business, financial condition, results of operations and growth prospects.

 

We may not be able to enforce covenants not-to-compete under current Israeli law.

 

We have non-competition agreements with most of our employees, many of which are governed by Israeli law. These agreements generally prohibit our employees from competing with us or working for our competitors for a specified period following termination of their employment. However, Israeli courts are reluctant to enforce non-compete undertakings of former employees and tend, if at all, to enforce those provisions for relatively brief periods of time in restricted geographical areas and only when the employee has unique value specific to that employer’s business and not just regarding the professional development of the employee. Any such inability to enforce non-compete covenants may cause us to lose any competitive advantage resulting from advantages provided to us by such confidential information.

 

 -54- 

 

 

We may become subject to claims for remuneration or royalties for assigned service invention rights by our employees, which could result in litigation and adversely affect our business.

 

A significant portion of our intellectual property has been developed by our Israeli employees in the course of their employment for us. Under the Israeli Patent Law, 5727-1967 (the “Israeli Patent Law”), inventions conceived by an employee during the term and as part of the scope of his or her employment with a company are regarded as “service inventions,” which belong to the employer, absent a specific agreement between the employee and employer giving the employee service invention rights. The Israeli Patent Law also provides that if there is no such agreement between an employer and an employee, the Israeli Compensation and Royalties Committee (the “C&R Committee”), a body constituted under the Israeli Patent Law, shall determine whether the employee is entitled to remuneration for his inventions. The C&R Committee (decisions of which have been upheld by the Israeli Supreme Court) has held that employees may be entitled to remuneration for their service inventions despite having specifically waived any such rights. We generally enter into intellectual property assignment agreements with our employees pursuant to which such employees assign to us all rights to any inventions created in the scope of their employment or engagement with us. Although our employees have agreed to assign to us service invention rights and have specifically waived their right to receive any special remuneration for such assignment beyond their regular salary and benefits, we may face claims demanding remuneration in consideration for assigned inventions. As a consequence of such claims, we could be required to pay additional remuneration or royalties to our current or former employees, or be forced to litigate such claims, which could negatively affect our business.

 

It may be difficult for investors in the United States to enforce any judgments obtained against us or some of our directors or officers.

 

The majority of our assets other than cash are located outside the U.S. In addition, certain of our officers are nationals and/or residents of countries other than the U.S., and all or a substantial portion of such persons’ assets are located outside the U.S. As a result, it may be difficult for investors to enforce within the United States any judgments obtained against us or any of our non-U.S. officers, including judgments predicated upon the civil liability provisions of the securities laws of the U.S. or any state thereof. Additionally, it may be difficult to assert U.S. securities law claims in actions originally instituted outside of the U.S. Israeli courts may refuse to hear a U.S. securities law claim because Israeli courts may not be the most appropriate forums in which to bring such a claim. Even if an Israeli court agrees to hear a claim, it may determine that the Israeli law, and not U.S. law, is applicable to the claim. Further, if U.S. law is found to be applicable, certain content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process, and certain matters of procedure would still be governed by the Israeli law. Consequently, you may be effectively prevented from pursuing remedies under U.S. federal and state securities laws against us or any of our non-U.S. directors or officers.

 

Risks Related to Our Common Stock, Preferred Stock and Warrants

 

The market prices of our common stock are subject to fluctuation and have been and may continue to be volatile, which could result in substantial losses for investors.

 

The market prices of our common stock have been and are likely to continue to be highly volatile and could fluctuate widely in response to various factors, many of which are beyond our control, including the following:

 

  ● technological innovations or new products and services by us or our competitors;
     
  ● additions or departures of key personnel;
     
  ● our ability to execute our business plan;
     
  ● operating results that fall below expectations;
     
  ● loss of any strategic relationship;
     
  ● industry developments;
     
  ● economic, political and other external factors; and
     
  ● period-to-period fluctuations in our financial results.

 

 -55- 

 

 

In addition, the securities markets have from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. These market fluctuations may also significantly affect the market prices of our common stock.

 

Our common stock could be delisted from the Nasdaq Capital Market if we fail to meet the Nasdaq Capital Market’s stockholders’ equity continued listing standards. Our ability to publicly or privately sell equity securities and the liquidity of our common stock could be adversely affected if we are delisted from the Nasdaq Capital Market.

 

Our common stock is listed on the Nasdaq Capital Market, and we are therefore subject to its continued listing requirements, including requirements with respect to the market value of publicly-held shares, market value of listed shares, minimum bid price per share, and minimum stockholders’ equity, among others, and requirements relating to board and committee independence. If we fail to satisfy one or more of the requirements, we may be delisted from the Nasdaq Capital Market.

 

Delisting from the Nasdaq Capital Market may adversely affect our ability to raise additional financing through the public or private sale of equity securities, may significantly affect the ability of investors to trade our securities and may negatively affect the value and liquidity of our common stock. Delisting also could have other negative results, including the potential loss of employee confidence, the loss of institutional investors or interest in business development opportunities.

 

Delaware law and our corporate charter and bylaws contain anti-takeover provisions that could delay or discourage takeover attempts that stockholders may consider favorable.

 

Our board of directors is authorized to issue shares of preferred stock in one or more series and to fix the voting powers, preferences and other rights and limitations of the preferred stock. Accordingly, we may issue shares of preferred stock with a preference over our common stock with respect to dividends or distributions on liquidation or dissolution, or that may otherwise adversely affect the voting or other rights of the holders of common stock. Issuances of preferred stock, depending upon the rights, preferences and designations of the preferred stock, may have the effect of delaying, deterring or preventing a change of control, even if that change of control might benefit our stockholders. In addition, we are subject to Section 203 of the Delaware General Corporation Law. Section 203 generally prohibits a public Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years after the date of the transaction in which the person became an interested stockholder, unless (i) prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; (ii) the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (a) shares owned by persons who are directors and also officers and (b) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or (iii) on or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66, 2/3%, of the outstanding voting stock which is not owned by the interested stockholder.

 

Section 203 could delay or prohibit mergers or other takeover or change in control attempts with respect to us and, accordingly, may discourage attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price.

 

We have a staggered board of directors, which could impede an attempt to acquire us or remove our management.

 

Our board of directors is divided into three classes, each of which serves for a staggered term of three years. This division of our board of directors could have the effect of impeding an attempt to take over our company or change or remove management, since only one class will be elected annually. Thus, only approximately one-third of the existing board of directors could be replaced at any election of directors.

 

 -56- 

 

 

As a former shell company, resales of shares of our restricted common stock in reliance on Rule 144 of the Securities Act are subject to the requirements of Rule 144(i).

 

We previously were a “shell company” and, as such, sales of our securities pursuant to Rule 144 under the Securities Act of 1933, as amended, cannot be made unless, among other things, at the time of a proposed sale, we are subject to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, and have filed all reports and other materials required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 as amended, as applicable, during the preceding 12 months, other than Form 8-K reports. Because, as a former shell company, the reporting requirements of Rule 144(i) will apply regardless of holding period, restrictive legends on certificates for shares of our common stock cannot be removed except in connection with an actual sale that is subject to an effective registration statement under, or an applicable exemption from the registration requirements of, the Securities Act of 1933, as amended. Because our unregistered securities cannot be sold pursuant to Rule 144 unless we continue to meet such requirements, any unregistered securities we issue will have limited liquidity unless we continue to comply with such requirements.

 

If securities and/or industry analysts fail to continue publishing research about our business, if they change their recommendations adversely or if our results of operations do not meet their expectations, our stock price and trading volume could decline.

 

The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. In addition, it is likely that in some future period our operating results will be below the expectations of securities analysts or investors. If one or more of the analysts who cover us downgrade our stock, or if our results of operations do not meet their expectations, our stock price could decline.

 

Aspects of the tax treatment of the securities may be uncertain.

 

The tax treatment of our preferred stock and our warrants is uncertain and may vary depending upon whether you are an individual or a legal entity and whether or not you are domiciled in the United States. In the event you are a non-U.S. investor, you should consult your tax advisors as to the consequences, under the tax laws of the country where you are resident for tax purposes, of acquiring, holding and disposing of our preferred stock and our warrants.

 

Item 1B. Unresolved Staff Comments.

 

Not applicable.

 

Item 1C. Cybersecurity

 

Risk management and strategy

 

We have developed and maintain a cybersecurity risk management program that focuses primarily on securing and safeguarding computer systems, networks, cloud services, business applications, and data and that is integrated in our overall risk management strategy and framework. We have implemented protocols to protect against cyber threats and ensure the containment and security of sensitive business data, including ongoing security reviews of critical systems, continuous monitoring of event data, and employee training programs, which processes are aligned with our overall business and operational goals and strategies. Our risk assessment occurs on an ongoing basis and covers identification of risks that could act against the company’s objectives as well as specific risks related to a compromise to the security of data.

 

We engage a third-party to provide operational support for cybersecurity risks. This forms a critical part of our risk management strategy, facilitating effective management and mitigation of risks, and ensuring adherence to applicable regulatory and industry standards.

 

 -57- 

 

 

Overall, we believe that we have established a robust framework for confidentiality, integrity, and availability of information, adhering to relevant security standards, practices, and compliance requirements. In addition, we maintain insurance to help protect against risks associated with cybersecurity threats. As of the date of this report, we do not believe that any risks from cybersecurity threats have materially affected, or are reasonably likely to materially affect, us, including our business strategy, results of operations, or financial condition. However, despite our efforts, we cannot eliminate all risks from cybersecurity threats, or provide assurances that we have not experienced an undetected cybersecurity incident. For more information about these risks, please see “Item 1.A – Risk Factors – Risks Related to Our Business Operations – Our business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber-security.” in this Form 10-K.

 

Governance

 

Our board of directors provides oversight of our cybersecurity program and helps guide our strategy for managing cybersecurity risks in the context of our overall risk management system. Our cybersecurity program is managed by our Senior Vice President of Finance, our internal IT team and our external Chief Information Security Officer (“CISO”) whose is responsible for leading enterprise-wide cybersecurity strategy, protocols, framework, standards and processes. The Senior Vice President of Finance reports to our board of directors, as well as our Chief Executive Officer and Chief Financial Officer and other members of senior management as appropriate.

 

Item 2. Properties.

 

Our headquarters are located in Tel Aviv, Israel, where we lease a 1,700 square meter office and manufacturing facility that has the capacity to manufacture and assemble 2,000 stents per month, based upon the production schedule of one shift per day. We believe that our current facility is sufficient to meet anticipated future demand by adding additional shifts to our current production schedule.

 

Item 3. Legal Proceedings.

 

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. There are currently no pending material legal proceedings, and we are currently not aware of any legal proceedings or claims against us or our property that we believe will have any significant effect on our business, financial position or operating results.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

PART II

 

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

 

Market Information

 

Our common stock has been quoted on the Nasdaq Capital Market (“Nasdaq”) since May 21, 2021, under the symbol “NSPR.” The last reported sales price of our common stock on the Nasdaq on March 4, 2024, was $2.57 per share.

 

Record Holders

 

As of March 3, 2023, we had 278 stockholders of record of our common stock. This figure includes an indeterminate number of stockholders who hold their shares in “street name.”

 

Dividends

 

In the past, we have not declared or paid cash dividends on our common stock. We do not intend to pay cash dividends in the future; rather, we intend to retain future earnings, if any, to fund the operation and expansion of our business and for general corporate purposes.

 

 -58- 

 

 

The holders of Series C Preferred Stock are not entitled to receive any dividends, unless and until specifically declared by our board of directors. However, holders of our Series C Preferred Stock are entitled to receive dividends on shares of Series C Preferred Stock equal (on an as-if-converted-to-common-stock basis, and without giving effect for such purposes to the 4.99% or 9.99% beneficial ownership limitation, as applicable) to and in the same form as dividends actually paid on shares of the common stock when such dividends are specifically declared by our board of directors. We are not obligated to redeem or repurchase any shares of Series C Preferred Stock. Shares of Series C Preferred Stock are not otherwise entitled to any redemption rights, or mandatory sinking fund or analogous fund provision.

 

Item 6. [Reserved]

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the accompanying consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K.

 

Overview

 

We are a medical device company focusing on the development and commercialization of our proprietary MicroNet™ stent platform for the treatment of carotid artery disease and other vascular disease. A stent is an expandable “scaffold-like” device, usually constructed of a metallic material, that is inserted into the lumen of the artery to create patency and revascularization of blood flow. MicroNet, a micron mesh sleeve, is attached over a stent to provide embolic protection both during and after stenting procedures.

 

Our CGuard EPS combines MicroNet and a unique self-expandable nitinol stent in a single device for use in carotid artery revascularization. Our CGuard EPS originally received CE mark approval under the MDD in the EU in March 2013 and was fully launched in Europe in September 2015. Subsequently, we launched CGuard EPS in over 30 countries and on February 3, 2021, we executed a distribution agreement with Chinese partners for the purpose of expanding our presence in the Asian markets. In January 2024, we received CE mark recertification under the EU’s Medical Device Regulation regulatory framework. Currently, we are seeking strategic partners for a potential launch of CGuard EPS in Japan and other Asian countries.

 

On September 8, 2020, we received approval from the FDA of our IDE, thereby allowing us to proceed with a pivotal study of our CGuard™ Carotid Stent System, C-GUARDIANS, for prevention of stroke in patients in the United States. C-GUARDIANS is a prospective, multicenter, single-arm, pivotal study to evaluate the safety and efficacy of the CGuard™ Carotid Stent System when used to treat symptomatic and asymptomatic carotid artery stenosis in patients undergoing CAS. The study, which completed enrollment in June 2023, enrolled 316 patients across 24 trial sites in the U.S. and Europe and from April 2023 included deployment of the CGuard stent using CGuard Prime, our next generation CAS stent platform.

 

The primary endpoint is a composite of: (1) incidence of major adverse events including Death (all-cause mortality), any Stroke, and Myocardial Infarction (DSMI) through 30-days post index procedure, or (2) ipsilateral stroke from day 31 to day 365 post-procedure. All events are adjudicated by an independent clinical events committee. The composite index will be compared to a performance goal based on the observed rate of the two components of the primary endpoint from previous pivotal stent trials which are considered industry standard. The performance goal will be considered met if the upper bound of the two-sided 95% confidence interval calculated from the observed primary endpoint rate is < 11.6% and the p-value is less than 0.025.

 

In November 2023, we announced positive 30-day follow up results from the C-GUARDIANS trial in which stenting with the C-Guard Carotid Stent System in patients with carotid artery stenosis and at high risk for carotid endarterectomy had a DSMI rate of 0.95%, measured from the date of the procedure through 30 days follow-up post-procedure. We anticipate reporting primary endpoint results from the C-GUARDIANS trial in mid 2024 that may support the submission of a PMA application in the third quarter of 2024 with a view to potential FDA approval of the CGuard Prime stent system in the first half of 2025.

 

 -59- 

 

 

We continue to invest in current and future potential new indications, products and manufacturing enhancements for CGuard that are expected to reduce cost of goods and/or provide the best-in-class performing delivery systems, such as CGuard Prime. In furtherance of our strategy that focuses on establishing the CGuard Carotid Stent System as a viable alternative to vascular surgery, we are developing a new transcarotid artery revascularization (TCAR) delivery system, SwitchGuard NPS, for transcarotid access and neuro protection. In addition, we intend to explore new indications for CGuard to leverage the advantages of stent design and mesh protection, well suited in labels such as acute stroke with tandem lesions.

 

We consider our current addressable market for our CGuard Carotid Stent System and SwitchGuard NPS to be both symptomatic and asymptomatic individuals with diagnosed high-grade carotid artery stenosis ) for whom intervention is preferable to medical (drug) therapy. This group includes not only carotid artery stenting patients but also individuals undergoing carotid endarterectomy, as the two approaches compete for the same patient population. Assuming full penetration of the intervention caseload by CGuard Carotid Stent System, we estimate that the addressable market for CGuard Carotid Stent System and SwitchGuard NPS is approximately $1.3 billion (source: Health Research International Personal Medical Systems, Inc. September 13, 2021 Results of Update Report on Global Carotid Stenting Procedures and Markets by Major Geography and Addressable Markets and internal estimates). According to this same report and internal estimates, assuming full penetration of treatment for all individuals diagnosed with high-grade carotid artery stenosis, we estimate the total available market for CGuard Carotid Stent System and SwitchGuard NPS to be approximately $9.3 billion, which may grow over time if expanded treatment options such as CGuard Carotid Stent System and SwitchGuard NPS lead to increased patient screening for carotid artery disease.

 

Recent Developments

 

Private Placement

 

On May 12, 2023, we entered into a securities purchase agreement (the “Purchase Agreement pursuant to which we agreed to sell and issue in a private placement (the “Private Placement Offering) an aggregate of 10,266,270 shares (the “Private Placement Shares”) of our common stock, pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 15,561,894 shares of common stock and warrants to purchase up to an aggregate of 51,656,328 shares of common stock, consisting of Series H warrants to purchase up to 12,914,078 shares of common stock (the “Series H Warrants”), Series I warrants to purchase up to 12,914,078 shares of common stock (the “Series I Warrants”), Series J warrants to purchase up to 12,914,086 shares of Common Stock (the “Series J Warrants”) and Series K warrants to purchase up to 12,914,078 shares of common stock (the “Series K Warrants” and together with the Series H Warrants, Series I Warrants and Series J Warrants, the “Warrants”), at an offering price of $1.6327 per Private Placement Share and associated Warrants and an offering price of $1.6326 per Pre-Funded Warrant and associated Warrants.

 

The Pre-Funded Warrants will be immediately exercisable at an exercise price of $0.0001 per share and will not expire until exercised in full. The Warrants will be immediately exercisable upon issuance at an exercise price of $1.3827 per share, subject to adjustment as set forth therein. The Warrants have a term of the earlier of (i) five years from the date of issuance and (ii) (A) in the case of the Series H Warrants, 20 trading days following the Company’s public release of primary and secondary end points related to one year follow up study results from the Company’s C-GUARDIANS pivotal trial, (B) in the case of the Series I Warrants, 20 trading days following the Company’s announcement of receipt of Premarket Approval from the Food and Drug Administration (“FDA”) for the CGuard Prime Carotid Stent System (135 cm), (C) in the case of the Series J Warrants, 20 trading days following the Company’s announcement of receipt of FDA approval for the SwitchGuard and CGuard Prime 80 and (D) in the case on the Series K Warrants, 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of the CGuard Carotid Stent System in the United States begins.

 

 -60- 

 

 

The Warrants may be exercised on a cashless basis if there is no effective registration statement registering the shares underlying the Warrants. Under the terms of the Pre-Funded Warrants and Warrants, certain of the selling stockholders may not exercise the Pre-Funded Warrants or Warrants to the extent such exercise would cause such selling stockholder, together with its affiliates and attribution parties, to beneficially own a number of shares of common stock which would exceed 4.99% or 9.99% of our then outstanding common stock following such exercise, excluding for purposes of such determination common stock issuable upon exercise of the Pre-Funded Warrants or Warrants which have not been exercised. The Warrants may be exercised into pre-funded warrants if the selling stockholder is unable to exercise the Warrant due to the foregoing beneficial ownership limitation or at the selling shareholder’s election.

 

In connection with the Purchase Agreement, we entered into a registration rights agreement (the “Registration Rights Agreement”). Pursuant to the Registration Rights Agreement, we were required to file a resale registration statement (the “Registration Statement”) with the SEC to register for resale the Private Placement Shares and the shares of common stock issuable upon exercise of the Pre-Funded Warrants and Warrants, within 20 days of the signing date of the Purchase Agreement (the “Signing Date”), and to have such Registration Statement declared effective within 45 days after the Signing Date in the event the Registration Statement is not reviewed by the SEC, or 90 days of the Signing Date in the event the Registration Statement is reviewed by the SEC. We were obligated to pay certain liquidated damages if we fail to file the Registration Statement when required, fails to cause the Registration Statement to be declared effective by the SEC when required, of if we fail to maintain the effectiveness of the Registration Statement. The Registration Statement was subsequently filed on May 23, 2023 and declared effective on June 1, 2023. We paid LifeSci Capital LLC, a placement fee equal to 5.6% of the aggregate gross proceeds from the closing of the Private Placement Offering, or approximately $2.4 million, and legal expenses of $41,600. In addition, we paid Piper Sandler & Co. a financial advisory fee of $1.5 million, AGP/Alliance Global Partners a financial advisory fee of $250,000 and lead investor counsel expenses of $125,000.

 

Critical Accounting Policies

 

We prepared our consolidated financial statements in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”). U.S. GAAP represents a comprehensive set of accounting and disclosure rules and requirements, and applying these rules and requirements requires management judgments and estimates including, in certain circumstances, choices between acceptable U.S. GAAP alternatives. The following is a discussion of our most critical accounting policies, judgments and uncertainties that are inherent in our application of U.S. GAAP.

 

Use of estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates using assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of sales and expenses during the reporting periods. Actual results could differ from those estimates.

 

As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to inventory valuations and assessing the likelihood of exercise of options to extend the lease term.

 

Marketable securities

 

Marketable securities consist of debt securities. We elected the fair value option to measure and recognize our investments in debt securities in accordance with ASC 825, Financial Instruments as we manage our portfolio and evaluates the performance on a fair value basis. Changes in fair value, realized gains and losses on sales of marketable securities, are reflected in the statements of operation as finance expense (income), net.

 

Concentration of credit risk and allowance for doubtful accounts

 

Financial instruments that may potentially subject us to a concentration of credit risk consist of cash and cash equivalents and short-term bank deposits, which are deposited in major financially sound institutions in the U.S, Israel and Germany, and trade accounts receivable and other receivables. Our trade accounts receivable is derived from revenues earned from customers from various countries. We perform ongoing credit evaluations of our customers’ financial condition and, requires no collateral from our customers. We also have a credit insurance policy for some of our customers. We maintain the allowance for estimated losses resulting from the inability of our customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of our ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses, and future expectations. The allowance for expected credit losses was immaterial during the periods presented.

 

 -61- 

 

 

Inventory

 

Inventories are stated at the lower of cost (cost is determined on a “first-in, first-out” basis) or net realizable value. Our inventories generally have a limited shelf life and are subject to impairment as they approach their expiration dates. We regularly evaluate the carrying value of our inventories and when, based on such evaluation, factors indicate that impairment has occurred, we impair the inventories’ carrying value. In addition, we write-off fails in production based on actual and estimated.

 

Leases

 

Operating leases are included in operating lease right-of-use (“ROU”) assets, Accounts payable and accruals - Other, and operating lease liabilities. ROU assets represent Company’s right to use an underlying asset for the lease term and lease liabilities represent obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, we use the incremental borrowing rate based on the information available at the lease commencement date as the rate implicit in the lease is not readily determinable. The determination of the incremental borrowing rate requires management judgment based on information available at lease commencement. The lease terms may include periods covered by options to extend the lease when it is reasonably certain that we will exercise such options, and periods covered by options to terminate the lease when it is reasonably certain that we will not exercise such options. Operating lease cost is recognized on a straight-line basis over the lease term. Lease agreements that include lease and non-lease components are accounted for as a single lease component. The Company elected the short-term lease recognition exemption for leases with a lease term of 12 months or less.

 

Revenue recognition

 

A contract with a customer exists only when: 1) the parties to the contract have approved it and are committed to perform their respective obligations, 2) we can identify each party’s rights regarding the distinct goods or services to be transferred (“Performance Obligations”), 3) we can determine the transaction price for the goods or services to be transferred, 4) the contract has commercial substance and 5) it is probable that we will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Revenues are recorded in the amount of consideration to which we expect to be entitled in exchange for Performance Obligations upon transfer of control to the customer, excluding sales taxes.

 

Revenue from sales of goods, including sales to distributors, is recognized when the customer obtains control of the product, once we have a present right to payment, legal title, and risk and rewards of ownership are obtained by the customer. This occurs when products are shipped.

 

We recognize the incremental costs of obtaining contracts as an expense since the amortization period of the assets that we otherwise would have recognized is one year or less. The costs are recorded under selling and marketing expenses.

 

We recognize revenue net of value added tax (VAT).

 

 -62- 

 

 

Share-based compensation

 

Employee option awards are classified as equity awards and accounted for using the grant-date fair value method. The fair value of share-based awards is estimated using the Black-Scholes valuation model and expensed over the requisite service period, net of estimated forfeitures. We elected to account for forfeitures as they occur.

 

We elected to recognize compensation expenses for awards with only service conditions that have graded vesting schedules using the accelerated multiple option approach.

 

The attribution for nonemployee awards is in the same manner as if we had paid cash for the goods or services.

In addition, certain of our share-based awards to service providers are performance based, i.e., the vesting of these awards depends upon achieving certain goals. We recognize compensation expenses for awards with performance conditions when we conclude that it is probable that the performance condition will be achieved.

 

Results of Operations

 

Twelve months ended December 31, 2023 compared to the twelve months ended December 31, 2022

 

Revenues. For the twelve months ended December 31, 2023, revenue increased by $1,034,000, or 20.0%, to $6,205,000, from $5,171,000 during the twelve months ended December 31, 2022. This increase was predominantly driven by a 21.1% increase in sales volume of CGuard EPS, from $5,123,000 during the twelve months ended December 31, 2022, to $6,205,000 during the twelve months ended December 31, 2023. This sales increase was mainly due to growth in existing and new markets.

 

With respect to regions, the increase in revenue was primarily attributable to a $1,036,000 increase in Europe, a $76,000 increase in Asia and $24,000 increase in Latin America. This growth was mainly due to growth in existing and new markets. This increase was offset by a $92,000 decline in revenue in the U.S. as less stents were used in our C-GUARDIANS FDA study as trial enrollment ended in June 2023 as well as a $10,000 decline in other markets.

 

Gross Profit. For the twelve months ended December 31, 2023, gross profit (revenue less cost of revenues) increased by 61.8%, or $690,000, to $1,807,000, compared to a gross profit of $1,117,000 for the same period in 2022. This increase in gross profit resulted from a $484,000 increase in revenues less the associated related material and labor costs, a decrease in write-offs of $179,000 and a decrease of $27,000 in miscellaneous expenses. Gross margin (gross profits as a percentage of revenue) increased to 29.1% during the twelve months ended December 31, 2023, from 21.6% during the twelve months ended December 31, 2022, driven by the reasons mentioned above.

 

Research and Development Expenses. For the twelve months ended December 31, 2023, research and development expenses increased by 2.2%, or $171,000, to $7,981,000, from $7,810,000 during the twelve months ended December 31, 2022. This increase resulted primarily from an increase of compensation expenses to employees and consultants of $638,000 mainly due to an increase of approximately $341,000 of share-based compensation-related expenses due to the expense recognition of grants made during the second quarter of 2023, an increase of $165,000 in expenses related to the SwitchGuard regulatory and approval process, and an increase of $513,000 in miscellaneous expenses offset, in part, by a decrease of $1,145,000 in expenses related to the C-GUARDIANS FDA study as we completed enrollment in June 2023.

 

Selling and Marketing Expenses. For the twelve months ended December 31, 2023, selling and marketing expenses increased by 5.5%, or $201,000, to $3,865,000, from $3,664,000 during the twelve months ended December 31, 2022. This increase resulted primarily from an increase of compensation expenses of $151,000 mainly due to an increase of share-based compensation-related expenses due to the expense recognition of grants made during the second quarter of 2023 and an increase of $50,000 in miscellaneous expenses.

 

General and Administrative Expenses. For the twelve months ended December 31, 2023, general and administrative expenses increased by 32.9%, or $2,748,000, to $11,104,000, from $8,356,000 during the twelve months ended December 31, 2022. This increase resulted primarily from an increase in compensation expenses of $2,177,000, mainly due to an increase of approximately $1,585,000 of share-based compensation-related expenses due to the expense recognition of grants made during the second quarter of 2023 and an increase in salary expenses and related accruals of $592,000 mainly due to hiring of a General Manager of North America and VP of Global Marketing (who was subsequently promoted to the Company’s Chief Commercial Officer in the third quarter of 2023), an increase in legal expenses of $292,000 and an increase of $279,000 in miscellaneous expenses.

 

 -63- 

 

 

Financial Income (Expenses). For the twelve months ended December 31, 2023, financial income increased by $1,042,000, to $1,292,000 from $250,000 during the twelve months ended December 31, 2022. The increase in financial income primarily resulted from a $1,152,000 increase in interest income from investment in marketable securities, money market funds and short-term bank deposits.

 

Tax Expenses. For the twelve months ended December 31, 2023, tax increased by $37,000 compared to the twelve months ended December 31, 2022. Our expenses for income taxes reflect primarily the tax liability due to potential tax exposure.

 

Net Loss. Our net loss increased by $1,425,000, or 7.7%, to $19,916,000 for the twelve months ended December 31, 2022, from $18,491,000 during the twelve months ended December 31, 2022. The increase in net loss resulted primarily from an increase of $3,120,000 in operating expenses, offset by an increase of $1,042,000 in financial income and increase of $690,000 in gross profit.

 

Liquidity and Capital Resources

 

As of the date of issuance of the consolidated financial statements, we have the ability to fund our planned operations for at least the next 12 months. However, we expect to continue incurring losses and negative cash flows from operations until our products (primarily CGuard reaches commercial profitability. Therefore, in order to fund our operations until such time that we can generate substantial revenues, we may need to raise additional funds.

 

Our plans include continued commercialization of our products and raising capital through sale of additional equity securities, debt or capital inflows from strategic partnerships. There are no assurances, however, that we will be successful in obtaining the level of financing needed for our operations. If we are unsuccessful in commercializing our products or raising capital, we may need to reduce activities, curtail or cease operations.

 

In May 2023, we closed a Private Placement Offering that resulted in aggregate gross proceeds of approximately $42.2 million, before deducting fees payable to the placement agent and other offering expenses payable by the Company. If the Warrants from the Private Placement Offering are exercised in cash in full this would result in an additional $71.4 million of gross proceeds. There can be no assurance that we will achieve any of the milestones set forth in the Warrants or that the Warrants will be exercised in cash in full.

 

Twelve months ended December 31, 2023 compared to the twelve months ended December 31, 2022

 

General. At December 31, 2023, we had cash and cash equivalents of $9,640,000 and marketable securities of $29,383,000 as compared to $4,632,000 of cash and cash equivalents and $13,171,000 Short-term bank deposits as of December 31, 2022. We have historically met our cash needs through a combination of issuing new shares, borrowing activities and product sales. Our cash requirements are generally for research and development, marketing and sales activities, finance and administrative cost, capital expenditures and general working capital.

 

For the twelve months ended December 31, 2023, net cash used in our operating activities increased by $834,000 to $16,376,000, from $15,542,000 during the same period in 2022. The primary reason for the increase in cash used in our operating activities was an increase of $731,000 in payments for third party related expenses and for professional services, an increase of $937,000 in salary and bonus payments from $8,558,000 in the twelve months ended December 31, 2022 to $9,495,000 during the same period in 2022, offset, in part, by an increase of $137,000 in payments received from customers to $5,470,000 during the twelve months ended December 31, 2023, from $5,333,000 during the same period in 2022 and an increase of $697,000 in interest income received from marketable securities, money market funds and short-term bank deposits

 

Cash used by our investing activities was $16,092,000 during the twelve months ended December 31, 2023, compared to cash provided by our investing activities of $8,441,000 during the twelve months ended December 31, 2022. The primary reason for the increase in cash used by our investing activities is an investment in marketable securities, net of withdrawal of $28,644,000, offset by an increase in withdrawal from short-term bank deposits, net of investment in short-term deposits, of $4,000,000, and a decrease of $92,000 in payments made for purchase of property, plant and equipment during the twelve months ended December 31, 2023.

 

 -64- 

 

 

Cash provided by financing activities for the twelve months December 31, 2023, was $37,534,000. The principal source of the cash provided by financing activities during the twelve months ended December 31, 2023 were the proceeds from the Private Placement Offering in May 2023 that resulted in approximately $37,534,000 of aggregate net proceeds. Cash used by financing activities for the twelve months ended December, 2022 was $140,000, the cash used by financing activities during the twelve months ended December, 2022 were due to issuance costs associated with a shelf registration statement on Form S-3 filed with the SEC on June 3, 2022.

 

As of December 31, 2023, our current assets exceeded our current liabilities by a multiple of 7.3. Current assets increased by $22,833,000 during the period and current liabilities increased by $950,000 during the period. As a result, our working capital increased by $21,883,000 to $38,139,000 as of December 31, 2023.

 

Contractual Obligations

 

Operating lease payments represent our commitment for future rent made under non-cancelable lease for our offices in Israel. The total future payments for our operating lease obligation at December 31, 2023 were approximately $1,815,000 and are due in the next twelve months. For additional details regarding our lease, see Note 7_ to our consolidated financial statements included in this Annual Report on Form 10-K.

 

Off Balance Sheet Arrangements

 

We have no off-balance sheet transactions, arrangements, obligations (including contingent obligations), or other relationships with unconsolidated entities or other persons that have, or may have, a material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

Recent Accounting Pronouncements

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments. This guidance replaces the current incurred loss impairment methodology. Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates (“ASU 2019-10”). The purpose of this amendment is to create a two tier rollout of major updates, staggering the effective dates between larger public companies and all other entities. This granted certain classes of companies, including Smaller Reporting Companies (“SRCs”), additional time to implement major FASB standards, including ASU 2016-13. Larger public companies had an effective date of December 15, 2019, including interim periods within those fiscal years. +All other entities are permitted to defer adoption of ASU 2016-13, and its related amendments, until the earlier of fiscal periods beginning after December 15, 2022. Under the current SEC definitions, we meet the definition of an SRC and are adopting the deferral period for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. We adopted the provisions of this update as of January 1, 2023 with no material impact on our consolidated financial statements.

 

 -65- 

 

 

In November 2023, the FASB issued ASU 2023-07 “Segment Reporting: Improvements to Reportable Segment Disclosures”. This guidance expands public entities ‘segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity’s financial statements. We are currently evaluating this guidance to determine the impact it may have on our consolidated financial statements related disclosures. In December 2023, the FASB issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”. This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. We are currently evaluating this guidance to determine the impact it may have on our consolidated financial statements related disclosures.

 

Factors That May Affect Future Operations

 

We believe that our future operating results will continue to be subject to quarterly variations based upon a wide variety of factors, including the cyclical nature of the ordering patterns of our distributors, timing of regulatory approvals, the implementation of various phases of our clinical trials and manufacturing efficiencies due to the learning curve of utilizing new materials and equipment. Our operating results could also be impacted by a weakening of the Euro and strengthening of the NIS, both against the U.S. dollar. Lastly, other economic conditions we cannot foresee may affect customer demand, such as individual country reimbursement policies pertaining to our products.

 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk.

 

Not applicable.

 

Item 8. Financial Statements and Supplementary Data.

 

The following financial statements are included as part of this Report (See Item 15):

 

  ● Report of Kesselman & Kesselman, Independent Registered Public Accounting Firm
  ● Consolidated Balance Sheets as of December 31, 2023 and 2021
  ● Consolidated Statements of Operations for the Years Ended December 31, 2023 and 2021
  ● Consolidated Statements of Changes in Equity for the Years Ended December 31, 2023 and 2021
  ● Consolidated Statements of Cash Flows for the Years Ended December 31, 2023 and 2021
  ● Notes to Consolidated Financial Statements

 

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

 

Not applicable.

 

Item 9A. Controls and Procedures.

 

Management’s Conclusions Regarding Effectiveness of Disclosure Controls and Procedures

 

We conducted an evaluation of the effectiveness of our “disclosure controls and procedures”, as defined by Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, as of December 31, 2023, the end of the period covered by this Annual Report on Form 10-K. The disclosure controls and procedures evaluation was done under the supervision and with the participation of management, including our chief executive officer and chief financial officer. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon this evaluation, our chief executive officer and chief financial officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2023.

 

 -66- 

 

 

Management’s Report on Internal Control Over Financial Reporting

 

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the consolidated financial statements for external reporting purposes in accordance with generally accepted accounting principles.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness of internal control over financial reporting to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate over time.

 

Management, including our chief executive officer and our chief financial officer, assessed the effectiveness of our internal control over financial reporting as of December 31, 2023. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control—Integrated Framework 2013. Based on its assessment and those criteria, management has concluded that we maintained effective internal control over financial reporting as of December 31, 2023.

 

Changes in Internal Control over Financial Reporting

 

There have been no changes in our internal control over financial reporting during the fiscal quarter ended December 31, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Item 9B. Other Information.

 

None.

 

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

 

Not applicable.

 

PART III

 

Item 10. Directors, Executive Officers and Corporate Governance.

 

Code of Ethics

 

We have adopted a code of ethics and business conduct that applies to our officers, directors and employees, including our principal executive officer, principal financial officer and principal accounting officer, which is posted on our website at www.inspiremd.com. We intend to disclose future amendments to certain provisions of the code of ethics, or waivers of such provisions granted to executive officers and directors, on this website within four business days following the date of such amendment or waiver.

 

Other Information

 

The remaining information required by this Item 10 will be included in our definitive Proxy Statement for the 2024 Annual Meeting of Stockholders and is incorporated herein by reference.

 

Item 11. Executive Compensation.

 

The information required by this Item 11 will be included in our definitive Proxy Statement for the 2024 Annual Meeting of Stockholders and is incorporated herein by reference.

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

 

The information required by this Item 12 will be included in our definitive Proxy Statement for the 2024 Annual Meeting of Stockholders and is incorporated herein by reference.

 

 -67- 

 

 

Item 13. Certain Relationships and Related Transactions, and Director Independence.

 

The information required by this Item 13 will be included in our definitive Proxy Statement for the 2024 Annual Meeting of Stockholders and is incorporated herein by reference.

 

Item 14. Principal Accountant Fees and Services.

 

The information required by this Item 13 will be included in our definitive Proxy Statement for the 2024 Annual Meeting of Stockholders and is incorporated herein by reference.

 

PART IV

 

Item 15. Exhibits and Financial Statement Schedules.

 

Documents filed as part of report:

 

1. Financial Statements

 

The following financial statements are included herein:

 

  ● Report of Kesselman & Kesselman, Independent Registered Public Accounting Firm
  ● Consolidated Balance Sheets as of December 31, 2023 and 2022
  ● Consolidated Statements of Operations for the Years Ended December 31, 2023 and 2022
  ● Consolidated Statements of Changes in Equity for the Years Ended December 31, 2023 and 2022
  ● Consolidated Statements of Cash Flows for the Years Ended December 31, 2023 and 2022
  ● Notes to Consolidated Financial Statements

 

2. Financial Statement Schedules

 

None

 

3. Exhibits

 

See Index to Exhibits

 

Item 16. Form 10-K Summary

 

Not applicable.

 

 -68- 

 

 

Index to Exhibits

 

Exhibit No.   Description
3.1   Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2015)
     
3.2   Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to Current Report on Form 8-K filed with the Securities and Exchange Commission on June 29, 2021).
     
3.3   Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on May 25, 2016)
     
3.4   Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on September 29, 2016)
     
3.5   Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on March 15, 2017)
     
3.6   Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitation of Series C Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on November 29, 2017)
     
3.7   Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitation of Series B Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on December 12, 2017)
     
3.8   Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on February 7, 2018)
     
3.9   Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitation of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on March 1, 2018)
     
3.10   Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitation of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on April 3, 2018)

 

3.11   Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc., dated March 27, 2019 (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on March 28, 2019)
     
3.12   Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc., dated April 14, 2021 (incorporated by reference to Exhibit 3.1 to Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2021)
     
3.13   Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to Amendment No. 3 to Registration Statement on Form S-1 filed with the Securities and Exchange Commission on March 5, 2013)
     
3.15   Form of Series B Warrant Agent Agreement and Form of Series B Warrant (incorporated by reference to Exhibit 4.3 to Amendment No.3 to Registration Statement on Form S-1 filed with the Securities and Exchange Commission on March 6, 2017)
     
4.1*   Description of Securities

 

 -69- 

 

 

10.1+   Form of Indemnity Agreement between InspireMD, Inc. and each of the directors and executive officers thereof (incorporated by reference to Exhibit 10.22 to Amendment No. 1 to Registration Statement on Form S-1 filed with the Securities and Exchange Commission on August 26, 2011)
     
10.2+   InspireMD, Inc. 2013 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the Securities and Exchange Commission on December 20, 2013)
     
10.3+   Amended and Restated Employment Agreement, dated May 5, 2014, by and between InspireMD, Inc. and Craig Shore (incorporated by reference to Exhibit 10.2 to Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 7, 2014)

 

10.4+   First Amendment to the InspireMD, Inc. Amended and Restated 2011 UMBRELLA Option Plan (incorporated by reference to Exhibit 10.3 to Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 7, 2014)
     
10.5+   Form of Incentive Stock Option Award Agreement under the InspireMD, Inc. 2013 Long-Term Incentive Plan (incorporated by reference to Exhibit 99.2 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 5, 2014)
     
10.6+   Form of Nonqualified Stock Option Award Agreement under the InspireMD, Inc. 2013 Long-Term Incentive Plan (incorporated by reference to Exhibit 99.3 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 5, 2014)

 

10.7+   Form of Restricted Stock Award Agreement under the InspireMD, Inc. 2013 Long-Term Incentive Plan (incorporated by reference to Exhibit 99.4 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 5, 2014)
     
10.8+   Form of Restricted Stock Unit Award Agreement under the InspireMD, Inc. 2013 Long-Term Incentive Plan (incorporated by reference to Exhibit 99.5 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 5, 2014)
     
10.9+   Form of Section 3(i) Stock Option Award Agreement under the InspireMD, Inc. 2013 Long-Term Incentive Plan (Israeli) (incorporated by reference to Exhibit 99.6 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 5, 2014)
     
10.10+   Form of Section 102 Capital Gain Stock Option Award Agreement under the InspireMD, Inc. 2013 Long-Term Incentive Plan (Israeli) (incorporated by reference to Exhibit 99.7 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 5, 2014)
     
10.11+   Form of Section 102 Capital Gain Restricted Stock Award Agreement under the InspireMD, Inc. 2013 Long-Term Incentive Plan (Israeli) (incorporated by reference to Exhibit 99.8 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 5, 2014)
     
10.12+   Form of Stock Option Award Agreement under the InspireMD, Inc. 2013 Long-Term Incentive Plan (European) (incorporated by reference to Exhibit 99.9 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 5, 2014)
     
10.13+   Form of Restricted Stock Award Agreement under the InspireMD, Inc. 2013 Long-Term Incentive Plan (European) (incorporated by reference to Exhibit 99.10 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 5, 2014)

 

 -70- 

 

 

10.14+   Form of Stock Option Award Agreement outside the InspireMD, Inc. 2013 Long-Term Incentive Plan (incorporated by reference to Exhibit 99.11 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 5, 2014)
     
10.15+   First Amendment to Amended and Restated Employment Agreement, dated January 5, 2015, by and between InspireMD, Inc. and Craig Shore (incorporated by reference to Exhibit 10.3 to Current Report on Form 8-K filed with the Securities and Exchange Commission on January 6, 2015)
     
10.16+   First Amendment to the InspireMD, Inc. 2013 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on September 9, 2015)
     
10.17+   Second Amendment to the InspireMD, Inc. 2013 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on May 25, 2016)
     
10.18+   Second Amendment to Amended and Restated Employment Agreement, dated July 25, 2016, by and between InspireMD, Inc. and Craig Shore agent (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on July 29, 2016)
     
10.19+   Third Amendment to the InspireMD, Inc. 2013 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on September 29, 2016)
     
10.20+   Director Offer Letter, between InspireMD, Inc. and Thomas J. Kester, dated September 6, 2016
     
10.21+   Fourth Amendment to the InspireMD, Inc. 2013 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on October 26, 2018)
     
10.22+   Fifth Amendment to the InspireMD, Inc. 2013 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on March 21, 2019)
     
10.23+   Third Amendment to Amended and Restated Employment Agreement, dated March 25, 2019, by and between InspireMD, Inc. and Craig Shore (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on March 28, 2019)
     
10.24   Form of Underwriter Warrant, dated April 8, 2019 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on April 8, 2019)
     
10.25   Form of Series E Warrant (incorporated by reference to Exhibit 4.3 to the Company’s Registration Statement on Form S-1, Amendment No. 1, filed with the SEC on September 13, 2019 (File No. 333-233432)).
     
10.26   Form of Underwriter Warrant (incorporated by reference to Exhibit 4.5 to the Company’s Registration Statement on Form S-1, Amendment No. 1, filed with the SEC on September 13, 2019 (File No. 333-233432)).
     
10.27+   Employment Agreement, dated December 9, 2019, by and between the Company and Marvin Slosman (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on December 10, 2019).
     
10.28+   First Amendment to Employment Agreement, dated December 31, 2019, by and between the Company and Marvin Slosman (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on January 6, 2020).

 

 -71- 

 

 

10.29+   Nonqualified Stock Option Agreement, by and between the Company and Marvin Slosman (incorporated by reference to Exhibit 10.60 to the Annual Report on Form 10-K filed on March 10, 2020)
     
10.30+   Restricted Stock Unit Award agreement, by and between the Company and Marvin Slosman (incorporated by reference to Exhibit 10.61 to the Annual Report on Form 10-K filed on March 10, 2020)

 

10.31   Form of Series F Warrant (incorporated by reference to Exhibit 4.5 to the Company’s Registration Statement on Form S-1, Amendment No. 1, filed with the SEC on June 1, 2020 (File No. 333-238247)).
     
10.32   Form of Underwriter Warrant (incorporated by reference to Exhibit 1.1 to the Company’s Registration Statement on Form S-1, Amendment No. 1, filed with the SEC on June 1, 2020 (File No. 333-238247))
     
10.33   Form of Series G Warrant (incorporated by reference to Exhibit 4.5 to the Company’s Registration Statement on Form S-1, Amendment No. 1, filed with the SEC on February 3, 2021 (File No. 333-238247))
     
10.34   Form of Underwriter Warrant (incorporated by reference to Exhibit 4.6 to the Company’s Registration Statement on Form S-1, Amendment No. 1, filed with the SEC on February 3, 2021 (File No. 333-238247))
     
10.35+   Sixth Amendment to the InspireMD, Inc. 2013 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on August 31, 2020)
     
10.36+   Seventh Amendment to the InspireMD, Inc. 2013 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed on August 9, 2021)
     
10.37+   First Amendment to Employment Agreement, dated November 8, 2021, by and between InspireMD, Inc. and Marvin Slosman (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed on November 8, 2021).
     
10.38+   Fifth Amendment to Employment Agreement, dated November 4, 2021, by and between InspireMD, Inc. and Craig Shore (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q filed on November 8, 2021).
     
10.39+   Sixth Amendment to Employment Agreement, dated January 17, 2022, by and between InspireMD, Inc. and Craig Shore (incorporated by reference to Exhibit 10.51 to the Annual Report on Form 10-K filed on March 7, 2022)
     
10.40+   2021 Equity Compensation Plan (incorporated by reference to Annex A to the registrant’s Proxy Statement on Schedule 14A filed with the Commission on August 12, 2021).
     
10.41+   Form of Nonqualified Stock Option Agreement for U.S. employees under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.53 to the Annual Report on Form 10-K filed on March 7, 2022)
     
10.42+   Form of Nonqualified Stock Option Agreement for European employees under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.54 to the Annual Report on Form 10-K filed on March 7, 2022)
     
10.43+   Form of Nonqualified Stock Option Agreement for consultants under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.55 to the Annual Report on Form 10-K filed on March 7, 2022)

 

 -72- 

 

 

10.44+   Form of Nonqualified Stock Option Agreement for Israeli employees under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.56 to the Annual Report on Form 10-K filed on March 7, 2022)
     
10.45+   Form of Nonqualified Stock Option Agreement for U.S. directors under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.57 to the Annual Report on Form 10-K filed on March 7, 2022)
     
10.46+   Form of Restricted Stock Award Agreement for U.S. employees under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.58 to the Annual Report on Form 10-K filed on March 7, 2022)

 

10.47+   Form of Restricted Stock Award Agreement for U.S. directors under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.59 to the Annual Report on Form 10-K filed on March 7, 2022)
     
10.48+   Form of Restricted Stock Award Agreement for Israeli employees under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.60 to the Annual Report on Form 10-K filed on March 7, 2022)
     
10.49+   Form of Restricted Stock Award Agreement for European employees under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.61 to the Annual Report on Form 10-K filed on March 7, 2022)
     
10.50+   Form of Restricted Stock Unit Award Agreement under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.62 to the Annual Report on Form 10-K filed on March 7, 2022)
     
10.51   Sales Agreement by and between InspireMD, Inc. and A.G.P./Alliance Global Partners, dated June 3, 2022 (incorporated by reference to Exhibit 1.2 of the Registration Statement on Form S-3 as filed on June 3, 2022).
     
10.52+   Third Amendment to Employment Agreement, dated January 5, 2023, by and between InspireMD, Inc. and Marvin Slosman (incorporated by reference to Exhibit 10.64 to the Annual Report on Form 10-K filed on March 30, 2023)
     
10.53+   Seventh Amendment to Employment Agreement, dated January 18, 2023, by and between InspireMD, Inc. and Craig Shore (incorporated by reference to Exhibit 10.65 to the Annual Report on Form 10-K filed on March 30, 2023)
     
10.54+^   Employment Agreement, dated November 2, 2020, by and between the Company and Andrea Tommasoli (incorporated by reference to Exhibit 10.66 to the Annual Report on Form 10-K filed on March 30, 2023)
     
10.55   Form of Securities Purchase Agreement dated as of May 12, 2023 between the Company and purchaser identified therein (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K dated May 15, 2023)
     
10.56   Form of Pre-Funded Warrant dated May 15, 2023 (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K dated May 15, 2023)
     
10.57   Form of Series H Warrant dated May 15, 2023 (incorporated by reference to Exhibit 10.3 of the Current Report on Form 8-K dated May 15, 2023)
     
10.58   Form of Series I Warrant dated May 15, 2023 (incorporated by reference to Exhibit 10.4 of the Current Report on Form 8-K dated May 15, 2023)

 

 -73- 

 

 

10.59   Form of Series J Warrant dated May 15, 2023 (incorporated by reference to Exhibit 10.5 of the Current Report on Form 8-K dated May 15, 2023)
     
10.60   Form of Series K Warrant dated May 15, 2023 (incorporated by reference to Exhibit 10.6 of the Current Report on Form 8-K dated May 15, 2023)
     
10.61   Form of Registration Rights Agreement dated as of May 12, 2023 between the Company and purchaser identified therein (incorporated by reference to Exhibit 10.7 of the Current Report on Form 8-K dated May 15, 2023)
     
10.62+*   Fourth Amendment to Employment Agreement, dated August 14, 2020, by and between InspireMD, Inc. and Craig Shore
     
21.1   List of Subsidiaries (incorporated by reference to Exhibit 21.1 to Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2011)
     
23.1*   Consent of Kesselman & Kesselman, Certified Public Accountants
     
31.1*   Certification of Chief Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002
     
31.2*   Certification of Chief Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002
     
32.1*   Certification of Chief Executive Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
32.2*   Certification of Chief Financial Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
97.1*   InspireMD, Inc. Executive Officer Clawback Policy
     
101.INS*   Inline XBRL Instance Document (the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document)
     
101.SCH*   Inline XBRL Taxonomy Extension Schema Document
     
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB*   Inline XBRL Taxonomy Extension Labels Linkbase Document
     
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.

 

+ Management contract or compensatory plan or arrangement.

 

^ Portions of this exhibit (indicated by asterisks) have been omitted under rules of the U.S. Securities and Exchange Commission permitting the confidential treatment of select information.

 

 -74- 

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  INSPIREMD, INC.
     
Date: March 5, 2024 By: /s/ Marvin Slosman
    Marvin Slosman
    President and Chief Executive Officer

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ Marvin Slosman   President, Chief Executive Officer and Director   March 5, 2024
Marvin Slosman   (principal executive officer)    
         
/s/ Craig Shore   Chief Financial Officer, Chief Administrative Officer, Secretary and Treasurer   March 5, 2024
Craig Shore   (principal financial and accounting officer)    
         
/s/ Paul Stuka   Chairman of the Board of Directors   March 5, 2024
Paul Stuka        
         
/s/ Michael Berman   Director   March 5, 2024
Michael Berman        
         
/s/ Thomas J. Kester   Director   March 5, 2024
Thomas J. Kester        
         
/s/ Gary Roubin   Director   March 5, 2024
Gary Roubin        
         
/s/ Kathryn Arnold   Director   March 5, 2024
Kathryn Arnold        

 

 -75- 

 

 

INSPIREMD, INC.

CONSOLIDATED FINANCIAL STATEMENTS

AS OF AND FOR THE YEAR ENDED DECEMBER 31, 2023

 

TABLE OF CONTENTS

 

  Page
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB name: Kesselman & Kesselman C.P.A.s and PCAOB ID: 1309) F-2
CONSOLIDATED FINANCIAL STATEMENTS:  
Consolidated Balance Sheets F-3
Consolidated Statements of Operations F-5
Consolidated Statements of Changes in Equity F-6 - F-7
Consolidated Statements of Cash Flows F-8
Notes to the Consolidated Financial Statements F-9 - F-27

 

F-1
 

 

Report of Independent Registered Public Accounting Firm

 

To the board of directors and shareholders of InspireMD Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of InspireMD Inc. and its subsidiaries (the “Company”) as of December 31, 2023 and 2022, and the related consolidated statements of operations, changes in equity and cash flows for the years then ended, including the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments.

 

We determined there are no critical audit matters.

 

/s/ Kesselman & Kesselman  
Certified Public Accountants (Isr.)  
A member of PricewaterhouseCoopers International Limited  

 

Tel-Aviv, Israel

 

March 5, 2024

 

We have served as the Company’s auditor since 2010

 

F-2
 

 

INSPIREMD, INC.

CONSOLIDATED BALANCE SHEETS

(U.S. dollars in thousands)

 

   2023   2022 
   December 31, 
   2023   2022 
ASSETS          
CURRENT ASSETS:          
Cash and cash equivalents  $9,640   $4,632 
Short-term bank deposits   -    13,171 
Marketable securities   29,383    - 
Accounts receivable:          
Trade, net   1,804    1,034 
Other   648    213 
Prepaid expenses   578    655 
Inventory   2,106    1,621 
TOTAL CURRENT ASSETS   44,159    21,326 
           
NON-CURRENT ASSETS:          
Property, plant and equipment, net   1,060    917 
Operating lease right of use assets   1,473    1,554 
Fund in respect of employee rights upon retirement   951    856 
TOTAL NON-CURRENT ASSETS   3,484    3,327 
TOTAL ASSETS  $47,643   $24,653 

 

F-3
 

 

   December 31, 
   2023   2022 
LIABILITIES AND EQUITY          
           
CURRENT LIABILITIES:          
Accounts payable and accruals:          
Trade   939    659 
Other   5,081    4,411 
TOTAL CURRENT LIABILITIES   6,020    5,070 
           
LONG-TERM LIABILITIES:          
Operating lease liabilities   1,038    1,195 
Liability for employee rights upon retirement   1,084    995 
           
TOTAL LONG-TERM LIABILITIES   2,122    2,190 
           
COMMITMENTS AND CONTINGENT LIABILITIES (Note 8)          
TOTAL LIABILITIES   8,142    7,260 
           
EQUITY:          
           
Common stock, par value $0.0001 per share; 150,000,000 shares authorized at December 31, 2023 and 2022; 21,841,215 and 8,330,918 shares issued and outstanding at December 31, 2023 and 2022, respectively   2    1 
Preferred C shares, par value $0.0001 per share;
1,172,000 shares authorized at December 31, 2023 and 2022; 1,718 shares issued and outstanding at December 31, 2023 and 2022;		   -*    -* 
Additional paid-in capital   261,000    218,977 
Accumulated deficit   (221,501)   (201,585)
Total equity   39,501    17,393 
Total liabilities and equity  $47,643   $24,653 

 

*Represents an amount less than $1

 

The accompanying notes are an integral part of the consolidated financial statements.

 

F-4
 

 

INSPIREMD, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(U.S. dollars in thousands, except per share data)

 

   2023   2022 
   Year Ended December 31, 
   2023   2022 
         
REVENUES  $6,205   $5,171 
COST OF REVENUES   4,398    4,054 
GROSS PROFIT   1,807    1,117 
OPERATING EXPENSES:          
Research and development   7,981    7,810 
Selling and marketing   3,865    3,664 
General and administrative   11,104    8,356 
Total operating expenses   22,950    19,830 
LOSS FROM OPERATIONS   (21,143)   (18,713)
FINANCIAL INCOME , net:   1,292    250 
LOSS BEFORE TAX EXPENSES   (19,851)   (18,463)
TAX EXPENSES   65    28 
NET LOSS  $(19,916)  $(18,491)
NET LOSS PER SHARE - basic and diluted   (0.82)   (2.35)
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES USED IN COMPUTING NET LOSS PER SHARE - basic and diluted   24,268,181    7,871,814 

 

The accompanying notes are an integral part of the consolidated financial statements.

 

F-5
 

 

INSPIREMD, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(U.S. dollars in thousands, except share data)

 

   Shares   Amount   Shares   Amount   capital   deficit   equity 
   Common stock   Series C
Convertible
Preferred Stock		   Additional paid-in   Accumulated   Total 
   Shares   Amount   Shares   Amount   capital   deficit   equity 
                             
BALANCE as of January 1, 2022   8,296,256    1    1,718    -*    216,625    (183,094)   33,532 
Net loss             -    -         (18,491)   (18,491)
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 10,832 shares   34,662         -    -    2,352         2,352 
BALANCE as of December 31, 2022   8,330,918    1    1,718    -*    218,977    (201,585)   17,393 

 

*Represents an amount less than $1

 

F-6
 

 

INSPIREMD, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(U.S. dollars in thousands, except share data)

 

   Shares   Amount   Shares   Amount   capital   deficit   equity 
   Common stock   Series C
Convertible
Preferred Stock		   Additional paid-in   Accumulated   Total 
   Shares   Amount   Shares   Amount   capital   deficit   equity 
                             
BALANCE as of January 1, 2023   8,330,918    1    1,718    -*    218,977    (201,585)   17,393 
Net loss                            (19,916)   (19,916)
Exercise of pre-funded warrants   307,260    -*    -    -         -    - 
Issuance of common shares, pre-funded warrants and warrants, net of $4,635 issuance costs   10,266,270    1    -    -    37,533         37,534 
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures of 29,695 shares   2,936,767    -*    -    -    4,490         4,490 
BALANCE as of December 31, 2023   21,841,215    2    1,718    -*    261,000    (221,501)   39,501 

 

*Represents an amount less than $1

 

F-7
 

 

INSPIREMD, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(U.S. dollars in thousands)

 

   2023   2022 
   Year ended December 31, 
   2023   2022 
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss  $(19,916)  $(18,491)
Adjustments required to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   232    188 
Gain from sale of property, plant and equipment   (6)   - 
Change in fair value of markable securities, net of interest received
   (739)   - 
Change in liability for employees rights upon retirement   89    (57)
Other financial expense   58    131 
Change in operating right of use asset and operating leasing liability   62    (60)
Share-based compensation expenses   4,490    2,352 
Decrease (increase) in interest receivable on short term deposits   171    (135)
Loss (gain) on amounts funded in respect of employee rights upon retirement, net   (16)   135 
Changes in operating asset and liability items:          
Decrease in prepaid expenses   77    7 
Decrease (increase) in trade receivables   (770)   190 
Increase in other receivables   (435)   (48)
Increase in inventory   (485)   (478)
Increase (decrease) in trade payables   280    (234)
Increase in other payables   532    958 
Net cash used in operating activities   (16,376)   (15,542)
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchase of property, plant and equipment   (381)   (473)
Proceeds from sale of property, plant and equipment   12    - 
Investment in short-term bank deposits   (5,500)   (19,000)
Investments in marketable securities   (34,644)   - 
Proceeds from matured marketable securities   6,000    - 
Amounts funded in respect of employee rights upon retirement   (79)   (86)
Withdrawal from short-term bank deposits   18,500    28,000 
           
Net cash provided by (used in) investing activities   (16,092)   8,441 
CASH FLOWS FROM FINANCING ACTIVITIES:          
Issuance costs of At The Market offering   -    (140)
Proceeds from issuance of shares and warrants net of $4,635 issuance costs,   37,534    - 
Net cash provided by (used in) financing activities   37,534    (140)
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS   (58)   (131)
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS   5,008    (7,372)
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR   4,632    12,004 
BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR   9,640   $4,632 
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:          
Acquisition of right-of-use assets by means of lease liabilities   419    835 
Non-cash lease incentive   45    - 
Decrease in right-of-use assets and lease liabilities due to shortening lease term   131    - 

 

The accompanying notes are an integral part of the consolidated financial statements.

 

F-8
 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 1 - DESCRIPTION OF BUSINESS

 

  a. General
     
    InspireMD, Inc., a Delaware corporation (the “Company”), together with its subsidiaries, is a medical device company focusing on the development and commercialization of its proprietary MicroNet™ stent platform technology for the treatment of complex vascular and coronary disease. MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures.
     
    The Company’s carotid product (CGuard™ EPS) combines MicroNet and a self-expandable nitinol stent in a single device to treat carotid artery disease.
     
   

The Company ceased sales of the Company’s MGuard Prime EPS in the beginning of 2022.

     
   

The Company market its products through distributors in international markets, mainly in Europe.

 

As of the date of issuance of these consolidated financial statements, the Company has the ability to fund its planned operations for at least the next 12 months. However, the Company expects to continue incurring losses and negative cash flows from operations until its product, CGuard™ EPS, reaches commercial profitability. Therefore, in order to fund the Company’s operations until such time that the Company can generate substantial revenues, the Company may need to raise additional funds.

     
  b.

Status of European Medical Device Regulation for marketing CGuard EPS in countries requiring the CE Mark.

 

For the European Union (“EU”) nations, medical devices must obtain a CE mark before they may be placed on the market. In order to obtain and maintain the CE mark, the Company must comply with EU law on medical devices, which, until May 26, 2021 was governed by the Medical Device Directive 93/42/EEC (“MDD”), by presenting comprehensive technical files for the Company’s products demonstrating safety and efficacy of the product to be placed on the market and passing initial and annual quality management system audit as per ISO 13485 standard by a European Notified Body. The Company has obtained ISO 13485 quality system certification and CGuard EPS that the Company currently distribute into the European Union, displays the required CE mark. In order to maintain certification, the Company is required to pass an annual surveillance audit conducted by Notified Body auditors. The European Union replaced the MDD with the new European Medical Device Regulation (MDR 2017/745) (“MDR”) regulations. The MDR entered into force after a transitional period of three years and a one year extension of that transition period due to the COVID-19 pandemic on May 26, 2021 and which changes several aspects of the regulatory framework in the EU. Manufacturers had the duration of the transition period to update their technical documentation and processes to meet the new requirements in order to obtain a CE Mark.

 

In the Company’s specific case, the Company’s CE mark for CGuard EPS under the MDD expired on November 12, 2022. On February 14, 2023, the Company received a derogation per Article 97 paragraph 1 of Regulation 2017/745 from the Agency for Medicines and Health Products (FAMHP) allowing the Company to continue marketing CGuard EPS in the EU until August 15, 2023. Subsequently, on March 20, 2023 Regulation (EU) 2023/607 was published allowing the Company to continue marketing CGuard EPS in EU countries under the MDD directive until December 31, 2027.

 

In January 2024, the Company received CE mark recertification for the CGuard™ EPS under the EU’s Medical Device Regulation regulatory framework and can market Cguard permanently in EU countries as long as the Company is able to maintain its regulatory approvals.

 

  c.

Risks Related to Our Operations in Israel including the recent attack by Hamas and other terrorist organizations from the Gaza Strip and Israel’s war against them.

 

In October 2023, Israel was attacked by a terrorist organization and entered a state of war. As of the date of these consolidated financial statements, the war in Israel is ongoing and continues to evolve. The Company operations including the production facility are located in Israel. Currently, such activities in Israel remain largely unaffected. During the year ended December 31, 2023, the impact of this war on the Company’s results of operations and financial condition was immaterial, but such impact may increase, which could be material, as a result of the continuation, escalation or expansion of such war.

     
  d. Risks Related to the Geopolitical and Military Tensions Between Russia and Ukraine in Europe
     
   

The Company derived approximately 13.5% and 12.1% in the years ended December 31, 2023 and 2022, respectively, of total sales in Russia and Belarus. The escalation of geopolitical instability in Russia and Ukraine as well as currency fluctuations in the Russian Ruble could negatively impact the Company’s operations, sales, and future growth prospects in that region.

 

As a result of the crisis in Ukraine, the United States and the EU have implemented sanctions against certain Russian individuals and entities and have made it more difficult for the Company to collect on outstanding accounts receivable from customers in this region. The Company cannot provide assurance that potential future changes in sanctions will not have a material impact on the Company’s operations in Russia and Belarus or on the Company’s financial results.

 

F-9
 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES

 

  a. Use of estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates using assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

 

As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to inventory valuations and assessing the likelihood of exercise of options to extend the lease term.

 

  b. Functional currency

 

The currency of the primary economic environment in which the operations of the Company and its subsidiaries are conducted is the U.S. dollar (“$” or “dollar”). Accordingly, the functional currency of the Company and its subsidiaries is the U.S. dollar.

 

The dollar figures are determined as follows: transactions and balances originally denominated in dollars are presented in their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. The resulting translation gains or losses are recorded as financial income or expense, as appropriate. For transactions reflected in the statements of operations in foreign currencies, the exchange rates at transaction dates are used. Depreciation and changes in inventories and other changes deriving from non-monetary items are based on historical exchange rates.

 

  c. Principles of consolidation

 

The consolidated financial statements include the accounts of the Company and of its subsidiaries. Intercompany transactions and balances have been eliminated upon consolidation.

 

  d. Cash and cash equivalents

 

The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. As of December 31, 2023, cash and cash equivalents consisted of cash, short-term deposits (up to three months from the date of deposit) and money market funds. As of December 31, 2022, this balance consisted solely of cash.

 

  e. Marketable securities

 

Marketable securities consist of debt securities. The Company elected the fair value option to measure and recognize its investments in debt securities in accordance with ASC 825, Financial Instruments as the Company manages its portfolio and evaluates the performance on a fair value basis. Changes in fair value, realized gains and losses on sales of marketable securities, are reflected in the statements of operation as finance expense (income), net.

 

Marketable securities are classified under current assets in the consolidated balance sheet as they represent the investment of funds available for the Company’s current operations.

 

F-10
 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

 

  f. Short-term bank deposits

 

Bank deposits with original maturities of more than three months but less than one year are presented as part of short-term bank deposits. Deposits are presented at their cost which approximates market values including accrued interest. Interest on deposits is recorded as financial income.

 

  g. Concentration of credit risk and allowance for doubtful accounts

 

Financial instruments that may potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and short-term bank deposits, which are deposited in major financially sound institutions in the U.S, Israel and Germany, and trade accounts receivable and other receivables. The Company’s trade accounts receivable is derived from revenues earned from customers from various countries. The Company performs ongoing credit evaluations of its customers’ financial condition and, requires no collateral from its customers. The Company also has a credit insurance policy for some of its customers. The Company maintains the allowance for estimated losses resulting from the inability of the Company’s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company’s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses, and future expectations. The allowance for expected credit losses was immaterial during the periods presented.

 

  h. Inventory

 

Inventories are stated at the lower of cost (cost is determined on a “first-in, first-out” basis) or net realizable value. The Company’s inventories generally have a limited shelf life and are subject to impairment as they approach their expiration dates. The Company regularly evaluates the carrying value of its inventory and when, based on such evaluation, factors indicate that impairment has occurred, the Company impairs the inventories’ carrying value.

 

  i. Leases

 

Operating leases are included in operating lease right-of-use (“ROU”) assets. Short-term balances regarding lease liabilities are included in accounts payable and accruals - Other and long-term balances regarding lease liabilities are included in operating lease liabilities. ROU assets represent Company’s right to use an underlying asset for the lease term and lease liabilities represent obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses the incremental borrowing rate based on the information available at the lease commencement date as the rate implicit in the lease is not readily determinable. The determination of the incremental borrowing rate requires management judgment based on information available at lease commencement. The lease terms may include periods covered by options to extend the lease when it is reasonably certain that the Company will exercise such options, and periods covered by options to terminate the lease when it is reasonably certain that the Company will not exercise such options. Operating lease cost is recognized on a straight-line basis over the lease term. Lease agreements that include lease and non-lease components are accounted for as a single lease component. The Company elected the short-term lease recognition exemption for leases with a lease term of 12 months or less.

 

  j. Property, plant and equipment

 

Property, plant and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets: over three years for computers and other electronic equipment, and seven to fifteen years for office furniture and equipment and machinery and equipment (mainly seven years). Leasehold improvements are amortized on a straight-line basis over the term of the lease, which is shorter than the estimated life of the improvements.

 

  k. Impairment in value of long-lived assets

 

The Company tests long-lived tangible assets for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future cash flows (undiscounted and without interest charges) of the long-lived assets is less than the carrying amount of such assets, an impairment would be recognized, and the assets would be written down to their estimated fair values, based on expected future discounted cash flows.

 

F-11
 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

 

  l. Revenue recognition

 

A contract with a customer exists only when: 1) the parties to the contract have approved it and are committed to perform their respective obligations, 2) the Company can identify each party’s rights regarding the distinct goods or services to be transferred (“Performance Obligations”), 3) the Company can determine the transaction price for the goods or services to be transferred, 4) the contract has commercial substance and 5) it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for Performance Obligations upon transfer of control to the customer, excluding sales taxes.

 

Revenue from sales of goods, including sales to distributors, is recognized when the customer obtains control of the product, once the Company has a present right to payment and the customer has legal title, and risk and rewards of ownership are obtained by the customer. Generally, this occurs when products are shipped. In few cases when products are directly sold to medical centers on consignment basis, revenue is recognized when the product is consumed.

 

The Company recognizes the incremental costs of obtaining contracts as an expense since the amortization period of the assets that the Company otherwise would have recognized is one year or less. The costs are recorded under selling and marketing expenses. Disaggregated revenue is disclosed in Note 13.

 

The Company recognizes revenue net of value added tax (VAT).

 

  m. Research and development costs

 

Research and development costs, including the costs of the Company’s US based clinical trial costs were approximately $3,300,000 and $4,468,000 for the years ended December 31, 2023 and 2022, respectively, and charged to the statement of operations as incurred.

 

  n. Share-based compensation

 

The Company has equity incentive plans under which the Company grants equity awards, including stock options, restricted stock and restricted stock units (“RSUs”) to employees, directors and service providers. Employee and service providers equity awards are accounted for using the grant-date fair value method. The Company determines compensation expense associated with restricted stock and RSUs based on the fair value of our common stock on the date of grant. The fair value of option awards is estimated using the Black-Scholes valuation model and expensed over the requisite service period. The Company elected to account for forfeitures as they occur.

 

The Company elected to recognize compensation expenses for awards to employees with only service conditions that have graded vesting schedules using the accelerated multiple option approach.   The attribution for nonemployee awards is in the same manner as if the Company had paid cash for the goods or services.

 

In addition, certain of our share-based awards to service providers are performance based, i.e., the vesting of these awards depends upon achieving certain goals. The company recognizes compensation expenses for awards with performance conditions when the company concludes that it is probable that the performance condition will be achieved.

 

  o. Uncertain tax positions

 

The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. If under the first step a tax position is assessed to be more likely than not of being sustained on audit, the second step is performed, under which the tax benefit is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Such liabilities are classified as long-term, unless the liability is expected to be resolved within twelve months from the balance sheet date. The Company’s policy is to include interest related to unrecognized tax benefits within “Financial expenses - net”.

 

F-12
 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

 

p. Deferred income taxes

 

Deferred taxes are determined utilizing the “asset and liability” method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred taxes are expected to be paid or realized. The Company assesses realization of deferred income tax assets and, based on all available evidence, concludes whether it is more likely than not that the net deferred income tax assets will be realized. A valuation allowance is provided for the amount of deferred income tax assets not considered to be realizable.

 

The Company may incur an additional tax liability in the event of intercompany dividend distributions by its subsidiaries. Such additional tax liability in respect of these foreign subsidiaries has not been provided for in these financial statements as it is the Company’s policy to permanently reinvest the subsidiaries’ earnings and to consider distributing dividends only in connection with a specific tax opportunity that may arise.

 

Taxes that would apply in the event of disposal of investments in a foreign subsidiary have not been taken into account in computing the deferred taxes, as it is the Company’s intention to hold, and not to realize, these investments.

 

  q. Advertising

 

Costs related to advertising and promotion of products are charged to sales and marketing expense as incurred. Advertising expenses were approximately $426,000 and $359,000 for the years ended December 31, 2023 and 2022, respectively.

 

  r. Net loss per share

 

Basic and diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock, pre-funded warrants and fully vested restricted stock units outstanding during the period. The calculation of diluted net loss per share excludes the effect of potential dilution of share options, warrants, and unvested restricted stocks, unvested restricted stock units and Series C preferred stock as the effect is anti-dilutive.

 

For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the Pre-funded Warrants have been included since the shares are issuable for a negligible consideration, as determined by the Company according to ASC 260-10-45-13, and have no vesting or other contingencies associated with them. For the year ended December 31, 2023, we had weighted average Pre-funded Warrants to purchase 9,612,502 share of common stock, which was used in the computation of net loss per share for the year.

 

The total number of shares of common stock related to outstanding options, warrants, unvested restricted stock, unvested restricted stock units and Series C Preferred Stock, which were excluded from the calculations of diluted loss per share were 74,978,006 and 2,741,355 for the years ended December 31, 2023 and 2022, respectively. This amount includes 3,054,086 and 355,951 of unvested restricted stock included in the number of issued and outstanding shares as of December 31, 2023 and 2022, respectively.

 

  s. Segment reporting

 

The Company has one operating and reportable segment.

 

  t. Fair value measurement

 

The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

 

The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:

 

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

 

Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data.

 

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

 

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.

 

F-14
 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

 

  u. Recently adopted accounting pronouncement

 
In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments. This guidance replaces the incurred loss impairment methodology. Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates (“ASU 2019-10”). The purpose of this amendment is to create a two-tier rollout of major updates, staggering the effective dates between larger public companies and all other entities. This granted certain classes of companies, including Smaller Reporting Companies (“SRCs”), additional time to implement major FASB standards, including ASU 2016-13. Larger public companies had an effective date for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All other entities are permitted to defer adoption of ASU 2016-13, and its related amendments, until the earlier of fiscal periods beginning after December 15, 2022. Under the current SEC definitions, the Company met the definition of an SRC and adopted the deferral period for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The Company adopted the provisions of this update as of January 1, 2023 with no material impact on its consolidated financial statements.

 

  v. Recently issued accounting pronouncement, not yet adopted

 

1)

In November 2023, the FASB issued ASU 2023-07 “Segment Reporting: Improvements to Reportable Segment Disclosures”. This guidance expands public entities segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity’s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements related disclosures.

     
  2) In December 2023, the FASB issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”. This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.

 

  3)

In August 2020, the FASB issued ASU 2020-06 “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40).” This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. This ASU is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The initial adoption of ASU 2020-06 is not expected to have a material impact on the Company’s consolidated financial statements.

 

F-15
 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 3 – FAIR VALUE MEASUREMENTS

 

As of December 31, 2023, the carrying amounts of accounts payable, accounts receivable and other receivable approximate their fair values due to the short-term maturities of these instruments.

 

The Company’s financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:

 

   Total   Level 1   Level 2   Level 3 
  

As of December 31, 2023

($ in thousands)

 
   Total   Level 1   Level 2   Level 3 
                 
Assets:                    
Cash equivalents-                    
Money market funds  $7,094   $7,094   $-   $- 
                     
Marketable securities-                    
U.S government bonds  $29,383   $-   $29,383   $- 

 

The Company’s debt securities are classified within Level 2 because it uses quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair value.

 

The cost of Marketable securities as of December 31, 2023 is $28,727,000 .

 

NOTE 4 - MARKETABLE SECURITIES

 

The following table sets forth the Company’s marketable securities for the indicated period:

 

   December 31, 2023 
   ($ in thousands) 
      
U.S government bonds  $29,383 

 

The following table summarizes the fair value of the Company’s marketable securities classified by maturity as of December 31, 2023:

 

   December 31, 2023 
   ($ in thousands) 
     
Amounts maturing within one year  $24,523 
Amounts maturing after one year through two years   4,860 
   $29,383 

 

The table below sets forth a summary of the changes in the fair value of the Company’s marketable securities for the year ended December 31, 2023:

 

   Year ended
December 31,		 
   2023 
   ($ in thousands) 
     
Balance at beginning of the period  $- 
Additions   34,644 
Sale or maturity   (6,000)
Interest Received   (38)
Changes in fair value   777 
Balance at end of the period   29,383 
      

 

F-16
 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 5 - PROPERTY, PLANT AND EQUIPMENT

 

a.Composition of assets, grouped by major classifications, is as follows:

 

   2023   2022 
   December 31, 
   2023   2022 
   ($ in thousands) 
Cost:          
Computer equipment  $425   $396 
Office furniture and equipment   249    231 
Machinery and equipment   1,702    1,704 
Leasehold improvements   724    494 
Property plant and equipment, gross   3,100    2,825 
Less - accumulated depreciation and amortization   (2,040)   (1,908)
Net carrying amount  $1,060   $917 

 

  b. Depreciation and amortization expenses totaled approximately $232,000 and $188,000 for the years ended December 31, 2023 and 2022, respectively.

 

NOTE 6 - LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT

 

Israeli labor law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances.

 

Pursuant to section 14 of the Israeli Severance Compensation Act, 1963, most of the Company’s employees are entitled to have monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments in accordance with section 14 relieve the Company from any future severance payments to these employees. The severance pay expenses for such employees were approximately $256,000 and $241,000 for the years ended December 31, 2023 and 2022, respectively.

 

The severance pay liability of the Company for the rest of its Israeli employees, which reflects the undiscounted amount of the liability, is based upon the number of years of service and the latest monthly salary. The severance pay liability is partly covered by insurance policies and by regular deposits with recognized severance payment funds. The Company may only withdraw funds previously deposited for savings in connection with the payment of severance. The severance pay expenses for such employees were approximately $116,000 and $68,000 for the years ended December 31, 2023 and 2022, respectively.

 

F-17
 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 7 – LEASE AGREEMENTS

 

  1)

The Company’s Israeli subsidiary had a lease agreement for a facility in Israel, which expired on December 31, 2022 with an option to extend the agreement for two additional years until December 31, 2024. On May 25, 2022 the Company amended the agreement mentioned above and extended it until December 31, 2026 as well as leasing of additional space in the facility. On August 24, 2023, the Company amended the lease agreement mentioned above, leasing additional space in the facility and shortened the lease term of another space in the building. The balances of right of use assets and lease liabilities increased due to the newly leased space and decreased due to the lease that was shortened.

     
  2)

Operating lease cost for the years ended December 31, 2023 and 2022 was $433,000 and $442,000 respectively.

 

Supplemental information related to leases are as follows:

   2023   2022 
   December 31, 
   2023   2022 
  

($ in thousands)

 
Operating lease right-of-use assets   1,473    1,554 
Current Operating lease liabilities   (557)   (419)
Non-current operating lease liabilities   (1,038)   (1,195)

 

Other information:

 

Operating cash flows from operating leases (cash paid in thousands)   (429)   (436)
Weighted Average Remaining Lease Term   3    4 
Weighted Average Discount Rate   9.73%   8.69%

 

Maturities of lease liabilities are as follows:

   Amount 
   ($ in thousands) 
2024   579 
2025   584 
2026   653 
Total lease payments   1,816 
Less imputed interest   (221)
Total   1,595 

 

F-18
 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 8 - COMMITMENTS AND CONTINGENT LIABILITIES:

 

Distribution Agreement with Chinese Partner

 

On February 3, 2021, the Company entered into a distribution agreement (the “Distribution Agreement”) with three China-based partners, pursuant to which the Chinese partners will be responsible for conducting the necessary registration trials for commercial approval of the Company’s products in China, followed by an eight-year exclusive distribution right to sell the Company’s products in China with the term of the agreement continuing on a year-to-year basis unless terminated. Under the Distribution Agreement, the China-based partners will be subject to minimum purchase obligations. The Distribution Agreement may be terminated for cause upon failure to meet minimum purchase obligations, failure to obtain regulatory approvals or for other material breaches.

 

In addition, the agreement stipulates that if the Distributor fails to obtain the Regulatory Approvals by the time stipulated in the agreement due to the failure of the clinical trials, and this Agreement was terminated as a result of such failure to obtain Regulatory Approvals, InspireMD shall reimburse Distributor in an amount which is 50% of Distributor’s direct out of pocket costs to 3rd parties for conducting the clinical trials, which reimbursement will not exceed USD 1,000,000. The financial statements include a liability, based on 50% of the Distributor costs incurred until December 31, 2023. The liability at December 31, 2023 is immaterial.

 

NOTE 9 - EQUITY

 

  a. Share capital

 

The Company’s common stock are listed on the Nasdaq Capital Market.

 

Private Placement

 

    On May 12, 2023, the Company entered into a securities purchase agreement (the “Purchase Agreement”) pursuant to which the Company agreed to sell and issue in a private placement (the “Private Placement Offering) an aggregate of 10,266,270 shares (the “Private Placement Shares”) of the Company’s common stock, pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 15,561,894 shares of common stock and warrants to purchase up to an aggregate of 51,656,328 shares of common stock, consisting of Series H warrants to purchase up to 12,914,086 shares of common stock (the “Series H Warrants”), Series I warrants to purchase up to 12,914,078 shares of common stock (the “Series I Warrants”), Series J warrants to purchase up to 12,914,086 shares of Common Stock (the “Series J Warrants”) and Series K warrants to purchase up to 12,914,078 shares of common stock (the “Series K Warrants” and together with the Series H Warrants, Series I Warrants and Series J Warrants, the “Warrants”), at an offering price of $1.6327 per Private Placement Share and associated Warrants and an offering price of $1.6326 per Pre-Funded Warrant and associated Warrants. The Private Placement Offering closed on May 16, 2023.
     
    Aggregate gross proceeds to the Company in respect of the Private Placement Offering were $42.2 million, before deducting fees payable to the placement agent and other offering expenses payable by the Company which amounted to approximately $4.6 million. If the Warrants are exercised in cash in full this would result in an additional $71.4 million of gross proceeds.

 

F-19
 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 9 – EQUITY (continued):

 

   

The Pre-Funded Warrants are immediately exercisable at an exercise price of $0.0001 per share and will not expire until exercised in full. The Warrants are immediately exercisable upon issuance at an exercise price of $1.3827 per share. The Warrants have a term of the earlier of (i) five years from the date of issuance and (ii) (A) in the case of the Series H Warrants, 20 trading days following the Company’s public release of primary and secondary end points related to one year follow up study results from the Company’s C-Guardians pivotal trial, (B) in the case of the Series I Warrants, 20 trading days following the Company’s announcement of receipt of Premarket Approval (PMA) from the Food and Drug Administration, or FDA, for the CGuard Prime Carotid Stent System (135 cm), (C) in the case of the Series J Warrants, 20 trading days following the Company’s announcement of receipt of FDA approval for the SwitchGuard transcarotid system and CGuard Prime 80 cm and (D) in the case on the Series K Warrants, 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of the CGuard Carotid Stent System in the United States begin. The Warrants may be exercised on a cashless basis if there is no effective registration statement registering the shares underlying the warrants.

 

The Company issued a total of 307,260 shares of its common stock in connection with the exercise of Pre-Funded Warrants to purchase 307,271 shares of common stock on a cashless basis.  As of December 31, 2023, there are Pre-Funded Warrants to purchase an aggregate of 15,254,623 share of common stock outstanding.

 

Pursuant to the full ratchet anti-dilution adjustment provisions in the respective certificate of designation for the Company’s Series C Preferred Stock, the conversion price of the outstanding shares of the Series C Preferred Stock was reduced to $1.3827 per share, effective as of the date of the securities purchase agreement entered for the Offering, and the number of shares of common stock issuable upon conversion of the Series C Preferred Stock increased by 5,668 additional shares of common stock upon conversion of the Series C Preferred Stock, based on 1,718 shares of Series C Preferred Stock outstanding as of May 16, 2023.

 

As of December 31, 2023 and 2022, there were 1,718 shares of Series C Preferred Stock outstanding, convertible into an aggregate of 7,952 and 2,284 shares of the Company’s common stock, respectively with a total stated value of $10,997.

 

As of December 31, 2023, the Company has outstanding warrants to purchase an aggregate of 53,396,008 shares of common stock as follows:

 

  

Number of underlying

Common stock

  

Exercise

price

 
Series E Warrants   198,159   $27.0000 
Series F Warrants   433,878   $7.4250 
Series G Warrants   1,092,344   $10.2300 
Series H Warrants   12,914,086   $1.3827 
Series I Warrants   12,914,078   $1.3827 
Series J Warrants   12,914,086   $1.3827 
Series K Warrants   12,914,078   $1.3827 
Underwriter Warrants   15,299   $7.4250 
Total Warrants   53,396,008   $ 

 

As of December 31, 2023, the Company has 155,000,000 authorized shares of capital stock, par value $0.0001 per share, of which 150,000,000 are shares of common stock and 5,000,000 are shares of “blank check” preferred stock.

 

F-20
 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 9 – EQUITY (continued):

 

  b. Share-Based Compensation

 

  1)

On September 30, 2021, at our 2021 annual meeting of stockholders, our stockholders approved our 2021 Equity Incentive Plan.

 

The Company’s. 2021 Equity Incentive Plan provides for the granting of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, dividend equivalent rights, and other awards, which may be granted singly, in combination, or in tandem.

 

As of December 31, 2023, we had 7,731,618 shares of common stock available for future issuance under our 2021 Equity Incentive Plan.

 

  5) The following table summarizes information about stock options granted to employees:

 

   Year ended December 31 
   2023   2022 
   Number of options  

Weighted

average

exercise price

   Number of options   Weighted average exercise price 
Outstanding - beginning of period   294,712    5.21    289,408   $5.29 
Granted   1,097,250    1.89    7,841    2.61 
Forfeited   (12,266)   4.00    (2,537)   5.70 
Outstanding- end of period   1,379,696    2.58    294,712   $5.21 
Exercisable at the end of the period   215,709    5.38    123,115    5.51 

 

  6) The following table summarizes information about stock options granted to non-employees:

 

   Year ended December 31 
   2023   2022 
   Number of options   Weighted average exercise price   Number of options   Weighted average exercise price 
Outstanding - beginning of period   166,669    3.37    20,002    6.90 
Granted   625,000    1.71    146,667    2.89 
Outstanding - end of period   791,669    2.06    166,669    3.37 
Exercisable at the end of the period   84,667    3.42    35,667    3.61 

 

  7) The following table summarizes information about restricted stock granted to employees:

 

   Year ended December 31 
   2023   2022 
   Number of restricted stock 
Outstanding - beginning of period   355,951    527,668 
Granted   2,914,340    45,494 
Forfeited   (29,695)   (10,832)
Vested   (186,510)   (206,379)
Outstanding - end of period   3,054,086    355,951 

 

F-21
 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 9 – EQUITY (continued):

 

  8) The following table summarizes information about RSUs granted to employees:

 

   Year ended December 31 
   2023   2022 
   Number of RSUs 
Outstanding - beginning of period   237,078    237,078 
Granted   1,045,150    - 
Outstanding - end of period   1,282,228    237,078 

 

  9) The following table provides additional information about all options outstanding and exercisable:

 

   Outstanding as of December 31, 2023 

Exercise

price

  Options outstanding   Weighted average remaining contractual life (years)   Options exercisable 
$1.15-2.97   1,786,211    9.28    73,946 
$3.30-4.12   227,932    8.53    95,075 
$4.95-10.05   153,169    7.00    127,303 
$16.50   4,053    6.01    4,053 
    2,171,365    9.03    300,376 

 

The weighted average of the remaining contractual life of total vested and exercisable options as of December 31, 2023 was 7.54 years.

 

The aggregate intrinsic value of the total exercisable options as of December 31, 2023 was approximately $10,983.

 

The weighted average fair value of options granted to employees was $1.65 and $2.33 for the years ended December 31, 2023 and 2022, respectively. The weighted average fair value of options granted was estimated using the Black-Scholes option-pricing model.

 

The weighted average fair value of options granted to consultants was $1.50 and $2.57 for the years ended December 31, 2023 and 2022, respectively. The weighted average fair value of options granted was estimated using the Black-Scholes option-pricing model.

 

The weighted average fair value of restricted stock granted was $1.95 and $2.42 for the years ended December 31, 2023 and 2022, respectively.

 

The weighted average fair value of RSU granted was $1.76 for the year ended December 31, 2023.

 

The vesting period for outstanding stock options, restricted stock, and RSUs is typically three years, with one-third of the awards vesting annually. Additionally, some of our share-based awards to service providers are performance-based, vesting upon the achievement of specified performance criteria related to clinical or marketing activities.

 

F-22
 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 9 – EQUITY (continued):

 

  10) The following table sets forth the assumptions that were used in determining the fair value of options granted to employees for the year December 31, 2023 and 2022:

 

    Year ended December 31 
    2023    2022 
Expected life   5.125-6.5 years    5.125-6.5 years 
Risk-free interest rates   3.58%-4.73%    1.79%-2.88% 
Volatility   109.62%-125.61%    127.43%-130.93%  
Dividend yield   -    - 

 

The Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. Accordingly, as to ordinary course options granted, the expected term was determined using the simplified method, which takes into consideration the option’s contractual life and the vesting periods (for non-employees, the expected term is equal to the option’s contractual life).

 

The annual risk-free rates are based on the yield rates of zero coupon non-index linked U.S. Federal Reserve treasury bonds as both the exercise price and the share price are in dollar terms. The Company’s expected volatility is derived from its historical data.

 

  11) As of December 31, 2023, the total unrecognized compensation cost on employee and non-employee stock options, restricted stock and RSUs, related to unvested stock-based compensation, amounted to approximately $7.18 million. This cost is expected to be recognized over a weighted-average period of approximately 0.97 years. This expected cost does not include the impact of any future stock-based compensation awards.
     
  12) The following table summarizes the allocation of total share-based compensation expense in the consolidated statements of operations:

 

   Year ended December 31 
   2023   2022 
   ($ in thousands) 
Cost of revenues  $93   $72 
Research and development   649    582 
Sales and marketing   416    318 
General and administrative   3,332    1,380 
   $4,490   $2,352 

 

F-23
 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 10 – RELATED PARTIES TRANSACTIONS

 

  1) During the twelve months ended December 31, 2023 and 2022, a consulting company whose founder and CEO is our board member provided certain marketing services in the amount of $788 and $9,645, respectively.
     
  2) On September 15, 2023, the board approved the company’s entry into a consultancy agreement with a member of the immediate family of the CEO for certain administrative projects in connection with the Company’s expansion to the U.S. until a full-time Company employee is retained in such capacity. Pursuant to the Consultancy Agreement, the Company will pay a fixed hourly fee of $50 for a maximum of 20 hours per week and customary expenses. The Company may terminate this Agreement for any reason or no reason, at any time, upon 30 days prior written notice to consultant.

 

Consulting expenses for the year ended December 31, 2023, were $11,440.

 

3) Election to Receive Shares of Common Stock in lieu of Cash Compensation

 

For the year 2023, certain non-employee directors elected to receive all or a portion of their cash retainer amount in shares of the Company’s common stock under the 2021 Equity Incentive Plan. For a director that made that election, a stock award under the 2021 Equity Incentive Plan was paid quarterly on the first day of each next quarter (“Issuance Dates”) and became fully vested on the Issuance Dates. The stock award was determined by dividing (x) the product of the cash retainer amount and percentage of the cash retainer amount elected to be taken in shares by (y) the “Fair Market Value” (as defined in the 2021 Equity Incentive Plan) of a share on the Issuance Dates.

 

During the years ended December 31, 2023 the Company issued 52,129 shares of common stock to non-employee directors who elected to receive all or a portion of their cash retainer amount for the nine months ended September 30, 2023 in shares of the Company’s common stock under the 2021 Equity Incentive Plan.

 

As of December 31, 2023, there was an accrual for $55,000 for director’s fees for the three months ended December 31, 2023. Out of this an amount of $22,875 was paid in cash and $32,125 was issued in shares of the Company’s common stock under the 2021 Equity Incentive Plan. On January 1, 2024 the Company issued 11,854 shares of common stock.

 

NOTE 11 - TAXES ON INCOME:

 

  a. Tax laws applicable to the Company and its subsidiaries

 

Taxation in the United States

 

InspireMD, Inc. is taxed under U.S. tax laws. Accordingly, the applicable federal corporate tax rate in 2023 is 21%. the applicable state income tax rate in 2023 is 3.42%.

 

Taxation in Israel

 

InspiredMD, Ltd is taxed under Israeli tax laws. Accordingly, the applicable corporate tax rate in 2023 is 23%.

 

Taxation in Germany

 

InspireMD GmbH is taxed according to the tax laws in Germany. Accordingly, the applicable tax rates are corporate tax rate of 15.825% and trade tax rate of 17.15%.

 

F-24
 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 11 - TAXES ON INCOME: (continued):

 

  b. Tax benefits under the Law for the Encouragement of Capital Investments, 1959 (the “Law”):

 

On December 29, 2016, the Investment Law was amended (“73 Amendment”), which includes, inter alia, two new tax incentive opportunities. These are the Preferred Technological Enterprise (“PTE”) and Special Preferred Technological Enterprise (“SPTE”). In order to benefit from either of these options, a Company must meet certain qualifications and receive formal approval from the Israel Innovation Authority (“IIA”) which allows the Company to use the reduced corporate tax rate of 12% on its “Preferred Technological Income” (earned from enterprises located in Development outside of Zone A) in the case of a “preferred technology enterprise”, or 6% on its “preferred technology income” (earned from enterprises located in Development Zone A or outside it) in the case of a “special preferred technology enterprise”. Additionally, any “technology income”, as this term is defined by the Law, not classified as “preferred technology income” is subject to the corporate tax rate.

 

Furthermore, according to the provisions regarding “preferred technology enterprise” and “special preferred technology enterprise” in the Law and the regulations thereunder, and to the extent the income is attributable to manufacturing, this income is classified as “preferred income” and is taxed at 7.5% or 16% according to the development zone. To the extent the income is from an intangible asset used for marketing, it is subject to the normal corporate tax rate.

 

Additionally, when income of a company originating from “preferred technology income” is distributed as dividend to a foreign-resident corporation, tax withholding from the dividend is 4%, provided that 90% or more of that company’s shares are directly held by one or more foreign corporations, and the profits resulted after they acquired the shares.

 

   c. Carry forward tax losses

 

As of December 31, 2023, the Company had a net carry forward tax loss of approximately $54 million, of which approximately $35 million (arising before January 1, 2018), expires until 2038, and approximately $19 million, which does not expire, but is limited to offset 80% of the net income in the year it is utilized.

 

Under the U.S. tax laws, for net operating losses (NOLs) arising after December 31, 2017, the Tax Cuts and Jobs Act enacted on December 22, 2017 (the “2017 Act”) limits a taxpayer’s ability to utilize NOL carryforwards to 80% of taxable income.

 

In addition, NOLs arising after 2017 can be carried forward indefinitely, but carryback is generally prohibited. NOLs generated in tax years beginning before January 1, 2018, will not be subject to the foregoing taxable income limitation and will continue to have a two-year carryback and twenty-year carryforward period.

 

As of December 31, 2023, InspireMD Ltd., an Israeli subsidiary, had a net carry forward tax loss of approximately $107 million. Under Israeli tax laws, the carry forward tax losses can be utilized indefinitely.

 

The Israeli subsidiary is taxed in the New Israeli Shekel (“NIS”), which is different from its functional currency (U.S. Dollar). The change in the Israeli subsidiary NOL’s for tax purposes is partly resulted by such rate differences.

 

  d. Loss before income taxes

 

The components of loss before income taxes are as follows:

  

   Year ended December 31 
   2023   2022 
   ($ in thousands) 
Loss before taxes on income:          
InspireMD, Inc.  $(5,772)  $(4,773)
Subsidiaries   (14,079)   (13,690)
   $(19,851)  $(18,463)

 

F-25
 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 11 - TAXES ON INCOME (continued):

 

  e. Current taxes on income

 

The main reconciling item between the statutory tax rate of the Company and the effective tax rate is the change in valuation allowance in respect of tax benefits from carried forward tax losses due to uncertainty of the realization of such tax benefits.

 

The changes in the valuation allowance for the year ended December 31, 2023 and 2022 were as follows:

 

   Year ended December 31 
   2023   2022 
   ($ in thousands) 
Balance at the beginning of the year  $40,071   $39,212 
Changes during the year:          
Losses during the year (including foreign exchange rate effect)   2,580    859 
Balance at the end of the year  $42,651   $40,071 

 

  f. Accounting for Uncertain Tax position

 

The following is a reconciliation of the total amounts of the Company’s uncertain tax positions during the year ended December 31, 2023 and 2022 were as follows:

 

   Year ended December 31, 
   2023   2022 
   ($ in thousands) 
Balance at beginning of period  $106   $89 
Increase in uncertain tax positions because of tax positions taken during the year   62    17 
Balance at end of period  $168   $106 

 

A summary of open tax years by major jurisdiction is presented below:

 

Jurisdiction    Years 
U.S.    2020-2023 
Israel    2019-2023 
Germany    2020-2023 

 

  g. Deferred income tax:

 

   2023   2022 
   December 31, 
   2023   2022 
   ($ in thousands) 
     
Provision for vacation and recreation pay   68    45 
R&D expenses   1,691    1,452 
Operating lease right of use assets   (339)   (357)
Operating lease liabilities   367    371 
Share-based compensation   3,492    3,021 
Carry forward tax losses   37,342    35,507 
Accrued severance pay, net   30    32 
Deferred tax assets noncurrent   42,651    40,071 
Less-valuation allowance   (42,651)   (40,071)
Deferred tax assets   -    - 

 

F-26
 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 12 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:

 

Balance sheets:

 

    Inventory:

  

   2023   2022 
   December 31, 
   2023   2022 
   ($ in thousands) 
Finished goods  $210   $179 
Work in process   562    510 
Raw materials and supplies   1,334    932 
Total inventory  $2,106   $1,621 

 

 

  a. Accounts payable and accruals-other:

 

   2023   2022 
   December 31, 
   2023   2022 
   ($ in thousands) 
Employees and employee institutions  $2,188   $1,853 
Accrued vacation and recreation pay   287    197 
Accrued expenses   1,115    554 
Clinical trial accrual   744    1,258 
Current Operating lease liabilities   557    419 
Other   190    130 
Accounts Payable and Accruals - Other  $5,081   $4,411 

 

NOTE 13 – DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES:

 

Revenues are attributed to geographic areas based on the location of the customers. The following is a summary of revenues:

 

   Year ended December 31, 
   2023   2022 
   ($ in thousands) 
Italy  $1,195   $970 
Germany   896    866 
Russia   738    381 
Other   3,376    2,954 
   $6,205   $5,171 

 

By product:

 

   Year ended December 31, 
   2023   2022 
   ($ in thousands) 
CGuard™ EPS  $6,205   $5,123 
MGuard Prime™ EPS   -    48 
   $6,205   $5,171 

 

By principal customers:

  

   Year ended December 31, 
   2023   2022 
Customer A   14%   17%
Customer B   12%   7%

 

All tangible long lived assets are located in Israel.

 

NOTE 14 - SUBSEQUENT EVENTS:

 

On January 23, 2024, the Company granted 1,528,316 restricted shares of the Company’s common stock to employees and directors. The shares to employees are subject to a three-year vesting period, with one-third of such awards vesting each year. The shares to directors are subject to a one-year vesting period.

 

On January 23, 2024, the Company granted 563,499 restricted share units of the Company’s common stock to the chief executive officer. The shares are subject to a three-year vesting period, with one-third of such awards vesting each year.

 

On January 23, 2024, the Company granted to employees and directors options to purchase a total of 669,464 shares of the Company’s common stock. The options have an exercise prices of $3.14 per share, which was the fair market value of the Company’s common stock on the date of the grant. The options to employees are subject to a three-year vesting period, with one-third of such awards vesting each year. The options to directors are subject to a one-year vesting period.

 

F-27

 

 EX-4.1 2 ex4-1.htm

 

Exhibit 4.1

 

DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

 

As of March 5, 2024, InspireMD, Inc., a Delaware corporation (“we,” “our” and the “Company”) has one class of security registered under Section 12 of the Securities Exchange Act of 1934, as amended: common stock, par value $0.0001 per share. The following description of such security is intended as a summary of the terms of such security as currently in effect and is qualified in its entirety by the provisions of our amended and restated certificate of incorporation, as amended (the “Certificate of Incorporation”) and the bylaws are filed as exhibits to this Annual Report on Form 10-K and are incorporated by reference herein. We encourage you to read our amended and restated Certificate of Incorporation and amendments thereto, our bylaws and the applicable provisions of the Delaware General Corporation Law, as amended (the “DGCL”), for additional information.

 

Authorized Capital Stock

 

Pursuant to our Certificate of Incorporation, we have authorized 155,000,000 shares of capital stock, par value $0.0001 per share, of which 150,000,000 are shares of common stock and 5,000,000 are shares of “blank check” preferred stock. The authorized and unissued shares of common stock and the authorized and undesignated shares of preferred stock are available for issuance without further action by our stockholders, unless such action is required by applicable law or the rules of any stock exchange on which our securities may be listed. Unless approval of our stockholders is so required, our board of directors does not intend to seek stockholder approval for the issuance and sale of our common stock or preferred stock.

 

Common Stock

 

The holders of our common stock are entitled to one vote per share. Our Certificate of Incorporation does not provide for cumulative voting. Our directors are divided into three classes. At each annual meeting of stockholders, directors elected to succeed those directors whose terms expire are elected for a term of office to expire at the third succeeding annual meeting of stockholders after their election. The holders of our common stock are entitled to receive ratably such dividends, if any, as may be declared by our board of directors out of legally available funds; however, the current policy of our board of directors is to retain earnings, if any, for operations and growth. Upon liquidation, dissolution or winding-up, the holders of our common stock are entitled to share ratably in all assets that are legally available for distribution. The holders of our common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of any series of preferred stock, which may be designated solely by action of our board of directors and issued in the future.

 

On April 26, 2021, Company effectuated a reverse stock split of its common stock at a ratio of 1-for-15.

 

The transfer agent and registrar for our common stock is Securities Transfer Corporation. The transfer agent’s address is 2901 Dallas Parkway, Suite 380, Plano, Texas 75093.

 

Our common stock is listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “NSPR.”

 

 
 

 

Preferred Stock

 

The board of directors is authorized, subject to any limitations prescribed by law, without further vote or action by the stockholders, to issue from time to time shares of preferred stock in one or more series. Each such series of preferred stock shall have such number of shares, designations, preferences, voting powers, qualifications, and special or relative rights or privileges as shall be determined by the board of directors, which may include, among others, dividend rights, voting rights, liquidation preferences, conversion rights and preemptive rights. Issuance of preferred stock by our board of directors may result in such shares having dividend and/or liquidation preferences senior to the rights of the holders of our common stock and could dilute the voting rights of the holders of our common stock.

 

Prior to the issuance of shares of each series of preferred stock, the board of directors is required by the Delaware General Corporation Law and our Certificate of Incorporation to adopt resolutions and file a certificate of designation with the Secretary of State of the State of Delaware. The certificate of designation fixes for each class or series the designations, powers, preferences, rights, qualifications, limitations and restrictions, including, but not limited to, some or all of the following:

 

  ● the number of shares constituting that series and the distinctive designation of that series, which number may be increased or decreased (but not below the number of shares then outstanding) from time to time by action of the board of directors;  
       
  ● the dividend rate and the manner and frequency of payment of dividends on the shares of that series, whether dividends will be cumulative, and, if so, from which date;  
       
  ● whether that series will have voting rights, in addition to any voting rights provided by law, and, if so, the terms of such voting rights;  
       
  ● whether that series will have conversion privileges, and, if so, the terms and conditions of such conversion, including provision for adjustment of the conversion rate in such events as the board of directors may determine;  
       
  ● whether or not the shares of that series will be redeemable, and, if so, the terms and conditions of such redemption;  
       
  ● whether that series will have a sinking fund for the redemption or purchase of shares of that series, and, if so, the terms and amount of such sinking fund;  
       
  ● whether or not the shares of the series will have priority over or be on a parity with or be junior to the shares of any other series or class in any respect;  
       
  ● the rights of the shares of that series in the event of voluntary or involuntary liquidation, dissolution or winding up of the corporation, and the relative rights or priority, if any, of payment of shares of that series; and  
       
  ● any other relative rights, preferences and limitations of that series.  

 

Once designated by our board of directors, each series of preferred stock may have specific financial and other terms.

 

2
 

 

Series C Convertible Preferred Stock (the “Series C Preferred Stock”)

 

As of March 5, 2024, there were 1,718 shares of Series C Preferred Stock outstanding, convertible into an aggregate of 2,284 shares of our common stock.

 

On March 14, 2017, we issued 1,069,822 shares of Series C Preferred Stock in a public offering. Our Series C Preferred Stock has a stated value of $6.40, and each share of Series C Preferred Stock was initially convertible into 0.00015267 of a share of common stock at an initial conversion price equal to $42,000 per share of common stock. Series C Preferred Stock, to the extent that it has not been converted previously, is subject to full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than the conversion price then in effect, subject to adjustment as provided in the certificate of designation. In accordance with the anti-dilution price protection contained in the certificate of designation for the Series C Preferred Stock as further described below, we reduced the Series C Preferred Stock conversion price to $2250.00 per share in connection with the underwritten public offering that closed on March 1, 2018, to $1312.50 per share in connection with the underwritten public offering that closed on April 2, 2018, to $225.00 per share in connection with the underwritten public offering that closed on July 3, 2018, to $75.00 per share in connection with the underwritten public offering that closed on April 8, 2019, then to $27 per share in connection with the underwritten public offering that closed on September 24, 2019, to $6.75 per share in connection with the underwritten public offering that closed on June 5, 2020, to $4.815 per share in connection with the utilization of the ATM Facility, and to $1.3827 per share in connection with the Private Placement Offering that closed on May 17, 2023.

 

The Series C Preferred Stock is convertible at any time at any time at the option of the holder, provided that the holder will be prohibited from converting Series C Preferred Stock into shares of our common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of our common stock then issued and outstanding. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days after such notice to us.

 

In the event of our liquidation, dissolution, or winding up, holders of our Series C Preferred Stock will be entitled to receive the amount of cash, securities or other property to which such holder would be entitled to receive with respect to such shares of Series C Preferred Stock if such shares had been converted to common stock immediately prior to such event (without giving effect for such purposes to the 4.99% or 9.99% beneficial ownership limitation, as applicable) subject to the preferential rights of holders of any class or series of our capital stock specifically ranking by its terms senior to the Series C Preferred Stock as to distributions of assets upon such event, whether voluntarily or involuntarily.

 

Shares of Series C Preferred Stock are not entitled to receive any dividends, unless and until specifically declared by our board of directors. However, holders of our Series C Preferred Stock are entitled to receive dividends on shares of Series C Preferred Stock equal (on an as-if-converted-to-common-stock basis, and without giving effect for such purposes to the 4.99% or 9.99% beneficial ownership limitation, as applicable) to and in the same form as dividends actually paid on shares of the common stock when such dividends are specifically declared by our board of directors. We are not obligated to redeem or repurchase any shares of Series C Preferred Stock. Shares of Series C Preferred Stock are not otherwise entitled to any redemption rights, or mandatory sinking fund or analogous fund provision.

 

The holders of the Series C Preferred Stock have no voting rights, except as required by law. Any amendment to our Certificate of Incorporation, bylaws or certificate of designation that adversely affects the powers, preferences and rights of the Series C Preferred Stock requires the approval of the holders of a majority of the shares of Series C Preferred Stock then outstanding.

 

3
 

 

Pursuant to the anti-dilution provisions contained in the certification of designation for our Series C Preferred Stock, in the event that, while any of our Series C Preferred Stock is outstanding, we issue equity or equity-linked securities at an effective common stock purchase price of less than the Series C Preferred Stock conversion price then in effect, we are required, subject to certain limitations and adjustments as provided in the certificate of designation, to reduce the Series C Preferred Stock conversion price to equal the effective common stock purchase price. This reduction in the Series C Preferred Stock conversion price will result in a greater number of shares of common stock becoming issuable upon conversion of the Series C Preferred Stock for no additional consideration.

 

We have not listed, and we do not plan on making an application to list, the Series C Preferred Stock on Nasdaq, any other national securities exchange or any other nationally recognized trading system.

 

Shares of Series C Preferred Stock were issued in book-entry form under a transfer agency and service agreement between Action Stock Transfer Corp., as transfer agent, and us, and are represented by one or more book-entry certificates deposited with DTC and registered in the name of Cede & Co., a nominee of DTC, or as otherwise directed by DTC.

 

The transfer agent and registrar for our Series C Preferred Stock is Securities Transfer Corporation. The transfer agent’s address is 2901 Dallas Parkway, Suite 380, Plano, Texas 75093.

 

You should review the certificate of designation of the Series C Preferred Stock, and a subsequent amendment, which are filed as an exhibit to this Annual Report on Form 10-K, for a complete description of the terms and conditions of the Series C Preferred Stock.

 

Delaware Anti-Takeover Law, Provisions of our Certificate of Incorporation and Bylaws

 

Delaware Anti-Takeover Law

 

We are subject to Section 203 of the Delaware General Corporation Law. Section 203 generally prohibits a public Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years after the date of the transaction in which the person became an interested stockholder, unless:

 

  ● prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;  
       
  ● the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (i) shares owned by persons who are directors and also officers and (ii) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or  
       
  ● on or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder.  

 

4
 

 

Section 203 defines a business combination to include:

 

  ● any merger or consolidation involving the corporation and the interested stockholder;  
       
  ● any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;  
       
  ● subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; or  
       
  ● the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.  

 

In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with, or controlling, or controlled by, the entity or person. The term “owner” is broadly defined to include any person that, individually, with or through that person’s affiliates or associates, among other things, beneficially owns the stock, or has the right to acquire the stock, whether or not the right is immediately exercisable, under any agreement or understanding or upon the exercise of warrants or options or otherwise or has the right to vote the stock under any agreement or understanding, or has an agreement or understanding with the beneficial owner of the stock for the purpose of acquiring, holding, voting or disposing of the stock.

 

The restrictions in Section 203 do not apply to corporations that have elected, in the manner provided in Section 203, not to be subject to Section 203 of the Delaware General Corporation Law or, with certain exceptions, which do not have a class of voting stock that is listed on a national securities exchange or held of record by more than 2,000 stockholders. Our Certificate of Incorporation and bylaws do not opt out of Section 203.

 

Section 203 could delay or prohibit mergers or other takeover or change in control attempts with respect to us and, accordingly, may discourage attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price.

 

Certificate of Incorporation and Bylaws

 

Provisions of our Certificate of Incorporation and bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our Certificate of Incorporation and bylaws:

 

  ● permit our board of directors to issue up to 5,000,000 shares of preferred stock, without further action by the stockholders, with any rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change in control;  
       
  ● provide that the authorized number of directors may be changed only by resolution of the board of directors;  
     
  ● provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;  
       
  ● divide our board of directors into three classes, with each class serving staggered three-year terms;  
       
  ● do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose);  
       
  ● provide that special meetings of our stockholders may be called only by our board of directors; and  
       
  ● set forth an advance notice procedure with regard to the nomination, other than by or at the direction of our board of directors, of candidates for election as directors and with regard to business to be brought before a meeting of stockholders.  

 

5

 

 EX-10.62 3 ex10-62.htm

 

Exhibit 10.62

 

 

 

 

 

 

 

 

 

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Fourth Amendment to Amended and Restated Employment Agreement as of the Amendment Effective Date.

 

  THE COMPANY:
     
  INSPIREMD, INC.
     
  By: /s/ Marvin Slosman
  Name: Marvin Slosman
  Title Chief Executive Officer

 

  EXECUTIVE:
   
  /s/ Craig Shore
  Craig Shore
   
  August 14, 2020

 

 

 EX-23.1 4 ex23-1.htm

 

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the incorporation by reference in the Registration Statements on Form S-1 (Nos. 333-238247, 333-233432, 333-225680, 333-215682, 333-252199), Form S-3 (Nos. 333-272149, 333-265409, 333-255038, 333-223530) and Form S-8 (Nos. 333-248837, 333-249320, 333-232348, 333-218499, 333-196533, 333-188839, 333-260216, 333-272003, 333-274890, 333-276349) of InspireMD Inc. of our report dated March 5, 2024 relating to the financial statements, which appears in this Form 10-K.

 

Tel-Aviv, Israel /s/Kesselman & Kesselman
March 5, 2024 Certified Public Accountants (Isr.)
  A member of PricewaterhouseCoopers International Limited

 

 

 EX-31.1 5 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO RULE 13a-14(a)

 

I, Marvin Slosman, certify that:

 

  1. I have reviewed this Annual Report on Form 10-K of InspireMD, Inc. (the “registrant”);
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 5, 2024    
     
  By: /s/ Marvin Slosman
  Name: Marvin Slosman
    President and Chief Executive Officer (Principal Executive Officer)

 

 

 

 EX-31.2 6 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13a-14(a)

 

I, Craig Shore, certify that:

 

  1. I have reviewed this Annual Report on Form 10-K of InspireMD, Inc. (the “registrant”);
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 5, 2024    
     
  By: /s/ Craig Shore
  Name: Craig Shore
  Title: Chief Financial Officer (Principal Financial Officer)

 

 

 

 

 EX-32.1 7 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION FURNISHED PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

This certification is furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350) and accompanies the Annual Report on Form 10-K (the “Form 10-K”) for the fiscal year ended December 31, 2023 of InspireMD, Inc. (the “Company”). I, Marvin Slosman, the Chief Executive Officer of the Company, certify that, based on my knowledge:

 

  (1) The Form 10-K fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
     
  (2) The information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods covered in this report.

 

Date: March 5, 2024

 

  By: /s/ Marvin Slosman
  Name: Marvin Slosman
  Title: President and Chief Executive Officer (Principal
    Executive Officer)

 

The foregoing certification is being furnished as an exhibit to the Form 10-K pursuant to Item 601(b)(32) of Regulation S-K and Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and, accordingly, is not being filed as part of the Form 10-K for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

 

 

 

 EX-32.2 8 ex32-2.htm

 

Exhibit 32.2

 

CERTIFICATION FURNISHED PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

This certification is furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350) and accompanies the Annual Report on Form 10-K (the “Form 10-K”) for the fiscal year ended December 31, 2023 of InspireMD, Inc. (the “Company”). I, Craig Shore, the Chief Financial Officer of the Company, certify that, based on my knowledge:

 

  (1) The Form 10-K fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
     
  (2) The information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods covered in this report.

 

Date: March 5, 2024

 

  By: /s/ Craig Shore
  Name: Craig Shore
  Title: Chief Financial Officer (Principal Financial Officer)

 

The foregoing certification is being furnished as an exhibit to the Form 10-K pursuant to Item 601(b)(32) of Regulation S-K and Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and, accordingly, is not being filed as part of the Form 10-K for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

 

 

 

 EX-97.1 9 ex97-1.htm

 

Exhibit 97.1

 

InspireMD, Inc.

Executive Officer Clawback Policy

 

I.Purpose

 

This Executive Officer Clawback Policy describes the circumstances under which Covered Persons of InspireMD, Inc. and any of its direct or indirect subsidiaries (the “Company”) will be required to repay or return Erroneously-Awarded Compensation to the Company.

 

This Policy and any terms used in this Policy shall be construed in accordance with any SEC regulations promulgated to comply with Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, including without limitation Rule 10D-1 promulgated under the Securities Exchange Act of 1934, as amended, and the rules adopted by Nasdaq.

 

Each Covered Person of the Company shall sign an Acknowledgement and Agreement to the Clawback Policy in the form attached hereto as Exhibit A as a condition to his or her participation in any of the Company’s incentive-based compensation programs; provided that this Policy shall apply to each Covered Person irrespective of whether such Covered Person shall have failed, for any reason, to have executed such Acknowledgement and Agreement.

 

II.Definitions

 

For purposes of this Policy, the following capitalized terms shall have the respective meanings set forth below:

 

(a) “Accounting Restatement” shall mean an accounting restatement (i) due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial restatements that is material to the previously issued financial statements (a “Big R” restatement), or (ii) that corrects an error that is not material to previously issued financial statements, but would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (a “little r” restatement). Notwithstanding the foregoing, none of the following changes to the Company’s financial statements represent error corrections and shall not be deemed an Accounting Restatement: (a) retrospective application of a change in accounting principle; (b) retrospective revision to reportable segment information due to a change in the structure of the Company’s internal organization; (c) retrospective reclassification due to a discontinued operation; (d) retrospective application of a change in reporting entity, such as from a reorganization of entities under common control; and (e) retrospective revision for share splits, reverse share splits, share dividends or other changes in capital structure.
   
(b) “Board” shall mean the Board of Directors of the Company.
   
(c) “Clawback-Eligible Incentive Compensation” shall mean, in connection with an Accounting Restatement, any Incentive-Based Compensation Received by a Covered Person (regardless of whether such Covered Person was serving at the time that Erroneously-Awarded Compensation is required to be repaid) (i) on or after the Nasdaq Effective Date, (ii) after beginning service as a Covered Person, (iii) while the Company has a class of securities listed on a national securities exchange or national securities association and (iv) during the Clawback Period.
   
(d) “Clawback Period” shall mean, with respect to any Accounting Restatement, the three completed fiscal years immediately preceding the Restatement Date and any transition period (that results from a change in the Company’s fiscal year) of less than nine months within or immediately following those three completed fiscal years.

 

 1 

 

 

(e) “Committee” shall mean the Compensation Committee of the Board.
   
(f) “Covered Person” shall mean any person who is, or was at any time, during the Clawback Period, an Executive Officer of the Company. For the avoidance of doubt, Covered Person may include a former Executive Officer that left the Company, retired or transitioned to an employee non-Executive Officer role (including after serving as an Executive Officer in an interim capacity) during the Clawback Period, and this Policy applies regardless of whether the Covered Person was at fault for an accounting error or other action that resulted in, or contributed to, the Accounting Restatement.
   
(g) “Erroneously-Awarded Compensation” shall mean the amount of Clawback-Eligible Incentive Compensation that exceeds the amount of Incentive-Based Compensation that otherwise would have been Received had it been determined based on the restated amounts. This amount must be computed without regard to any taxes paid.
   
(h) “Executive Officer” shall mean the Company’s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person (including an officer of the Company’s parent(s) or subsidiaries) who performs similar policy-making functions for the Company. For the sake of clarity, at a minimum, all persons who would be executive officers pursuant to Rule 401(b) under Regulation S-K shall be deemed “Executive Officers”.
   
(i) “Financial Reporting Measures” shall mean measures that are determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and all other measures that are derived wholly or in part from such measures, including, without limitation, measures that are “non-GAAP financial measures” for purposes of Exchange Act Regulation G and Item 10(e) of Regulation S-K, as well other measures, metrics and ratios that are not non- GAAP measures. For purposes of this Policy, Financial Reporting Measures shall include stock price and total shareholder return (and any measures that are derived wholly or in part from stock price or total shareholder return). A Financial Reporting Measure need not be presented within the Company’s financial statements or included in a Company filing with the SEC.
   
(j) “Incentive-Based Compensation” shall have the meaning set forth in Section III below.
   
(k) “Nasdaq” shall mean The Nasdaq Stock Market.
   
(l) “Nasdaq Effective Date” shall mean October 2, 2023.
   
(m) “Policy” shall mean this Executive Officer Clawback Policy, as the same may be amended and/or restated from time to time.
   
(n) “Received” shall mean Incentive-Based Compensation received, or deemed to be received, in the Company’s fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation is attained, even if the payment or grant occurs after the fiscal period.
   
(o) “Repayment Agreement” shall have the meaning set forth in Section V below.

 

 2 

 

 

(p) “Restatement Date” shall mean the earlier of (i) the date the Board, a committee of the Board or the officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (ii) the date that a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.
   
(q) “SARs” shall mean stock appreciation rights.
   
(r) “SEC” shall mean the U.S. Securities and Exchange Commission.

 

III.Incentive-Based Compensation

 

“Incentive-Based Compensation” shall mean any compensation that is granted, earned or vested wholly or in part upon the attainment of a Financial Reporting Measure.

 

For purposes of this Policy, specific examples of Incentive-Based Compensation include, but are not limited to:

 

  ● Non-equity incentive plan awards that are earned based, wholly or in part, based on satisfaction of a Financial Reporting Measure performance goal;
  ● Bonuses paid from a “bonus pool,” the size of which is determined, wholly or in part, based on satisfaction of a Financial Reporting Measure performance goal;
  ● Other cash awards based on satisfaction of a Financial Reporting Measure performance goal;
  ● Restricted stock, restricted stock units, performance share units, stock options and SARs that are granted or become vested, wholly or in part, on satisfaction of a Financial Reporting Measure performance goal; and
  ● Proceeds received upon the sale of shares acquired through an incentive plan that were granted or vested based, wholly or in part, on satisfaction of a Financial Reporting Measure performance goal.

 

For purposes of this Policy, Incentive-Based Compensation excludes:

 

  ● Any base salaries (except with respect to any salary increases earned, wholly or in part, based on satisfaction of a Financial Reporting Measure performance goal);
  ● Bonuses paid solely at the discretion of the Committee or Board that are not paid from a “bonus pool” that is determined by satisfying a Financial Reporting Measure performance goal;
  ● Bonuses paid solely upon satisfying one or more subjective standards and/or completion of a specified employment period;
  ● Non-equity incentive plan awards earned solely upon satisfying one or more strategic measures or operational measures; and
  ● Equity awards that vest solely based on the passage of time and/or satisfaction of one or more non-Financial Reporting Measures.

 

IV.Determination and Calculation of Erroneously-Awarded Compensation

 

In the event of an Accounting Restatement, the Committee shall promptly determine the amount of any Erroneously-Awarded Compensation for each Executive Officer in connection with such Accounting Restatement and shall promptly thereafter provide each Executive Officer with a written notice containing the amount of Erroneously-Awarded Compensation and a demand for repayment, forfeiture or return thereof, as applicable.

 

 3 

 

 

(a) Cash Awards. With respect to cash awards, the Erroneously-Awarded Compensation is the difference between the amount of the cash award (whether payable as a lump sum or over time) that was Received and the amount that should have been Received applying the restated Financial Reporting Measure.
   
(b) Cash Awards Paid From Bonus Pools. With respect to cash awards paid from bonus pools, the Erroneously-Awarded Compensation is the pro rata portion of any deficiency that results from the aggregate bonus pool that is reduced based on applying the restated Financial Reporting Measure.
   
(c) Equity Awards. With respect to equity awards, if the shares, options, SARs or other equity awards are still held at the time of recovery, the Erroneously-Awarded Compensation is the number of such securities Received in excess of the number that should have been received applying the restated Financial Reporting Measure (or the value in excess of that number). If the options, SARs or other equity awards have been exercised, vested, settled or otherwise converted into underlying shares, but the underlying shares have not been sold, the Erroneously-Awarded Compensation is the number of shares underlying the excess options or SARs (or the value thereof). If the underlying shares have already been sold, the Erroneously-Awarded Compensation is the higher of the value of the stock upon vesting, exercise or sale.
   
(d) Compensation Based on Stock Price or Total Shareholder Return. For Incentive-Based Compensation based on (or derived from) stock price or total shareholder return, where the amount of Erroneously-Awarded Compensation is not subject to mathematical recalculation directly from the information in the applicable Accounting Restatement, the amount shall be determined by the Committee based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was Received (in which case, the Committee shall maintain documentation of such determination of that reasonable estimate and provide such documentation to Nasdaq in accordance with applicable listing standards).

 

V.Recovery of Erroneously-Awarded Compensation

 

Once the Committee has determined the amount of Erroneously-Awarded Compensation recoverable from the applicable Covered Person, the Committee shall take all necessary actions to recover the Erroneously-Awarded Compensation. Unless otherwise determined by the Committee, the Committee shall pursue the recovery of Erroneously-Awarded Compensation in accordance with the below:

 

(a) Cash Awards. With respect to cash awards, the Committee shall either (i) require the Covered Person to repay the Erroneously-Awarded Compensation in a lump sum in cash (or such property as the Committee agrees to accept with a value equal to such Erroneously-Awarded Compensation) reasonably promptly following the Restatement Date or (ii) if approved by the Committee, offer to enter into a Repayment Agreement. If the Covered Person accepts such offer and signs the Repayment Agreement within a reasonable time as determined by the Committee, the Company shall countersign such Repayment Agreement.
   
(b) Unvested Equity Awards. With respect to those equity awards that have not yet vested, the Committee shall take all necessary action to cancel, or otherwise cause to be forfeited, the awards in the amount of the Erroneously-Awarded Compensation.
   
(c) Vested Equity Awards. With respect to those equity awards that have vested and the underlying shares have not been sold, the Committee shall take all necessary action to cause the Covered Person to deliver and surrender the underlying shares in the amount of the Erroneously-Awarded Compensation.

 

 4 

 

 

In the event that the Covered Person has sold the underlying shares, the Committee shall either (i) require the Covered Person to repay the Erroneously-Awarded Compensation in a lump sum in cash (or such property as the Committee agrees to accept with a value equal to such Erroneously-Awarded Compensation) reasonably promptly following the Restatement Date or (ii) if approved by the Committee, offer to enter into a Repayment Agreement. If the Covered Person accepts such offer and signs the Repayment Agreement within a reasonable time as determined by the Committee, the Company shall countersign such Repayment Agreement.

 

(d) Repayment Agreement. “Repayment Agreement” shall mean an agreement (in a form reasonably acceptable to the Committee) with the Covered Person for the repayment of the Erroneously-Awarded Compensation as promptly as possible without unreasonable economic hardship to the Covered Person.
   
(e) Effect of Non-Repayment. To the extent that a Covered Person fails to repay all Erroneously-Awarded Compensation to the Company when due (as determined in accordance with this Policy), the Company shall, or shall cause one or more other members of the Company to, take all actions reasonable and appropriate to recover such Erroneously-Awarded Compensation from the applicable Covered Person. Unless otherwise determined by the Committee in its discretion, the applicable Covered Person shall be required to reimburse the Company for any and all expenses reasonably incurred (including legal fees) by the Company in recovering such Erroneously-Awarded Compensation in accordance with the immediately preceding sentence.

 

The Committee shall have broad discretion to determine the appropriate means of recovery of Erroneously-Awarded Compensation based on all applicable facts and circumstances and taking into account the time value of money and the cost to shareholders of delaying recovery. However, in no event may the Company accept an amount that is less than the amount of Erroneously-Awarded Compensation in satisfaction of a Covered Person’s obligations hereunder.

 

VI.Discretionary Recovery

 

Notwithstanding anything herein to the contrary, the Company shall not be required to take action to recover Erroneously-Awarded Compensation if any one of the following conditions are met and the Committee determines that recovery would be impracticable:

 

  (i) The direct expenses paid to a third party to assist in enforcing this Policy against a Covered Person would exceed the amount to be recovered, after the Company has made a reasonable attempt to recover the applicable Erroneously-Awarded Compensation, documented such attempts and provided such documentation to Nasdaq;
     
  (ii) Recovery would violate home country law where that law was adopted prior to November 28, 2022, provided that, before determining that it would be impracticable to recover any amount of Erroneously-Awarded Compensation based on violation of home country law, the Company has obtained an opinion of home country counsel, acceptable to Nasdaq, that recovery would result in such a violation and a copy of the opinion is provided to Nasdaq; or
     
  (iii) Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and regulations thereunder.

 

 5 

 

 

VII.Reporting and Disclosure Requirements

 

The Company shall file all disclosures with respect to this Policy in accordance with the requirements of the federal securities laws, including the disclosure required by the applicable filings required to be made with the SEC.

 

VIII.Effective Date

 

This Policy shall apply to any Incentive-Based Compensation Received on or after the Nasdaq Effective Date.

 

IX.No Indemnification

 

The Company shall not indemnify any Covered Person against the loss of Erroneously-Awarded Compensation and shall not pay, or reimburse any Covered Persons for premiums, for any insurance policy to fund such Covered Person’s potential recovery obligations.

 

X.Administration

 

The Committee has the sole discretion to administer this Policy and ensure compliance with Nasdaq Rules and any other applicable law, regulation, rule or interpretation of the SEC or Nasdaq promulgated or issued in connection therewith. Actions of the Committee pursuant to this Policy shall be taken by the vote of a majority of its members. The Committee shall, subject to the provisions of this Policy, make such determinations and interpretations and take such actions as it deems necessary, appropriate or advisable. All determinations and interpretations made by the Committee shall be final, binding and conclusive.

 

XI.Amendment; Termination

 

The Committee may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary, including as and when it determines that it is legally required by any federal securities laws, SEC rule or the rules of any national securities exchange or national securities association on which the Company’s securities are then listed. The Committee may terminate this Policy at any time. Notwithstanding anything in this Section XI to the contrary, no amendment or termination of this Policy shall be effective if such amendment or termination would (after taking into account any actions taken by the Company contemporaneously with such amendment or termination) cause the Company to violate any federal securities laws, SEC rule, or the rules of any national securities exchange or national securities association on which the Company’s securities are then listed.

 

XII.Other Recoupment Rights; No Additional Payments

 

The Committee intends that this Policy will be applied to the fullest extent of the law. The Committee may require that any employment agreement, equity award agreement or any other agreement entered into on or after the Adoption Date shall, as a condition to the grant of any benefit thereunder, require a Covered Person to agree to abide by the terms of this Policy. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other rights under applicable law, regulation or rule or pursuant to any similar policy in any employment agreement, equity plan, equity award agreement or similar arrangement and any other legal remedies available to the Company. However, this Policy shall not provide for recovery of Incentive-Based Compensation that the Company has already recovered pursuant to Section 304 of the Sarbanes-Oxley Act or other recovery obligations.

 

XIII.Successors

 

This Policy shall be binding and enforceable against all Covered Persons and their beneficiaries, heirs, executors, administrators or other legal representatives.

 

 6 

 

 

Exhibit A

 

ACKNOWLEDGEMENT AND AGREEMENT

TO THE

EXECUTIVE OFFICER CLAWBACK POLICY

OF

INSPIREMD, INC.

 

By signing below, the undersigned acknowledges and confirms that the undersigned has received and reviewed a copy of InspireMD, Inc. Executive Officer Clawback Policy (the “Policy”). Capitalized terms used but not otherwise defined in this Acknowledgement Form (this “Acknowledgement Form”) shall have the meanings ascribed to such terms in the Policy.

 

By signing this Acknowledgement Form, the undersigned acknowledges and agrees that the undersigned is and will continue to be subject to the Policy and that the Policy will apply both during and after the undersigned’s employment with the Company. Further, by signing below, the undersigned agrees to abide by the terms of the Policy, including, without limitation, by returning any Erroneously-Awarded Compensation (as defined in the Policy) to the Company to the extent required by, and in a manner permitted by, the Policy.

 

   
  Signature
   
  Name
   
  Date

 

 7 

 

 GRAPHIC 10 form10-k_001.jpg begin 644 form10-k_001.jpg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end GRAPHIC 11 ex10-62_001.jpg begin 644 ex10-62_001.jpg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end GRAPHIC 12 ex10-62_002.jpg begin 644 ex10-62_002.jpg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�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�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�/'=KJUXO@#0M8OOB7>^%?CA\,;?3[+4+3Q'KNB0_&3XB:5X]^$>OO MX2TKXL6L?PTN!\5? ^'5Q9>,JE9-\DN?W9:75G)14HI-I*=Y>SC)U+1:)?"2_"^W^*7@6X^(1\6^"_"UEX[\7^%3X-AUY_$(\2 M^%?!&HZ=XT\1: VFKJVC>$KRW\1ZA:0:/)]M&=^S=<_LX_\ "(^*=*_9G\5^ M!/%'A'2_B/XQU7QBG@+Q\GQ M-*^*7Q(OH_B]XXGUV]_X2#Q#<:9XG\=ZA\0 MH_BQK$5W;X@I\1&CO?^$U_MK5?S7^-7_!+?QW\:#\6O#=W\3-'\/># M/BO^U5XW^--SKUEJ7B*_^)6A_#_QS_P2%U7_ ()/W5A9:MJ.@26=Y\3]+T[4 MS\>;/Q/?/-I=SJT*> +NS,9?QP_VW^QQ^SYX[^#.G>//$GQ?T+]GBU^,'Q"N M/"EEXT\5_ #PQX]TBV\>V7P]TV^T+POXD\5ZM\3?%'BOQ?+>7&GWDTVB^!I] M6U?2/A9IMP?"&C>*O&<$,OB6_&E>Z;Y4ERWC:4I>[=N-VHI7?NW2YDH\S33BI**C)7]U73-KP#^WI^QQ\2?"WAGQEX9_:4^#$ MGA_QIX[\=?#7P=>ZE\1/">CGQ5XP^'GQ(TWX3>(=,\/P:EK%O-J8;QSXB\$Z M+I$UNK1ZS-\1OAFM@99?B%X1AU?TO3?VF/V=-8U#5M)TKX^?!74]4T&?XHVF MN:=I_P 5/ M[?Z+>? Y_#T/QKM-6L[;7Y;C3;GX/3^+?"L/Q3M[N.&7X?2>) M_#R^+ET=M:TW[5^/_P 1/^"8/[47C+X=W7POM?BM\$_^$9MIOVO[S0IKG3_B M+H>L+J_QD_;-TS]JSX6ZOXDU?PY%!KOB?2'\/1ZI\-/'_P ,-3UN?X<^'_$R M>'/C#8Z1\3M;\-Z'X7TGZ,\=_L,?'G5OB)^U1\3_ (<_$OX1>!/$G[9OP+^- M7PB^,^FZ[\.+'XD^!++Q;IOA.Y^'O[''QFT/P#XM\.SZ#XM\2> OA[Y'A7]I M/PM\2D\2^'?C_IT/A;0IVT;P/\+/ /@NU%RN"ES>\XMJ-]$_8TYI-I-V]HZD M':[7+%W?-=4W:32UBF[2>[_>RBDD^5)^RY9N3]V_-%+9GKGQ1_X*+? 7X>>* MO@-=6'Q*^!.O_ GXG>-_BYX"^)GQYE^.GA;2O"OP7UWX8_!/6?C1;6NMR+8: MAX9NWUK2=*ABU&'7/&O@^_T*QUKPYK5II_B&QUV)K7T'PU^V'X,UKXY_&+X< M:A=^ =,^%OPX_9U_9'_:+\*?'>V^)>FZIX3^(7AG]K+QQ^TKX$\.VT .D6&@ MZ9!::G^SU!<>&-7TCQAXNL_'UM\0M"&FIIEU!';:E\7_ \_8&_:%^'GQ97X M\V7B7X5:YXIC_:[7]IZ/X?>)/B#\:O$]H;'Q?_P3G^%7[#WC3P7=?'#QSI/C M+X@ZMJ/@WQ%\/I/'WA?Q;K7A+4SX\\/%/"E_HOPP?4;>\\+^=K_P23^(W@KP M;:^&/A5\7/ T-]\//V>/^">7PW^&%WXIT#Q98^$O$GCS]@[XQ?M*?%W4;?Q_ MX(\)ZK8WGACX3_&6/]I?Q!X.T#0O!?C:]UGX!?\ "(^$?%WAZ7Q]-I=KX9M* M?+9)-NW,KK5-.I&TNSY:?/*.D>9\L6E)\RGK?51E&+<9/WHR5.3:2Z7FX1E[ MTE%*4U=+E?Z]7G[07P'T[X0/^T%J7QH^$VF_ :'2%\0S_&O4?B)X0L?A);: M]ZNFIK=S\1KO6(?!]MI;:C(FG+J$^L):_P!H,+/S!+M)G\3G5=9M3H%OJ/A'PW MXD\6VEQJRVD$WA;P[K_B-9#HNBZG?6WBT'PL^'/PG_8T\5?##XY?#/PSK'P[ M\1^&OB+9?&KX5_L^?!_XN?$KPUXCM_CUXH\1:C\4M"T#X:>#-*^(7QC^(Y\5 M:I\0_$,_COQ-!H4_B'QMJFK>*_B1K6A^$K75;_2M!^&M._X)_?M#:Q\%OV9? M&&H_$KPS\3?VB_ L?CBW^+5K^TM8>.--\/\ QM^'WQ1\$?#[X76X^*47PQ\5 MW=]X5_:!\'?"OX/?!F/Q7XE\-2^)? GC+QMH_P 8-)?P_9Z7\6AXK\*Q9ZJ\ M;JR3=VFY*2;YE9VC)1E+W;NG)M)3CRR=]8Z2LU-MZ)JSBXKE;?O33E'XVE-) M.\)\T?U!U+]IW]G'1/$NJ^#=:^/?P:T?Q7H/A_5/%>M^'=4^)G@O3M8T?PQH M7A*R\?ZUX@U/3[S6H;BPT?2/ 6I:;XYU6_NHXK?3O!FI:?XKO'@T"]M=1EU/ M"W[0?P'\<_#[Q'\6_!7QK^$?B_X4^#K?6;OQ9\3?#'Q&\(:]\/O"]KX=T6W\ M2:_=>(?&>EZS<^&]&MM#\.7=KK^L7.HZG;0:;HES;ZK>20V$R7!_*;Q+_P $ MR_C"_P 2/#>K^#O$WP$\-_#?X:^/(]:^&7@_PIX;\8_##P_I'@*X_P""77C7 M]@F/P$GPO\(?;O 5E>^#?'VL6OCOP[\2?$3?$;XHZK\'M8T/X#MXS\+> ?@% M\.=!\2_:U[^S;\4XO^"=DG[)/A?QC\.]&^+]E^R-'^SWX?\ '?B#P3:?$'X7 M1^+].^$J?#BP\2Z]\.O%^GWVG>)?!]]>V\>H:GX0\1Z5K>G/I=U-I6IV/B2V MAEAU%WT;5VN:-KN-^1RDI.T=%*,%%I7MS-[I69ULM=U=W2NHQ:LG>3BY.2YG MK9:I7N>DZS^VE^R!X;\.0>+_ !)^U/\ L[>'?"UROCPP>(-?^-'PYT729/\ MA5DFG0_$Y1>ZGXDM81+\.)]7TFW\>P%O.\(7.J:;;^($T^;4+..?@_VG_P!M M;X??L]67PI@TK6?AEXZ\9_%'XV_LC?#:P^'UQ\5])\->+;CP%^U=^T;X&_9[ MTSXJ>$=(M-'\4WWC&U\.W'B_5/&6G:.+;1-+\8Z'X%\;?8/%VG_\(]J,T'QC MX"_X)S_&WPC\5=7^)$WBSX975MJ/Q/\ VE?B;9Z%J'BOXN>,M9T[_AH+]DKX M!? RR\.7WQ&\?6VO^*_%%WX-\:?"OQ#"[RXF\ M&Z/Q'P^_X)A_M'_#;P)I'PAT_P"+WPA\0> =3\6?\$J/BSXIUS7="\;KXM\* M?$?_ ()NZ[^R7I_B3PKX#LK9VT[4_A3\;?!W[*^A>*- L]7U30M6^%/Q'\0> M/XIX_B%IWQ'36_ %I0<4W*497BN5)-6:BY-3O;23:ORZQC=)-B;EVO%*5[/W MFU*25HVUO!*5N9-3?)=VN?LE\0/C%\)OA/\ V+_PM#XG?#_X=?\ "27D6G>' MSXY\8>'_ F-:OY]5T308+736UW4;!;R:;7?$OAK0XU@+[]9\1Z!I*_Z?K.F M6]US&@_M,?LY>*O'US\*/"_Q\^"_B/XH6;>.8KSX#/$WARWUCQ%I%U%K>C^+_ (8^-$?P?\7-!U3P_!?>*O ESX'M[C7_ M )M^-G_!+7XG_'/PM\1/A]JGQ/\ ?@[PY\3/C9_P4"^(.J^)=!TKQ)JOB70 M_"_[:?[*WQ4_9IT*#2]*N8=(L-0\6?#QOBG+XQU.[N=9L].U]/#-MH-F-(_M MEM6T7-:_%HG";4DT^6:DXP35DVI)QDG&2>\;1DN9V[)-K5IPT>B:=G/OK%G:D\FG:1X?\)ZAX7TOX:7VOP0V7B[QA;:UX"O[3Q]/? M:+HYN(+7ZE^(WQ8\/^"/#O@37H?%WPETVV^(/Q$^%O@?PQ?_ !'^)5EX%T#Q M5)\1/%&DZ;!I'@76$TS7H_&/Q&U[1+J_D^%W@73XHC\0?%"Z5H*:UHUG?S:S M9_E=XX_8"_:?^+GBGXA?%[XH:[\$++XM^/++]F\Z+>? SXE_'_X&>(?@YX]^ M!OPO_:I^&^J_&7X-_&S2--\0Z_HOB;Q#)\?M,O+#P'XT^&GCOP#^%M=\:?"_P",W[%WQ1\= M?$'5_#/_ ANG>-7_9;^-?PJ^-/BR[T3P3X2BO\ 2_">H?$S4?AC)HVEZ)8W M'_"/^"(O%#WENVL6OA^WT;5ZE9.*CJK4U)K5N\IJ;OHI-+D;2BE=R2;W4>\N M;52UFU]E*T(.$;:OEAZ[?ZPNE>!_B0#\/\ QC?F MT^S^&/&I3PMKDEAKDB6+;/\ PO+X,?\ "S$^"_\ PMGX;CXO.)BGPO\ ^$V\ M-_\ "?N;?P_:^++B)/"/]I?V\]Q!X6O;+Q/-:K8&YB\-WEKKTD*Z3<0WC_!O MP0_8A^)_PP^,7P5^(>K>)_ %YHGPQ^)O_!4+QSK%GILGB.35]6L?^"A7[4+_ M +3F@V>FM=:-8V=M=_#"[<^!-;^URRP^+;>.+Q;9/X?F_P"*75/$?[%OQJ\0 M?MK^#OVCIO'/P\;X?^ _VN-._:&T#0+>'Q;H6O7'@K4?^">/Q&_8R\1>"=<\ M,^'K>Q^'WB'Q_HOCKQ8/B/I7QQ\7P>+/B?XI\ Z_8_!>[\1^#/AY\$/A[X<\ M0I6]U-O:7,[62M\*\^;>UKI*5VI+WAMIRTNE;E:OJVYRC9*][OFC9-7: M_0/Q%\7/A9X2\7>'? 'BGXD>!/#GCGQ));^>^M;"WT M+1-0O[?4-5NM2GTS5(M,MK*WFGU)])U<6,=Q_96H?9N'@_:H_9GN= \2^*K; M]H/X+77AOP;J6F:-XMURU^)W@NXTOPWJ^N:,GB+0M+UF\AUIX=/U#7?#\D.O M:%9W#I<:WHDT.JZ5'=Z?-%<'Y:_:@_8L\9_'KX[Z#\0?"/C6;X/Z9?>"O WP M\^(_Q"\!?$+QSHOCSQE\-?#_ (C^*>I>*_A+XY^$EUI>O_!;XL>'=2TCXC7T MGP0^(>L#P7\6/V5OB9KGB_XI?#WQ/XC@U[5O .M?+G@G_@G5^U1\/-%^!7Q! M\,^+/V0K;]I/]FSX@_#\:9X@L_AU\7-/\'?M+_"GX?\ P1^/W[/MK:?&/5+[ MQOXA\5?##Q+!X7_:+\8>./AGH7@2T\;>%O@QXNA\5^'K"^\<>$/C!XBB\-ST MO=)[-2;;U;49*R2:BU%R3DI.+?+;D?M*TO9W>G165[7:;;>^JC+E:BU'F34O M<_5G_AI']GK^U?A]H/\ PO3X/MK7Q:TCPMKWPMTM/B3X->]^)&B>.;75+[P1 MJW@2W366?Q9IWC6RT+7KSP?>:&+ZW\46F@Z[%OB_\/O$,GAGX?:-JFIZ'K'CG7_[)\07 M@TCPAI&MZ)J^DZMXDU#[/H^F:CIUY9WUW!<6[H/A'5_^"%?#&I_#W4/@=XU_83UWX)WMKX3_ &>O FE/KNA: M5\(?B9X>^ 'P\T;P'X7E\;>&-2_9E\42>+OB#I>I_&B?Q';>%] \>\5?\$KO MC)XZ\!^'O!M_\6OA]X,U+0OA%_P4(\%P>(?#6E^(];TYO%?[:'[;?P(_;.\+ M2ZKX0O[70H_$?PZ\&7OP"TGX7_$_P;-XDTFX^+/A+QOXI:UU7P4MM#8ZG:4. M9IRJ*-X)248MV;:IN"E%(Z*S3;%=#LM#T+5M6M-8?6=2\5^+/"7A"/P_<64&NVOC7Q9X:\$7^G6GB_6K#0 MY\']E7X'?%SX8^-OVKOB7\7M2^&IUW]J'XP_#KXT2>%/AK+XHU72_ NK^&?V M5_V>_P!G?Q#H!\7>*+#P[=>+["XO_@5%KVAZJ?!OA6ZCLM6,&H6+2K'%:_F] M=_\ !+_]J2Y^#G[-'P>G^+?P0N=*_9Z^"W[+_P -+*YBTKXCZ"^K>)OV._VH MOAM\7/!GBO7;G09;74_'.A?&3X;?#ZUTW5? 'C?4-0\+?LZ?$42:_P##ZR^) MMSK&J>(!5J;<8\SC?V?O:M:Z5.;3I[LDTK)723NDHNU&:- MFT[[4=?UUC_ &G?V:]0L=;NX/V@_@C<:?H6C_%?6?$%]:?%WP(T M&A:'\#-8L/#7QQUG5;VU\1XTC3?@UXBU;3- ^*6J7,UK;_#G7-2T[3?%EQHV MH7=K"_QMH_[7W['?[+'B+X+_ =\%>+?@'X!_95\;?"_]KGXLR?'74/V@/#^ ME?#KP!XV^!'QF^!OA;XB> -2N?%-S=:&FM:_XW_:'\2:KXJN;[X@Z9JGA#Q1 MX)\5Z3K?A*:_U#4;_1.#\??L&_M#3:[^UWXW^$/Q ^"W@KQ3^VM\//%%E\7O M#WB/PC<>+/A[8_%KP1?KH'[.7Q!\,Z3J/A>XD>XO/@C:Q?"K]H:;Q)!KD'B7 MQ&GA#XM> M!\+W_@'6/!WQ3POAE_P3X^/_PB^)"_%?POXM^"GB/6&U_]N/2[ M?PG\0+OXL^+]$M/ _P"VW>_LL^-9M=\1^*O$=QKGC#XE>*OA!XS_ &=+K0=3 M\,:Y/H=M\>/"GB>36KOX@?!G5]^AP9JUG)/WN1VBW92FE)\C:7P*=G"?3F]Z M-XRYJ:5^6[^)>]&RLKTO>LT]7^\A*-GS1BVG%2CR_:_AC]KC0+CXO_M1> OB M!%X)^'/@;]GF7X&_V3\3=2^(EO-IWCBS^-7@F3Q18W.H6FIZ!X>T[PMJ5MK$ M;^&]'T73=?\ &9\2(=/U2UU*WO=5_P"$>T[V[6?CM\$_#OPIL/CMXA^,'PMT M+X(:MHOA;Q'I?QEUCX@^$M,^%.H^'O',^D6W@G7K'XAWNKQ>$;O1O&5QX@T* M#PIJEOJ\UCXBGUG2HM(GNY-1LUG_ !\A_P""4'Q3^&>G>#X?@G\3? .HG]GZ MY_8]E^ ^D?%MO'@LO'NC_LR?L<_%+]BSQ'X9^..M?#>?POKFCWOCKX>_%WQ% MXN\/>,O 1OE\%?$C1/"FMZGX,\;^'[35/">J??GB'X+?!?X8?L,ZY^SS\5_A MO9W'P3U;X::G\'_B'\-/V9_@G\5M?TB3P]\8KV;P?XGT/X=?"?X0:9\0OBM; MZ$]SXWNWO-;T>TU+4?#6DC4_B%XHU/1M+TK6]:TT;T*]2^(?QN^$G@73O >HVNC^.KWQA\1O"'AZW\%:I>>%(O'D%A MXNEU76+5?#5R_@.5/'31:U]A:/P26\72[/#T( M/CW\&=#\2?"[PGXE\>?$K0=9^)W@K2M5^'_@GP98>&=5\9>+?&=GJ&MV\OAG MP[X.TGQMX(U;Q=K.LBRL/"^F^-O!NHZ]/I]GXL\/SZC^7UW_ ,$^_P!HKQ?\ M,_V5O'GC#QM\*_BM^T1HOPH^*/P[_:VT7]HKPEXFL/ GQRTK]I+1_P!G^T^( M.K:]I?P5\:"ST_XB?#33?V<_AIX-TO2X)/$_PP\?^"[7QWX-U*ST*7QEH_Q M\(*O$ M?C30_$=A%X>B;2BYI2YG%3Y&HN$9RA"3C&\G)Q]I/V<=;M*4];T7[1P:DX-W MC%NGS6:DXJ4X*;6D5)0A[6=[1"? MB9X3&JZQH1\3^ /%6A>,?#_]M:!?2Z9KFDC6?#M_J.G?VEH^HP3V.I67VC[3 M974+PW$<;K@\=K_[2G[._A76O$?AOQ1\>/@[X9U_P?;0WGBS1?$/Q,\%Z'J? MANTN-:\+>'(+G7+/5-;M+C2X9/$7CKP/H'F7B0JNM>-/".E/LO\ Q+HL%[B_ M"N+XM>%-9\(_##Q#X5\)3_#SPK\!_ EO=^/]$US7%OU^*VCW4^@ZWX9MM"U3 MP[96>J>%-3T*"RUK1-;L=735-%N=/U'3_$6C(NMZ%!+?Q+\2?&_P +_%/QLU+XE?#_ .('PM^+ M^K_"[Q/ ;+]GK6=&T[P-JWA3X\1?L_\ BI]#_::UCX@W?Q:\:^%M&\>^"=!F MU*GRJHUS-TE4:4[7E*FJR@IJ%_BE1YZL87OS*,'92;C,7-QCSJ,9.,7)7]V, MG3YFD[-M*K:#=OAYI;Q2?Z,^)_VI?V:/!FE>)==\7_M!_!/PQHG@WQ9J_@+Q MCJVO_%/P-I6G>$O''AW2],UWQ%X0\47=[KT,/A_Q-XL/9:EH M.@ZC9:UK%O8Z7<173^2? #]M+P-\7OBE\9/@AXNU3X8_#OXQ_#KXW_%;X:^# M?A;#\5])\0^//B3X!^&&D^!-7N/BII?A34M'\(^)HK*6U\=Z8/$>FZ=H>N:3 MX3OB; >+->MQ'JUQ\8S?\$_OVG(/V@?B!^T;8^,/V6-?O_CGXP^.^A?&#X*_ M%'X<^/\ X@?"P_ C]I3X!?L"_"_QAH=K>_V[H%YXX\6^ ?$_[#MD[:9KOASP MSX(^.O@#Q]J^@>([+X5:C::->:)ZOX8_8=^*^C?'7P1\4;OQ?\/KC0_"W_!0 M/XX_MD7UI"/$2Z[JOA?XH?L@>-?V5="\%_\ ('@TU/$FE/XV?QUJVLE_[)FB MT.V\*:=IUNNH#7])F-G>]]825U;W:B<6G:[O%VE"^GNN3Y>:*O6CC)WM)23B MMU)>]=2=ERMIQEHI/F44I:R/U,HHHIC"BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BDW#&[MC.?;U M^G?/IS1D9QWX['OG^>#WXQS0 M%)N&<=_;G\\=._7'0^E&1G'?D\@]!@$CCG M&1T]: %HI P/3TSTZCU'J*,CW^F#GZXQG'OTH 6BD+ 8]S@<'K^1_P#U9/8T MM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%9>JZWHVA0VUSKFK:9HUM>:CINCVEQJM_:Z=!=:OK-[!INCZ5;RWN2>"=/\8ZCJ>C^$;[Q&[3Q5JV MB:5KNLZ7X;N=9%E#KFHZ1HFL:G8Z9)=75AI>H7445G-TM% 'X2^%?@'^VM:0 M?L[SZOX5U"TUGP/^UG^V!XQ\9Z/=_%^Z\<>'O&GP\^(7[?O@7XO^$=5U/QFO M@SP;XC^'?B]_A[I_B[QUX!\4:9XZ_\4?A5X?U#XN?L@_L M4?#X?M5^"M9\2Z=\)-7^%&J?LA?%7X4>*->^"KV=KJ/CJ[MKWXQ>!?#W@R_U MKQ)I?Q@Z>G/Y_Y^M"LG9>]=.R6B;D[)VNK.&/@U> M_#_XP^(OAIX!^(OPBO?@IX?\,?'G1_%^H_$#PIX9O_&%I\'I/C1XE@^3_&O[ M+7[0]E\'O$]E\&M!\2WE]XH_: \?_&6SU#Q;X%^$'PA^+'Q3G\9_ ;5M"\0^ M#/VD;GX*:3X-TZ7QYXE^)6J77@[X2_MJZ'H>D?%3X%:_I7PO^*GQ"TSXQ>!/ MA_XTUSXX?O#^0QGZ#TR/IC^E&!Z# X&1_C_GWI0;@XN-O=G&HDU=-P?-%23O M>/-JUHIW:FI0M",M735VN9^,-UX]^-'C6S\6:)HR:5KWAKP2WB7X1_#_ .">B>,OBGX/'ASP]X#\ M)>!>/OV>OVA/'O[/7Q2\+^!;SQQX2^*&L?';]O\ T/X?Z+K^F7\7A:R3]H7X ME_$*;X+_ +1#^)5\3^%M0\#S_ J/7/"/Q<\#^./#FI>(O%.C^&H_''@OP!\/ M]5^*>K^&'\)?M'M Z] .G;ZX]?SI< C& 1SP,8QZ>G_U_2DDHQY4E:T%;6WN M24TM&GRZ./*FER2DDT^64:;=]+)7C):_; O/B#I>K_ !+\,WGC_P"'J_M)_&OQO\>K&*33+7QO\1_AS=I^W#X._9S^ M%O@XQ^)3H'B'X3>%/"_B[]BWQSX=\/,?!\7PQ\<^'+[X@^)-=UKXL7'Q8B\ M?4_AWP=^VGX1\(?L2^'-9^(=WXTUQ/@YHGP;_:YU[1(?AV\&G?%.U\$^ O$^ MJ_M06>N^./#UWKNL0PZU\,_B7\)].\&:-I6K0:]XE_:)\&>-->\,VNB> -9U M;3OT#VCC@8QZ=?H<_P"-+@>@/7L/R_I3UM;W7906JU;C&44VTTKOG;:48IR4 M6U[J2SY--W>SBG=MVTW;O=WBG=ZWHIM[MMMZL****H84444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 ?CW'Z=OQ_K7Y_\ _!1.U^#^O_!._P#A_P#%;X3>)_B>_P 5M!\? M_##PUJ&B?LF?&O\ :YTKX;?\)KX,U'1/$WCWQ!X)^"WPJ^*FIZ>FE^';J[CT M:WU2T\-+XWUB>U\!P>+/#>F^(-=\0Z/^@'/?\/I2=<8(X_'\.#[_ ,JF24E9 M[/??;JKJS5U=733LW9IZH3L[IV:V?9Z-;IIZI:--/9IIM/A_AE;:9:?#KP%: MZ)-XMN-&MO!?A:VTB?Q]!XDM?'(XM9-]'K=I;:FEU#'W-(,< 8X]/\]_>EJG>3E*5VY2E)MN[;E*4FV[* M[;DVVE%7;M&*T4Q2C&*6R22TMHDDM+OHEU?J]V4444%!1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117S+^U;^V-^ MSA^Q%\/-&^*W[3_Q&_X5CX!\0>--.^'ND:]_PB'COQI]K\8:MH?B+Q)I^D?V M7\/?#'BS6K?[1HOA/Q!>_P!H76G0Z7%_9_V>:]CN[JR@N0#Z:HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "OYE?^#K+_E'E\&_^SSOAY_ZH_P#:)HHH # __9 end GRAPHIC 13 ex10-62_003.jpg begin 644 ex10-62_003.jpg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nspr-20231231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Changes in Equity link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Changes in Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000008 - Statement - Consolidated Statements of Cash Flows (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - MARKETABLE SECURITIES link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - PROPERTY, PLANT AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - LEASE AGREEMENTS link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - EQUITY link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - RELATED PARTIES TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - TAXES ON INCOME: link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - MARKETABLE SECURITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - LEASE AGREEMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - TAXES ON INCOME: (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - DESCRIPTION OF BUSINESS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - SCHEDULE OF FINANCIAL ASSETS SUBJECT TO FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - SCHEDULE OF MARKETABLE SECURITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - SCHEDULE OF FAIR VALUE OF MARKETABLE SECURITIES CLASSIFIED BY MATURITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - SCHEDULE OF CHANGES IN FAIR VALUE OF MARKETABLE SECURITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - LEASE AGREEMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - SCHEDULE OF STOCK OPTIONS GRANTED (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - SCHEDULE OF RESTRICTED STOCK GRANTED TO EMPLOYEES (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNIT GRANTED TO EMPLOYEES (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - SCHEDULE OF ADDITIONAL INFORMATION ABOUT ALL OPTIONS OUTSTANDING AND EXERCISABLE (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - SCHEDULE OF FAIR VALUE OF OPTIONS GRANTED TO EMPLOYEES (Details) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - SCHEDULE OF ALLOCATION OF TOTAL SHARE-BASED COMPENSATION EXPENSE (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - RELATED PARTIES TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - SCHEDULE OF COMPONENTS OF LOSS BEFORE INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - SCHEDULE OF CHANGES IN VALUATION ALLOWANCE (Details) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - SCHEDULE OF RECONCILIATION OF UNCERTAIN TAX POSITIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - SCHEDULE OF OPEN TAX YEARS BY MAJOR JURISDICTION (Details) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - SCHEDULE OF DEFERRED INCOME TAX (Details) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - TAXES ON INCOME: (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - SCHEDULE OF INVENTORIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000061 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER (Details) link:presentationLink link:calculationLink link:definitionLink 00000062 - Disclosure - SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS (Details) link:presentationLink link:calculationLink link:definitionLink 00000063 - Disclosure - SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRODUCT (Details) link:presentationLink link:calculationLink link:definitionLink 00000064 - Disclosure - SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 15 nspr-20231231_cal.xml XBRL CALCULATION FILE EX-101.DEF 16 nspr-20231231_def.xml XBRL DEFINITION FILE EX-101.LAB 17 nspr-20231231_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series C Preferred Stock [Member] Equity Components [Axis] Common Stock [Member] Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Geographical [Axis] Russia and Belarus [Member] Concentration Risk Benchmark [Axis] Sales [Member] Concentration Risk Type [Axis] Geographic Concentration Risk [Member] Measurement Frequency [Axis] Fair Value, Recurring [Member] Cash and Cash Equivalents [Axis] Money Market Funds [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Financial Instrument [Axis] US Government Agencies Debt Securities [Member] Long-Lived Tangible Asset [Axis] Computer Equipment [Member] Office Furniture And Equipment [Member] Machinery and Equipment [Member] Leasehold Improvements [Member] Restructuring Type [Axis] Severance Type One [Member] Severance Type Two [Member] Sale of Stock [Axis] Private Placement [Member] Pre-Funded Warrants [Member] Warrant [Member] Series H Warrants [Member] Series I Warrants [Member] Series J Warrants [Member] Series K Warrants [Member] At The Market Offering [Member] Preferred Stock Blank Check [Member] Award Type [Axis] Restricted Stock [Member] Share-Based Payment Arrangement, Option [Member] Title of Individual [Axis] Employees and Directors [Member] Consultants [Member] Restricted Stock Units (RSUs) [Member] Employee And Non Employee Stock Option [Member] Series E Warrants [Member] Series F Warrants [Member] Series G Warrants [Member] Underwriter Warrants [Member] Employee [Member] Non Employee [Member] Exercise Price Range [Axis] Exercise Price One [Member] Exercise Price Two [Member] Exercise Price Three [Member] Exercise Price Four [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Income Statement Location [Axis] Cost of Sales [Member] Research and Development Expense [Member] Selling and Marketing Expense [Member] General and Administrative Expense [Member] Director [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Consultancy Agreement [Member] Related Party, Type [Axis] Related Party [Member] Non Employee Directors [Member] Plan Name [Axis] 2021 Equity Incentive Plan [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Income Tax Authority, Name [Axis] Israel Tax Authority [Member] Germany [Member] Tax Period [Axis] Arising Before January One 2018 [Member] Limited [Member] Consolidated Entities [Axis] Parent Company [Member] Subsidiaries [Member] UNITED STATES Earliest Tax Year [Member] Latest Tax Year [Member] ISRAEL GERMANY ITALY RUSSIAN FEDERATION Other Countries [Member] Product and Service [Axis] C Guard E P S [Member] M Guard Prime E P S [Member] Customer [Axis] Customer A [Member] Customer Concentration Risk [Member] Customer B [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Auditor Firm ID Auditor Name Auditor Location Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS: Cash and cash equivalents Short-term bank deposits Marketable securities Accounts receivable: Trade, net Other Prepaid expenses Inventory TOTAL CURRENT ASSETS NON-CURRENT ASSETS: Property, plant and equipment, net Operating lease right of use assets Fund in respect of employee rights upon retirement TOTAL NON-CURRENT ASSETS TOTAL ASSETS LIABILITIES AND EQUITY CURRENT LIABILITIES: Accounts payable and accruals: Trade Other TOTAL CURRENT LIABILITIES LONG-TERM LIABILITIES: Operating lease liabilities Liability for employee rights upon retirement TOTAL LONG-TERM LIABILITIES COMMITMENTS AND CONTINGENT LIABILITIES (Note 8) TOTAL LIABILITIES EQUITY: Common stock, par value $0.0001 per share; 150,000,000 shares authorized at December 31, 2023 and 2022; 21,841,215 and 8,330,918 shares issued and outstanding at December 31, 2023 and 2022, respectively Preferred C shares, par value $0.0001 per share; 1,172,000 shares authorized at December 31, 2023 and 2022; 1,718 shares issued and outstanding at December 31, 2023 and 2022; Additional paid-in capital Accumulated deficit Total equity Total liabilities and equity Statement [Table] Statement [Line Items] Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Income Statement [Abstract] REVENUES COST OF REVENUES GROSS PROFIT OPERATING EXPENSES: Research and development Selling and marketing General and administrative Total operating expenses LOSS FROM OPERATIONS FINANCIAL INCOME , net: LOSS BEFORE TAX EXPENSES TAX EXPENSES NET LOSS NET LOSS PER SHARE - basic NET LOSS PER SHARE - diluted WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING NET LOSS PER SHARE - basic WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING NET LOSS PER SHARE - diluted Beginning balance, value Balance, shares Net loss Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures, shares Exercise of pre-funded warrants Exercise of pre-funded warrants, shares Issuance of common shares, pre-funded warrants and warrants, net of $4,635 issuance costs Issuance of common shares, pre-funded warrants and warrants, net of $4,635 issuance costs, shares Ending balance, value Balance, shares Statement of Stockholders' Equity [Abstract] Shares, restricted stock award, forfeited Payments of stock issuance costs Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments required to reconcile net loss to net cash used in operating activities: Depreciation and amortization Gain from sale of property, plant and equipment Change in fair value of markable securities, net of interest received Change in liability for employees rights upon retirement Other financial expense Change in operating right of use asset and operating leasing liability Share-based compensation expenses Decrease (increase) in interest receivable on short term deposits Loss (gain) on amounts funded in respect of employee rights upon retirement, net Changes in operating asset and liability items: Decrease in prepaid expenses Decrease (increase) in trade receivables Increase in other receivables Increase in inventory Increase (decrease) in trade payables Increase in other payables Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property, plant and equipment Proceeds from sale of property, plant and equipment Investment in short-term bank deposits Investments in marketable securities Proceeds from matured marketable securities Amounts funded in respect of employee rights upon retirement Withdrawal from short-term bank deposits Net cash provided by (used in) investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Issuance costs of At The Market offering Proceeds from issuance of shares and warrants net of $4,635 issuance costs, Net cash provided by (used in) financing activities EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES: Acquisition of right-of-use assets by means of lease liabilities Non-cash lease incentive Decrease in right-of-use assets and lease liabilities due to shortening lease term Organization, Consolidation and Presentation of Financial Statements [Abstract] DESCRIPTION OF BUSINESS Accounting Policies [Abstract] SIGNIFICANT ACCOUNTING POLICIES Fair Value Disclosures [Abstract] FAIR VALUE MEASUREMENTS Investments, Debt and Equity Securities [Abstract] MARKETABLE SECURITIES Property, Plant and Equipment [Abstract] PROPERTY, PLANT AND EQUIPMENT Retirement Benefits [Abstract] LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT Lease Agreements LEASE AGREEMENTS Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENT LIABILITIES Equity [Abstract] EQUITY Related Party Transactions [Abstract] RELATED PARTIES TRANSACTIONS Income Tax Disclosure [Abstract] TAXES ON INCOME: SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION Segment Reporting [Abstract] DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES Subsequent Events [Abstract] SUBSEQUENT EVENTS Use of estimates Functional currency Principles of consolidation Cash and cash equivalents Marketable securities Short-term bank deposits Concentration of credit risk and allowance for doubtful accounts Inventory Leases Property, plant and equipment Impairment in value of long-lived assets Revenue recognition Research and development costs Share-based compensation Deferred income taxes Advertising Net loss per share Segment reporting Fair value measurement Recently adopted accounting pronouncement Recently issued accounting pronouncement, not yet adopted SCHEDULE OF FINANCIAL ASSETS SUBJECT TO FAIR VALUE MEASUREMENTS SCHEDULE OF MARKETABLE SECURITIES SCHEDULE OF FAIR VALUE OF MARKETABLE SECURITIES CLASSIFIED BY MATURITY SCHEDULE OF CHANGES IN FAIR VALUE OF MARKETABLE SECURITIES SCHEDULE OF PROPERTY PLANT AND EQUIPMENT SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES SCHEDULE OF MATURITIES OF LEASE LIABILITIES SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK SCHEDULE OF STOCK OPTIONS GRANTED SCHEDULE OF RESTRICTED STOCK GRANTED TO EMPLOYEES SCHEDULE OF RESTRICTED STOCK UNIT GRANTED TO EMPLOYEES SCHEDULE OF ADDITIONAL INFORMATION ABOUT ALL OPTIONS OUTSTANDING AND EXERCISABLE SCHEDULE OF FAIR VALUE OF OPTIONS GRANTED TO EMPLOYEES SCHEDULE OF ALLOCATION OF TOTAL SHARE-BASED COMPENSATION EXPENSE SCHEDULE OF COMPONENTS OF LOSS BEFORE INCOME TAXES SCHEDULE OF CHANGES IN VALUATION ALLOWANCE SCHEDULE OF RECONCILIATION OF UNCERTAIN TAX POSITIONS SCHEDULE OF OPEN TAX YEARS BY MAJOR JURISDICTION SCHEDULE OF DEFERRED INCOME TAX SCHEDULE OF INVENTORIES SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRODUCT SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS Schedule of Product Information [Table] Product Information [Line Items] Sales percentage [custom:ResearchAndDevelopmentExpenseIncludingUSBasedClinicalTrialCost] Significant Change in Unrecognized Tax Benefits, Nature of Event Advertising Expense Weighted Average Number of Shares Outstanding, Diluted, Adjustment Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Number of Operating Segments Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash equivalents Marketable securities Cost of marketable securities Marketable Securities [Table] Marketable Securities [Line Items] Amounts maturing within one year Amounts maturing after one year through two years Balance at beginning of the period Additions Sale or maturity Interest Received Changes in fair value Balance at end of the period Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property plant and equipment, gross Less - accumulated depreciation and amortization Net carrying amount Depreciation and amortization expenses Schedule of Restructuring and Related Costs [Table] Restructuring Cost and Reserve [Line Items] Percentage of monthly deposits on salary Severance expenses Schedule Of Supplemental Information Related To Leases Operating lease right-of-use assets Current Operating lease liabilities Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Non-current operating lease liabilities Operating cash flows from operating leases (cash paid in thousands) Weighted average remaining lease Weighted average discount rate Schedule Of Maturities Of Lease Liabilities 2024 2025 2026 Total lease payments Less imputed interest Total Operating lease expense Distribution cost rate Distribution reimbursement Schedule of Stock by Class [Table] Class of Stock [Line Items] Total Warrants Weighted average exercise price Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Number of options Outstanding - beginning of period Weighted average exercise price Outstanding - beginning of period Number of options Outstanding, Granted Weighted average exercise price, Granted Number of options Outstanding, Forfeited Weighted average exercise price, Forfeited Number of options Outstanding, Outstanding -end of period Weighted average exercise price, Outstanding -end of period Number of options Outstanding, Exercisable at the end of the period Weighted average exercise price, Exercisable at the end of the period Number of restricted stock, Outstanding - beginning of period Number of restricted stock, Granted Number of restricted stock, Forfeited Number of restricted stock, Vested Number of restricted stock, Outstanding - end of period Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Exercise price lower range Exercise price Options outstanding Weighted average remaining contractual life (years) Options exercisable Expected life Risk-free interest rate, minimum Risk-free interest rate, maximum Volatility, minimum Volatility, maximum Dividend yield Total share-based compensation expense Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] Issuance of shares Warrants to purchase common stock Offering price per share Private placement Fees payable and other offering expenses Gross proceeds from warrant exercises Warrant exercise price Exercise of prefunded warrants Warrants outstanding Preferred stock conversion price Preferred stock convertible shares issuable Preferred stock outstanding Preferred stock stated value Capital stock shares authorized Capital stock par value Common stock shares authorized Preferred stock shares authorized Weighted average of the remaining contractual life of vested and exercisable options Aggregate intrinsic value of exercisable options Stock option exercise price Unvested stock-based compensation Unvested stock-based compensation weighted-average period for recognition Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Marketing services from related party Fixed hourly consulting fee Consulting expenses Accrued fees Cash paid Loss before taxes on income Balance at the beginning of the year Changes during the year: Losses during the year (including foreign exchange rate effect) Balance at the end of the year Uncertain tax positions balance at beginning of period Increase in uncertain tax positions because of tax positions taken during the year Uncertain tax positions balance at end of period Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Line Items] Open Tax Year Provision for vacation and recreation pay R&D expenses Operating lease right of use assets Operating lease liabilities Share-based compensation Carry forward tax losses Accrued severance pay, net Deferred tax assets noncurrent Less-valuation allowance Deferred tax assets Federal corporate tax rate Corporate trade tax rate Revised tax rate on income of preferred enterprises Tax rate on income of beneficiary enterprises Corporate trade tax rate Tax rate on income of beneficiary enterprises Net carry forward tax loss Operating loss carryforwards expiration description Net loss carryforwards percentage Finished goods Work in process Raw materials and supplies Total inventory Employees and employee institutions Accrued vacation and recreation pay Accrued expenses Clinical trial accrual Current Operating lease liabilities Other Accounts Payable and Accruals - Other Schedule of Revenues from External Customers and Long-Lived Assets [Table] Revenues from External Customers and Long-Lived Assets [Line Items] Revenues Revenue from External Customers by Products and Services [Table] Revenue from External Customer [Line Items] Revenue Schedule of Revenue by Major Customers, by Reporting Segments [Table] Revenue, Major Customer [Line Items] Percentage of revenues per major customer Short term bank deposits. Fair Value Of Marketable Securities Classified By Maturity [Table Text Block] Marketable securities maturities within one year fair value. Marketable securities maturities after one year through two years fair value. Schedule Of Changes In Fair Value Of Marketable Securities [Table Text Block] Changes in fair value of marketable securities. Office Furniture And Equipment [Member] Series C Convertible Preferred Stock [Member] Share based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures. Share based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures, shares. Percentage of monthly deposits on salary. Severance Type One [Member] Schedule of supplemental information related to leases. Pre-Funded Warrants [Member] Series H Warrants [Member] Series I Warrants [Member] Series J Warrants [Member] Series K Warrants [Member] Change in liability for employees rights upon retirement. Change In Operating Lease Assets And Liabilities. Interest income from short term bank deposits. At The Market Offering [Member] Amounts with drawn in respect of employee rights upon retirement net. Issuance costs of at market offering. Series E Warrants [Member] Series F Warrants [Member] Series G Warrants [Member] Non cash acquisition of right of use assets by means of lease liabilities. Non-cash lease incentive. Decrease in right-of-use assets and lease liabilities due to shortening lease term. Underwriter Warrants [Member] Capital stock par value. Preferred Stock Blank Check [Member] Employees and Directors [Member] Consultants [Member] Fixed hourly consulting fee. Consultancy Agreement [Member] Germany [Member] Effective income tax rate reconciliation change in enacted tax rate 2 Limited [Member] Severance Type Two [Member] Customer B [Member] Sharebased compensation related to restricted stock and stock options award net offorfeitures of shares shares Loss gain on amounts funded in respect of employee rights upon retirement net Employee [Member] Non Employee [Member] Exercise Price One [Member] Exercise Price Two [Member] Exercise Price Three [Member] Exercise Price Four [Member] Non Employee Directors [Member] 2021 Equity Incentive Plan [Member] Effective income tax rate reconciliation foreign income tax rate differential 1 Arising Before January One 2018 [Member] Deferred Tax Assets Losses During Year Including Foreign Exchange Rate Effect. Operating Loss Carry forwards Expiration Description. Changes in fair value marketable securities. Russia and Belarus [Member] Accounts Payable, Other, Current Assets, Current Assets, Noncurrent Assets Liabilities, Current Liabilities, Noncurrent Liabilities Equity, Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Shares, Outstanding Gain (Loss) on Disposition of Property Plant Equipment ChangesInFairValueOfMarketableSecurities ChangeInLiabilityForEmployeesRightsUponRetirement Other Noncash Income (Expense) ChangeInRightOfUseAssetAndLeasingLiability InterestIncomeFromShorttermBankDeposits LossGainOnAmountsFundedInRespectOfEmployeeRightsUponRetirementNet Increase (Decrease) in Prepaid Expense Increase (Decrease) in Accounts Receivable Increase (Decrease) in Other Receivables Increase (Decrease) in Inventories Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Payments to Acquire Other Investments AmountsWithdrawnInRespectOfEmployeeRightsUponRetirementNet Net Cash Provided by (Used in) Investing Activities IssuanceCostsOfAtMarketOffering Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Cash and Cash Equivalents, Policy [Policy Text Block] Marketable Securities, Policy [Policy Text Block] Investment, Policy [Policy Text Block] Inventory, Policy [Policy Text Block] Proceeds from Sale and Maturity of Marketable Securities Proceeds from Interest Received Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Operating Lease, Liability, Current Operating Lease, Payments Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Deferred Tax Assets, Valuation Allowance Unrecognized Tax Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOperatingLeaseRightOfUseAssets DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOperatingLeaseLiabilities Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Deferred Tax Assets, Gross Deferred Tax Assets, Net of Valuation Allowance EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRatePreferredIncome EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate3 Other Accrued Liabilities, Current EX-101.PRE 18 nspr-20231231_pre.xml XBRL PRESENTATION FILE XML 19 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2023
Mar. 05, 2024
Jun. 30, 2023
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2023    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2023    
Current Fiscal Year End Date --12-31    
Entity File Number 001-35731    
Entity Registrant Name InspireMD, Inc.    
Entity Central Index Key 0001433607    
Entity Tax Identification Number 26-2123838    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 4 Menorat Hamaor St.    
Entity Address, City or Town Tel Aviv    
Entity Address, Country IL    
Entity Address, Postal Zip Code 6744832    
City Area Code (888)    
Local Phone Number 776-6804    
Title of 12(b) Security Common Stock, par value $0.0001 per share    
Trading Symbol NSPR    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 46,130,594
Entity Common Stock, Shares Outstanding   23,456,590  
Documents Incorporated by Reference [Text Block] Portions of the Registrant’s definitive proxy statement for its 2024 Annual Meeting of Stockholders, which the Registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after December 31, 2023, are incorporated by reference into Part III of this Annual Report on Form 10-K    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Auditor Firm ID 1309    
Auditor Name Kesselman & Kesselman    
Auditor Location Tel-Aviv, Israel    

XML 20 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
CURRENT ASSETS:    
Cash and cash equivalents $ 9,640 $ 4,632
Short-term bank deposits 13,171
Marketable securities 29,383
Accounts receivable:    
Trade, net 1,804 1,034
Other 648 213
Prepaid expenses 578 655
Inventory 2,106 1,621
TOTAL CURRENT ASSETS 44,159 21,326
NON-CURRENT ASSETS:    
Property, plant and equipment, net 1,060 917
Operating lease right of use assets 1,473 1,554
Fund in respect of employee rights upon retirement 951 856
TOTAL NON-CURRENT ASSETS 3,484 3,327
TOTAL ASSETS 47,643 24,653
Accounts payable and accruals:    
Trade 939 659
Other 5,081 4,411
TOTAL CURRENT LIABILITIES 6,020 5,070
LONG-TERM LIABILITIES:    
Operating lease liabilities 1,038 1,195
Liability for employee rights upon retirement 1,084 995
TOTAL LONG-TERM LIABILITIES 2,122 2,190
TOTAL LIABILITIES 8,142 7,260
EQUITY:    
Common stock, par value $0.0001 per share; 150,000,000 shares authorized at December 31, 2023 and 2022; 21,841,215 and 8,330,918 shares issued and outstanding at December 31, 2023 and 2022, respectively 2 1
Preferred C shares, par value $0.0001 per share; 1,172,000 shares authorized at December 31, 2023 and 2022; 1,718 shares issued and outstanding at December 31, 2023 and 2022; [1]
Additional paid-in capital 261,000 218,977
Accumulated deficit (221,501) (201,585)
Total equity 39,501 17,393
Total liabilities and equity $ 47,643 $ 24,653
[1] Represents an amount less than $1
XML 21 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2023
Dec. 31, 2022
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 150,000,000 150,000,000
Common stock, shares issued 21,841,215 8,330,918
Common stock, shares outstanding 21,841,215 8,330,918
Series C Preferred Stock [Member]    
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 1,172,000 1,172,000
Preferred stock, shares issued 1,718 1,718
Preferred stock, shares outstanding 1,718 1,718
XML 22 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]    
REVENUES $ 6,205 $ 5,171
COST OF REVENUES 4,398 4,054
GROSS PROFIT 1,807 1,117
OPERATING EXPENSES:    
Research and development 7,981 7,810
Selling and marketing 3,865 3,664
General and administrative 11,104 8,356
Total operating expenses 22,950 19,830
LOSS FROM OPERATIONS (21,143) (18,713)
FINANCIAL INCOME , net: 1,292 250
LOSS BEFORE TAX EXPENSES (19,851) (18,463)
TAX EXPENSES 65 28
NET LOSS $ (19,916) $ (18,491)
NET LOSS PER SHARE - basic $ (0.82) $ (2.35)
NET LOSS PER SHARE - diluted $ (0.82) $ (2.35)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING NET LOSS PER SHARE - basic 24,268,181 7,871,814
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING NET LOSS PER SHARE - diluted 24,268,181 7,871,814
XML 23 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Changes in Equity - USD ($)
$ in Thousands
Common Stock [Member]
Preferred Stock [Member]
Series C Convertible Preferred Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2021 $ 1 [1] $ 216,625 $ (183,094) $ 33,532
Balance, shares at Dec. 31, 2021 8,296,256 1,718      
Net loss     (18,491) (18,491)
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures   2,352   2,352
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures, shares 34,662        
Ending balance, value at Dec. 31, 2022 $ 1 [2] 218,977 (201,585) 17,393
Balance, shares at Dec. 31, 2022 8,330,918 1,718      
Net loss       (19,916) (19,916)
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures [2] 4,490   4,490
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures, shares 2,936,767        
Exercise of pre-funded warrants [2]  
Exercise of pre-funded warrants, shares 307,260       307,260
Issuance of common shares, pre-funded warrants and warrants, net of $4,635 issuance costs $ 1 37,533   $ 37,534
Issuance of common shares, pre-funded warrants and warrants, net of $4,635 issuance costs, shares 10,266,270       7,731,618
Ending balance, value at Dec. 31, 2023 $ 2 [2] $ 261,000 $ (221,501) $ 39,501
Balance, shares at Dec. 31, 2023 21,841,215 1,718      
[1] Represents an amount less than $1
[2] Represents an amount less than $1
XML 24 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Changes in Equity (Parenthetical) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Statement of Stockholders' Equity [Abstract]    
Shares, restricted stock award, forfeited 29,695 10,832
Payments of stock issuance costs $ 4,635  
XML 25 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (19,916) $ (18,491)
Adjustments required to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 232 188
Gain from sale of property, plant and equipment (6)
Change in fair value of markable securities, net of interest received (739)
Change in liability for employees rights upon retirement 89 (57)
Other financial expense 58 131
Change in operating right of use asset and operating leasing liability 62 (60)
Share-based compensation expenses 4,490 2,352
Decrease (increase) in interest receivable on short term deposits 171 (135)
Loss (gain) on amounts funded in respect of employee rights upon retirement, net (16) 135
Changes in operating asset and liability items:    
Decrease in prepaid expenses 77 7
Decrease (increase) in trade receivables (770) 190
Increase in other receivables (435) (48)
Increase in inventory (485) (478)
Increase (decrease) in trade payables 280 (234)
Increase in other payables 532 958
Net cash used in operating activities (16,376) (15,542)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of property, plant and equipment (381) (473)
Proceeds from sale of property, plant and equipment 12
Investment in short-term bank deposits (5,500) (19,000)
Investments in marketable securities (34,644)
Proceeds from matured marketable securities 6,000
Amounts funded in respect of employee rights upon retirement (79) (86)
Withdrawal from short-term bank deposits 18,500 28,000
Net cash provided by (used in) investing activities (16,092) 8,441
CASH FLOWS FROM FINANCING ACTIVITIES:    
Issuance costs of At The Market offering (140)
Proceeds from issuance of shares and warrants net of $4,635 issuance costs, 37,534
Net cash provided by (used in) financing activities 37,534 (140)
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS (58) (131)
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 5,008 (7,372)
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR 4,632 12,004
BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR 9,640 4,632
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Acquisition of right-of-use assets by means of lease liabilities 419 835
Non-cash lease incentive 45
Decrease in right-of-use assets and lease liabilities due to shortening lease term $ 131
XML 26 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Cash Flows (Parenthetical)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
USD ($)
Statement of Cash Flows [Abstract]  
Payments of stock issuance costs $ 4,635
XML 27 R9.htm IDEA: XBRL DOCUMENT v3.24.0.1
DESCRIPTION OF BUSINESS
 12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
DESCRIPTION OF BUSINESS

NOTE 1 - DESCRIPTION OF BUSINESS

 

  a. General
     
    InspireMD, Inc., a Delaware corporation (the “Company”), together with its subsidiaries, is a medical device company focusing on the development and commercialization of its proprietary MicroNet™ stent platform technology for the treatment of complex vascular and coronary disease. MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures.
     
    The Company’s carotid product (CGuard™ EPS) combines MicroNet and a self-expandable nitinol stent in a single device to treat carotid artery disease.
     
   

The Company ceased sales of the Company’s MGuard Prime EPS in the beginning of 2022.

     
   

The Company market its products through distributors in international markets, mainly in Europe.

 

As of the date of issuance of these consolidated financial statements, the Company has the ability to fund its planned operations for at least the next 12 months. However, the Company expects to continue incurring losses and negative cash flows from operations until its product, CGuard™ EPS, reaches commercial profitability. Therefore, in order to fund the Company’s operations until such time that the Company can generate substantial revenues, the Company may need to raise additional funds.

     
  b.

Status of European Medical Device Regulation for marketing CGuard EPS in countries requiring the CE Mark.

 

For the European Union (“EU”) nations, medical devices must obtain a CE mark before they may be placed on the market. In order to obtain and maintain the CE mark, the Company must comply with EU law on medical devices, which, until May 26, 2021 was governed by the Medical Device Directive 93/42/EEC (“MDD”), by presenting comprehensive technical files for the Company’s products demonstrating safety and efficacy of the product to be placed on the market and passing initial and annual quality management system audit as per ISO 13485 standard by a European Notified Body. The Company has obtained ISO 13485 quality system certification and CGuard EPS that the Company currently distribute into the European Union, displays the required CE mark. In order to maintain certification, the Company is required to pass an annual surveillance audit conducted by Notified Body auditors. The European Union replaced the MDD with the new European Medical Device Regulation (MDR 2017/745) (“MDR”) regulations. The MDR entered into force after a transitional period of three years and a one year extension of that transition period due to the COVID-19 pandemic on May 26, 2021 and which changes several aspects of the regulatory framework in the EU. Manufacturers had the duration of the transition period to update their technical documentation and processes to meet the new requirements in order to obtain a CE Mark.

 

In the Company’s specific case, the Company’s CE mark for CGuard EPS under the MDD expired on November 12, 2022. On February 14, 2023, the Company received a derogation per Article 97 paragraph 1 of Regulation 2017/745 from the Agency for Medicines and Health Products (FAMHP) allowing the Company to continue marketing CGuard EPS in the EU until August 15, 2023. Subsequently, on March 20, 2023 Regulation (EU) 2023/607 was published allowing the Company to continue marketing CGuard EPS in EU countries under the MDD directive until December 31, 2027.

 

In January 2024, the Company received CE mark recertification for the CGuard™ EPS under the EU’s Medical Device Regulation regulatory framework and can market Cguard permanently in EU countries as long as the Company is able to maintain its regulatory approvals.

 

  c.

Risks Related to Our Operations in Israel including the recent attack by Hamas and other terrorist organizations from the Gaza Strip and Israel’s war against them.

 

In October 2023, Israel was attacked by a terrorist organization and entered a state of war. As of the date of these consolidated financial statements, the war in Israel is ongoing and continues to evolve. The Company operations including the production facility are located in Israel. Currently, such activities in Israel remain largely unaffected. During the year ended December 31, 2023, the impact of this war on the Company’s results of operations and financial condition was immaterial, but such impact may increase, which could be material, as a result of the continuation, escalation or expansion of such war.

     
  d. Risks Related to the Geopolitical and Military Tensions Between Russia and Ukraine in Europe
     
   

The Company derived approximately 13.5% and 12.1% in the years ended December 31, 2023 and 2022, respectively, of total sales in Russia and Belarus. The escalation of geopolitical instability in Russia and Ukraine as well as currency fluctuations in the Russian Ruble could negatively impact the Company’s operations, sales, and future growth prospects in that region.

 

As a result of the crisis in Ukraine, the United States and the EU have implemented sanctions against certain Russian individuals and entities and have made it more difficult for the Company to collect on outstanding accounts receivable from customers in this region. The Company cannot provide assurance that potential future changes in sanctions will not have a material impact on the Company’s operations in Russia and Belarus or on the Company’s financial results.

 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 
XML 28 R10.htm IDEA: XBRL DOCUMENT v3.24.0.1
SIGNIFICANT ACCOUNTING POLICIES
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES

 

  a. Use of estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates using assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

 

As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to inventory valuations and assessing the likelihood of exercise of options to extend the lease term.

 

  b. Functional currency

 

The currency of the primary economic environment in which the operations of the Company and its subsidiaries are conducted is the U.S. dollar (“$” or “dollar”). Accordingly, the functional currency of the Company and its subsidiaries is the U.S. dollar.

 

The dollar figures are determined as follows: transactions and balances originally denominated in dollars are presented in their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. The resulting translation gains or losses are recorded as financial income or expense, as appropriate. For transactions reflected in the statements of operations in foreign currencies, the exchange rates at transaction dates are used. Depreciation and changes in inventories and other changes deriving from non-monetary items are based on historical exchange rates.

 

  c. Principles of consolidation

 

The consolidated financial statements include the accounts of the Company and of its subsidiaries. Intercompany transactions and balances have been eliminated upon consolidation.

 

  d. Cash and cash equivalents

 

The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. As of December 31, 2023, cash and cash equivalents consisted of cash, short-term deposits (up to three months from the date of deposit) and money market funds. As of December 31, 2022, this balance consisted solely of cash.

 

  e. Marketable securities

 

Marketable securities consist of debt securities. The Company elected the fair value option to measure and recognize its investments in debt securities in accordance with ASC 825, Financial Instruments as the Company manages its portfolio and evaluates the performance on a fair value basis. Changes in fair value, realized gains and losses on sales of marketable securities, are reflected in the statements of operation as finance expense (income), net.

 

Marketable securities are classified under current assets in the consolidated balance sheet as they represent the investment of funds available for the Company’s current operations.

 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

 

  f. Short-term bank deposits

 

Bank deposits with original maturities of more than three months but less than one year are presented as part of short-term bank deposits. Deposits are presented at their cost which approximates market values including accrued interest. Interest on deposits is recorded as financial income.

 

  g. Concentration of credit risk and allowance for doubtful accounts

 

Financial instruments that may potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and short-term bank deposits, which are deposited in major financially sound institutions in the U.S, Israel and Germany, and trade accounts receivable and other receivables. The Company’s trade accounts receivable is derived from revenues earned from customers from various countries. The Company performs ongoing credit evaluations of its customers’ financial condition and, requires no collateral from its customers. The Company also has a credit insurance policy for some of its customers. The Company maintains the allowance for estimated losses resulting from the inability of the Company’s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company’s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses, and future expectations. The allowance for expected credit losses was immaterial during the periods presented.

 

  h. Inventory

 

Inventories are stated at the lower of cost (cost is determined on a “first-in, first-out” basis) or net realizable value. The Company’s inventories generally have a limited shelf life and are subject to impairment as they approach their expiration dates. The Company regularly evaluates the carrying value of its inventory and when, based on such evaluation, factors indicate that impairment has occurred, the Company impairs the inventories’ carrying value.

 

  i. Leases

 

Operating leases are included in operating lease right-of-use (“ROU”) assets. Short-term balances regarding lease liabilities are included in accounts payable and accruals - Other and long-term balances regarding lease liabilities are included in operating lease liabilities. ROU assets represent Company’s right to use an underlying asset for the lease term and lease liabilities represent obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses the incremental borrowing rate based on the information available at the lease commencement date as the rate implicit in the lease is not readily determinable. The determination of the incremental borrowing rate requires management judgment based on information available at lease commencement. The lease terms may include periods covered by options to extend the lease when it is reasonably certain that the Company will exercise such options, and periods covered by options to terminate the lease when it is reasonably certain that the Company will not exercise such options. Operating lease cost is recognized on a straight-line basis over the lease term. Lease agreements that include lease and non-lease components are accounted for as a single lease component. The Company elected the short-term lease recognition exemption for leases with a lease term of 12 months or less.

 

  j. Property, plant and equipment

 

Property, plant and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets: over three years for computers and other electronic equipment, and seven to fifteen years for office furniture and equipment and machinery and equipment (mainly seven years). Leasehold improvements are amortized on a straight-line basis over the term of the lease, which is shorter than the estimated life of the improvements.

 

  k. Impairment in value of long-lived assets

 

The Company tests long-lived tangible assets for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future cash flows (undiscounted and without interest charges) of the long-lived assets is less than the carrying amount of such assets, an impairment would be recognized, and the assets would be written down to their estimated fair values, based on expected future discounted cash flows.

 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

 

  l. Revenue recognition

 

A contract with a customer exists only when: 1) the parties to the contract have approved it and are committed to perform their respective obligations, 2) the Company can identify each party’s rights regarding the distinct goods or services to be transferred (“Performance Obligations”), 3) the Company can determine the transaction price for the goods or services to be transferred, 4) the contract has commercial substance and 5) it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for Performance Obligations upon transfer of control to the customer, excluding sales taxes.

 

Revenue from sales of goods, including sales to distributors, is recognized when the customer obtains control of the product, once the Company has a present right to payment and the customer has legal title, and risk and rewards of ownership are obtained by the customer. Generally, this occurs when products are shipped. In few cases when products are directly sold to medical centers on consignment basis, revenue is recognized when the product is consumed.

 

The Company recognizes the incremental costs of obtaining contracts as an expense since the amortization period of the assets that the Company otherwise would have recognized is one year or less. The costs are recorded under selling and marketing expenses. Disaggregated revenue is disclosed in Note 13.

 

The Company recognizes revenue net of value added tax (VAT).

 

  m. Research and development costs

 

Research and development costs, including the costs of the Company’s US based clinical trial costs were approximately $3,300,000 and $4,468,000 for the years ended December 31, 2023 and 2022, respectively, and charged to the statement of operations as incurred.

 

  n. Share-based compensation

 

The Company has equity incentive plans under which the Company grants equity awards, including stock options, restricted stock and restricted stock units (“RSUs”) to employees, directors and service providers. Employee and service providers equity awards are accounted for using the grant-date fair value method. The Company determines compensation expense associated with restricted stock and RSUs based on the fair value of our common stock on the date of grant. The fair value of option awards is estimated using the Black-Scholes valuation model and expensed over the requisite service period. The Company elected to account for forfeitures as they occur.

 

The Company elected to recognize compensation expenses for awards to employees with only service conditions that have graded vesting schedules using the accelerated multiple option approach.   The attribution for nonemployee awards is in the same manner as if the Company had paid cash for the goods or services.

 

In addition, certain of our share-based awards to service providers are performance based, i.e., the vesting of these awards depends upon achieving certain goals. The company recognizes compensation expenses for awards with performance conditions when the company concludes that it is probable that the performance condition will be achieved.

 

  o. Uncertain tax positions

 

The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. If under the first step a tax position is assessed to be more likely than not of being sustained on audit, the second step is performed, under which the tax benefit is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Such liabilities are classified as long-term, unless the liability is expected to be resolved within twelve months from the balance sheet date. The Company’s policy is to include interest related to unrecognized tax benefits within “Financial expenses - net”.

 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

 

p. Deferred income taxes

 

Deferred taxes are determined utilizing the “asset and liability” method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred taxes are expected to be paid or realized. The Company assesses realization of deferred income tax assets and, based on all available evidence, concludes whether it is more likely than not that the net deferred income tax assets will be realized. A valuation allowance is provided for the amount of deferred income tax assets not considered to be realizable.

 

The Company may incur an additional tax liability in the event of intercompany dividend distributions by its subsidiaries. Such additional tax liability in respect of these foreign subsidiaries has not been provided for in these financial statements as it is the Company’s policy to permanently reinvest the subsidiaries’ earnings and to consider distributing dividends only in connection with a specific tax opportunity that may arise.

 

Taxes that would apply in the event of disposal of investments in a foreign subsidiary have not been taken into account in computing the deferred taxes, as it is the Company’s intention to hold, and not to realize, these investments.

 

  q. Advertising

 

Costs related to advertising and promotion of products are charged to sales and marketing expense as incurred. Advertising expenses were approximately $426,000 and $359,000 for the years ended December 31, 2023 and 2022, respectively.

 

  r. Net loss per share

 

Basic and diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock, pre-funded warrants and fully vested restricted stock units outstanding during the period. The calculation of diluted net loss per share excludes the effect of potential dilution of share options, warrants, and unvested restricted stocks, unvested restricted stock units and Series C preferred stock as the effect is anti-dilutive.

 

For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the Pre-funded Warrants have been included since the shares are issuable for a negligible consideration, as determined by the Company according to ASC 260-10-45-13, and have no vesting or other contingencies associated with them. For the year ended December 31, 2023, we had weighted average Pre-funded Warrants to purchase 9,612,502 share of common stock, which was used in the computation of net loss per share for the year.

 

The total number of shares of common stock related to outstanding options, warrants, unvested restricted stock, unvested restricted stock units and Series C Preferred Stock, which were excluded from the calculations of diluted loss per share were 74,978,006 and 2,741,355 for the years ended December 31, 2023 and 2022, respectively. This amount includes 3,054,086 and 355,951 of unvested restricted stock included in the number of issued and outstanding shares as of December 31, 2023 and 2022, respectively.

 

  s. Segment reporting

 

The Company has one operating and reportable segment.

 

  t. Fair value measurement

 

The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

 

The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:

 

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

 

Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data.

 

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

 

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.

 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

 

  u. Recently adopted accounting pronouncement

 
In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments. This guidance replaces the incurred loss impairment methodology. Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates (“ASU 2019-10”). The purpose of this amendment is to create a two-tier rollout of major updates, staggering the effective dates between larger public companies and all other entities. This granted certain classes of companies, including Smaller Reporting Companies (“SRCs”), additional time to implement major FASB standards, including ASU 2016-13. Larger public companies had an effective date for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All other entities are permitted to defer adoption of ASU 2016-13, and its related amendments, until the earlier of fiscal periods beginning after December 15, 2022. Under the current SEC definitions, the Company met the definition of an SRC and adopted the deferral period for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The Company adopted the provisions of this update as of January 1, 2023 with no material impact on its consolidated financial statements.

 

  v. Recently issued accounting pronouncement, not yet adopted

 

1)

In November 2023, the FASB issued ASU 2023-07 “Segment Reporting: Improvements to Reportable Segment Disclosures”. This guidance expands public entities segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity’s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements related disclosures.

     
  2) In December 2023, the FASB issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”. This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.

 

  3)

In August 2020, the FASB issued ASU 2020-06 “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40).” This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. This ASU is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The initial adoption of ASU 2020-06 is not expected to have a material impact on the Company’s consolidated financial statements.

 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 
XML 29 R11.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE MEASUREMENTS
 12 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS

NOTE 3 – FAIR VALUE MEASUREMENTS

 

As of December 31, 2023, the carrying amounts of accounts payable, accounts receivable and other receivable approximate their fair values due to the short-term maturities of these instruments.

 

The Company’s financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:

 

   Total   Level 1   Level 2   Level 3 
  

As of December 31, 2023

($ in thousands)

 
   Total   Level 1   Level 2   Level 3 
                 
Assets:                    
Cash equivalents-                    
Money market funds  $7,094   $7,094   $-   $- 
                     
Marketable securities-                    
U.S government bonds  $29,383   $-   $29,383   $- 

 

The Company’s debt securities are classified within Level 2 because it uses quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair value.

 

The cost of Marketable securities as of December 31, 2023 is $28,727,000 .

 
XML 30 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1
MARKETABLE SECURITIES
 12 Months Ended
Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]  
MARKETABLE SECURITIES

NOTE 4 - MARKETABLE SECURITIES

 

The following table sets forth the Company’s marketable securities for the indicated period:

 

   December 31, 2023 
   ($ in thousands) 
      
U.S government bonds  $29,383 

 

The following table summarizes the fair value of the Company’s marketable securities classified by maturity as of December 31, 2023:

 

   December 31, 2023 
   ($ in thousands) 
     
Amounts maturing within one year  $24,523 
Amounts maturing after one year through two years   4,860 
   $29,383 

 

The table below sets forth a summary of the changes in the fair value of the Company’s marketable securities for the year ended December 31, 2023:

 

   Year ended
December 31,		 
   2023 
   ($ in thousands) 
     
Balance at beginning of the period  $- 
Additions   34,644 
Sale or maturity   (6,000)
Interest Received   (38)
Changes in fair value   777 
Balance at end of the period   29,383 
      

 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 
XML 31 R13.htm IDEA: XBRL DOCUMENT v3.24.0.1
PROPERTY, PLANT AND EQUIPMENT
 12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
PROPERTY, PLANT AND EQUIPMENT

NOTE 5 - PROPERTY, PLANT AND EQUIPMENT

 

a.Composition of assets, grouped by major classifications, is as follows:

 

   2023   2022 
   December 31, 
   2023   2022 
   ($ in thousands) 
Cost:          
Computer equipment  $425   $396 
Office furniture and equipment   249    231 
Machinery and equipment   1,702    1,704 
Leasehold improvements   724    494 
Property plant and equipment, gross   3,100    2,825 
Less - accumulated depreciation and amortization   (2,040)   (1,908)
Net carrying amount  $1,060   $917 

 

  b. Depreciation and amortization expenses totaled approximately $232,000 and $188,000 for the years ended December 31, 2023 and 2022, respectively.

 
XML 32 R14.htm IDEA: XBRL DOCUMENT v3.24.0.1
LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT
 12 Months Ended
Dec. 31, 2023
Retirement Benefits [Abstract]  
LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT

NOTE 6 - LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT

 

Israeli labor law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances.

 

Pursuant to section 14 of the Israeli Severance Compensation Act, 1963, most of the Company’s employees are entitled to have monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments in accordance with section 14 relieve the Company from any future severance payments to these employees. The severance pay expenses for such employees were approximately $256,000 and $241,000 for the years ended December 31, 2023 and 2022, respectively.

 

The severance pay liability of the Company for the rest of its Israeli employees, which reflects the undiscounted amount of the liability, is based upon the number of years of service and the latest monthly salary. The severance pay liability is partly covered by insurance policies and by regular deposits with recognized severance payment funds. The Company may only withdraw funds previously deposited for savings in connection with the payment of severance. The severance pay expenses for such employees were approximately $116,000 and $68,000 for the years ended December 31, 2023 and 2022, respectively.

 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 
XML 33 R15.htm IDEA: XBRL DOCUMENT v3.24.0.1
LEASE AGREEMENTS
 12 Months Ended
Dec. 31, 2023
Lease Agreements  
LEASE AGREEMENTS

NOTE 7 – LEASE AGREEMENTS

 

  1)

The Company’s Israeli subsidiary had a lease agreement for a facility in Israel, which expired on December 31, 2022 with an option to extend the agreement for two additional years until December 31, 2024. On May 25, 2022 the Company amended the agreement mentioned above and extended it until December 31, 2026 as well as leasing of additional space in the facility. On August 24, 2023, the Company amended the lease agreement mentioned above, leasing additional space in the facility and shortened the lease term of another space in the building. The balances of right of use assets and lease liabilities increased due to the newly leased space and decreased due to the lease that was shortened.

     
  2)

Operating lease cost for the years ended December 31, 2023 and 2022 was $433,000 and $442,000 respectively.

 

Supplemental information related to leases are as follows:

   2023   2022 
   December 31, 
   2023   2022 
  

($ in thousands)

 
Operating lease right-of-use assets   1,473    1,554 
Current Operating lease liabilities   (557)   (419)
Non-current operating lease liabilities   (1,038)   (1,195)

 

Other information:

 

Operating cash flows from operating leases (cash paid in thousands)   (429)   (436)
Weighted Average Remaining Lease Term   3    4 
Weighted Average Discount Rate   9.73%   8.69%

 

Maturities of lease liabilities are as follows:

   Amount 
   ($ in thousands) 
2024   579 
2025   584 
2026   653 
Total lease payments   1,816 
Less imputed interest   (221)
Total   1,595 

 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 
XML 34 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
COMMITMENTS AND CONTINGENT LIABILITIES
 12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENT LIABILITIES

NOTE 8 - COMMITMENTS AND CONTINGENT LIABILITIES:

 

Distribution Agreement with Chinese Partner

 

On February 3, 2021, the Company entered into a distribution agreement (the “Distribution Agreement”) with three China-based partners, pursuant to which the Chinese partners will be responsible for conducting the necessary registration trials for commercial approval of the Company’s products in China, followed by an eight-year exclusive distribution right to sell the Company’s products in China with the term of the agreement continuing on a year-to-year basis unless terminated. Under the Distribution Agreement, the China-based partners will be subject to minimum purchase obligations. The Distribution Agreement may be terminated for cause upon failure to meet minimum purchase obligations, failure to obtain regulatory approvals or for other material breaches.

 

In addition, the agreement stipulates that if the Distributor fails to obtain the Regulatory Approvals by the time stipulated in the agreement due to the failure of the clinical trials, and this Agreement was terminated as a result of such failure to obtain Regulatory Approvals, InspireMD shall reimburse Distributor in an amount which is 50% of Distributor’s direct out of pocket costs to 3rd parties for conducting the clinical trials, which reimbursement will not exceed USD 1,000,000. The financial statements include a liability, based on 50% of the Distributor costs incurred until December 31, 2023. The liability at December 31, 2023 is immaterial.

 
XML 35 R17.htm IDEA: XBRL DOCUMENT v3.24.0.1
EQUITY
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
EQUITY

NOTE 9 - EQUITY

 

  a. Share capital

 

The Company’s common stock are listed on the Nasdaq Capital Market.

 

Private Placement

 

    On May 12, 2023, the Company entered into a securities purchase agreement (the “Purchase Agreement”) pursuant to which the Company agreed to sell and issue in a private placement (the “Private Placement Offering) an aggregate of 10,266,270 shares (the “Private Placement Shares”) of the Company’s common stock, pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 15,561,894 shares of common stock and warrants to purchase up to an aggregate of 51,656,328 shares of common stock, consisting of Series H warrants to purchase up to 12,914,086 shares of common stock (the “Series H Warrants”), Series I warrants to purchase up to 12,914,078 shares of common stock (the “Series I Warrants”), Series J warrants to purchase up to 12,914,086 shares of Common Stock (the “Series J Warrants”) and Series K warrants to purchase up to 12,914,078 shares of common stock (the “Series K Warrants” and together with the Series H Warrants, Series I Warrants and Series J Warrants, the “Warrants”), at an offering price of $1.6327 per Private Placement Share and associated Warrants and an offering price of $1.6326 per Pre-Funded Warrant and associated Warrants. The Private Placement Offering closed on May 16, 2023.
     
    Aggregate gross proceeds to the Company in respect of the Private Placement Offering were $42.2 million, before deducting fees payable to the placement agent and other offering expenses payable by the Company which amounted to approximately $4.6 million. If the Warrants are exercised in cash in full this would result in an additional $71.4 million of gross proceeds.

 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 9 – EQUITY (continued):

 

   

The Pre-Funded Warrants are immediately exercisable at an exercise price of $0.0001 per share and will not expire until exercised in full. The Warrants are immediately exercisable upon issuance at an exercise price of $1.3827 per share. The Warrants have a term of the earlier of (i) five years from the date of issuance and (ii) (A) in the case of the Series H Warrants, 20 trading days following the Company’s public release of primary and secondary end points related to one year follow up study results from the Company’s C-Guardians pivotal trial, (B) in the case of the Series I Warrants, 20 trading days following the Company’s announcement of receipt of Premarket Approval (PMA) from the Food and Drug Administration, or FDA, for the CGuard Prime Carotid Stent System (135 cm), (C) in the case of the Series J Warrants, 20 trading days following the Company’s announcement of receipt of FDA approval for the SwitchGuard transcarotid system and CGuard Prime 80 cm and (D) in the case on the Series K Warrants, 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of the CGuard Carotid Stent System in the United States begin. The Warrants may be exercised on a cashless basis if there is no effective registration statement registering the shares underlying the warrants.

 

The Company issued a total of 307,260 shares of its common stock in connection with the exercise of Pre-Funded Warrants to purchase 307,271 shares of common stock on a cashless basis.  As of December 31, 2023, there are Pre-Funded Warrants to purchase an aggregate of 15,254,623 share of common stock outstanding.

 

Pursuant to the full ratchet anti-dilution adjustment provisions in the respective certificate of designation for the Company’s Series C Preferred Stock, the conversion price of the outstanding shares of the Series C Preferred Stock was reduced to $1.3827 per share, effective as of the date of the securities purchase agreement entered for the Offering, and the number of shares of common stock issuable upon conversion of the Series C Preferred Stock increased by 5,668 additional shares of common stock upon conversion of the Series C Preferred Stock, based on 1,718 shares of Series C Preferred Stock outstanding as of May 16, 2023.

 

As of December 31, 2023 and 2022, there were 1,718 shares of Series C Preferred Stock outstanding, convertible into an aggregate of 7,952 and 2,284 shares of the Company’s common stock, respectively with a total stated value of $10,997.

 

As of December 31, 2023, the Company has outstanding warrants to purchase an aggregate of 53,396,008 shares of common stock as follows:

 

  

Number of underlying

Common stock

  

Exercise

price

 
Series E Warrants   198,159   $27.0000 
Series F Warrants   433,878   $7.4250 
Series G Warrants   1,092,344   $10.2300 
Series H Warrants   12,914,086   $1.3827 
Series I Warrants   12,914,078   $1.3827 
Series J Warrants   12,914,086   $1.3827 
Series K Warrants   12,914,078   $1.3827 
Underwriter Warrants   15,299   $7.4250 
Total Warrants   53,396,008   $ 

 

As of December 31, 2023, the Company has 155,000,000 authorized shares of capital stock, par value $0.0001 per share, of which 150,000,000 are shares of common stock and 5,000,000 are shares of “blank check” preferred stock.

 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 9 – EQUITY (continued):

 

  b. Share-Based Compensation

 

  1)

On September 30, 2021, at our 2021 annual meeting of stockholders, our stockholders approved our 2021 Equity Incentive Plan.

 

The Company’s. 2021 Equity Incentive Plan provides for the granting of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, dividend equivalent rights, and other awards, which may be granted singly, in combination, or in tandem.

 

As of December 31, 2023, we had 7,731,618 shares of common stock available for future issuance under our 2021 Equity Incentive Plan.

 

  5) The following table summarizes information about stock options granted to employees:

 

   Year ended December 31 
   2023   2022 
   Number of options  

Weighted

average

exercise price

   Number of options   Weighted average exercise price 
Outstanding - beginning of period   294,712    5.21    289,408   $5.29 
Granted   1,097,250    1.89    7,841    2.61 
Forfeited   (12,266)   4.00    (2,537)   5.70 
Outstanding- end of period   1,379,696    2.58    294,712   $5.21 
Exercisable at the end of the period   215,709    5.38    123,115    5.51 

 

  6) The following table summarizes information about stock options granted to non-employees:

 

   Year ended December 31 
   2023   2022 
   Number of options   Weighted average exercise price   Number of options   Weighted average exercise price 
Outstanding - beginning of period   166,669    3.37    20,002    6.90 
Granted   625,000    1.71    146,667    2.89 
Outstanding - end of period   791,669    2.06    166,669    3.37 
Exercisable at the end of the period   84,667    3.42    35,667    3.61 

 

  7) The following table summarizes information about restricted stock granted to employees:

 

   Year ended December 31 
   2023   2022 
   Number of restricted stock 
Outstanding - beginning of period   355,951    527,668 
Granted   2,914,340    45,494 
Forfeited   (29,695)   (10,832)
Vested   (186,510)   (206,379)
Outstanding - end of period   3,054,086    355,951 

 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 9 – EQUITY (continued):

 

  8) The following table summarizes information about RSUs granted to employees:

 

   Year ended December 31 
   2023   2022 
   Number of RSUs 
Outstanding - beginning of period   237,078    237,078 
Granted   1,045,150    - 
Outstanding - end of period   1,282,228    237,078 

 

  9) The following table provides additional information about all options outstanding and exercisable:

 

   Outstanding as of December 31, 2023 

Exercise

price

  Options outstanding   Weighted average remaining contractual life (years)   Options exercisable 
$1.15-2.97   1,786,211    9.28    73,946 
$3.30-4.12   227,932    8.53    95,075 
$4.95-10.05   153,169    7.00    127,303 
$16.50   4,053    6.01    4,053 
    2,171,365    9.03    300,376 

 

The weighted average of the remaining contractual life of total vested and exercisable options as of December 31, 2023 was 7.54 years.

 

The aggregate intrinsic value of the total exercisable options as of December 31, 2023 was approximately $10,983.

 

The weighted average fair value of options granted to employees was $1.65 and $2.33 for the years ended December 31, 2023 and 2022, respectively. The weighted average fair value of options granted was estimated using the Black-Scholes option-pricing model.

 

The weighted average fair value of options granted to consultants was $1.50 and $2.57 for the years ended December 31, 2023 and 2022, respectively. The weighted average fair value of options granted was estimated using the Black-Scholes option-pricing model.

 

The weighted average fair value of restricted stock granted was $1.95 and $2.42 for the years ended December 31, 2023 and 2022, respectively.

 

The weighted average fair value of RSU granted was $1.76 for the year ended December 31, 2023.

 

The vesting period for outstanding stock options, restricted stock, and RSUs is typically three years, with one-third of the awards vesting annually. Additionally, some of our share-based awards to service providers are performance-based, vesting upon the achievement of specified performance criteria related to clinical or marketing activities.

 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 9 – EQUITY (continued):

 

  10) The following table sets forth the assumptions that were used in determining the fair value of options granted to employees for the year December 31, 2023 and 2022:

 

    Year ended December 31 
    2023    2022 
Expected life   5.125-6.5 years    5.125-6.5 years 
Risk-free interest rates   3.58%-4.73%    1.79%-2.88% 
Volatility   109.62%-125.61%    127.43%-130.93%  
Dividend yield   -    - 

 

The Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. Accordingly, as to ordinary course options granted, the expected term was determined using the simplified method, which takes into consideration the option’s contractual life and the vesting periods (for non-employees, the expected term is equal to the option’s contractual life).

 

The annual risk-free rates are based on the yield rates of zero coupon non-index linked U.S. Federal Reserve treasury bonds as both the exercise price and the share price are in dollar terms. The Company’s expected volatility is derived from its historical data.

 

  11) As of December 31, 2023, the total unrecognized compensation cost on employee and non-employee stock options, restricted stock and RSUs, related to unvested stock-based compensation, amounted to approximately $7.18 million. This cost is expected to be recognized over a weighted-average period of approximately 0.97 years. This expected cost does not include the impact of any future stock-based compensation awards.
     
  12) The following table summarizes the allocation of total share-based compensation expense in the consolidated statements of operations:

 

   Year ended December 31 
   2023   2022 
   ($ in thousands) 
Cost of revenues  $93   $72 
Research and development   649    582 
Sales and marketing   416    318 
General and administrative   3,332    1,380 
   $4,490   $2,352 

 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 
XML 36 R18.htm IDEA: XBRL DOCUMENT v3.24.0.1
RELATED PARTIES TRANSACTIONS
 12 Months Ended
Dec. 31, 2023
Related Party Transactions [Abstract]  
RELATED PARTIES TRANSACTIONS

NOTE 10 – RELATED PARTIES TRANSACTIONS

 

  1) During the twelve months ended December 31, 2023 and 2022, a consulting company whose founder and CEO is our board member provided certain marketing services in the amount of $788 and $9,645, respectively.
     
  2) On September 15, 2023, the board approved the company’s entry into a consultancy agreement with a member of the immediate family of the CEO for certain administrative projects in connection with the Company’s expansion to the U.S. until a full-time Company employee is retained in such capacity. Pursuant to the Consultancy Agreement, the Company will pay a fixed hourly fee of $50 for a maximum of 20 hours per week and customary expenses. The Company may terminate this Agreement for any reason or no reason, at any time, upon 30 days prior written notice to consultant.

 

Consulting expenses for the year ended December 31, 2023, were $11,440.

 

3) Election to Receive Shares of Common Stock in lieu of Cash Compensation

 

For the year 2023, certain non-employee directors elected to receive all or a portion of their cash retainer amount in shares of the Company’s common stock under the 2021 Equity Incentive Plan. For a director that made that election, a stock award under the 2021 Equity Incentive Plan was paid quarterly on the first day of each next quarter (“Issuance Dates”) and became fully vested on the Issuance Dates. The stock award was determined by dividing (x) the product of the cash retainer amount and percentage of the cash retainer amount elected to be taken in shares by (y) the “Fair Market Value” (as defined in the 2021 Equity Incentive Plan) of a share on the Issuance Dates.

 

During the years ended December 31, 2023 the Company issued 52,129 shares of common stock to non-employee directors who elected to receive all or a portion of their cash retainer amount for the nine months ended September 30, 2023 in shares of the Company’s common stock under the 2021 Equity Incentive Plan.

 

As of December 31, 2023, there was an accrual for $55,000 for director’s fees for the three months ended December 31, 2023. Out of this an amount of $22,875 was paid in cash and $32,125 was issued in shares of the Company’s common stock under the 2021 Equity Incentive Plan. On January 1, 2024 the Company issued 11,854 shares of common stock.

 
XML 37 R19.htm IDEA: XBRL DOCUMENT v3.24.0.1
TAXES ON INCOME:
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
TAXES ON INCOME:

NOTE 11 - TAXES ON INCOME:

 

  a. Tax laws applicable to the Company and its subsidiaries

 

Taxation in the United States

 

InspireMD, Inc. is taxed under U.S. tax laws. Accordingly, the applicable federal corporate tax rate in 2023 is 21%. the applicable state income tax rate in 2023 is 3.42%.

 

Taxation in Israel

 

InspiredMD, Ltd is taxed under Israeli tax laws. Accordingly, the applicable corporate tax rate in 2023 is 23%.

 

Taxation in Germany

 

InspireMD GmbH is taxed according to the tax laws in Germany. Accordingly, the applicable tax rates are corporate tax rate of 15.825% and trade tax rate of 17.15%.

 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 11 - TAXES ON INCOME: (continued):

 

  b. Tax benefits under the Law for the Encouragement of Capital Investments, 1959 (the “Law”):

 

On December 29, 2016, the Investment Law was amended (“73 Amendment”), which includes, inter alia, two new tax incentive opportunities. These are the Preferred Technological Enterprise (“PTE”) and Special Preferred Technological Enterprise (“SPTE”). In order to benefit from either of these options, a Company must meet certain qualifications and receive formal approval from the Israel Innovation Authority (“IIA”) which allows the Company to use the reduced corporate tax rate of 12% on its “Preferred Technological Income” (earned from enterprises located in Development outside of Zone A) in the case of a “preferred technology enterprise”, or 6% on its “preferred technology income” (earned from enterprises located in Development Zone A or outside it) in the case of a “special preferred technology enterprise”. Additionally, any “technology income”, as this term is defined by the Law, not classified as “preferred technology income” is subject to the corporate tax rate.

 

Furthermore, according to the provisions regarding “preferred technology enterprise” and “special preferred technology enterprise” in the Law and the regulations thereunder, and to the extent the income is attributable to manufacturing, this income is classified as “preferred income” and is taxed at 7.5% or 16% according to the development zone. To the extent the income is from an intangible asset used for marketing, it is subject to the normal corporate tax rate.

 

Additionally, when income of a company originating from “preferred technology income” is distributed as dividend to a foreign-resident corporation, tax withholding from the dividend is 4%, provided that 90% or more of that company’s shares are directly held by one or more foreign corporations, and the profits resulted after they acquired the shares.

 

   c. Carry forward tax losses

 

As of December 31, 2023, the Company had a net carry forward tax loss of approximately $54 million, of which approximately $35 million (arising before January 1, 2018), expires until 2038, and approximately $19 million, which does not expire, but is limited to offset 80% of the net income in the year it is utilized.

 

Under the U.S. tax laws, for net operating losses (NOLs) arising after December 31, 2017, the Tax Cuts and Jobs Act enacted on December 22, 2017 (the “2017 Act”) limits a taxpayer’s ability to utilize NOL carryforwards to 80% of taxable income.

 

In addition, NOLs arising after 2017 can be carried forward indefinitely, but carryback is generally prohibited. NOLs generated in tax years beginning before January 1, 2018, will not be subject to the foregoing taxable income limitation and will continue to have a two-year carryback and twenty-year carryforward period.

 

As of December 31, 2023, InspireMD Ltd., an Israeli subsidiary, had a net carry forward tax loss of approximately $107 million. Under Israeli tax laws, the carry forward tax losses can be utilized indefinitely.

 

The Israeli subsidiary is taxed in the New Israeli Shekel (“NIS”), which is different from its functional currency (U.S. Dollar). The change in the Israeli subsidiary NOL’s for tax purposes is partly resulted by such rate differences.

 

  d. Loss before income taxes

 

The components of loss before income taxes are as follows:

  

   Year ended December 31 
   2023   2022 
   ($ in thousands) 
Loss before taxes on income:          
InspireMD, Inc.  $(5,772)  $(4,773)
Subsidiaries   (14,079)   (13,690)
   $(19,851)  $(18,463)

 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 11 - TAXES ON INCOME (continued):

 

  e. Current taxes on income

 

The main reconciling item between the statutory tax rate of the Company and the effective tax rate is the change in valuation allowance in respect of tax benefits from carried forward tax losses due to uncertainty of the realization of such tax benefits.

 

The changes in the valuation allowance for the year ended December 31, 2023 and 2022 were as follows:

 

   Year ended December 31 
   2023   2022 
   ($ in thousands) 
Balance at the beginning of the year  $40,071   $39,212 
Changes during the year:          
Losses during the year (including foreign exchange rate effect)   2,580    859 
Balance at the end of the year  $42,651   $40,071 

 

  f. Accounting for Uncertain Tax position

 

The following is a reconciliation of the total amounts of the Company’s uncertain tax positions during the year ended December 31, 2023 and 2022 were as follows:

 

   Year ended December 31, 
   2023   2022 
   ($ in thousands) 
Balance at beginning of period  $106   $89 
Increase in uncertain tax positions because of tax positions taken during the year   62    17 
Balance at end of period  $168   $106 

 

A summary of open tax years by major jurisdiction is presented below:

 

Jurisdiction    Years 
U.S.    2020-2023 
Israel    2019-2023 
Germany    2020-2023 

 

  g. Deferred income tax:

 

   2023   2022 
   December 31, 
   2023   2022 
   ($ in thousands) 
     
Provision for vacation and recreation pay   68    45 
R&D expenses   1,691    1,452 
Operating lease right of use assets   (339)   (357)
Operating lease liabilities   367    371 
Share-based compensation   3,492    3,021 
Carry forward tax losses   37,342    35,507 
Accrued severance pay, net   30    32 
Deferred tax assets noncurrent   42,651    40,071 
Less-valuation allowance   (42,651)   (40,071)
Deferred tax assets   -    - 

 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 
XML 38 R20.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION
 12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION

NOTE 12 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:

 

Balance sheets:

 

    Inventory:

  

   2023   2022 
   December 31, 
   2023   2022 
   ($ in thousands) 
Finished goods  $210   $179 
Work in process   562    510 
Raw materials and supplies   1,334    932 
Total inventory  $2,106   $1,621 

 

 

  a. Accounts payable and accruals-other:

 

   2023   2022 
   December 31, 
   2023   2022 
   ($ in thousands) 
Employees and employee institutions  $2,188   $1,853 
Accrued vacation and recreation pay   287    197 
Accrued expenses   1,115    554 
Clinical trial accrual   744    1,258 
Current Operating lease liabilities   557    419 
Other   190    130 
Accounts Payable and Accruals - Other  $5,081   $4,411 

 
XML 39 R21.htm IDEA: XBRL DOCUMENT v3.24.0.1
DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES
 12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES

NOTE 13 – DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES:

 

Revenues are attributed to geographic areas based on the location of the customers. The following is a summary of revenues:

 

   Year ended December 31, 
   2023   2022 
   ($ in thousands) 
Italy  $1,195   $970 
Germany   896    866 
Russia   738    381 
Other   3,376    2,954 
   $6,205   $5,171 

 

By product:

 

   Year ended December 31, 
   2023   2022 
   ($ in thousands) 
CGuard™ EPS  $6,205   $5,123 
MGuard Prime™ EPS   -    48 
   $6,205   $5,171 

 

By principal customers:

  

   Year ended December 31, 
   2023   2022 
Customer A   14%   17%
Customer B   12%   7%

 

All tangible long lived assets are located in Israel.

 
XML 40 R22.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUBSEQUENT EVENTS
 12 Months Ended
Dec. 31, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 14 - SUBSEQUENT EVENTS:

 

On January 23, 2024, the Company granted 1,528,316 restricted shares of the Company’s common stock to employees and directors. The shares to employees are subject to a three-year vesting period, with one-third of such awards vesting each year. The shares to directors are subject to a one-year vesting period.

 

On January 23, 2024, the Company granted 563,499 restricted share units of the Company’s common stock to the chief executive officer. The shares are subject to a three-year vesting period, with one-third of such awards vesting each year.

 

On January 23, 2024, the Company granted to employees and directors options to purchase a total of 669,464 shares of the Company’s common stock. The options have an exercise prices of $3.14 per share, which was the fair market value of the Company’s common stock on the date of the grant. The options to employees are subject to a three-year vesting period, with one-third of such awards vesting each year. The options to directors are subject to a one-year vesting period.
XML 41 R23.htm IDEA: XBRL DOCUMENT v3.24.0.1
SIGNIFICANT ACCOUNTING POLICIES (Policies)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Use of estimates

  a. Use of estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates using assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

 

As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to inventory valuations and assessing the likelihood of exercise of options to extend the lease term.

 
Functional currency

  b. Functional currency

 

The currency of the primary economic environment in which the operations of the Company and its subsidiaries are conducted is the U.S. dollar (“$” or “dollar”). Accordingly, the functional currency of the Company and its subsidiaries is the U.S. dollar.

 

The dollar figures are determined as follows: transactions and balances originally denominated in dollars are presented in their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. The resulting translation gains or losses are recorded as financial income or expense, as appropriate. For transactions reflected in the statements of operations in foreign currencies, the exchange rates at transaction dates are used. Depreciation and changes in inventories and other changes deriving from non-monetary items are based on historical exchange rates.

 
Principles of consolidation

  c. Principles of consolidation

 

The consolidated financial statements include the accounts of the Company and of its subsidiaries. Intercompany transactions and balances have been eliminated upon consolidation.

 
Cash and cash equivalents

  d. Cash and cash equivalents

 

The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. As of December 31, 2023, cash and cash equivalents consisted of cash, short-term deposits (up to three months from the date of deposit) and money market funds. As of December 31, 2022, this balance consisted solely of cash.

 
Marketable securities

  e. Marketable securities

 

Marketable securities consist of debt securities. The Company elected the fair value option to measure and recognize its investments in debt securities in accordance with ASC 825, Financial Instruments as the Company manages its portfolio and evaluates the performance on a fair value basis. Changes in fair value, realized gains and losses on sales of marketable securities, are reflected in the statements of operation as finance expense (income), net.

 

Marketable securities are classified under current assets in the consolidated balance sheet as they represent the investment of funds available for the Company’s current operations.

 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

 
Short-term bank deposits

  f. Short-term bank deposits

 

Bank deposits with original maturities of more than three months but less than one year are presented as part of short-term bank deposits. Deposits are presented at their cost which approximates market values including accrued interest. Interest on deposits is recorded as financial income.

 
Concentration of credit risk and allowance for doubtful accounts

  g. Concentration of credit risk and allowance for doubtful accounts

 

Financial instruments that may potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and short-term bank deposits, which are deposited in major financially sound institutions in the U.S, Israel and Germany, and trade accounts receivable and other receivables. The Company’s trade accounts receivable is derived from revenues earned from customers from various countries. The Company performs ongoing credit evaluations of its customers’ financial condition and, requires no collateral from its customers. The Company also has a credit insurance policy for some of its customers. The Company maintains the allowance for estimated losses resulting from the inability of the Company’s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company’s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses, and future expectations. The allowance for expected credit losses was immaterial during the periods presented.

 
Inventory

  h. Inventory

 

Inventories are stated at the lower of cost (cost is determined on a “first-in, first-out” basis) or net realizable value. The Company’s inventories generally have a limited shelf life and are subject to impairment as they approach their expiration dates. The Company regularly evaluates the carrying value of its inventory and when, based on such evaluation, factors indicate that impairment has occurred, the Company impairs the inventories’ carrying value.

 
Leases

  i. Leases

 

Operating leases are included in operating lease right-of-use (“ROU”) assets. Short-term balances regarding lease liabilities are included in accounts payable and accruals - Other and long-term balances regarding lease liabilities are included in operating lease liabilities. ROU assets represent Company’s right to use an underlying asset for the lease term and lease liabilities represent obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses the incremental borrowing rate based on the information available at the lease commencement date as the rate implicit in the lease is not readily determinable. The determination of the incremental borrowing rate requires management judgment based on information available at lease commencement. The lease terms may include periods covered by options to extend the lease when it is reasonably certain that the Company will exercise such options, and periods covered by options to terminate the lease when it is reasonably certain that the Company will not exercise such options. Operating lease cost is recognized on a straight-line basis over the lease term. Lease agreements that include lease and non-lease components are accounted for as a single lease component. The Company elected the short-term lease recognition exemption for leases with a lease term of 12 months or less.

 
Property, plant and equipment

  j. Property, plant and equipment

 

Property, plant and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets: over three years for computers and other electronic equipment, and seven to fifteen years for office furniture and equipment and machinery and equipment (mainly seven years). Leasehold improvements are amortized on a straight-line basis over the term of the lease, which is shorter than the estimated life of the improvements.

 
Impairment in value of long-lived assets

  k. Impairment in value of long-lived assets

 

The Company tests long-lived tangible assets for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future cash flows (undiscounted and without interest charges) of the long-lived assets is less than the carrying amount of such assets, an impairment would be recognized, and the assets would be written down to their estimated fair values, based on expected future discounted cash flows.

 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

 
Revenue recognition

  l. Revenue recognition

 

A contract with a customer exists only when: 1) the parties to the contract have approved it and are committed to perform their respective obligations, 2) the Company can identify each party’s rights regarding the distinct goods or services to be transferred (“Performance Obligations”), 3) the Company can determine the transaction price for the goods or services to be transferred, 4) the contract has commercial substance and 5) it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for Performance Obligations upon transfer of control to the customer, excluding sales taxes.

 

Revenue from sales of goods, including sales to distributors, is recognized when the customer obtains control of the product, once the Company has a present right to payment and the customer has legal title, and risk and rewards of ownership are obtained by the customer. Generally, this occurs when products are shipped. In few cases when products are directly sold to medical centers on consignment basis, revenue is recognized when the product is consumed.

 

The Company recognizes the incremental costs of obtaining contracts as an expense since the amortization period of the assets that the Company otherwise would have recognized is one year or less. The costs are recorded under selling and marketing expenses. Disaggregated revenue is disclosed in Note 13.

 

The Company recognizes revenue net of value added tax (VAT).

 
Research and development costs

  m. Research and development costs

 

Research and development costs, including the costs of the Company’s US based clinical trial costs were approximately $3,300,000 and $4,468,000 for the years ended December 31, 2023 and 2022, respectively, and charged to the statement of operations as incurred.

 
Share-based compensation

  n. Share-based compensation

 

The Company has equity incentive plans under which the Company grants equity awards, including stock options, restricted stock and restricted stock units (“RSUs”) to employees, directors and service providers. Employee and service providers equity awards are accounted for using the grant-date fair value method. The Company determines compensation expense associated with restricted stock and RSUs based on the fair value of our common stock on the date of grant. The fair value of option awards is estimated using the Black-Scholes valuation model and expensed over the requisite service period. The Company elected to account for forfeitures as they occur.

 

The Company elected to recognize compensation expenses for awards to employees with only service conditions that have graded vesting schedules using the accelerated multiple option approach.   The attribution for nonemployee awards is in the same manner as if the Company had paid cash for the goods or services.

 

In addition, certain of our share-based awards to service providers are performance based, i.e., the vesting of these awards depends upon achieving certain goals. The company recognizes compensation expenses for awards with performance conditions when the company concludes that it is probable that the performance condition will be achieved.

 
Deferred income taxes

  o. Uncertain tax positions

 

The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. If under the first step a tax position is assessed to be more likely than not of being sustained on audit, the second step is performed, under which the tax benefit is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Such liabilities are classified as long-term, unless the liability is expected to be resolved within twelve months from the balance sheet date. The Company’s policy is to include interest related to unrecognized tax benefits within “Financial expenses - net”.

 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

 

p. Deferred income taxes

 

Deferred taxes are determined utilizing the “asset and liability” method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred taxes are expected to be paid or realized. The Company assesses realization of deferred income tax assets and, based on all available evidence, concludes whether it is more likely than not that the net deferred income tax assets will be realized. A valuation allowance is provided for the amount of deferred income tax assets not considered to be realizable.

 

The Company may incur an additional tax liability in the event of intercompany dividend distributions by its subsidiaries. Such additional tax liability in respect of these foreign subsidiaries has not been provided for in these financial statements as it is the Company’s policy to permanently reinvest the subsidiaries’ earnings and to consider distributing dividends only in connection with a specific tax opportunity that may arise.

 

Taxes that would apply in the event of disposal of investments in a foreign subsidiary have not been taken into account in computing the deferred taxes, as it is the Company’s intention to hold, and not to realize, these investments.

 
Advertising

  q. Advertising

 

Costs related to advertising and promotion of products are charged to sales and marketing expense as incurred. Advertising expenses were approximately $426,000 and $359,000 for the years ended December 31, 2023 and 2022, respectively.

 
Net loss per share

  r. Net loss per share

 

Basic and diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock, pre-funded warrants and fully vested restricted stock units outstanding during the period. The calculation of diluted net loss per share excludes the effect of potential dilution of share options, warrants, and unvested restricted stocks, unvested restricted stock units and Series C preferred stock as the effect is anti-dilutive.

 

For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the Pre-funded Warrants have been included since the shares are issuable for a negligible consideration, as determined by the Company according to ASC 260-10-45-13, and have no vesting or other contingencies associated with them. For the year ended December 31, 2023, we had weighted average Pre-funded Warrants to purchase 9,612,502 share of common stock, which was used in the computation of net loss per share for the year.

 

The total number of shares of common stock related to outstanding options, warrants, unvested restricted stock, unvested restricted stock units and Series C Preferred Stock, which were excluded from the calculations of diluted loss per share were 74,978,006 and 2,741,355 for the years ended December 31, 2023 and 2022, respectively. This amount includes 3,054,086 and 355,951 of unvested restricted stock included in the number of issued and outstanding shares as of December 31, 2023 and 2022, respectively.

 
Segment reporting

  s. Segment reporting

 

The Company has one operating and reportable segment.

 
Fair value measurement

  t. Fair value measurement

 

The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

 

The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:

 

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

 

Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data.

 

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

 

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.

 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

 
Recently adopted accounting pronouncement

  u. Recently adopted accounting pronouncement

 
In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments. This guidance replaces the incurred loss impairment methodology. Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates (“ASU 2019-10”). The purpose of this amendment is to create a two-tier rollout of major updates, staggering the effective dates between larger public companies and all other entities. This granted certain classes of companies, including Smaller Reporting Companies (“SRCs”), additional time to implement major FASB standards, including ASU 2016-13. Larger public companies had an effective date for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All other entities are permitted to defer adoption of ASU 2016-13, and its related amendments, until the earlier of fiscal periods beginning after December 15, 2022. Under the current SEC definitions, the Company met the definition of an SRC and adopted the deferral period for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The Company adopted the provisions of this update as of January 1, 2023 with no material impact on its consolidated financial statements.

 
Recently issued accounting pronouncement, not yet adopted

  v. Recently issued accounting pronouncement, not yet adopted

 

1)

In November 2023, the FASB issued ASU 2023-07 “Segment Reporting: Improvements to Reportable Segment Disclosures”. This guidance expands public entities segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity’s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements related disclosures.

     
  2) In December 2023, the FASB issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”. This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.

 

  3)

In August 2020, the FASB issued ASU 2020-06 “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40).” This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. This ASU is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The initial adoption of ASU 2020-06 is not expected to have a material impact on the Company’s consolidated financial statements.
XML 42 R24.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE MEASUREMENTS (Tables)
 12 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Abstract]  
SCHEDULE OF FINANCIAL ASSETS SUBJECT TO FAIR VALUE MEASUREMENTS

The Company’s financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:

 

   Total   Level 1   Level 2   Level 3 
  

As of December 31, 2023

($ in thousands)

 
   Total   Level 1   Level 2   Level 3 
                 
Assets:                    
Cash equivalents-                    
Money market funds  $7,094   $7,094   $-   $- 
                     
Marketable securities-                    
U.S government bonds  $29,383   $-   $29,383   $- 
XML 43 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
MARKETABLE SECURITIES (Tables)
 12 Months Ended
Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]  
SCHEDULE OF MARKETABLE SECURITIES

The following table sets forth the Company’s marketable securities for the indicated period:

 

   December 31, 2023 
   ($ in thousands) 
      
U.S government bonds  $29,383 
SCHEDULE OF FAIR VALUE OF MARKETABLE SECURITIES CLASSIFIED BY MATURITY

The following table summarizes the fair value of the Company’s marketable securities classified by maturity as of December 31, 2023:

 

   December 31, 2023 
   ($ in thousands) 
     
Amounts maturing within one year  $24,523 
Amounts maturing after one year through two years   4,860 
   $29,383 
SCHEDULE OF CHANGES IN FAIR VALUE OF MARKETABLE SECURITIES

The table below sets forth a summary of the changes in the fair value of the Company’s marketable securities for the year ended December 31, 2023:

 

   Year ended
December 31,		 
   2023 
   ($ in thousands) 
     
Balance at beginning of the period  $- 
Additions   34,644 
Sale or maturity   (6,000)
Interest Received   (38)
Changes in fair value   777 
Balance at end of the period   29,383 
      

 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)
XML 44 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1
PROPERTY, PLANT AND EQUIPMENT (Tables)
 12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
SCHEDULE OF PROPERTY PLANT AND EQUIPMENT

 

   2023   2022 
   December 31, 
   2023   2022 
   ($ in thousands) 
Cost:          
Computer equipment  $425   $396 
Office furniture and equipment   249    231 
Machinery and equipment   1,702    1,704 
Leasehold improvements   724    494 
Property plant and equipment, gross   3,100    2,825 
Less - accumulated depreciation and amortization   (2,040)   (1,908)
Net carrying amount  $1,060   $917 

 

  b. Depreciation and amortization expenses totaled approximately $232,000 and $188,000 for the years ended December 31, 2023 and 2022, respectively.

 
XML 45 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
LEASE AGREEMENTS (Tables)
 12 Months Ended
Dec. 31, 2023
Lease Agreements  
SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES

Supplemental information related to leases are as follows:

   2023   2022 
   December 31, 
   2023   2022 
  

($ in thousands)

 
Operating lease right-of-use assets   1,473    1,554 
Current Operating lease liabilities   (557)   (419)
Non-current operating lease liabilities   (1,038)   (1,195)

 

Other information:

 

Operating cash flows from operating leases (cash paid in thousands)   (429)   (436)
Weighted Average Remaining Lease Term   3    4 
Weighted Average Discount Rate   9.73%   8.69%
SCHEDULE OF MATURITIES OF LEASE LIABILITIES

Maturities of lease liabilities are as follows:

   Amount 
   ($ in thousands) 
2024   579 
2025   584 
2026   653 
Total lease payments   1,816 
Less imputed interest   (221)
Total   1,595 
XML 46 R28.htm IDEA: XBRL DOCUMENT v3.24.0.1
EQUITY (Tables)
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK

  

Number of underlying

Common stock

  

Exercise

price

 
Series E Warrants   198,159   $27.0000 
Series F Warrants   433,878   $7.4250 
Series G Warrants   1,092,344   $10.2300 
Series H Warrants   12,914,086   $1.3827 
Series I Warrants   12,914,078   $1.3827 
Series J Warrants   12,914,086   $1.3827 
Series K Warrants   12,914,078   $1.3827 
Underwriter Warrants   15,299   $7.4250 
Total Warrants   53,396,008   $ 
SCHEDULE OF STOCK OPTIONS GRANTED

 

   Year ended December 31 
   2023   2022 
   Number of options  

Weighted

average

exercise price

   Number of options   Weighted average exercise price 
Outstanding - beginning of period   294,712    5.21    289,408   $5.29 
Granted   1,097,250    1.89    7,841    2.61 
Forfeited   (12,266)   4.00    (2,537)   5.70 
Outstanding- end of period   1,379,696    2.58    294,712   $5.21 
Exercisable at the end of the period   215,709    5.38    123,115    5.51 

 

  6) The following table summarizes information about stock options granted to non-employees:

 

   Year ended December 31 
   2023   2022 
   Number of options   Weighted average exercise price   Number of options   Weighted average exercise price 
Outstanding - beginning of period   166,669    3.37    20,002    6.90 
Granted   625,000    1.71    146,667    2.89 
Outstanding - end of period   791,669    2.06    166,669    3.37 
Exercisable at the end of the period   84,667    3.42    35,667    3.61 
SCHEDULE OF RESTRICTED STOCK GRANTED TO EMPLOYEES

 

   Year ended December 31 
   2023   2022 
   Number of restricted stock 
Outstanding - beginning of period   355,951    527,668 
Granted   2,914,340    45,494 
Forfeited   (29,695)   (10,832)
Vested   (186,510)   (206,379)
Outstanding - end of period   3,054,086    355,951 
SCHEDULE OF RESTRICTED STOCK UNIT GRANTED TO EMPLOYEES

 

   Year ended December 31 
   2023   2022 
   Number of RSUs 
Outstanding - beginning of period   237,078    237,078 
Granted   1,045,150    - 
Outstanding - end of period   1,282,228    237,078 
SCHEDULE OF ADDITIONAL INFORMATION ABOUT ALL OPTIONS OUTSTANDING AND EXERCISABLE

 

   Outstanding as of December 31, 2023 

Exercise

price

  Options outstanding   Weighted average remaining contractual life (years)   Options exercisable 
$1.15-2.97   1,786,211    9.28    73,946 
$3.30-4.12   227,932    8.53    95,075 
$4.95-10.05   153,169    7.00    127,303 
$16.50   4,053    6.01    4,053 
    2,171,365    9.03    300,376 
SCHEDULE OF FAIR VALUE OF OPTIONS GRANTED TO EMPLOYEES

 

    Year ended December 31 
    2023    2022 
Expected life   5.125-6.5 years    5.125-6.5 years 
Risk-free interest rates   3.58%-4.73%    1.79%-2.88% 
Volatility   109.62%-125.61%    127.43%-130.93%  
Dividend yield   -    - 
SCHEDULE OF ALLOCATION OF TOTAL SHARE-BASED COMPENSATION EXPENSE

 

   Year ended December 31 
   2023   2022 
   ($ in thousands) 
Cost of revenues  $93   $72 
Research and development   649    582 
Sales and marketing   416    318 
General and administrative   3,332    1,380 
   $4,490   $2,352 
XML 47 R29.htm IDEA: XBRL DOCUMENT v3.24.0.1
TAXES ON INCOME: (Tables)
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
SCHEDULE OF COMPONENTS OF LOSS BEFORE INCOME TAXES

The components of loss before income taxes are as follows:

  

   Year ended December 31 
   2023   2022 
   ($ in thousands) 
Loss before taxes on income:          
InspireMD, Inc.  $(5,772)  $(4,773)
Subsidiaries   (14,079)   (13,690)
   $(19,851)  $(18,463)
SCHEDULE OF CHANGES IN VALUATION ALLOWANCE

The changes in the valuation allowance for the year ended December 31, 2023 and 2022 were as follows:

 

   Year ended December 31 
   2023   2022 
   ($ in thousands) 
Balance at the beginning of the year  $40,071   $39,212 
Changes during the year:          
Losses during the year (including foreign exchange rate effect)   2,580    859 
Balance at the end of the year  $42,651   $40,071 

 

  f. Accounting for Uncertain Tax position
SCHEDULE OF RECONCILIATION OF UNCERTAIN TAX POSITIONS

The following is a reconciliation of the total amounts of the Company’s uncertain tax positions during the year ended December 31, 2023 and 2022 were as follows:

 

   Year ended December 31, 
   2023   2022 
   ($ in thousands) 
Balance at beginning of period  $106   $89 
Increase in uncertain tax positions because of tax positions taken during the year   62    17 
Balance at end of period  $168   $106 
SCHEDULE OF OPEN TAX YEARS BY MAJOR JURISDICTION

A summary of open tax years by major jurisdiction is presented below:

 

Jurisdiction    Years 
U.S.    2020-2023 
Israel    2019-2023 
Germany    2020-2023 
SCHEDULE OF DEFERRED INCOME TAX

 

   2023   2022 
   December 31, 
   2023   2022 
   ($ in thousands) 
     
Provision for vacation and recreation pay   68    45 
R&D expenses   1,691    1,452 
Operating lease right of use assets   (339)   (357)
Operating lease liabilities   367    371 
Share-based compensation   3,492    3,021 
Carry forward tax losses   37,342    35,507 
Accrued severance pay, net   30    32 
Deferred tax assets noncurrent   42,651    40,071 
Less-valuation allowance   (42,651)   (40,071)
Deferred tax assets   -    - 
XML 48 R30.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)
 12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
SCHEDULE OF INVENTORIES

  

   2023   2022 
   December 31, 
   2023   2022 
   ($ in thousands) 
Finished goods  $210   $179 
Work in process   562    510 
Raw materials and supplies   1,334    932 
Total inventory  $2,106   $1,621 
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER

 

  a. Accounts payable and accruals-other:

 

   2023   2022 
   December 31, 
   2023   2022 
   ($ in thousands) 
Employees and employee institutions  $2,188   $1,853 
Accrued vacation and recreation pay   287    197 
Accrued expenses   1,115    554 
Clinical trial accrual   744    1,258 
Current Operating lease liabilities   557    419 
Other   190    130 
Accounts Payable and Accruals - Other  $5,081   $4,411 
XML 49 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES (Tables)
 12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS

Revenues are attributed to geographic areas based on the location of the customers. The following is a summary of revenues:

 

   Year ended December 31, 
   2023   2022 
   ($ in thousands) 
Italy  $1,195   $970 
Germany   896    866 
Russia   738    381 
Other   3,376    2,954 
   $6,205   $5,171 
SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRODUCT

By product:

 

   Year ended December 31, 
   2023   2022 
   ($ in thousands) 
CGuard™ EPS  $6,205   $5,123 
MGuard Prime™ EPS   -    48 
   $6,205   $5,171 
SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS

By principal customers:

  

   Year ended December 31, 
   2023   2022 
Customer A   14%   17%
Customer B   12%   7%
XML 50 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
DESCRIPTION OF BUSINESS (Details Narrative)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Russia and Belarus [Member] | Sales [Member] | Geographic Concentration Risk [Member]    
Product Information [Line Items]    
Sales percentage 13.50% 12.10%
XML 51 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)
 12 Months Ended
Dec. 31, 2023
USD ($)
segment
shares
Dec. 31, 2022
USD ($)
shares
[custom:ResearchAndDevelopmentExpenseIncludingUSBasedClinicalTrialCost] | $ $ 3,300,000 $ 4,468,000
Significant Change in Unrecognized Tax Benefits, Nature of Event the tax benefit is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement.  
Advertising Expense | $ $ 426,000 $ 359,000
Weighted Average Number of Shares Outstanding, Diluted, Adjustment 9,612,502  
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number 3,054,086 355,951
Number of Operating Segments | segment 1  
Series C Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 74,978,006 2,741,355
XML 52 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE OF FINANCIAL ASSETS SUBJECT TO FAIR VALUE MEASUREMENTS (Details)
Dec. 31, 2023
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Marketable securities $ 28,727,000
Fair Value, Recurring [Member] | US Government Agencies Debt Securities [Member]  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Marketable securities 29,383,000
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | US Government Agencies Debt Securities [Member]  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Marketable securities
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | US Government Agencies Debt Securities [Member]  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Marketable securities 29,383,000
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | US Government Agencies Debt Securities [Member]  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Marketable securities
Fair Value, Recurring [Member] | Money Market Funds [Member]  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Cash equivalents 7,094,000
Fair Value, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Cash equivalents 7,094,000
Fair Value, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Cash equivalents
Fair Value, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Cash equivalents
XML 53 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE MEASUREMENTS (Details Narrative)
Dec. 31, 2023
USD ($)
Fair Value Disclosures [Abstract]  
Cost of marketable securities $ 28,727,000
XML 54 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE OF MARKETABLE SECURITIES (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Marketable Securities [Line Items]    
Marketable securities $ 29,383
US Government Agencies Debt Securities [Member]    
Marketable Securities [Line Items]    
Marketable securities $ 29,383  
XML 55 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE OF FAIR VALUE OF MARKETABLE SECURITIES CLASSIFIED BY MATURITY (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]    
Amounts maturing within one year $ 24,523  
Amounts maturing after one year through two years 4,860  
Marketable securities $ 29,383
XML 56 R38.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE OF CHANGES IN FAIR VALUE OF MARKETABLE SECURITIES (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]    
Balance at beginning of the period  
Additions 34,644
Sale or maturity (6,000)  
Interest Received (38)  
Changes in fair value 777  
Balance at end of the period $ 29,383
XML 57 R39.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Property plant and equipment, gross $ 3,100 $ 2,825
Less - accumulated depreciation and amortization (2,040) (1,908)
Net carrying amount 1,060 917
Depreciation and amortization expenses 232,000 188,000
Computer Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment, gross 425 396
Office Furniture And Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment, gross 249 231
Machinery and Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment, gross 1,702 1,704
Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment, gross $ 724 $ 494
XML 58 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]    
Percentage of monthly deposits on salary 8.33%  
Severance Type One [Member]    
Restructuring Cost and Reserve [Line Items]    
Severance expenses $ 256,000 $ 241,000
Severance Type Two [Member]    
Restructuring Cost and Reserve [Line Items]    
Severance expenses $ 116,000 $ 68,000
XML 59 R41.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Lease Agreements    
Operating lease right-of-use assets $ 1,473 $ 1,554
Current Operating lease liabilities $ (557) $ (419)
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Accounts Payable, Other, Current Accounts Payable, Other, Current
Non-current operating lease liabilities $ (1,038) $ (1,195)
Operating cash flows from operating leases (cash paid in thousands) $ (429) $ (436)
Weighted average remaining lease 3 years 4 years
Weighted average discount rate 9.73% 8.69%
XML 60 R42.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details)
$ in Thousands
Dec. 31, 2023
USD ($)
Lease Agreements  
2024 $ 579
2025 584
2026 653
Total lease payments 1,816
Less imputed interest (221)
Total $ 1,595
XML 61 R43.htm IDEA: XBRL DOCUMENT v3.24.0.1
LEASE AGREEMENTS (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Lease Agreements    
Operating lease expense $ 433,000 $ 442,000
XML 62 R44.htm IDEA: XBRL DOCUMENT v3.24.0.1
COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative) - USD ($)
Feb. 03, 2021
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]    
Distribution cost rate 50.00% 50.00%
Distribution reimbursement $ 1,000,000  
XML 63 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK (Details)
Dec. 31, 2023
$ / shares
shares
Class of Stock [Line Items]  
Total Warrants 53,396,008
Series E Warrants [Member]  
Class of Stock [Line Items]  
Total Warrants 198,159
Weighted average exercise price | $ / shares $ 27.0000
Series F Warrants [Member]  
Class of Stock [Line Items]  
Total Warrants 433,878
Weighted average exercise price | $ / shares $ 7.4250
Series G Warrants [Member]  
Class of Stock [Line Items]  
Total Warrants 1,092,344
Weighted average exercise price | $ / shares $ 10.2300
Series H Warrants [Member]  
Class of Stock [Line Items]  
Total Warrants 12,914,086
Weighted average exercise price | $ / shares $ 1.3827
Series I Warrants [Member]  
Class of Stock [Line Items]  
Total Warrants 12,914,078
Weighted average exercise price | $ / shares $ 1.3827
Series J Warrants [Member]  
Class of Stock [Line Items]  
Total Warrants 12,914,086
Weighted average exercise price | $ / shares $ 1.3827
Series K Warrants [Member]  
Class of Stock [Line Items]  
Total Warrants 12,914,078
Weighted average exercise price | $ / shares $ 1.3827
Underwriter Warrants [Member]  
Class of Stock [Line Items]  
Total Warrants 15,299
Weighted average exercise price | $ / shares $ 7.4250
XML 64 R46.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE OF STOCK OPTIONS GRANTED (Details) - $ / shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Employee [Member]    
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]    
Number of options Outstanding - beginning of period 294,712,000 289,408,000
Weighted average exercise price Outstanding - beginning of period $ 5.21 $ 5.29
Number of options Outstanding, Granted 1,097,250 7,841
Weighted average exercise price, Granted $ 1.89 $ 2.61
Number of options Outstanding, Forfeited (12,266) (2,537)
Weighted average exercise price, Forfeited $ 4.00 $ 5.70
Number of options Outstanding, Outstanding -end of period 1,379,696,000 294,712,000
Weighted average exercise price, Outstanding -end of period $ 2.58 $ 5.21
Number of options Outstanding, Exercisable at the end of the period 215,709,000 123,115,000
Weighted average exercise price, Exercisable at the end of the period $ 5.38 $ 5.51
Non Employee [Member]    
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]    
Number of options Outstanding - beginning of period 166,669,000 20,002,000
Weighted average exercise price Outstanding - beginning of period $ 3.37 $ 6.90
Number of options Outstanding, Granted 625,000 146,667
Weighted average exercise price, Granted $ 1.71 $ 2.89
Number of options Outstanding, Outstanding -end of period 791,669,000 166,669,000
Weighted average exercise price, Outstanding -end of period $ 2.06 $ 3.37
Number of options Outstanding, Exercisable at the end of the period 84,667,000 35,667,000
Weighted average exercise price, Exercisable at the end of the period $ 3.42 $ 3.61
XML 65 R47.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE OF RESTRICTED STOCK GRANTED TO EMPLOYEES (Details) - shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]    
Number of restricted stock, Outstanding - beginning of period 355,951  
Number of restricted stock, Outstanding - end of period 3,054,086 355,951
Employee [Member] | Restricted Stock [Member]    
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]    
Number of restricted stock, Outstanding - beginning of period 355,951 527,668
Number of restricted stock, Granted 2,914,340 45,494
Number of restricted stock, Forfeited (29,695) (10,832)
Number of restricted stock, Vested (186,510) (206,379)
Number of restricted stock, Outstanding - end of period 3,054,086 355,951
XML 66 R48.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE OF RESTRICTED STOCK UNIT GRANTED TO EMPLOYEES (Details) - shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]    
Number of restricted stock, Outstanding - beginning of period 355,951  
Number of restricted stock, Outstanding - end of period 3,054,086 355,951
Employee [Member] | Restricted Stock Units (RSUs) [Member]    
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]    
Number of restricted stock, Outstanding - beginning of period 237,078 237,078
Number of restricted stock, Granted 1,045,150
Number of restricted stock, Outstanding - end of period 1,282,228 237,078
XML 67 R49.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE OF ADDITIONAL INFORMATION ABOUT ALL OPTIONS OUTSTANDING AND EXERCISABLE (Details)
 12 Months Ended
Dec. 31, 2023
$ / shares
shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Options outstanding 2,171,365
Weighted average remaining contractual life (years) 9 years 10 days
Options exercisable 300,376
Exercise Price One [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price lower range | $ / shares $ 1.15
Exercise price | $ / shares $ 2.97
Options outstanding 1,786,211
Weighted average remaining contractual life (years) 9 years 3 months 10 days
Options exercisable 73,946
Exercise Price Two [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price lower range | $ / shares $ 3.30
Exercise price | $ / shares $ 4.12
Options outstanding 227,932
Weighted average remaining contractual life (years) 8 years 6 months 10 days
Options exercisable 95,075
Exercise Price Three [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price lower range | $ / shares $ 4.95
Exercise price | $ / shares $ 10.05
Options outstanding 153,169
Weighted average remaining contractual life (years) 7 years
Options exercisable 127,303
Exercise Price Four [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price | $ / shares $ 16.50
Options outstanding 4,053,000
Weighted average remaining contractual life (years) 6 years 3 days
Options exercisable 4,053
XML 68 R50.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE OF FAIR VALUE OF OPTIONS GRANTED TO EMPLOYEES (Details)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Risk-free interest rate, minimum 3.58% 1.79%
Risk-free interest rate, maximum 4.73% 2.88%
Volatility, minimum 109.62% 127.43%
Volatility, maximum 125.61% 130.93%
Dividend yield
Minimum [Member]    
Expected life 5 years 1 month 15 days 5 years 1 month 15 days
Maximum [Member]    
Expected life 6 years 6 months 6 years 6 months
XML 69 R51.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE OF ALLOCATION OF TOTAL SHARE-BASED COMPENSATION EXPENSE (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Total share-based compensation expense $ 4,490 $ 2,352
Cost of Sales [Member]    
Total share-based compensation expense 93 72
Research and Development Expense [Member]    
Total share-based compensation expense 649 582
Selling and Marketing Expense [Member]    
Total share-based compensation expense 416 318
General and Administrative Expense [Member]    
Total share-based compensation expense $ 3,332 $ 1,380
XML 70 R52.htm IDEA: XBRL DOCUMENT v3.24.0.1
EQUITY (Details Narrative) - USD ($)
 12 Months Ended
May 12, 2023
Dec. 31, 2023
Dec. 31, 2022
May 16, 2023
Subsidiary, Sale of Stock [Line Items]        
Issuance of shares   7,731,618    
Warrants to purchase common stock   53,396,008    
Exercise of prefunded warrants   307,260    
Preferred stock stated value [1]    
Capital stock shares authorized   155,000,000    
Capital stock par value   $ 0.0001    
Common stock shares authorized   150,000,000 150,000,000  
Restricted Stock [Member]        
Subsidiary, Sale of Stock [Line Items]        
Weighted average of the remaining contractual life of vested and exercisable options   7 years 6 months 14 days    
Aggregate intrinsic value of exercisable options   $ 10,983    
Restricted Stock [Member] | Consultants [Member]        
Subsidiary, Sale of Stock [Line Items]        
Stock option exercise price   $ 1.95 $ 2.42  
Share-Based Payment Arrangement, Option [Member] | Employees and Directors [Member]        
Subsidiary, Sale of Stock [Line Items]        
Stock option exercise price   1.65 2.33  
Share-Based Payment Arrangement, Option [Member] | Consultants [Member]        
Subsidiary, Sale of Stock [Line Items]        
Stock option exercise price   1.50 $ 2.57  
Restricted Stock Units (RSUs) [Member] | Consultants [Member]        
Subsidiary, Sale of Stock [Line Items]        
Stock option exercise price   $ 1.76    
Employee And Non Employee Stock Option [Member]        
Subsidiary, Sale of Stock [Line Items]        
Unvested stock-based compensation   $ 7,180,000    
Unvested stock-based compensation weighted-average period for recognition   11 months 19 days    
Series C Preferred Stock [Member]        
Subsidiary, Sale of Stock [Line Items]        
Preferred stock conversion price $ 1.3827      
Preferred stock convertible shares issuable 5,668 7,952 2,284  
Preferred stock outstanding   1,718 1,718 1,718
Preferred stock stated value   $ 10,997 $ 10,997  
Preferred stock shares authorized   1,172,000 1,172,000  
Pre-Funded Warrants [Member]        
Subsidiary, Sale of Stock [Line Items]        
Warrant exercise price $ 0.0001      
Warrants outstanding   15,254,623    
Warrant [Member]        
Subsidiary, Sale of Stock [Line Items]        
Warrants to purchase common stock   307,271    
Warrant exercise price $ 1.3827      
Preferred Stock Blank Check [Member]        
Subsidiary, Sale of Stock [Line Items]        
Preferred stock shares authorized   5,000,000    
Private Placement [Member]        
Subsidiary, Sale of Stock [Line Items]        
Issuance of shares 10,266,270      
Private placement $ 42,200,000      
Fees payable and other offering expenses 4,600,000      
Gross proceeds from warrant exercises $ 71,400,000      
Private Placement [Member] | Pre-Funded Warrants [Member]        
Subsidiary, Sale of Stock [Line Items]        
Warrants to purchase common stock 15,561,894      
Offering price per share $ 1.6326      
Private Placement [Member] | Warrant [Member]        
Subsidiary, Sale of Stock [Line Items]        
Warrants to purchase common stock 51,656,328      
Offering price per share $ 1.6327      
Private Placement [Member] | Series H Warrants [Member]        
Subsidiary, Sale of Stock [Line Items]        
Warrants to purchase common stock 12,914,086      
Private Placement [Member] | Series I Warrants [Member]        
Subsidiary, Sale of Stock [Line Items]        
Warrants to purchase common stock 12,914,078      
Private Placement [Member] | Series J Warrants [Member]        
Subsidiary, Sale of Stock [Line Items]        
Warrants to purchase common stock 12,914,086      
Private Placement [Member] | Series K Warrants [Member]        
Subsidiary, Sale of Stock [Line Items]        
Warrants to purchase common stock 12,914,078      
At The Market Offering [Member] | Warrant [Member]        
Subsidiary, Sale of Stock [Line Items]        
Warrants to purchase common stock   53,396,008    
[1] Represents an amount less than $1
XML 71 R53.htm IDEA: XBRL DOCUMENT v3.24.0.1
RELATED PARTIES TRANSACTIONS (Details Narrative) - USD ($)
 12 Months Ended
Jan. 01, 2024
Sep. 15, 2023
Dec. 31, 2023
Dec. 31, 2022
Related Party Transaction [Line Items]        
Issuance of shares     7,731,618  
Accrued fees     $ 55,000  
Subsequent Event [Member]        
Related Party Transaction [Line Items]        
Issuance of shares 11,854      
2021 Equity Incentive Plan [Member]        
Related Party Transaction [Line Items]        
Issuance of shares     32,125  
Cash paid     $ 22,875  
Related Party [Member]        
Related Party Transaction [Line Items]        
Consulting expenses     11,440  
Consultancy Agreement [Member]        
Related Party Transaction [Line Items]        
Fixed hourly consulting fee   $ 50,000    
Director [Member]        
Related Party Transaction [Line Items]        
Marketing services from related party     $ 788,000 $ 9,645,000
Non Employee Directors [Member]        
Related Party Transaction [Line Items]        
Issuance of shares     52,129  
XML 72 R54.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE OF COMPONENTS OF LOSS BEFORE INCOME TAXES (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Loss before taxes on income $ (19,851) $ (18,463)
Parent Company [Member]    
Loss before taxes on income (5,772) (4,773)
Subsidiaries [Member]    
Loss before taxes on income $ (14,079) $ (13,690)
XML 73 R55.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE OF CHANGES IN VALUATION ALLOWANCE (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
Balance at the beginning of the year $ 40,071 $ 39,212
Changes during the year: Losses during the year (including foreign exchange rate effect) 2,580 859
Balance at the end of the year $ 42,651 $ 40,071
XML 74 R56.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE OF RECONCILIATION OF UNCERTAIN TAX POSITIONS (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
Uncertain tax positions balance at beginning of period $ 106 $ 89
Increase in uncertain tax positions because of tax positions taken during the year 62 17
Uncertain tax positions balance at end of period $ 168 $ 106
XML 75 R57.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE OF OPEN TAX YEARS BY MAJOR JURISDICTION (Details)
 12 Months Ended
Dec. 31, 2023
UNITED STATES | Earliest Tax Year [Member]  
Operating Loss Carryforwards [Line Items]  
Open Tax Year 2020
UNITED STATES | Latest Tax Year [Member]  
Operating Loss Carryforwards [Line Items]  
Open Tax Year 2023
ISRAEL | Earliest Tax Year [Member]  
Operating Loss Carryforwards [Line Items]  
Open Tax Year 2019
ISRAEL | Latest Tax Year [Member]  
Operating Loss Carryforwards [Line Items]  
Open Tax Year 2023
GERMANY | Earliest Tax Year [Member]  
Operating Loss Carryforwards [Line Items]  
Open Tax Year 2020
GERMANY | Latest Tax Year [Member]  
Operating Loss Carryforwards [Line Items]  
Open Tax Year 2023
XML 76 R58.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE OF DEFERRED INCOME TAX (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]      
Provision for vacation and recreation pay $ 68 $ 45  
R&D expenses 1,691 1,452  
Operating lease right of use assets (339) (357)  
Operating lease liabilities 367 371  
Share-based compensation 3,492 3,021  
Carry forward tax losses 37,342 35,507  
Accrued severance pay, net 30 32  
Deferred tax assets noncurrent 42,651 40,071  
Less-valuation allowance (42,651) (40,071) $ (39,212)
Deferred tax assets  
XML 77 R59.htm IDEA: XBRL DOCUMENT v3.24.0.1
TAXES ON INCOME: (Details Narrative) - USD ($)
$ in Millions
 12 Months Ended
Dec. 29, 2016
Dec. 31, 2023
Dec. 31, 2017
Operating Loss Carryforwards [Line Items]      
Federal corporate tax rate   21.00%  
Revised tax rate on income of preferred enterprises 12.00%    
Tax rate on income of beneficiary enterprises 6.00% 4.00%  
Tax rate on income of beneficiary enterprises   90.00%  
Net carry forward tax loss   $ 54 $ 35
Net loss carryforwards percentage   80.00%  
Arising Before January One 2018 [Member]      
Operating Loss Carryforwards [Line Items]      
Operating loss carryforwards expiration description   expires until 2038  
Limited [Member]      
Operating Loss Carryforwards [Line Items]      
Net carry forward tax loss   $ 19  
Minimum [Member]      
Operating Loss Carryforwards [Line Items]      
Corporate trade tax rate   7.50%  
Maximum [Member]      
Operating Loss Carryforwards [Line Items]      
Corporate trade tax rate   16.00%  
Israel Tax Authority [Member]      
Operating Loss Carryforwards [Line Items]      
Federal corporate tax rate   23.00%  
Net carry forward tax loss   $ 107  
Germany [Member]      
Operating Loss Carryforwards [Line Items]      
Federal corporate tax rate   15.825%  
Corporate trade tax rate   17.15%  
XML 78 R60.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE OF INVENTORIES (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Finished goods $ 210 $ 179
Work in process 562 510
Raw materials and supplies 1,334 932
Total inventory $ 2,106 $ 1,621
XML 79 R61.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Employees and employee institutions $ 2,188 $ 1,853
Accrued vacation and recreation pay 287 197
Accrued expenses 1,115 554
Clinical trial accrual 744 1,258
Current Operating lease liabilities 557 419
Other 190 130
Accounts Payable and Accruals - Other $ 5,081 $ 4,411
XML 80 R62.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]    
Revenues $ 6,205 $ 5,171
ITALY    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Revenues 1,195 970
GERMANY    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Revenues 896 866
RUSSIAN FEDERATION    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Revenues 738 381
Other Countries [Member]    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Revenues $ 3,376 $ 2,954
XML 81 R63.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRODUCT (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenue from External Customer [Line Items]    
Revenue $ 6,205 $ 5,171
C Guard E P S [Member]    
Revenue from External Customer [Line Items]    
Revenue 6,205 5,123
M Guard Prime E P S [Member]    
Revenue from External Customer [Line Items]    
Revenue $ 48
XML 82 R64.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS (Details) - Sales [Member] - Customer Concentration Risk [Member]
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Customer A [Member]    
Revenue, Major Customer [Line Items]    
Percentage of revenues per major customer 14.00% 17.00%
Customer B [Member]    
Revenue, Major Customer [Line Items]    
Percentage of revenues per major customer 12.00% 7.00%
EXCEL 84 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

X2@%*5)_:-EZS,$BD6Y);?S?A8*J&:3 M.2K ZD^\:6B0>Z6#6BMR0Y G0(_Y*7RG]F #TN&(=3M;OV]B]-;WKD[_HB;/ MUA"L+.N2HY<5=!M,JN0J.-N=PN)=+=127QAJQZP)BJ@)HZ;(=I9"*NX&K(2' MY3%-%(_=;9-ZFHT<]UH);R@%MO%U0"I8C2$3+5$@[11_2&FZTO EPC/=$7DN M&;3[+V\[+RL&I%[E"^%!+E\[D:&)A-NCP.;6P$T69-1"9$;#8XRG!":F9KN]N^3";-0-Y=;YXU=04WW;A M317&VW\#U!+ P04 " "P@&58*LH7 M6Y8, Y(0 &0 'AL+W=O^[=R[*)X_S;?5*G(^$7!RLUJ M%15WQSS-;]_M67O-P%1<+RL:.'K_=AU=\QFO+M<7!=Z.6BJ)6/&L%'G&"KYX MM]>W7A^[M%XN^"3X;=EY9B3)59Y_H9=1\F[/)(9XRN.**$3XN>$#GJ9$"&Q\ MK6GNM4?2QNYS0_U4R@Y9KJ*2#_+TLTBJY;N]WAY+^"+:I-4TO_W(:WD\HA?G M:2G_9[=JK87%\::L\E6]&1RL1*9^HV^U'CH;>N83&^QZ@RWY5@=)+D^B*GK_ MMLAO64&K08T>I*AR-Y@3&1EE5A68%=A7O1_^\W(T_^/M405:-'(4U_N.U3[[ MB7V6S<[SK%J6;)@E/-DE< 0F6D[LAI-C^UF*)SPVF&/IS#9MYQEZ3BN9(^DY M3TGV=2.J._:O_E59%3#^OQ\34I%P'R=! ?&Z7$R0*:I:9+#9,BJX%D=K444IFR^Y-LA7 MZRB[^_67GFT%;TH6YZL5(@-.%G]A6,Q2458\81BKEIR-HS*)OK)!3>$\*K[P MRF 7A;B)*JY=I. !\5EIDTP[C^Z892OCZ7)W?1C# EZ J,BJG$6LY/&F$)7@ M)5MOBGB)B&+1=<$E);9/.XD_VWQST4SWFVDY8;TYH)WE)L)ZD+Q=BGA))S;B M*7()S2'Z4Q9E.+PL-QPL@(&U8I^M&_9W#ZUG6^'89+'@A0E5%'D.FDH3J*E<0,I9K0!PQ1#-/"\!N80?VBKFV83/7\%E@&2X; MC6<7H^GP_$371N.!P[*/CAZ8: @GV.B@*6*Z6_B=6* M)P+LIO"3;[R(11E=I7"(BI1=CW R62PU_HJ9AFF:%M3D]*"MCE,K$RGI@]5B_U$ &*,Q75[QHD5B&#QYLR11L)KU(;0GTT+.9K=L] MEX(A#(.GJ.Q" J)Z1XK;QB? VQ84[D6;Y^A.Z.NFV6.SP79D$U.V6@V MNX1;RN?/_>FT3UX)][VXG X^]F?DP^?GDS%\=C+X31MO)%L@1]Y8I'=T_* + M@\,=I]-JE0ZW?FN%/=WR0BC1#L@9S6;-Z7:-ZSAZ#T']B@6&:WOMD@\=,KH9 MVKKCNF0-T["=+:&/G55;K&B,UJP:/5PE3]Q=]8\7T?KM>5J7I*M;H#94MUV( M: K#K8AS&7;M=,=G@,9TPD MRJ 4E?&L60<,*6_&UU4MCRGE@50 KGQ3R!%2@?J*TV6%4D[!,D-R!L^:HS[(-H3R(W(&NZGX2_>$=VJ0#U(?0\[7(LMIU M8$"1(SN$+M*!S3P#'FCW0MV508_74/M0BTYPARSLH50R>B&TVW.QUO M#/$LS?\KK8^0.MQZP/^+?2T4N;X? M,L> .6S"7YOY1FBVQO5M"8R#[,,PS/+\XF?PR1D'[ MPO=Y>(%A'&3+T+.89P=4R+7V4"G<<4WF>KH;NMT8LRE2/$35/BJVGF.S ^T3 M+U7X]7S=LTR:LTV?@@J3SUG0T4U/%10-)W][6N[]A'6GL\N78/ #BUZ.1_/_ MV:QT^$LPU EDS57_=G$3-D0-Q Z?-86%(ASH:6\IA(]KJJT%HB01I"24* ]5 M%J$=:@"D6ZE3"NXT:KL*[)^ED>MZG-]8_GES.6?_LK,UO>(?1 MQR>C\0>&'S;\?3@=C&;]X[/ACI"1[&P>Y&AMMT9GDT<8?8!Z!:!DT/(@3>R$(#B@XU^^&AR?$9-6R!K]1L7[/5NV]GY" MZ[*)# S/E>=O6S.!8T16BIBA7-NTC*BC?I2^+(&_B96Z$G@EN\J>\[C$BT@4 MVS.?J[4D:;*D3Y9T?I8>-%INTDJV-PU%F U%1_ 2BD\FF8962-PAF[V %E#E MP?;:,\BZ9/\:&*CDW[DQV"WD'U;KY!82,07Z\;NUB($%=S!IP3F3@8(2651+ MEF?\L%J*HLW+JBAG]?F::G_2.Y3:+=)065[F*Z5@:G]DAT6WZDFS7=[:%3<4 MUS54%>JNJ-,MJ!UZ"GZCKKVHWUJC.Z'V1>NV&K%L9$4$V=.H M,6V*H(GIVJA .T'WG!)_Z&9'WE4:?W]FL\PG4ANO9.-6+96()7)=[9O5$M61 MO(_9E/*&E24DU Y;9FCX-O#60X%(L&NX6.F81NAH)TW#>2=XFB"O'N[<*B8YR&=Y MA9Z0.N3-8B%B0>ZU%(B70OI,6U G417).RSEN(Q<+"KA^&1'^"PB2KIJ?64- M[<-_">M HI:=S(>(B>.\2%0?JT4R*.1[5-P!A39%R>_;4EVE[)"1P- X!,8V M9>,5I8#555^_XM4RQ^Z:I>B+K*!JL*/@4U4!7:^K$SL?#^[E%_(0HKX+0"7; M)\_:Z7P>8Q:ZX73=T-QP/WV:1J<=J%N0^HZE:!U#^0/AA4*5&AB4<=4D N%/ M7I"$TAC$F8!;?H,4V1=LN31F!COE)'O*INH#"ZO(DANH_RK/$IG#KO(Z(AOS M:ZH::=0@L:VN4.1=-Z(3H8T@('E+R?^#&^%6)S=;[Q5DQ4+<8'11Y- 4\*#C M?>1TAF99!\_?LJE\O,D*'N?7&2KEA&Y'VCLMO"":\-L82;.'2M M ZR;K*XVY)H:ZKL'(^&L\DT#1_?S?V!8/88X#33+_F[E+^$1L[&2J*UWNEEF M1V;2=E;RYC*?7#Y/11(I?O%#B:14R%E'PKV> 57M9*#*7+S-)W-"_8_]Z?#P MN#\# @XFYQ?#\4RM&/Y.S\/O(^'^*\52OBFAU/( :%16JH2XX<@AE.]#A]1C M:^2@48'8)?4GF$_SM\N)8?[0D"X";J MRW8[VOY=0%]]#M\N5W]4&ULE5;?;^)&$'[W7S'BJE.0 M.+ -)-PE02()IT;J)2APUX>J#XL]X&ULK[.[#O%_WYFUS=&*4/4EL9>9[_OF MI_=JI_2S21 MO&5I;JX[B;7%E\' 1 EFPO15@3G]LE$Z$Y9>]79@"HTB=DY9 M.@A]_WR0"9EWIE?N;*&G5ZJTJ6#P?2J M$%M+#2]#?8HLP4RUH8O%7I[S*VR75G MTH$8-Z),[9/:_8I-/&/&BU1JW%_8U;9#,HY*8U76.)."3.;U?_'6Y.' 8>*_ MXQ V#J'371,YE7?"BNF55CO0;$UH_.!"==XD3N9K^\>'Y=7 $@/;#:(&[:9&"]]!"T+XIG*;&)CG,<;_ M!!B0M+V^L-5W$YY$O,.H#\.@!Z$?#D_@#??Q#AW>\+UX,1468U@(;2M8:9$; MX?K#P!^SM;&:WOX\%G@-.SH.RZ/SQ10BPNL.S89!_8J=Z<4+T:"]Z M= K]?Q?I)-IQK0^/J[D7^/#QPR0,@DLX1>D%7;@KM"(@HW30U!$"/62'R"G:),@@;59*[=L:W\T>0!E1) M8Z>$CB&K$0NM7B5S1*@M;1V/ELDS.C".149H0.; RD1&>!;4!GZ!B\D$/O?. M1V,O[,)C[BVQL#5@,*XE]IQ/S24*IB$2/FHTNM1<7'*(5E?$8=7/6$0>52"V M&I$VEJ4AM@G]V$@F 8PCLPQC2>T'&Y')M/*:&[VZI4D"V>![?]D'2H1,2=*F3--/EO9JZ^=A5J2J M0N1L:V0%%#=QF3)*(!+4*=)6?5B4VI2"8FM0;P\"G[6!]PX5D<0TA4)43"O? M"#6A:J85;(C,%67LMS#<3"2\-NS!O M5[U5WA/9<_*6B: >9S8212T*2ZNB9PXOE5BZ_MZ6NNMC2Y MRC_M\Q5+381*4\J9F;M%409K8D&A4Q@""J4=:EUL265FPB;1NNU1SO=>ZI&J M>E$MWSCY]92P&YSB(OU5)YL+2IR/&^JG],/) MUJABQZW_']@>8\-.&"JLC.&EI$6*7%15S]Q&:F,AIJ)3("BHA7)\LZT=G'% MH7]Y;[B9(@3Z:J%QA\%EUPW^&B-![^LZ")JFN(QLF^:CQ6 5!6J.F"XFITR]@\JO*;'B&?.# M6I* LZKF;>+^*J@#OKF-!3]$6F(3.IPYZ9MV^$[7MLN:1,U"N?$.8&5Y11T:/7(B8LRWX8A7I4J1N:FFDQSW?]X$6 M_>1B#$,&&O.,3L8C./8I'!S<73+46W=#,[3H*+OU-69_NK\$SNJ[ST_S^@9) M:=U*^I"GN"%7OW\Q[H"N;V7UBU6%NPFME:5[E7M,Z"*+F@WH]XU2MGUA@OW5 M>/HW4$L#!!0 ( +" 95B;64)*: H " 9 9 >&PO=V]R:W-H965T MU?)$KY7@<[LHB4_"1N/T).$R MK5V^MV.WZO)]EIM8IN)6,9TG"5?;CR+.-A]J0:T5E+E,1*IEEC(E%A]JW>#B8XOFVPF_2;'1>\^,-)EEV7=Z&AE\>]R;E8?:FTVLBBON.&7[U6V88IF0QH]6%7M:H"3*3EE8A2^2JPSE]/N/_L3 M-AZQP:@WONE?O#\QD$K?3J)"PD(F7*A5[S2'RH(16T4 ^B=OGK+\%IX]TK>%L5WM9KTG_* M)Z]*>![?:#SM>T' WK+##3Q>)^MX,=]HQM?K6$9\%@MF,F96@O6R9,W3+>/I MG$FCD< S+>>2*RDTK>.47YY,[>3[5!HQ9Q/##;X.4KV62MQ<^1Z\4&=2,\-_ MX'N.6%'LOCZITP"CG>NL&T69FLMT&6]]*VP/RT)@ 8\99JPS!>%VG7W SA0I M)#P,'@$::,5%7**8$XRAF1^B<+/D3P+Y+P":CP!\$F .F*ZR@_ >#E M1J6M2PQLM_AU."4(.$X]"RY;L*!=/PO;+.C4@S9\/KD=W/6M2T:].J.PF'C3 M,9M^[K/>>#09#P=7W6G_BET/1MU1;] =LLD4 S?]T73"CB(DNTQS,3]FKT34 MS$743*1B03'C+$W8AWS#4$SL$-(>7TO#R6,/0AL:U3X+SMOG M[(CF__K+61@VWD&$?0K>'5^P<>J!,$0R@_SPG$@C.'56V@FQFVXX;(0WD!0[ M*B1UFJQ+0S2I%.FSS4I&*W@@BO.Y "9&@CGL>00O,E8BF)#]L4,K$-58=D: M9CF*R2==0CAN$6A$0KQQZ8B6J59G"WAO!C:0^Q:24PM\=Q.^R4, MFVZ3M8@DIOX%$9,]&75D'4/HD.DS5CB#+526,"$!39'-C06;K2EFH2RO\CU! M^6$)=0:14 8%GOV1PP@+[&SG6H0*MB<+V/X@ILA4V0,>[";6"S:[ "3%N*W$ MW=RL,B7-ML(\&'0KM9WQ>8QV03^B'VB0:V=1&"*/8(P7PCUDI^PZ5Z1@DBGA M>T_2C$!*;9508LG=MP+,NK*U*6V]9:(R= '4*E^LT(67?FYER904DR3$*;3, MX\*J!%O8?/'==P=9_# 4R?0H74$#BW!CE)SEIJ1K\$6^0$W+%12B+)!Z;W84 M[3U1UTW5VGH0N$$(..[-M :7=K4'=2I>*9L1_U% MKCC0@0R0'R2''@>3860/5 M$V[W;!W=+XV^94S:"=VX"8H]]09+A ,.<;<]0+V0<.,JLI07+S#+/ M(QV=[1P?DC>LB+*TTN(5!ZER*C=O"8:W4\)RP@:!O[5?'AF5(3QD!H5>#."J M$V'HA.K$,%7_4_5UL-O?B>V@T6&H?-Y3>3LB*;AOA I:3INLQ'$6< M%)XFQ;4U#)%CEE)30^:S9GQN*O4-G+#8&GC!)KW/_:O[89^-K]&@W=R.1[83 MP]MP/)FPC_WK\5V_Z+Q<)^9]I#'BV2\5/Z!V]<1;)< ^- M@Y&5S'[A[=IX9MOX-^RH[7F^S8F^R?"XZ"EM_HG&/&4=#T3\\; MF("YP;E_U@[<.J1.ZQ0+_R\MJ0=:Z=DP,=Z!?M8W=(%!S4R61N KY"N((8%! MD&G"A8Y&NN8F0\3L-QN'!R1;JA$3]K9A[XC@>IE=,*)'RHOT)S=S1!"&/439 MFNC#D2*K^F<;]8=4MU>PYHXUD!*N50/W%N"40,_VI]L*0S9T]T7776A:8+I, MD^?0E4W[]MG8C]R&.+D;L&:4?9A1$LYC>LU4!,!GAHGOMA$'J]0NNY[9>JF1M"4,H+GUHW.\\?L]!OHYJ?M<\/D5$#G=-=!-)"VT1\2?&9B#B=-XI,W'TP_#L8X= NIR'.U_L0"D_O-C\] M*R!TO>(*E+[3]>JNV:#BDO!OXNJ0K1/4YJZP_=I#XVZ_BV[^SW MM=^]0T7XRFZZ7\9W[,O]W6!R->B12;TO^Q*_VM;&5DL8LV&3MRC[9@EA#O?9 M5[2=#(9MM;V[7WFR?G=%O;5(*7D#5)T OZUVZ(UW;;/UNZ++6C(_>1B'(H'$ M.&HV;;EJMCNH58_#!O@Y5TV^=A_AM MA('7>[9_(BD=O]G"K+;?;G0\Y+Q"!6-:/&!CBB&HYML.K-E@3;);878244!. MD>VNII4T4I#(4&C]]CD2/RKF0<^"#(^?E?P6__Z'9?FY6]&3O5OK1*BEO9O' M(95HREU@5Z/5]7_7W7KOIKN_'=QPA7S7<-4"2QOU3KOF7%R^F&QM[\!GF3%9 M8A]7@N.L11/P?9%EIGRA#:H_BES^!U!+ P04 " "P@&58C!YJ-:H# "Z M!P &0 'AL+W=O-G5ZG0?3#* M4FQ#RJ]HA:G@I\E+UW)W65% 7WV J60OQU2S& M6<_U#2',,=4&@='K&8>8YP:(:/QUQ'3/*4W@Y?<)_=[63K6LF<*AR#_S3.]Z M;MN%##=LG^NY.#S@L9[8X*4B5_8)AZ.O[T*Z5UH4QV!B4/"R?K.7HPX_$Q > M T++NTYD6=XQS?I=*0X@C3>AF0];JHTFQP]C2;+ M9/X%[L>39#(<)X^P6"9+:X;QY'XZ?TJ6X^FDZVE*:0*]] @_J.'#'\ '(3R) M4N\4C,H,L^\!/.)Z)AR>" _"=Q'O,+V&9M" T ^;[^ USP(T+5[S!WA3N64E M_YN9'FG 4)1*Y#QC=0CY1Y'0^ M'BTZ/XQW)46*2D%\$T(<^,Z<'>C(:92TZ\HVA=I75$6LB\'CBIR4 MYGIO.EW5_-MMR[\=-YW$9"79GEGZ[7!(3&D2V"4QA+#=@N"V=?;%%YH=RLH4 M!#'$<>0,J8-X2J='&S5/M4 KBL@IC-O.<"\E20C3"B4AEUO(D6Y=R#E;\YQK MHWHE]!W/#; ;VC1A0$\-89\R[N MTP+EUDX-!1:^OEK/UO-@2NK[^)M[/=6>F-R2KE3$AD+]ZU;L@JPG1;W0HK*W M\UIHNNOMYXZ&*TKC0/\W0NC3PB0XC^O^/U!+ P04 " "P@&58C,:2 I@# M -" &0 'AL+W=OEP6D "F+M LH":U6I_M@DB%$3>+4=I;NOS\[ 99*+&JK^T(\ MXYEGGK%GQ@SVE'WC.T0!/](DXT-])T3>-PP>[# EO$YSS.3.EK*4""FRR. Y M0Q*63FEB6(U&QTA)G.FC0:E;L=& %B*),UPQX$6:$O8ZQH3NA[JI'Q5N'.V$ M4ABC04XB]%"L\Q63DG%"">,4,Q[3#!ANA[IM]L/26[N.-S"$#*N 0 M8ER%L-X)85KP1#.QX^!D(88_ QB2[XFT=20]MJXB3C&H0].L@=6PFE?PFJ=# M:)9XS7?P/(QDG0EP,:=,Q%D$_]@;+I@LF7\OY5NAM2ZCJ3;J\YP$.-1EGW!D M+ZB//GXP.XW[*UQ;)ZZM:^C_SX5=#7$Y@<72=S2S"1\_]"S3O(??YB%/]P6S M KE&& (1@L6;0F (@D*$-&(DW\4!R$W"RT8+07:MV"$D-"!E"]-M*5=M@8S7 MP9?BEB9RM*A;BSF0XWA1QNP0L0_>Y,&9KA\=6'X^Q/>T9"0-4)0NRX##=(%-%IZFB4Y5G:7_=0*PHTH*3+.2?M+D@ MR2O<@%DS[]KR>]=M:#.4PR-[A=Y=!WJ=CN86G,<$NLT>-'NFMI092=Q:L]L! MJW;7;FDWT*E9#>7>KIE=$\:O6LYH6 2BK_U!'C!^AI6[G*XG_I^D-)D5A(7R MUEL]ZQZ(0T"+3%33^J0]O75V M->+?S*N'\HFP*,XX)+B5KHUZMZT#JQZ?2A T+P?^A@J94;GE9R8A+:97+C(TFKWVV]76JV'*ZGN=(YHX*$L MA!YYN3'5N>_K),>2Z9ZL4-!.)E7)#"W5PM>50I8ZH[+PPWY_X)>,"V\\=+)K M-1[*VA11O"-+W)C!?YX6+$%SM#<5M>*5GZ+DO(2 MA>92@,)LY%T$YY/8ZCN%[QQ7>FL.-I*YE'=V\3$=>7U+" M,C$5@]%GB)1:% M!2(:]VM,KW5I#;?G&_3W+G:*9EW&F=#WQ"LW?23 M-<2D@0A?@ A"^"R%R35,18KI+H!/?%I2X8;4)-R+^ Z3'D1!%\)^&.W!B]H@ M(X<7O11D/==X7Z,P,%W2J.'GQ5P;15?BUW/Q-FCQ\VBV3,YUQ1(<>50'&M42 MO?&;5\&@_W8/U[CE&N]#/^Q ]D-\N;J90A##$3P!@RO1^<1$3?4'8>02''?! MY B7LJR8>(2%8L)@"D'W.#SM1L& 2H]2Q1,KU#FC% VUJZ9(7L]_DY[=8.1%(1X] M(E.P)!9<+*!"Q67:I3(Q.4B!1R;G*K64=)WDP%9,I;K51D8R:]^#7:]PW-W/(BZ\=G9D\Q!+;@Y.'U6)\DY9H /F-3V]>K(+.,)[D;S7[-V M<,POGS?(RC[ +NU5K9*<'E'+4AI66 :#P5DW'L3[+U=G.SM-^!O8G"T)3]@L MJ803=D4Y;X!>1SVJ PJ^ :?XX_FDYS-,3" MZJ3,M/HN";NL_N_%[OQSL;>\_LW[P3?[N6?+W^HI):J%ZYPV$[4P37MII6US MOFAZTE_UIK-_9FK!B5R!&9GV>R?''JBF6S8+(RO7H>;24+]STYQ^,%!9!=K/ MI#2;A770_K*,_P!02P,$% @ L(!E6"$I'K-W'0 75X !D !X;"]W M;W)K&ULS3S;Y@ 3AQ-FM/0]Q1'(NW3U][Y[Y M85O5G^U*ZT9]61>E_?%DU32;5T^?VFREUZD=5QM=PB^+JEZG#7RLET_MIM9I M3I/6Q=/99/+LZ3HUY 73U__L$F7^EXWGS9W-7QZZE?)S5J7UE2EJO7BQY.KZ:LWLPN<0"/^ M8?361G\K1&5>59_QPTW^X\D$(=*%SAI<(H7_/>IK712X$L#QNRQZXO?$B?'? M;O7WA#P@,T^MOJZ*?YJ\6?UX\N)$Y7J1MD7SL=K^K 6A2UPOJPI+_ZHMCWUV M>:*RUC;56B8#!&M3\O_3+T*(:,*+R9$),YDP([AY(X+R;=JDKW^HJZVJ<32L MAG\0JC0;@#,EGLI]4\.O!N8UK^]O?KJ]>7]S?77[H*ZNKS]\NGVXN?U)W7WX MY>;ZYMV]>G)7%28SVI[^\+2!_7#6TTS6?L-KSXZL/9VI7ZNR65GUKLQUWEW@ M*0#JH9TY:-_,!E=\J[.Q.I^.U&PR.Q]8[]QC?T[KG1]9[RK+JK9L3+E4#D_U M7U=SV]3 +?_=AS&O=]&_'HK0*[M),_WC"N4I =^7)@R+3.3 M%LHV, 9$L['*E"JK2M0.IMD![S8K]6E\/U8_75W=@=3^WAK8!QBV!!''&:JI MX--G';92K47ZIQ84PP;WLJI9I8U*%PN0W*19:5AG4]6-SE6ZQN.R" V,U_!7 M6N:J,.G<%*:!TQLI')\;FQ65;6M""N##$\;-HY$*MJ"Q ..PK][,80=C@)1 MZT==MIK!T%] 55KXD+-KDV5V[&ZRIH6=@"R@.*P %U;Y Q8%NK M15VM85YE(_J,DRN;I)L-L&T)D8Z\HVRIIE:1:P M A A4!ZACNE>ZP*I 3N8$A!KJGJG'M.B)18 ('BXMM:A5YC/NC"KJLJ)>[[H M.C/,294[R@J^;C3,I/$:%*AJ=+T>JP&!N/0"<3DH$._;DG0[8)VU=:W+;-/IJY*8G>0C^W*9"L:";:4 MQI.6.SH) ]Q@V[DUN4EKXM":#CEO,SQA@W*A$Y*NO"J*M%9/_OZW M%[/9Y/OOZ/_3[U55*_F*1\CWI\AU657G<&[%CMEB<8C='P+J$(PQ445 6IAE M6POLN<:3!G(CVZ@%#*BV]I4"Y5K:-&,ZX![SM #>A4E5;9; QT6Q@[E(RY)X M&VC(J_.R=$JE_ "PF-I/3$0VQ^J-6Q/&@'8"XUPZ/!UI"8Y"=@ ^=7NP/EH9 ML+TU2$Q!,/)<$)XOV2H%9:)JDB!86I55>;:N2MT@$Z"V\!\<8B.4]HTF!Z38 MC=4#:0:4?Q(D@0/5[!+\**2# O5E!^@)^H* M&!* &R?@MG2)#0X/>D.>3:H:.Y H6=F4V@K!D44+R#5IW &%SNB<,"Q&=B%6.:K"A^9HFAS3>>4 MLF_3JVK@JWW!'JL;D*DZDU'[0IIX(5VECT!WK4L%JM^):+NIRB[$@W1_[NG^ M?)#NUZE=L?CA'^A-@#E"3/NH/KC4$:H#AQ[=@VCNJ(:X&6!)($91 +;ZHR_]FLD MN5CCN3X #C0ZK00>L5[/06R<5SSBH;T($1(6SPOY"WX=*;L"_^0,]30(W*:R MR!9/V@U[&0'(Q /G_"49?4H[H63N ,?Z,\218%GRH_#-4(F #1%VBD "U@'E MZ" ;9)\7GGU>#++/KP00>4U69T+_/M897.8(Z^BQZEW_R+>"*)-NWD0_C3N, MID5#DXU.P;:A Z;%GR+O&7PH]&R1[F@:P+'[ER9QCO@P09O9W08U;DI> !&> MV//J_EJ]F%V.U'NO36Y*B'Y:<7UM1W.P%V]I+W1KP:*;BEU?]A(UCP;!>H,JO[V_N_GX M[M>WH^3F]GJL;C\\O+M/'CZHAY_?J>L/M_<0WK^]>GCW5KV_N;VZO;ZY^D7= M/\ 7O[Z[?8"@GT.F5N>G-#69J3/UM4S!@+R^]/+Z[X,RFJ?E9Z^1^D1V M<*4C(KL8JV-;@,,8?QI2WNL*G4=@X*X:G[<-ZW'Z"12BVFEPB+L>*QP\A-1T MOK8+2>+V)I^)H=B;VXBWFV%$QU$%^7M?))P3_4NRY'P!"JVSK&[9R]6P6B.F M7J,V*@/.QGI7,^EQ-0@1B434@K9+7.3:-J8S]S0(IA LD* MM?-FT1;>G>E-0PUN>809EJ"%_B(LD=HTD=JD],4ZW8&2A,BW,130@*_U M&VBFCD(%;9ZBFC@.1&0UCIIU.4:A>(R^8^6X3G^KZG#(""'@E!,B MIFE]&(#P0K W4C>V3C4'0S]IU.X02.('@#P/WF8"+*0!,E3.P:'DS=E3 %WY#9).^_P[DNY9,G8DY#].D=.T", MX)R#3MNMV2M]Z.SM[1L#):8J<>#@3H59:/C$9I@LM]#! M&?Y'74LJ#3%$D/,V"(O^ N(A2NZ =YS33F8QFCL,":W%H5Z"7(O0>>T>Q+>P9N!MHE&8P%F?E MP+4->4I-$D&,RJ[*2!SS4<<<\B#K?6&ADE.]7>B&^7 6^' VR(>_8$:ZWZD8 MG'B$":4GI7%NL4.O8V]IH2M+:WT^0C@C$"1_\#F6R.O"E'0OJP039#CD2;@55.X5>RD7H2Y!@F*0F&! 3^ +>Q1S0NS3'TT MC7:,ASLC!G@8VS&-]/MX_TAC%/;*4#YO2\%YT#LT#9QIV"?C=-XAQ,>6F]-K+:^[A=;JBUUKMY XL PX @S.O:I G7*\^@-*4W!% M_H^+4;^&I^03:#40=BRX-L['Y#D&_2?2I+FA*@#CA(NS"O/?.%OZ%:#[2I"_ MM?F2_O 8'<7F$!,&(]#>DJ?O$J_.7&9X2ACV[P8K8>1@F(9#K]16B.A.9;I& M1X[CB/B4MJ8H0I6-5*^LSD[ \.Z.Y#&2@D8=3K;2_@.6[#0PC =[#EX?5>C MGD4W9?R<<#T&R18KV'[AAX&]1N6)P8V^LJO71\,V8*R;%3(!U]@W7(= M+H^J16R6UE@^_Y=4%.)B$K(5>,49STQ:7Y/N\M9:-RNL3COF\I$0JCR,Y0L( M+7V-A O@N6CU5VX:9GDPF; MX$&"9@IV4@M(#?&B]'/\M73&?P:K^P3T[J@.<:?@F&M.DY=*0/>'!>/21 M/XPJ6"/I\2@;T@Z9J4$F0%[(Y7*&/"V=4RVF+RPR3FZ8[K9=:HQKA <.\ 5&"*G..'*0 CSE-]$R M\/@1P1ZA3#TO\]A%DES2RE/)C]G6I@&SJ?)J6TKSBXDR&E']P$I[E(@ MPCD0X]\N43X-G2_3X=:7CYP&BVU1+^=_2^]+ =[YX?+JBCJIL#/.&3B7M^ L M#&8[0"4A/[]2TU-V0M.:_&$^M[ A[L;4A+89.*C7'2U\+QSG"*).C[R)/10 M1#X\G/GLM..C9,AK.>9=%V#',21&(/9BBCB0D8XQ.$< ;%FA X49-R"&R1CT MN32++#0&K8D+SNY"G4M]"!"Y@&VDS@\A\SD&UK11Y\2F-I*DP5_^ !RCY.)T MGZJ6?=6:&P/:.>L0HN[EJ3AZ0/0Y=Y+UNG>2G/(E+$R@^7!)[$##0P$>I'-3 M %%,&1HO!I# +=W<"!?/(,)1G@/W6F D6 A:I@-AXB&,L6)5X CH %;[ !\Y M36YM<*"Z?L*Z*O9!'N%R7'%)N%39I%\HTA59HG#2%S&)-J.H2B-S*N+%VLQ; M3*.,]KQG\M?C74$4..GKH/)-:17VC8T45A>2F!R<;'9&Q4?8$A=Z->PWP/$% M" L@C(1C1>TK)+7>@AAQ^] 6'!6[,ALZ,H:+@Y#.R28_N:27M )0,DB2K0*V M).U@K0UF'"&Z7>@M*F[=-RZ' "]KJ()1Y%PBSRECBG45]-.D-\4L2Q?V&3M* MI))PC,*R!?F9,+E=(R3=+)I,.HRKEY$@*P9Y7F.7E+ M7]23?UP]G Z'1Z%S:SKT&?G;+FN$1CI_YA5Q$!3>T[D1DNI +(_J+7X;[E8J^G,*6:-.5]A\\V M=(=-A]O#[F%C?2:D !H!CQ[MR1M>ZLBIEIAM[=^CP]JH(S$X:R@3A"8&Y!#C M8"MB=6B5EF!1&C\K)2W:,0=-E7T.Z1UTS,%!H-H _I*P\NU^"9M1_Y9+'M]_ M\LX(I9_6FZ+::?236656$L.*>4:5]TA-;F/U3L;V_RY@)PQV3Z(EA..$YQFE M_Z(V( [+N_K!NT:V2VBG*4$)5AC\N]ZZ@'W"V".HB',W4QDW40$_MA3 K[%T MP10N.VUM!"[#M3>1LSR",2B\.),@R"9OBC3[?':?00P.6(2:W[K*I70NR.1Q M71-HB67Y0&;2_4<24I6C--$9_EMH2AZX;JU=0O:49B<]LT/+6!^1.3H5)&.6 MD8X8SCDPF*&$RFX=&9\E%O)SA8U,Q,792N _C0 MS;8ZLXW>1,77(%_>B:)V3?S4]B\NR@9+RXI6,RQY4IDEO1)/H!.-X_+YKE/[ M$<;?TGU$2K#Z@H9&_L23&@9?O$G:T%AS[UQ7(P M6MA7MA![UW112CLH4^,$W2-BE337_7L#['--6N1@*Q8CBU=NQ*K#?RL?]RXM@>$I6)"1I((@UYWC>N_.=8-(K:'C?41Y M2DY$(NTT76VDCF2^^*6C;U.-Y9XZ]ID M7!8[/SR9"*^HU00O7ASJLE%DJ0!6JL;\$7V&H6=^:$\2EWX6+1=PN8K\N=!4 MQ4818\BJ3;=1#M]_;M.';"S(%S3S#LPS,-VD)8[E%B M+Q-?Z,D-$2P/Z26R;/-=STT@TEQ#VT@,&/P7=UFLP6Q1$B&6EJ3SI(W)@9Z$0 M25+9?+FYY <$$DEZ(^9XE9:H4E';((9=.^7;?K%_! ^0Y(0SGI2=06$\/"4 M QC6O")A9M$AFY.[--5.L4\69OT,U;PRR@N(*BQ1(F9R$/)'77HV].>1CW+ MG.[%6N)("NP->S81P99F3H MNMUWZOSR)7T"%DC^1'YF[ZKIT*,+H6=_-MRS?ZNY4Q1%CH.@OK,97N3(V4"@ M>KBZ>I-:DU&*(S=%B\=4'@XRUI7B*R4'7*ZTY><.-M]B^B6*@CR9DJK;!0DPN MS"YL@Y/\5DD!SG+=%L> =N. MCO^6,$HX_UZ3FK]&VHB&D41,!SCT]@&R,X;K$33C>W!=O-FSR=ET38]YS,2 M;1\R!K6[)NU>M<";VBC#YI=N9VJ7HZ> M36>CR\DL$2[K'H-K&L'>\M;ZVEW",NLYO4>PXXPT2T=3857EN)#*P4K'LZ_\YQ_W\%9!T'-0U06"3D"GS@IW\.?9C^_&+U\CAGZ9Z0' M9Z/G%]/1^>7E7\K7(S51'-?B*(@F.1]-+B]&DQ>\%6PR>GDYQ>CD."WB/E\\ MU7 V*!K261(?@A.>_EO+WV2_PF6#V?!E@WO-_9[^-99>\_4MEP[06=Y?_* R M@"6XT O-B7M_V\3R]&%,0SO[;+B=_7V<8J<,H.DZ'D":^?;\MHR],"0I6E&ZX M,)Y$"U.\P'V-\[I*<[E;U+TL:#.(B]!HX=-MK]0O.$1-7ZG_;"O4 T1JZB=+ M\]]:U!*G?+N BE],&!ML,6;]K351E_@^@:1#E\XO5(? K4$#P]HU!1.9,3(YW=&N3I #R_]9MAQ/J^X MH#'WSR 2JG;\?R5^M1S0NZ9%$ZR *Y-02^ZE%6\"#E0+N]Q4)KJ(P7>;XHH MD7A*G'M*W)1)G#2.+^'''@JGP#JUK$9GJ]+\WCJ:K5,(8;">A/-:>?WI$%4, ME&"OO9%)'^-*'9FZY1O,&@O;8*G9/\/!U<::>KLZ5V;Q89G&)9C]97J/W[]= MS]\L='K/ACN]/^J,LQUI#BZ-SF-E I%D6;5R1Z%7WW]+UW>+70U_<--!'$.; M[VRXS==OY]R(([N-2"YWF(IEN'IQ_I:^W\<(YS\+1#(]1_H>SJ-E8/%QNM4%#1B% XFY0XZ6/J)K&$95;CEZ7&@DH>"-VW2$3 MIMU['+B0H.Q X][8HYM[=W0*B3\%EU'D"RF':PHMY9(UQEY,34EQ;#MPR7L% MKIW5?^_GFE*LA/I IO_O?L^ MO71!9$PM=PU)SF]HJ61_J8L14T73]502*VF'X[9@\:* .GFXW!"3:"Y%#PI: MFKH*P02E^H! 9!8/+S8G[.W1X81T:%^"NIN;-_X)EG"?EC,\D2!27V>G]1?; MX3,JO6+*F,+\BBQ7\O5GOER<&QWS.)FAZ@E'\S75\]*IGALN37"V^LE#M0$] M\?QB3:>R2@R?^5<'S]#;RD M(Q3GIPG8XZMV"0$*4F)R5"0F9Y-G3B3>XLM9I *FWROZ0'2ZKH"E:NONIO$] MZ0]RP?+)?3MO2'@NGD_.9A-^&.TM/EV2(MGXG8F?=;Y$_-WBU[XK&/C@75?U M?-C"5]P>&!9_,;WTDT%(QZ[VW#'[8%'P=NW"2#P0_!?*'KDVE$7OZS6$*A8Z M "R WD)@:_FACJB302ZCX76_T+*8$7T:PZY\](P8.^Z"*(G'OIK%NSV\H'@P M>"H'3!]')O]+1BIQ?13TZ&Z\(.L9@TTVF(MPO Z4B#E&+BS'E7!YRL&]IN&8 M63(4!Z^J1 R=]%J;/K_Z:?3B]UK72WK77((B?OS;?^O?3K_B%\/#<'YX_=>T M7N(%@D(O8.ID_/SRA&\%N _ >/1^.*BOIEK3GRN=@B^! ^#W107!L7S #?R+ M\J__!U!+ P04 " "P@&58"J\ZQ"X# -!P &0 'AL+W=O\Z;AD:XS0+,M'12NO0TEX@4)S M*4!A.G&#_F@VM/:UP3/'K=Z;@U6RDO+%+FZ3B=NSA##'V%@$1L,&YYCG%HAH M_&PQW2ZD==R?[]!O:NVD9<4TSF7^)T],-G&O7$@P955NGN3V.[9ZOEB\6.:Z M_H=M8WLQ="&NM)%%ZTP,"BZ:D?UJ\[#G<-4[XN"W#G[-NPE4L[QFADW'2FY! M66M"LY-::NU-Y+BPAQ(915\Y^9GI37#[!,_!W3*$^S"(ED_A??BPB.#C@JUR MU)_&GJ$HUM:+6\19@^@?0>S[<"^%R32$(L'D=P"/Z'4<_1W'F7\2\1KC(-.\Z#&&QS3S+B"9Y97"-=F,=,EBG+A4&QK5!MWIAW?]B]ZW$X2''>'A*?1I-/\>7B_O0OAQ S>W#\'# M_#:X@R"*0CJI:#G[(YPO8/$#CASF(3DG QZ6L\C0F#/BE." MK)S/#A4-OE)IJQ=JQ6E%6/ >+L]Z7X=[XV?[JYV=/>>CAO#JT'K_+;80W'>4([;PZ$;[^VUJ +5NF[$&F)9 M"=-TJVZWZ_5!T^+>S)N'@NBLN=!T55)R[9U??G%!-&PO=V]R:W-H965T7)N4"WQ0H-=9QM1VB*G<]-VZNY^8\65B[$1UT%NQ M)09H'E.^4R9QI',OV+QR;INUT7 M8ERP=6IFV<:9QQ4?RS;[LZ'#AT:Z\X M-'8.C3SN8J,\RC$S;-!3<@/*6A.:_9W[H3P(X"]D\17W>JQK:PUI6HQW>L,!KO()7;\"=%";1,!$QQC\" M5"FX,L+&/L)AXR3B&*,+:-8KT*@UFB?PFF7&S1RO^0J>+UY0&]*5T148X]P M$S%,OJZYV4* T5IQPU'#W]Y<&T6J^>=8%8H]6L?WL"?I2J]8A'V7CHI&]8+N MX-.'>KOV^40&K3*#UBGT03"ZF8P?B;'[:SC*W[& 3T(>#SA,T%G(E,XM%TLP M5A*@T6B@N\ D8!*$D@VZIW/FI2IGG%O69:2['-K+F(>,8,QK%!Q M&5_!/A7GM50+>/K[,#HULO"/QK?S*&X1/9A';A MZ1AI)_=]!VGYC6^X2AG=>-,_*'=_^I82'=/(Z;VL' HBY_8! M/CR_;/\2[U40)4PLB>>\MK\ND_UIS^N)]A4HQ>$<%\?[BN \E<#.<3D,6/!GD[MQA3Y' M%S"]#RF]\!["FPF,[J?!_:T_]D(Z#]?^U)N.?.\6@I F[B;3D%[IB%Y:+M88 MGQ]39?6@*\A0+?/>ATZQ/0!%@U#.ENV55W05W\V+WHSN4"JCAA07Y%J[Z-#% MI(I^IQ@8N&UL MA57;;MLX$'W75PS4HD@ -9(H);%3VX 3NVB!7-Q\+R2%GSISA4$>#E50_=89HX*7(2SUT,V.J"]_7288%UR>RPI). M%E(5W)"IEKZN%/*T"2IRGP7!F5]P4;JC0;,W4Z.!K$TN2IPIT'51<+6^Q%RN MAF[H;C?NQ3(S=L,?#2J^Q 5W**DHL-1"EJ!P,73'X<5E;/T;A[\$ MKO3.&FPE?4XB4RU\T(J]8WIHQ)K8TL-L%D M%Z)L9_ZRN8>=@%[P2@#;!+"&=YNH83GAAH\&2JY 66]"LXNFU"::R(G2-N7! M*#H5%&=&L_N[V?3^\9L'L^OQ[2.,;R78S)>OHD<]SU,<#WU N&^$G M&]S+%I>]@ALRN)&ER31,RQ33?P/X1+)CRK9,+]E!Q DF)Q"%'K" 10?PHJ[R MJ,&+7JMCVR_HPM= M\02'+GTH&M4SNJ-W;\*SX,,!WG''.SZ$/GJX^C2=/%U/X>XC;+NWKWG[>!]$ MWL\;MOF<_\GGV+[8YC"'6H7%')5MU\[VT5L0)9A,UIHN6Q\[5U*;"QJ+JC;D MC=WMOX68G=(8]<^1(?CP5))K2'RPB YO78 M*<'1QGL2EJ0NZIP;3$D/Z.82P5O%(0!>2&7$W^W&$?.".(!C. J]?M"#8^>6 M9#?A2JU%N;2^=5-\Z 5G Q&D M6)BO"85%E)9(A[U>,^][@_Z.@A2HEHU.:D@LH59,NMU.BL>M OUV;W7\AJNE M*#7DN*#0X.3\U 75:F-K&%DU>C27AM2M66;T.T%E'>A\(:79&C9!]X,:_0-0 M2P,$% @ L(!E6'=%1Z*+ P ,0@ !D !X;"]W;W)K&ULG591<^(V$'[G5^RXO0Z923 VF %9IS@])B!P #I/0M[C3UG M6ZXDA[M_WY5,*+D2KM,7+,F[G[_=;U?+Z,#%5YD@*OB69X4<6XE2Y="V99A@ MSF2+EUC0FYB+G"G:BKTM2X$L,DYY9KOM=L_.65I8DY$Y6XG)B%'YT)@9Y6M1/]NV8AS.'?OL#!_?HX!K>]8<,RRE3;#(2_ !"6Q.:7IA0 MC3>12PLMRD8)>IN2GYK, W\3@/_'.@@6P?-V \TMVV4H;T:V(GAM9(='J(<: MROT RG%AP0N52 B*"*/W #;Q.I%SW\@]N%<1IQBVH./<@MMV.U?P.J=@.P:O M\U&P2/J!OQ>(5%=*7HJQ1NA>1M M,I0E"W%L40](%*]H37[[Q>FU?[_"KWOB MU[V&/MD\?@ZF+_, ED^P>5FMYD83?PZSYZ?E>N%O9\MG6 =S?QM,8;L$(][F M4A0_^4Y5EIE) *0Z5Q)8 *!28AY1NTKA_#_*#:T@%I% MMT&:8KY#H74].V[^2D1 );R2K(CD36-9HB!2Q;YF D*WUQV/[RJI&4E4$IS; M[GV'?CVOVWBLA*" X$>_+&6[-$M52L$T/>\>;J#9=09PTWCFQ5UX].+7O)S; M=J>O_9Q;9^#18JD2%.>)&Y[1#9E,(-;9@ECP_$=HPC,6)4LC>!M#S.HTMI[XYTBC9=W.5 M4!7VG5YCCE)"FI>5EB,M%%(,"IJNZY"BM1^5*Q71)1WLLVL\1[$WPTJ"D;*^ MT4^GIWGHUV/@'_-ZF"Z8V*>%))(QN;9;]Y1U40^H>J-X:8;"CBL:,6:9T$Q' MH0WH?MOH#YS^)4S^!E!+ P04 " "P@&58\[":,]H& "M$P &0 M 'AL+W=OO./"*(0$4621U M[9( BJTTWAP[L^QVQ; 'Q:9C(;IX$ITT^_4[E&S9:5U5+?:R/,2D>&[D=V[D M^7.6/Q8KS@5\2N*TN.BLA%B_[7:+^8HG8:%E:Y[BRC++DU#@-'_H%NNM;A)&:>?RO/QVEU^>9QL11RF_RZ'8)$F8OUSQ.'N^Z)#.[L,D>E@) M^:%[>;X.'WC Q6Q]E^.L6TM91 E/BRA+(>?+BXY'WEX173*4%.\C_EP4NK=V"^*426;)G1 M@B1*J]_PT_8@VC#0+0,M[:X4E5;V0Q%>GN?9,^22&J7)0;G5DAN-BU*)2B!R M7(V03USZO\\&TX]P,@WO8UZN7X@S>9>*-I -,QW,TFO1LO\*$WOKT=CR"8CGN_'=M(HZKC M&_EA_TQB,J8[M((VM&=2L2=X=B%%UEZK, M,)"(Z!IE>T$W!U14=8FAZHXER33F4'M'-?B2JM3XFNK75K)^:Y8UDV?UG$<" MCVY/:*K4=?=;G&8BC/?+)E.9:ZFZ+N4T^)Q9^YS9VN=*+&%\-QV,1P&\DYC[ M_6.^U2CRN&_!-Q4I'WF8 Y?) S#T>>E1C"@R^F4*H =>EJUE*B_@0YELD2%\ MXCD6#^"OW R^FT,9;T0APG0A'?@,[OE#E*9RC"+6"&JV .H:JHW9SM0H >JX MJE%B@5-7>2=!0N'2"VT5X4.H'1=LU3&05K.(@B5DR2-)O/V_X$LL2[4L%YB&<% =0XV"I;EZ#:Y% M3?PHH;4)$$-2(R'B_)GPU[#9+BG%4DVW7NEH!YECE&H8)@5@YG9LD:848-4I MP&J= B9^,)T,>AB.VR#=!J=,_?[MW7#\T?>#8RFA446+E-!*\?>X$*H1B+@$ MK'30%L@STU1=DX!);3Q@IP:\2MW,T,$P5<,U#H.8RE T,6Q/B*XZC,*I\AXU ME_'M6*I)=+E&=4M&+2XVN0A3=;,J)#M+&M"U:W3M'T=W-AI,6T/1+,BC99F]EE\=W^'F9J!)5@ICYKQ(:HU,%\36L)3=@X-39.:VR\?G\@ MZZ$WA,'H>CRY]>0,O*OQ; K><%B72YP'4V_4'XS> ?Z _X<_Z0T"[VKH'T.M MT8(6J/T7=KTZV;"0QWH :]7@*Z\[1!AO$WIVP/I%/613O\%F M*8Z6'$Y>T(>*TUH.WV=9179@6/&HYMH(K(UQ2@D!5T-T;::ZAH44F)HQWC6L MK!33@8N1[6@F Q=SOVWBNJ%AV&.'J>-_;,H(9G/9MV(YM56F,ZG#TM"M,*"1 MS=)T4@T5JA(;:[AEHD*= 3:HF!JL)G=R:W=R6[O3M3>8P'MO."MGG[5:WPSU M1CTMG*:]]F^'NO]ISY'RF3J'@\6^:<8W."O32F7\A#@;T* MDPV2H=E,UFI9>AU'>9_%V+S$\B9(=%>S*")FRDJ*P&D&4C)=L/KRBG7GCX** MPO]#CH^&>+/*-C'^ X9\&[B3-X@']C#9IL#X+4Z57H;(E*7YB:<;Q.<-N$S> M=*@R0;O"?+X"I(0%KL?9.N&I ,O -M6A2A#&R"!7L1%]Y$+&O$&P4A+,Y3S% M=!"7J^$BP80@+_CRE0=+*L/(Q7!S=!FS6+UU><-4F4F/XMD]>$%)>/Y0OA,5 MF%TVJ:@>4^JO]5N45[W [,FKAZS;,,FO+J;:B:B&Q=OL?< M9T)D23E<\1"OA)( UY=9)G83J:!^H;O\%U!+ P04 " "P@&58\P%N<+$% M "6#@ &0 'AL+W=O]9HR'!#4R)/^98R_++B(B4*7\6Z M(;>"DL@HI4G#TH3O+FIN[6EB M'J\W2D\T^N=;LJ8+JNZV-P+?&J65*$XIDS%G(.CJHC9PSRZ[6MX(?(GI3NZ- M04>RY/R'?AE'%S5'.T03&BIM@>#?/1W2)-&&T(V?A<(NEVTU:Q!F4O&T4$8/ MTICE_^2AP&%/H>N\HN 5"I[Q.U_(>#DBBO3/!=^!T-)H30],J$8;G8N93LI" M"?P:HY[JWP[^"A8PF\)X.IQ=!V=0OR7+A,J3\X9"\UJH$1:F+G-3WBNF7 ^N M.5,;"0&+:/3<0 /]*IWSGIR[]"HMCFAX"KYK@^=X?H4]OPS6-_;\5^R-6U_KLW M;MOY4.%OL_2W666]OQA^"D9WDP!F5X#9N9E-@^GM0K]-9HL%7 97LWE09 Y, M)@]%4+W&[89:B,J6,\J4!+X"A$7"DF+!4XASQ!1YH!((3A )*YY@*F2"DRPI?.KD^Q9];>X)J@-SR1AD3RQ)GO>Y&Y@+>=NG5EC M)K>QH-BA1=WV[ MW7-0 &7=GMUMN;F>V[6;;52LR&"KS&#K^ Q^&DP_8K&-I_!E,+D;W(ZQ[ :3 MR>SK8#H,#F6NVK;)W(:P-49E,*-P3Y*,Y-U.YXBPD&*ZA/GV>!#ZO+8 L3;X MPXY6);DR@O^1W$N2&!^),BXNZ3IF+&9K3)$_#L5M>!;JOWNV<8 MU>\^>7:[Y9;.6:M3&(0ASYC"92P-^AWJ"X7[HFDX6RYCG9D*4K5+4K6/)M4\ M&,ZFP_%DG"<#9^XP%?/; >8(2PYN9HNQ_G*P,U0N<[BW:=+EW-!HQM@4<&L. M.0OC),Z95\"DN"()D%0C(I\FA]AH"'M\]Z;KN9T/$K(2(K4'TT M/1JC5QAL'TGA9_3=4A'S"/GA.FU\=GO8K$(\-DG=5%\-?$E#DJ&(QNO9!T5^ M4/8"E[8';F??A8*GOQ9O=PL7*GC7*7G7.9IWLYL@!^];,)ACK_\&UX//LSE\ MOIN/%Z/Q4.-YB'*5*QRFW, J3HPZ,GT:-=#H^!&O1SP,?<=B^X[(R"C.CWI( M2Z/.%"9RJ0^>SPEQC//6YWV+FAC2NCM=G&H:.*9I6F,I"$UP[/;RB8\4SXGL M\9=(%>K=$O7NT:B/@JM@/@]&>YOJ(9 K#1X&&?YCF;T2.+8R;@2_C\WA77?# M>Q(6.Q-2%%L&EH)YW9)'0)(V6];\'4FW'T;8FC''NHV[N#V[^&RV/&N&E":Z MM4)B:DCHT[8FA*X6@ET?FTS=]\V^[K['! M,\U[?:J/0!^"<-W<*]]N]CQ\.IYK#8E [F$,.R(BP[TDWV;\CNTW4:IEMYR. MA=U?9&A'TGM<6-8X8;O#A2H07P^XIS]?2B M%RBOHOU_ 5!+ P04 " "P@&58-U[=6ZT# 7" &0 'AL+W=OX!5;:^[NX3D?OW-KL%-)8JB?K%WQS//S#PSN^/N7LCO:HNHX27/ M"M5SMUJ7-YZGDBWF3%V*$@OZLA8R9YJV>:'O7WDYXX7;[UK9 M3/:[8JOUNR#2Y0/Y4S23NO1DEY MCH7BH@")ZYX;!S>WD=&W"E\X[M6;-9A,5D)\-YMQVG-]$Q!FF&B#P.CUC /, M,@-$8?PX8+JU2V/X=GU$']G<*9<54S@0V5>>ZFW/[;B0XIKM,CT7^WL\Y&,# M3$2F[!/V!UW?A62GM,@/QA1!SHOJS5X./+S'(#P8A#;NRI&-\HYIUN]*L0=I MM G-+&RJUIJ"XX4IRD)+^LK)3O<73[/9P_!Q.%G&\V\P&D_BR6 4G_(V?((1'4>BM@F&18OHK M@$=!UY&'Q\AOP[.(=YA<0C-H0.B'S3-XS9J)IL5K_@9O*C>LX/\QTRP-&(A" MB8RGK.J=(H691(6%K@1B#2->L"+A+(,%"9$:52OX)UXI+:G5_CU%415 ZW0 MYOC=J)(EV'-+XTL^H]O_ZT-PY?]])KU6G5[K''I_,;@?WCT]#&$ZHI)^H.=7>,<4QU0H=*A>F*]0FIJ]$7^\ %Z WHJ=(I;5)X=X MY=3/*6R$2!5<0!CX] S:U\Y7.N!&NY0B0:4@N@HA"GQGSO9T)C1*JH:RQ5*[ MLLPX*@@:S68+KINALQ2:90XOGJE00KX:X$;@7QGHQE48P!F.HYKCZ-TW!GA_"E^6,!GF"[OA_-3[)]U\0[VW^7889<0)XG84=,Z M)7LUQ]H2QY)$[HC%ST)O4=[\0?V&>9F)5\2J$'C8D9+27._,Z5$5]YV.Y;X3 M-9W8>*62/[/DYX&3F-"8L5N*$,).&X+K=JV++S28E"UQ$$0012UG0&SQA$ZD M-IUPS 7:K18IA5''&>RDI/+#M$1)R,4&,J0K'3+.5CSCVG1,%+6A%5P[4T, M>?0A:/I.3=;L#5GQ@2S#JM6^@*CA=P)ZMQJMX'1/>6\NZQSEQHXD!1:^NK=K M:3WUXNJR_ZE>C( GZD2<:'^DZ(O&\8/-QA2O@-S3&3.QO*4B+DE&T-GC,D4:F4)H;5;-I& M2N),'PW*M24;#6@ADCC#)0->I"EA+V-,Z'ZHF_IQP8NW.Z$6C-$@)UOT4:SR M)9,SHT:)XA0S'M,,&&Z&NF/VQ[:2+P6^Q+CG)V-0GJPI_:8F\VBH-Q4A3# 4 M"H'(WS-.,$D4D*3Q_8"IUR:5XNGXB/ZY]%WZLB8<)S3Y&D=B-]1[.D2X(44B M/+J_PX,_'847TH277]A7LMV.#F'!!4T/RI)!&F?5G_PXG,.)0J_YAH)U4+!* MWI6ADN64"#(:,+H'IJ0EFAJ4KI;:DER? $7^=3%Z34Y'[AKSS7AP\!62?(/PX,(>TK%",\V!I7 MMJPW;)D6/-!,[#BX6831SP"&)%ZSMX[LQ]9%Q"F&-] R&V UK=8%O%9]&JT2 MK_4&GH];F7 "/,PI$W&VA3^=-1=,YLY?Y_RMT-KGT50]]7E.0ASJLF XLF?4 M1^_?F7;STP6N[9IK^Q+ZR)_X^> $@3%T(C$!0V"+=,I+OXA#D)N%EQ40@ MRT_L$!(:DK(6Z::<5_F-C-] (*<;FL@[0IUZS($<[PDES X6^_ +7FM/2!B@ M2CF0"8/I&IE*&DTECC9MN85G,<$NJT>M'JFMI >2=Q&JVN#U;CMM+4KL!M64ZEW&F;7 MA M![]1![_S708?Q$RR]Q70U"<[%_Z*]\_$?OV@YHU$1BK[V>X1^)32364%8 M]/Y=K]VS/H&[].&G<[9:VD,I 4LFN\>IW!_0[OV;H-AU4.S_)RCSQ\E\Z=S# M9.4'BP?7.UN@EVV7L8BS,,Y)\EI/KW6B_3:G?Q"CR<$N.&"VX1K,+ER_+HY! M7OS7(-?.G;5QTKND]+;LT!Q"6F2B:F/U:OT(<*K>]RI>O2 >"-O&&8<$-U*U M>:-Z+JNZ+!36X;:_X(MM,.B1^/ M[:2AG=J*A[TDMG//\3DW\4FR%?)1E0 :/3'*U<@KM:XN?%_E)3"L>J(";IZL MA&18FZE<^ZJ2@ L'8M2/@F#H,TRXER9N;2[31-2:$@YSB53-&):_QT#%=N2% MWFYA0=:EM@M^FE1X#1GH^VHNSW/%3 MVX<]0#@\ 8A:0/0,]LP?'0,-H(W:= +XT'B;_9='*V*PJZJD>?OY0(# MN79QJ5 N:JZ;,]>M=HE\Z8+HV?K8)'43K/]HFIB_P7)-N$(45H8RZ+TWRF03 MG&ULK59M M;R(W$/[>7S&BU^I.2L.RL+RD@$06[HK4$!22WH?3?3"[ [C9M3G;"TG5']^Q MEVP(+ZO3J?D0UO;,,V^/Q]/=2O6H5X@&GM)$Z%YE9I55XV[OAR9>Q&M=]=LR7.T#RLIXI6U0(EYBD*S:4 A8M>95"["FN>57 2 M?W'@IDSC:%,/O/8K'J5=@5B7+ L,7=R^P?N @HL7B03[?[#=B?K52#*M)'I M3ID\2+G(?]G3+A'?H^#O%/P#!;]S1J&^4ZB[0'//7%A#9EB_J^06E)4F-/OA MOOG.!R/9O!^ MB(;Q1,.$*<5LRC]TJX8,6_5JM#-RG1OQSQBI^7 CA5EI&(D8X[< 5?*X<-M_ M^-T MOMY=8<:F8I6 Q$/<4,W:6V]'CW1U=0X%E&2Q5PL'V;71,\X M)!0>L>1><9:$4INO\"^\.U6#W'C@C-O;N^G7ZY[]ZU8W^SDXEFLTFNU]N3?1 M-8KH&J71S?A2\ 6Y2@4(5TPL$;B !Z$PDG3R#\9PSY[@&@4NN-$7Q"B3*02Y M@-&&XC\54KE%L\*?#$'.PFM@B+Q06D:!O$&E>&:. ,[$IVC2'!<>K]YS)!C ML7K0.4N09N%GL]3/SZZE4F8'Y"\]$3#)TCDJ2X"9NV)PFQEMF+#LOX A3S*2 MOH!!_#?=F_0,17*;S3U?.\V:'WC^04REOOU@A5I%Y*WRJV'#^\U=9PAE:DO$ MW",VH)Y*%\4UK?DS[,M-V;/;'FR9HB2,OF7T#9(H*KG,6W:PMG M[Y04&^*[35N>W5,I:QVEK.X%#:_=/$C9";D@Z 2UTS1H%\EHER;CM>JW:[1/ M"M%VEC=N3;S=]?!3?K>/_*D=>%QJ^0>+W"GBZI07&14G#H69H1J*!1IKBQ"1D] MV0>-LK%0,G7TSTS.?MOYF1)$ U3HH2C/]UWUZM/3AG>$0-:C4Z+WJY#ZIZ0 M]%N-&O'W@+S5O=$I17HL[$2I(;(NY.-(L5M,K0,WJQWL7]MIUHUDKS#Y*'Q# M;Q 7&A)<$*1WV:+&JO+I,E\8N78#VEP:&@_&ULS5E=;^(X%/TK5G:TFI6J)G'X:AWV.?>)[9)H[RE[X&D"@'V$0\9:Q M%F)S;YI\OH:0\%NZ@4B^65(6$B&;;&7R#0.R2(+"P,2653-#XD>&VTR>/3*W M26,1^!$\,L3C,"3L9P<"NFL9MO'Z8.*OUD(],-WFAJS S'=/#+9,K,L"S^$ MB/LT0@R6+:-MWW=P704D/9Y]V/&#>Z2HS"A]48WAHF58"A$$,!-[FM3(QE2!A_>OV0<)>4EF1CAT:?"WOQ#KEM$PT *6) [$A.X^0TJH MJO+-:<"37[1+^UH&FL=#Y2@[!%! MW":C.\14;YE-W214DV@)SH_4JGB"R;>^C!.NU_W<[TU'??1E@ ;#A_9#=]@> MH;;G]9\\Y$T[?_6[3^CI"QJTAQ/TW!Y-^VC<;WO327_&HI.8\';JS'QJ?&+H'\UODV#<(6]A!4Z^'/G[X5QI3LLDHX8P23O(Z)_(. MB,_0,PEBN$%MSD%P1*(%&OEDY@>^\(&C,1 >,U@@J8L)S&/&_&B5]'J@$ M= CW.?HZD@.@H8"0?SO&,9#[--4DC?I2MRYNU''=LJRFN3T"H)(!J&@! M'$YV/I-?QQ#.@'U#_\AU19_H%E@D/V6!VBN(YFH%>C 3R,L@9Q''L&L1%)S@ M:L:O>E5BJI; M99QK5U&3/LTM4,QW3D-YZ28ZAF ^OO$=-AA&&UBP6_0"+80 M(/O"FM,"+;@.C6P:&E>EN48)7.\RKG>7T9PVS7&02(//MO(":94E2GQA4>J1 M%EPI^\ JV%>ERQ3.A>GF-L+65N[SI9GF.7\_M//R;NOK^SO$YUQ:?%JD15)10 1?QYISCW$I@ZZHDALOP"SCW"UA;H,^26)KB;(GA M@U, ??DN36)8*S$]JJ)SGAL&[%R7Q,IP!3AW!5A__'"6Q I4^,"D'#Y'8-9 %,=9#OEY2*UX8Z3\[^#G!_ M 5!+ P04 " "P@&58!4[-[QD" J! &0 'AL+W=O$M50GG0$8])J+0D[*$PJZD4N7,V% =B2X5L(,7Y8+0('@@.>,%CD,_MU)Q*"LC> $KA725YTS] MG8*0=83[^#*QYL?,N D2AR4[P@;,MEPI&Y&.NX=+Y%"^U]4-[G#(49)I8W,6[%U MD/.B^;+7]ARN!)2^(:"M@'K?S4;>Y9P9%H=*UDBY;$MS U^J5UMSO'"7LC'* MKG*K,_'3Y'F-=I/OVP5:+B:;[7JQ7+S\V*"[.1C&A48O3"GF3NYS2(S=T,E( MTL*G#9R^ 9]#TD.#_A=$ SI V\T&ULM9;1;MHP%(9?Y2BKID[:&D@@:SN(1(&N:*U6 MD;)=3+LPX4"L.G9F&^C>?K:31B"EJ)78#?&Q_?_G?'9BT]L*^:@R1 U/.>.J M[V5:%Y>^K](,X5,;/M>VWONF-)5IFV''_<*LL($]:RXER;R:Y<%S9$K M*CA(7/:]0?MR&-GY;L(/BENUTP9+,A?BT0:31=]KV8*08:JM S&/#0Z1,6MD MROA3>7IU2BO<;3^[7SMVPS(G"H>"_:0+G?6]X,53]?ZI8(I M]PO;/LE3M0X[@G;G!4%0"8+7"L)*$#K0LC*'-2*: MQ#TIMB#M;.-F&VYMG-K04&YW,='2C%*CTW$RO!F/9K=C^'X-=X/IM_'#X,I$ MR7@XFTX>)N,$3D>H"67J WR"63*"TY,/< *4PT,FUHKPA>KYVE1B_?RTRGI5 M9@U>R#K"] S"]D<(6D'8(!^^7A[LRWW#7R]"4"]"X/S"%_SNB'PTD'.&D&"Z MEE135/#KUDR#B<9<_6Y"+#T[S9[VZ[M4!4FQ[YG/2Z'_?]>.6E^:@(]D MMH[* >3-:/ 8I.3=$Y2#%+ MX*O8H.3FC-$P6"%/[2Z.<*[W=O4.\SG*QAT]F."M.WHDL[VUZ-9KT?T/+W3W MF/A',MO#CVK\Z#@O=/2J%_I@LK>B^#MGM;TG3:TKRA4P7!K[UMEG4XTL[YXR MT*)PQ_=<:',9N&9FKFN4=H(97PJAGP-[(]1_ .)_4$L#!!0 ( +" 95C] M/-VEMP( "<' 9 >&PO=V]R:W-H965T$JD,OG& M%EN.9&5 :6*[CM.U4T(SR^^9N6ON]U@N$YKA-0>1IRGACP-,6-&W6M;3Q(QN M8JDG;+^W)1L,42ZVUUQ9=LVRHBEF@K(,.*[[5M Z'W:TOW&XH5B(O3%H)4O& M[K0Q7?4M1R>$"492,Q#UV^$0DT03J33N*TZK#JF!^^,G]HG1KK0LB< A2W[2 ME8S[UID%*UR3/)$S5EQ@I<YP5P+6W8M,#4QN#5FIHIGC94J6K@]I1E=J@ M3,U]);411J?@M4[ =5RO 3Y\.]Q]#K=5D>I*N76E7,/GO<(WS78HI#K 4IS M")<2E"P8W^=4/D*(4Q9.;RZ'-XA=C](6:Y*HU_4T76$GDM"F3,6;Z)01;,3#0> MZS)$=T]F^ZSKO%!Y,(]WJNS4*CL'55X1?J?NZS)!$/7!;5+2^7O#OGIG+S?L M8+!F*="DPMYK8_H)46EN:"8@P;5B=DZ_J$"\;,NE(=G6=+8EDZI/FF&L7C+D MVD&MKQF33X9NEO7;Z/\!4$L#!!0 ( +" 95@0VBCH/ , !,* 9 M>&PO=V]R:W-H965TNJ*U6P5E>S'MA4D.8BVQJ>W ^NUG)S2C-,VZ:F](_'#_N]\1GZ^WY>*G M3! 5_,I2)OM6HM3ZS+9EE&!&Y#%?(],K2RXRHO10K&RY%DCBPBA+;==Q?#LC ME%E!KYB[%D&/YRJE#*\%R#S+B+@;8,JW?:MEW4],Z2I19L(.>FNRPAFJ^?I: MZ)%=J<0T0R8I9R!PV;?"UMGPU.PO-GREN)5[[V!(%IS_-(-)W+<<$Q"F&"FC M0/1C@T-,4R.DP[C=:5J52V.X_WZO?EZP:Y8%D3CDZ3<:JZ1O=2V(<4GR5$WY M]@)W/"=&+^*I+'YAN]OK6!#E4O%L9ZPCR"@KG^37+@][!BW_"0-W9^ >&K2? M,/!V!EX!6D968(V((D%/\"T(LUNKF9SHN%JW#Z:7P3#O2VV7@XGTYN)GK;VQ$J M0E/Y#HY@/AO!V]?OX#50!C<)SR5AL>S92H=H'-G1+IQ!&8[[1#@M%ZXX4XF$ M,8LQ?BA@:[8*T+T''+B-BB.,CL%KO0?7<;V:@(;/-W<;PO&J?'N%GO>$WH1M M4"I]#)1\#R-<*-")@O%M3M4=S##*!544)7P/%U()_9'_J$MBZ:-=[\,<_#.Y M)A'V+7VR)8H-6L&;5RW?^5"7@/\D]B =[2H=[2;U8$!2PB($HF"!*\H892O@ M2U )PAH%Y7$=?J-F?<101_X"G;^2GU3D)XWD81Q34\AJ#TEIZA>FI@YO J_M MM]L]>[,??J.#9Z7A0>1^%;G?&/F,I AP#1Z.:%$-T*HML(,4P(6^EJH8ON MDE !&Y+F6 ?2?032Z70.0!I=O1#DM (Y?6X=0%T/_UH!2K63/1[WU.MZ!T2- M/O_A@-A[]VN&8E6T'1(BGC-5WD35;-79A,6%?C _T!U/V:#\D2G;I2LB=/F3 MD.)22SK''Z)RA>$]VUH3 ;]/J2@N#B/>-I1#QE6ER M=PDAX9C%9 %/(%[B&9,M,T?Q_! B[M,(,9CW MC6M\-<1=Y9!:_.G#FA>>D0KEE=(?JG'G]0U+,8( 7*$@B/Q;P1""0"%)'C\W MH$8^IG(L/F_1;]/@93"OA,.0!G_YGECVC8Z!/)B3)!"/=/T--@$U%9Y+ Y[^ MHG5FVVX9R$VXH.'&63((_2C[)V\;(0H.^)B#O7&P]QT:1QR4FU2;QF-'ZEI?!),OO6EGQ@\#;^-1R^3,7JX1;/'A]GX M\?EO-)M02"^ '_@KZBEZ<1^OSI"_J$_ @]+VG" M2>3QGBDD(05KNIO!;[+![2.#8QM-:226'(TC#[PR@"DCR<.QM^'JL=7ZON(Q<:%OR 7,@:W &/S^&VY9?U0%7A-8289& M+D-#AY[+@.),Z-+([=C,W*O%M MYGR;6KX3X%RF.7'=)$P"(L"3.X/4Q?5)MO?( $A(F?#_2SNJR&6TMOI),2P9L\H3A4)D3[@(SMR/-JG_.A&>YTBF8EVIV<=D=+>TC#.!' MB@MX"N$KL,K%JP4[=?'6!%:*NYO'W3WC'M:M4X::P$HR8&MW4EKGV,4VJ,5T M;!0VJ"RR"B.GVZI.6%PXV[&6\<-\[KN ;A,6^2)A@*[+]!].8N=PZVUT]Y.XPLC!1Y)X5SM@??$P M)>Y2=K'W_6G39:\6\N0IJPFM+,"N&,'-_"-T[8;^]E[:-3H[B>O6;@H"($M MTOL3CESUB9!]9.>]^1W-=7HSL==_H^YNT@N('4QV\3,E;.%'' 4PEY#695LR M8ME=2M80-$ZO(UZI$#1,'Y= /&#*0+Z?4RJV#35 ?J,U^!]02P,$% @ ML(!E6 WSXQ C P 3@L !D !X;"]W;W)K&UL MM99M;]HP$,>_RBF;IE;:R ,0H(-(A=(5"0H"NJFJ]L*$ Z(F<68;:+_]; =2 MZ )J)_H&;,?W\_WOSLG5UY0]\@6B@*E8EFM&)(@-KZ[7!LRKTZ4(@Q@'#/@RB@A[;F)(UPW# M-K8+PV"^$&K!].H)F>,(Q5TR8')F9I1I$&', QH#PUG#N+0O6K:E#/2.GP&N M^Z.M_1K+5Z* MF1".+1K^"J9BT3"J!DQQ1I:A&-+U#6X$E17/IR'7O[!.]U9< _PE%S3:&$L/ MHB!._\G3)A [!O8A V=CX+PV*!TP*&X,BEIHZIF6=44$\>J,KH&IW9*F!CHV MVEJJ"6*5QI%@\FD@[837[5PV.]W.^!ZN^T-H]P;=_GV[/8)AY\?-&.X&_5L8 MML>=8;O7OAW#V14*$H0<;@EC1"7@'+[!W>@*SCZ?UTTA'5)8T]\$+E@2U\L61#/H46Y !)/02XC6R$\=.5^Z B,^.^\Z*7P4CY<7? + MGA ?&X:\P9IH>%\^V:[U/4_YB6![<2AE<2@=HWL#9#[&0KX7@,X@4CD/G^5M M2R@/! =YG3D)Y5LD+P@IN:;)ZJ6T\JR"52W*[*YVY1UUX#_EE3-YY:/R1KA" M1F(?8?R<(/1E4A]Z&$V0Y:;U*.R]:3T1;$^WF^EV/[*\W5/&X42PO3A4LCA4 MWIA_?)+?5XX\3V[**.\4LE-V+U-S(MB>[EJFN_:1)5H[91Q.!-N+@VV]?.BM$Q3I!K);?K:=4Z4Y^]SJOU5J M[G0F$;*Y;M@X^'09B_2KGJUF3>&E;H5>K3=5LZ@[GA=,VFGV")L',8<09Q)I M%2K2)Y8V;^E$T$3W/Q,J9#>EAPO9\")3&^3S&:5B.U$'9"VT]Q=02P,$% M @ L(!E6+FEEU*= P V H !D !X;"]W;W)K&ULK59=;^(Z$/TKH]S552M!\T7XZ 4D"JFV$BVHT+L/JWTPB4.L36*N;:#] M]]%9[).A5JPA_T-6N,%%B^;.9,SNT*)28X+3F@!#"<#:^3>CEU' M.6B+?PG>\Y,Q*"DK2G^JR4,\L!S%"&RU>BEDACLWX< M+1]F3_ <3D?+< ++&4S#T2)%E,X.K+-7P!4L RI5N.BICW M;2'IJ8_844GE[D#%^X"*Z\$C+43*(2QB')\#V%)7)#1V_BK6O\?P/\*98UAN,U@QCN1&$,40'A)890>WI6[Y!$1Y8 M)-YDY?8"<^:[ M%>ON)S,?(9Y"(F]B#@FC^:4&#E?:8H-(K,YF<3R;KTV*NH8B]7H7@DQ&?MNL MIU?IZ=7J^::O6AP#VDGZ:WE48-5_5#),9.L1?7C#B)GR-JYW;)DN)F3*0[Q-*Q7&B/E UL\/_ 5!+ P04 " "P@&58^A2F MBW8" !0!@ &0 'AL+W=O'1FP$^H7X;+_O MY))+#::LQ*>)%&;HJ#R?01<[ :.YWQ,/+-UKLV$F\05 M7<,<]+)ZDABYC4O&"B@5$R61L!HX0^]V%)G]=L,O!CMU,":FDAU8RTO5,&=X+]9IO.!$SDD M@Q7=/P\7R>;J83N8FFDV&\PF938>CZ:R>O!R#IHRK*W)!6$D6N=@H6F8J=C5F M8OS<=$\=U53_!'4,Z37I>M^(W_&[9#D?D\N+JW]M7"RDJ<9OJO&M;_>$[PSP M@,AP+0'PXNC6S&J'7KN#^09N5453&#AXR17(+3C)UR]>V/EQ)K]NDU_WG'N" MY?;:Y$7MK/[#;M_ECT#I0@KJHV&#.^_ M!KP?N@W>/X)_]WVO'1XU\.CSPMM@T='5\8*;X#^8>] @3*]]I'+-2H4O6#])LP/65$/HC,&VH^1-)_@)02P,$% M @ L(!E6.C$]WM: @ I 4 !D !X;"]W;W)K&ULK51M;],P$/XK5IC0)D'SNH)&$JEO#"0ZJG:#SVYR3:PE=K"=IOQ[;"<- MV=16?.!+XSO?\]P]5]^%#>//(@>0Z% 65$16+F5U9]LBR:'$8L0JH.IFQWB) MI3)Y9HN* TX-J"QLSW'&=HD)M>+0^%8\#EDM"T)AQ9&HRQ+SWU,H6!-9KG5T MK$F62^VPX[#"&6Q /E4KKBR[9TE)"5001A&'761-W+M9H.--P \"C1BQ9&U_3R')T05! (C4#5I\]S* H-)$JXU?':?4I-7!X/K)_-MJ5EBT6,&/% M3Y+*/+(^6BB%':X+N6;-%^CTW&J^A!7"_**FC1U[%DIJ(5G9@54%):'M%Q^Z M/@P [O@,P.L WFM < ;@=P#?"&TK,[+F6.(XY*Q!7$W1.%D_&TQV2S0Y'Z]6"P7#X\;=#T'B4DAT /F'.L>WZ#WZ&DS1]=7-^@* M$8H>F^_:B9FPE[YIVH%M1OC+TV[OY:89X0*I6RG*)W1!U44;W=":TA6F;':,JF& MU!QSM4:!ZP!UOV-,'@V=H%_,\1]02P,$% @ L(!E6 3&AH)N @ ]@4 M !D !X;"]W;W)K&ULK51=;],P%/TK5D!HDZ#Y MZ@:,-%*7;A!I[:JU@P?$@Y/>MM;\$6RG'?\>VTFC%G5C2/2A\77N.?>R( RX(H(C""FP@DS0;V2AUP/O@X<6L,0UU7=B M^P5:/V>6KQ14N7^T;7+//WJHK)46K 4;!8SPYHD?VS[L <+^$X"H!40O!<0M M('9&&V7.U@AKG"92;)&TV8;-+EQO'-JX(=R>XDQ+\Y88G$ZSV_$XGX^O)O,9 M&DY&*+N=S//)9Q.CFWQXF=_D\_QJADY&H#&A"DVPE-AV_A2]0_>S$3IY?9KX MVBBQ?'[95KULJD9/5+V&HH>"^"V*@B@\ L^>AX^@[*$X=/#X$.X;_UT3HJX) MD>.+GVJ"8(QH\VUJA3!?H$QP3?@*>$E H1%1)16JEH"^#PNEI?GT?ASSW!3I M'R]BQ_%"5;B$@6?F38'<@)>^>16>!Y^.=> _D1WT(^[Z$3_'GAK'6I*B=H-6 M"J61.7,X9KGA"0-'9&^,31KTSA)_LV_E+TD'$ON=Q/[+)4H@K*BE GN$QV0V M7&=[ L+ _?Y0^FS-?VVZOS>5]D8<8[DB7"$*2T,?]-X;/;*Y99I B\H-:B&T M&7NW7)N+&:1-,.^70NA=8&>_N^K3WU!+ P04 " "P@&5824KWQ"L$ "B M%P &0 'AL+W=O$-,Y$XD5 OD!"'S/0:TB9QI8/OY$O\D6KQ;S M0@2=LN@Y7,KUR!I88$E7Y#V2<[:[I?F",H(!BT3V"7;[>WOJYN!=2!;GP8I! M'";[;_*1/XA2 $8U 2@/0!GO?:*,Y1619#SD; =X>K="2P^RI6;1BER8I%7Q M)5=70Q4GQ_[T]OIJ\?4:S&[ G>\O)@_3[/AY,I]/'IY\\#0#CXOY]';B7X/I M[/Y^]@#\I]GT"_CYBDH21N*7H2T5D13.#O*DE_NDJ";I%0TZ ,-? 7(0!C\" M&X@UX53D7_\%M-6*BF6A8EDHRX!K,DPC(@1@*^!+%KR!;U_5=7 G:2S^JJ*[ M!^M6@Z4OQH78D(".+*5\0?F66N.??H ]YS<#55Q0Q2;T\1.3) +/A'.22%'% M;A_?R^+3MVP[=C'V>HXS&-K;BLS=(G/7F-FG/%0/_;I(#K[=T_B%\LIG9,0Z M\AFY!5/WG.5T6Z#:*ZCV3BQG[Z".>7E MM4 5.KIA.R<*+ 5F!#NV@-H68/^LALMYUBVI3G!;!W_+[@F^CQK-"E\: M"JZ-80%IGT!G'1=0&_,"UN:!3YT7\.&\8.YP6)L!;G=BP(<3@TEP6/=];.[[ MBV1)^8Z'DO)FFC/C'5O%TB;16:<&W,;4@+5_X%.G!EPQ-;C(J]D$P=H,<+LS M SZ<&:I&5+NTXYKN7M\3_AHF D1TI>*<3E_!\/V&\/Y$LDVV"?O"I&1Q=KBF M1&DPO4%=7S$F/T_2?=UB6W[\+U!+ P04 " "P@&58&[K&V> $ #,%@ M&0 'AL+W=O=$WPT(J[ND"'^CN!>;+61EC)E M[+M^. ^/.[9F!#',I Y!U9\[&$$;L5ADO]']!FMWT&PM)$LVG16#)$KS MO_1ADXBM#MC?T8%L.I!Z!W='!V?3PHGAY/1I_'9E\]C=/4!36ZO1G^AJ^O;\ZO+"?IX7?20LZ=@%;5NH=;-HCL[ MLS<'SB%$(Y:H/470;%6><$[3!:AU+M5$EDMTGH;1712N:7R Q@^S>!U&Z0)- M]!PZ/%7++T37]%'#!:*I>F!"JV3Z'*MIPYB<\16.J,"7:VED"HW.F^': J+*$UU6T%6P",6FO*1 M#^)G@^B=_&Y(^FZ U>9N#ZR[;;$&9*_OVKUM9$6)7RCQ6Y5\S79056!Z!UR= M" @>@,\B 6C%HQF\35<^9&^+K=OT:Z"2)=?P?I?D&ZOT^J MU>D]AV@'Z7XCB8>8$-^OT3; B.<$9M[8+L]2>[]TMW+?!/>V6+DUWAM(=6KO MHKUE ? ^":\L5%";=.L*W8Q5F>].T/?[?G/O,6";VU15%"E%D?UJ\4I9Q##3 MO5Y=4!-5V9^J6DIC@=N=Q3,%&N?*Z#0&1"622R4VUZ.;+9J<9OJQ%]A]0Z6: M4$PKIJ5YSA^YB!7;NA%CK ]SFN] MRWM%JZHNSWSL_X]<(6YU**].[3M%JZ:V-"!X#P?R<@>%#7[$5S^F1=^$ZIVY M97RYB\45K3C3C=K5-]HZJ)\KL[W"$N/0O>R[2T^"S<-",^\0S5:.*P MJPJWX_@GI6LA>[J6%O*D:4AP-Z@;<@.*;'O)*O'2MY ?Z%M(TXL$?6Q<%P9H M9%M*T(T[7)75E)E3C'R]KZUXP ;[(KDL%FK%U*O-KMN)M<25[DEU$ MUMZ?XJ-1?K%:ALGO>2\H5WNS0#',54B[&RC_P?.KT_Q!LE5V^SAE4K(D:RZ! MAL U0'V?,R:?'O0 Q07V\#]02P,$% @ L(!E6.:"6$NM P 3@T !D M !X;"]W;W)K&ULU5=M;]I($/XK*Y]4]:0D?C>0 M Z0 ;AM=4A"DK:JJ'Q9[@%5L+[>[0"+=C[]9VW& &-J+4*5^@7V9>>9YQOLR MV]YP<2\7 (H\I$DF.\9"J>6E:XLB_[MJ,=Y>!0SI1+Z//G"8K7H&$V# MQ#"CJT2-^>8#E()\C1?Q1.:_9%/:6@:)5E+QM'1&!BG+BG_Z4"9BR\$.#C@X MI8.S[^ =<'!+!S<76C#+90VHHMVVX!LBM#6BZ4:>F]P;U;!,?\:)$CC+T$]U M)_T/X>#334B&[\@XG-R-K_MWX8!,[H;]O\G[\=5'W;L;DO!V=#/\&H83\G8 MBK)$_DG.B5Q0 ;)M*F2B\696D@29C'$NP F2JAT.$\Z M>LY1Q %$%\2USXAC.6X-H?[/NSM'Z+A56MT5HO;OS8)SZP49IV5[KF?MD7YIY_E>RZOG;%O/Y83U M:M98=\V '>!=XFX3.G=:0&^\IQ\+><7[#%.\-&ZIP,TL20(SA+0N&GA[B:)X+SJ*+_/Z=\H5 M5M-Y&ULU5=M;^(X$/XKHYQT MVI/:Y@4"M =(!;*[Z-J">+G5:K4?3#* U<3.V@9:Z7[\V0FD0%/N=H56VB_@ MEYEGYGEL#T-SP\6C7"(J>$IB)EO64JGTQK9EN,2$R"N>(M,[*Y@S'?M"S7VBV,Z&*I MS(+=;J9D@6-4TW0H],PN4"*:().4,Q X;UFW[DW7=8Q#9O$WQ8W<&X.A,N/\ MT4SZ4W+:A5Q#2.^^,=^ON,O"8S(Q*[//Y$ M([5L60T+(IR35:Q&?/,1MX1\@Q?R6&:?L-G:.A:$*ZEXLG76&224Y=_D:2O$ MGH-;>\/!VSIXQP[5-QPJ6X=*1C3/+*/5(XJTFX)O0!AKC68&F3:9MV9#F3G& ML1)ZEVH_U1YW/P:]Z5T @_ 45]P(\QZN4)-3]_^[>B70JA;:5#*_R)MX"D'8 O534/JLU1+Z+*)K&JU(? '!4QBO(LH6,#:J7G;T#8U@ M2)Z-N03"](1+)5!1D4-TD.&2Y5LMS-=7B1J8DQ):E MRX%$L4:K_?MO;LWYLTS(,X$=R%HM9*V>0F\_K)(9"N!S74:T%#146B+]4,+' M"QBLE%1:):/@)I_SR:Q^ MD+-? M">Q UD8A:^/GEHK&JT?A5>I.O7'T=O[3[(#-=<'F^H?9?- W11W_B.8Y7[]* MQG6JONL[1TF?#%Y^4'#BC%SGI05Q?E9QVT8Z(.LU/,\[/J$2P](CLO=:JP3% M(NLX)81\Q53>F!2K15=[F_5R1^L=T^UF+=L+3-XJWQ.A[YZ$&.<:TKFJZ\HK M\NXSGRB>9@W[841@#O3_G7.TF)D#Q'Z#]+U!+ P04 " "P M@&58DO$-G;\$ F%P &0 'AL+W=O&F>>)W=[&[!M?42K 4QA$O&.MA%B?VS:?K6A(>"U> MTTB^6<0L)$(.V=+F:T;)/%D4!C9R'-<.B1]9W7;R;,*Z[7@C C^B$P;X)@P) M>^[3(-YV+&B]/+CUERNA'MC=]IHLZ92*^_6$R9&=6YG[(8VX'T> T47'ZL'S M/L9J03+C3Y]N>>$>J% >XOB;&HSF'.$I0#(DBWS>(M8&JV MM*9NDE"3U1*<'ZE_92J8?.O+=:([O?@\'-Q?#<'X$O0&@]'=:'S3NP*CF\OQ M[75/C4"O/[Z_ [VK*S">J =3(,?3N][-8'3S!Y 7,/QK>'LQFO;ZTL[' 17$ M#_AO;5M(?,J+/HFNCXP6!W16 M QB> >0@##X &_ 5891G%X,'G.^?*6^Z_M]JX8]YVLR MHQU+=B2G[)%:W5]_@:[SNR&R>AY9W62]FP+G0+8R%R2:^]%R'\34B)L8413P MV$70@]AMM.W'/=X;N?>&T?N7I)UD4LDC99(>) ,HCI$@P$S6")/=O"$!"/P% M!1^?*6'["\[LI 62E0 Z8$Z>3>7@YK#=2DFCZ;]-'@*Z#Y:[DS3L.-AS]^?, MRYU[1N=O2FPL2^OK-0T?*-M;7$9C1Q97,X?:?,>V:?Z R%IY9*UJ?\(Z 2Q5 MCS*0! ;^+3#0/MBIX6:A*F -EO01=#3!._\'T"$0F;4B"E1K>24H"C(#3\$F MF95B9T"OZ2((2P @#0#]#$(YX.6%43 (4R4[3"U02PTT\GU56!%Z:E(,MX.B'H-HA(46E2@D=DKDTQS]YL%>2U,#.M_(@M!-)"@EKO22M&?3DR.*PE!I]T0X)W M-R30K97T,-9*@T^R(<&[&Y*ZTY"[=:<$@)8._%,V) >\N/F&Y, G BZ<>)UD M&X)WMR$J.+D/*ELD!+9<9V$0B/<7,G^:'P+WTZ%-/3T^0KPE;^A)7 M0!=RJ5/S)/VR]% V'8AXG1R$/L1"Q&%RNZ)D3IF:(-\OXEB\#)2#_&B\^Q]0 M2P,$% @ L(!E6'Y.RMTO P -@L !D !X;"]W;W)K&ULK59K;]HP%/TK5B9-F[21%PG0 1*OKI5*0=!VFJ9],.0"5I.8 MV>;U[V<[D$)GLF[M%V([]YQ[CB^.;WU#V2-? BT3>*4-ZR%$,L+V^;3!228 ME^@24OEF1EF"A9RRNXX3V@DFJ=6LZ[4A:];I2L0DA2%#?)4D MF.W:$---PW*MP\*(S!="+=C-^A+/80SB?CED>U,IS*N#Q M^,!^J[!4D) T>^+M?B.. %[Y#,#; [R7 OP]P-=&,V7:5A<+W*PSND%,14LV M-=![H]'2#4E5&<>"R;=$XD1SW+GJ=>]O>FAPB2Y;UR/TT+JYU[/!\.YZ<#M& M7T>MV[M>%]T-4*\_O!E\[_7&Z$,7!"8Q_UBWA52AN.SI/F,[R^B=R>AZJ$]3 ML>"HET80G1+84G[NP3MX:'N%C%V8EI#O?D*>X_D&09V7P[T".7Z^I;[F*Y_A M&Q'^^'G& !!)!3#@ C$LX),J'TE6B6G+,L::9E0G;]UT2HX?5.OV^MB(,L\TFL*\2MDW:PQSC>'+-9[?Q]"4/ C=9QI-8;Y3.Z.QDFNL%&KL MDC6)((W0CD 05XM45<\&7> H-2]XA'-@:K"8RG<#7\YP8K.8&JX4&^]F? M _WH0S(!]M-DL9#!+.W].S=TOIA\OA'9B=E:;K96:+:W7*OA7;J>&C MZ]E]75'_@@_WQ0BS8AC+^2J*S)=]U($DP.:Z,>-H2E>IR"[R?#5O_EJZY7FV MWE9-H>YLGFBRCK*/V9RD',4PDY1.J2*_VRQKTK*)H$O=YTRHD%V3'BYD8PM, M!&ULM59K;]HP%/TK5E9-G;0V+YX=(/%( MUTI0$*';I&D?3'(A49.8V0:Z?S_;"2G/J)7@"[&=>T_.O0?;I[$F](4% !R] MQE'"FEK ^>).UYD70(S9+5E (M[,"(TQ%U,ZU]F" O954ASIEF%4]!B'B=9J MJ+41;37(DD=A B.*V#*.,?W7@8BLFYJI;1;&X3S@ MH_AA# D+28(HS)I:V[SKFBI!1?P(8_:9F2$80@<>1B*E?M,YB#0UY2\9)G"4+!G&8I$_\FC5B*\&LG$BPL@1K/Z%T(L'. M$FQ5:,I,E=7#'+<:E*P1E=$"30Y4;U2VJ"9,I(PNI^)M*/)XR^T^.+WGOH.& M]ZC=[P^[[FT7:>'NL/!R'ERTPCGEQP[Z+H''(<1 M^X)NT+/;0]=77] 5"A,T"1ZJ2DK!.D3 L-2,(#AIS$ M!W\70!<5YF5:FS([5B%B#[Q;9)M?D658]A%"W?>G6P5T[+SKML(KG<";$(XC MQ ),X4;^"7WDD5CL3(;5?QM>Y1B.-2[%+2M@$2 MFP[U8"6.Z(4X<#ER4J*%HA5"?U2T,X'M=*&:=Z%Z(=&J!XI42O4]U0YCRK43 MLM5RPK5"PJZXPL)DKE0;8/H"7,[>HUDA[D0OJ%]*L?J!'R:SL M:7888YNUXYJ9QMNU:112_@X)4$%:JM;VQ<4<,DZQM"3ODJX8_:/:G0MMMQ=; M%L*\D'P9\/9-9=NVM2?@D2C3KAE[$NI;)B@&.E?>D DJRX2G1B%?S?UG6[FN MO?6.]*7*7+W!I*96;,]YF# 4P4Q &K=508FF/C&=<+)05FM*N#!N:A@(;PU4 M!HCW,T+X9B(_D+OUUG]02P,$% @ L(!E6*&+W5H1# C7D !D !X M;"]W;W)K&ULM9U=<]NX&87O^RLPZDYG,Y-8XK>4 MVIYQ;**;MMEUXW4SGT!(L<2*26I*RX\[^^ (4)0@4!1'N82X<2R8>4.K]<%A,%RR)BK-LQ5+^E\#R_/JO=O\\CQ;E\LX9;[X8 M6(/M&Y_C^:(4;PPOSU?1G-VQ\GYUF_-7PQUE%B(L)3E[O!A<6>]I,!$% MJB/^';/G8N]W(C[*0Y9]$R\^SBX&(W%&;,FFI4!$_+\G=LV62T'BY_%[#1WL MZA0%]W_?TFGUX?F'>8@*=ITMO\2SV4[;^>A+W[#I&7&LH\7#[L7MEN*TP[G[;94K4CB[D#D5SCF"NUL_%/$L MYGG@+;F+EHQDC^2NS*;?R-=_\D/)QY(EQ6\MIWF]X;KM7)'#WA>K:,HN!CQ) M%2Q_8H/+O_S9\D=_;5,<"0N1, J"*<%Q=\%Q=?3+CT6QCM)I%91B$?$*V@*A M99@&8@/S*YAH2)XN@\"Q?&M\/GS:UQA9*07!%(V]G<:>5N,O(D>E94'*C*S6 M^73!6Q8RS9*$MU2%N!':)-YK-0^_ MLWP:%]5US?&/:Y'7R7,=B3;!M3Q3P?T#P9U18/NCAMS(.BD(IL@=[.0.M'+? M 2-M+0&(0T$?3HG> M>!>]L5;OZV@5E]%R&[NJ&2#1NEQD>?S?9G=H$PLMT#06XX.[Q?*\4?6O<<,@ MJZ4@F"+Y9"?YQ$#R590?O5>NM2!3J3>P8$_JT1F7V6KHC*R3@F"*SM9(&H:1 M7NF]AK;;M:T'FBI>T]2K>]1Z=7<_E*+.415USX596E$_LZ+,XZG(\757_A-+ M'EC>FK?U+&,]D;002J,HFAH56T;%[LEIU6!4B)"T$$JC*)H:(NF%+:V;N_Q2 M#1WQVR9Z8GDTKT)4+AC)F1A6B],Y-P9IF4?3K^3QG<][5)3$/6IP6\733CHN@=8T4U%S7-&^_"1E-QDZSI8&::Q1- MC8*TUY;>7Q]MC,@?Y)JKOEZ6E?W6ME%0OPVEA5 :1='48$E?;OE]M5%0APZE MA5 :1='4$$DO;^GM]R80^3+4E7;6EM]5WPFR\^Q 5/#'=1B\)2TMR)0:@YDS\_I;\LI%X+UV% MR6J9O3!A47A;?Q/G;%IF^8G4!?7B4%H(I5$438VGM.S6I*_4!?7P4%H(I5$4 M39UTDV;?UIM]P]2EIYG&I:99EI*[_&;N:CO,/G,:732*.C=52>GP;;W#?T7R MZMK7TM=LK#IT/ !*HRB:&D,Y'F#W-1Y@0\<#H+002J,HFAHB.1Y@ZZVS:<*" MVOJ:UDA8!_G*:>EK>4$S7?7AQ&WIQ&V]$S_P@/=IS-/0CY_O[HLWKTI24%L. MI850&D71U,A)]VY[?24IJ&>'TD(HC:)H:HBD9[?UD^FF20IJU&N::@@#OYFD MH 8<15/UE@;U1@=J MV6O:_K!\8(U;IH"AU5(435WW*=VXHW?C)X4GS_5TV+OM=-B*Y7$V(X]93G(V MS>:\%W'ZC^)9>VFMB9'I[:@9T11-#5VTO\[)_P_#P0KR#612[M. MS_3KF<8Q@3I[*(VB:&ITI+-W^G+V#M390VDAE$91-#5$>ZO>]5ZKE[3?CG[R MO*E7MBZ+,DIG<3IOU0?JN9W#A>E6<+ 1H--1]-11JC[2^SIZ[VNXLOE:CS,6 MR&];SC$)F@IU.HRBSDV54MI:QW"1>)?%F'JFL9[!X45B!?9A/[SK@11U?JJF MTGXZ^CEFKND[NMG4%H(I5$4 M3=WY)NVIJS=U]0W3842S!IU:-G^CK]!4;"B-HFBJV-)/NGH_NHSQ M7D/K,(U[MN?Z=G-%)+1>BJ*I8DM[Z&J]S>[*UK4$>H2QT% C"*51%$T-AC2" M;E_[GUWH;"^4%D)I%$530[2W"5IO&E^U0U?/-([.H5D46T:#YLXL:*T415-U ME^;3[;0SNDL+['4;&=%7:'R10V=Q4315;.EDW:Y.=I-]/BRC]!NY7K 3@[IZ MK/%U#EUW#:51%$T-D/3';M!70P$UR5!:"*51%$T-D;3;[DF[;3Z$H6<:1^=P MMW3[7FEHM11%4X67=MK5S^'>YO&3V&=UN^1U5(M1M2D+:J&AM!!*HRB:^L4F MTD)[HYY2E@>=OH720BB-HFAJB*3Q]O3&N]LW_'@M1GED^[X=--+*C;XZ8ZFA MMAM%4Z66MMO3V^YMDEIMDU2KTO;!6+UKVRT)_$9?F['24$^-HJE*2T_MZ2=7 MJ=@BM8I>JLVU8JM45BY8SB]QWCJ+3=3LNUAC?YUGCB-E,:U%A#:11%4Y67QMK3&^M?MBUW-0(H MEH%N.JNM@H];Q@)]Q_:;!IK+C;4 MUVZL/-1PHVBJ\M)P^WK#;=)JU*B#5J,Y@Z2OTEANJ.M&T52YI>OV3RUIUK0: M]8:!G[JY#GU-QLD)ZM2A-(JBJ3&33MUW^VH_H//;4%H(I5$430V1M/-^#]\/ M[K'0STZE$91 M-#5FTJ/[?"]P Z*@"EA5 :1='4$,E1@4 _?_^ZA.9V[:'I:S=6'FKV M4315>6GV [W9ORK)KPM&/D7Y-U:2W0"FX?2+OA+C&P4Z0@"E411-#9<<(0CZ MFK0/H ,"4%H(I5$430W1WJ/'>IBTUS.-HW.X!.#( _:@]5(4355>^'SU'>D_ M [W__&K]]IE5=8F 1"F)DFR=EG]:LH+'9\'?^,%JJWJX]T38A.7SZMF]!8\B M+RQJVWMW]WS@#]53<1OOWUCO0ZOE_:M@_#[DGZSM+Q/^E^I1PT-9]>9!Q3Q+ MS^.T($OVR$]C=":24;YY]N_F19FMJF?5/F1EF275KPL6S5@N#N!_?\RR&ULM9IM;^HV%,>_BL6FZ5YI:V(3'MI1)(I]-:;; MKBJ]VXNKO7"#@>@F,;5-'[[]G()S)$2R_/.!)\Q$A4!Y1E_)^)1[VRC8BIW4OXH=F:+\TY8 MC$BD(C8%@MNW!S$5:5J0[#CN:VBGR5D$[FZ_T+^4D[>3N>-:3&7Z3[(PZ_/. ML(,68LFWJ;F1CW^(>D*]@A?+5)>OZ+$ZMW?:0?%6&YG5P78$69)7[_RI%F(G M $=O!) Z@+PWH%L'=/<#^F\$1'5 ]-X,O3J@G'I0S;T4CG+#QR,E'Y$JSK:T M8J-4OXRV>B5Y<:',C;*?)C;.C&_8U\DMH^AZS.YFD^FM[._KN;H M$Q6&)ZE&5UPI7E3T,_H-?9M3].GGSZ/ V/P%)8CK7+3*1=[(A0FZE+E9:\3R MA5BX@, .O!D]>1G]!?$2_^3Y"0KQKXB$)#HPH*D_?"XV)PCWRO#NH?GXPZF( M3U 7OQG.WA]./&)TFU)V2U[WK5**E!NQ0-=?5M_/[5GHIF1F3Z MWP/CO*BXT6%NT:K.](;'XKQC>Y$6ZD%TQK_\A/OA[X*;UEN>Q0'*)])K;!(<*X64<6PA(&*U@_1)6_/@\C >#+N[CX2AXV-48 M**FC<:_1N.?5>!+':FN_ $MQ6%UO]+'J0L)H!>OMJ-OKA6&XIRU02D?;?J-M MWZOM?'NGQ?U6Y :QA^+U^Z7([H0ZV$^\J&.%AH112!@#@CGUU&'Q0LQ] M%@<21B%A# CF%&?8%&<(T.R'KUHJQL->Y'[II]Y,QRH,"6- ,$?ATT;A4Z_" M]I8)(W:_3>S%/[-*Y\7-*;I.>>YM3%[HL=<^)(Q"PA@0S*D,#EM'$7Y0:ZK! M0/4!I5%0&H.BN27:,7T8H$'Y(4>7 Y)&:]IN]^P23'I[MTQ025V=2:LS\>H\ MY7J--CQ9')37&WNTO) T6M-V[T@)&0Y>R0N4U)6W-;S8:]GV.HVO\?M!1VL- MZG%!:0R*YI:DM;DX^JCF#VI^06D4E,:@:&Z)6I>,_39Y*G.]34V2KY!XVHA< MO]']0>TR*(W6-/?>.8KV#3-44E?HUC)COV>NA;8_M,]HLE)"9/]GG/W HS4' MM^^D>.@B9E4#17\-928[^GIHD2L9'*WZ% +30HC8+2 M&!3-?;#5NFCR42Z:@+IH4!H%I3$HFENBUD43OXN^Y.J'*'M2P4YBH=%2R0RI MNG2;HG0'*P1JK$%IM*;M=K[![N2GWBTH*!6&I3&H&AN;5K'33[J&3,!=>"@- I*8U TMT2M R<0 M3YK]D*/+ >JVR>N'S3V"R>E^!P*UT<'.&II,J%6Y>$G;&\]M;JH%*SDY !"FB3^H7X<<_).;[X MWO36C+^*%$"BMSRCHF^D4A;7IBGB%'(L+E@!5.W,&<^Q5%.^,$7! 2$&D&O7)ORH,>6,B,4IAR)99YC_CZ C*W[AFUL%I[((I5ZP0QZ!5Y M!/*EF'(U,QN6A.1 !6$4<9CWC1O[>NCK^#+@&X&UV!HC[63&V*N>W"=]P]*" M((-8:@:L'BL80I9I(B7C=\UI-*_4P.WQAOVV]*Z\S+" (/20 G, M\3*33VQ]![6?KN:+62;*7[2N8RT#Q4LA65Z#E8*9VO$=;1BTX/R;$JT#:'@7 MCEX>0C2Y1#IY#!^?(SU[F$01&H2WDZ<0W3^JO1 ]W_P((W0Z HE))L[0 M.7J)1NCTY R=($+1<\J6 M-$]$RII.D7F'$M8U#)< [(L!TT9E2F H4T@627 MP%2>&F/.QMC .9 )1JRO,#T'?T<0SX#_JM-YU$B78&N18%CZ!NJQ C@*S""SY]LS_K: MEI$/(MOQW&T\=S\R/Q69MWWP7=]W]M+3$M7Q_0/9\1JEWE&ET7(F2$(P)TKD ML=PH_3EC&PO=V]R:W-H965T"^Q@DF@B)>/GFM,JEM3 [?&&_]Q[:>N^0*6"/.$Y3K7L2#(A&3I&JP4I#'-WV2UWH$G&JQOU7#5SW"UZ MR JZL0@2)C*.\*TU$9*K7_A[V9;EC+5R1GVL;\6B&Y?E)R)R)TA@+"C&NA&Y6W,&!"',;A M/*9!DH4ZIEJJ:AH4I/$Y#@5%$ZEU=*$\_[>3Z1;&Y:XH1)U6#-,%)7 M('*=H+Y/&9.;B5Z@N%3]7U!+ P04 " "P@&58I_0BE.<" !]!P &0 M 'AL+W=OSDY !#6C2]B6Q[^/X'#_N;6^Y>)8A MHH*7.&*R8X5*);>V+?T08R*O>(),>U9>W,-A%>FZ0'^ 2+61\N M+S[ !5 &\Y"GDK! MFVEV9DU;+]@G^?[IRATRBWNI'A-4[@#9G/8X0Y>8$^E7[$ M92H0?G274@E]FW]6;5F.V*Q&-"_\5B;$QXZEG[!$L4'+>_^N[M:^5,G]3V ' MXINE^.8Y=&_!?!3ZSC!06G_")36O6.HG&!'M J)@B6O*&&5KX"M(4% >5&U) MODXK6\?4J(U7K[EM>[.O]&W,S>RCNS1'SBIB]@\NIVWN5+$:QS@J\!)^G3.4/O[26/:2;E)+5RR57NOIFPU#W1Q0F0/M7G*O=Q"Q0 M=ESO-U!+ P04 " "P@&583(:Y:#D# !<#P &0 'AL+W=O\3]MH$CVYJ&M9V+T;NTNJI6=&P/WG'?M=?'EYF3GAT*+>#]<1JYIVHR$'%F3MB1'=W,/V0M<1 MGTT]'O]%FV3O=45#]IH+ZF_!4H'O!LDO>=D68@^ 2P< YA9@QKJ3@V*5;2)( MO8K'N"; M]CL3JXW&D\;$&J,_R"+,^'-@O]ZZO9([:J];'A(;:IKL M'P[L&;3ZQP^X9'Q5*"^FRHLQ>^& \D$(C @W6*(NY1RU"&.OLF2554E#2=\:AA=<]N="7IA87#1O8?V\C/ M\RWW?]:^ES;X?;8?P9L&KJB$F)D0\S3GS^ET->>EQFEU&ULK9=M;]HZ M%,>_BI5-TR:-YCE !T@=H5JE[;:"]MY)TUZ8<(!HB9UK.]!^^VLG:0K!1+U1 MWT"%4YI8CJ6%9@ICHDQ&17O[MAD1'.1Q 3N&.)YFF+V]!42NA\;MO'\ M8AYOMD*],">C#&]@ >(ANV.R9=8JJS@%PF-*$(/UV+BR+T/;40Z%Q=\Q[/G! M,U(H2TK_J,;-:FQ8*B)((!)* LN_'4PA2922C./?2M2H^U2.A\_/ZM<%O(19 M8@Y3FOP3K\1V; P,M((USA,QI_MO4 'Y2B^B"2]^T;ZT#?H&BG(N:%HYRPC2 MF)3_^+%*Q(&#[9UQ<"H'Y[4.;N7@OM;!JQR\(C,E2I&'$ L\&3&Z1TQ92S7U M4"2S\);X,5'COA!,?HVEGY@LIM]FXC:?ST)T\]?T]L<,W5_] M1!]#$#A.^"?40P^+$'U\_PF]1S%!]UN:_AZ=_O8W93)JS/HU!ET"CWWC-X-B6@*Z!X_HC#F M44)YS@#]NEIRP>2L_JW+3ZGHZ1754K_D&8Y@;,BUS('MP)A\>&<'UA==MMY2 M+'PCL:-,NG4FW3;UR1VCN[@H*+*>H1V.<%D:R$I6F$A6M:*9X2==2DMIOY!6 MQ6XW"08C8J%,3SS\V"5L#[(COU?A>*_[\ TZS+R&"1UG4.6@75JD0'"#8 MP=!N<&J,/-]ID+;&TI'4KTG]5M+;#)@<3+)!"-R@@3/5V/0;DR)L M#:HCM!)/,6-/JHSM,5LA(?<&N2^<6=,#S>BY7A-98^7[5G-BMT;5D7E8,P]; MF:^BB.5RA#GLY PG$:A2_1D1$#KJH68(&\@:DV85:XVH(Z]MO9R=K%;B$-; M&)0#7-8M1"B)# M$M*>==](*.PB='XRF =7"G4!_('9)B9<[EEK*6]=]&7F67FG*AN"9L4M8TF% MO+,4CUMY#P6F#.3W-:7BN:$N+O7-=O(?4$L#!!0 ( +" 95BR/!N"6 4 M $&PO=V]R:W-H965T? MU_:3'.>\F\\' M;MC]1NH#SF*6^??TELJOV357>TZE$K*8)H*E">)T/>^=X&./3'5 WN(O1G=B M;QOIJ=REZ7>]ZX>$8UH(+6$K_X]T"6-(JVDQO&C%.U5?>K _>UG]<_Y MY-5D[GQ!EVGT-POE9MZ;]%!(U_XVDC?I[@]:3FBH]8(T$OE?M"O:CE2/P5;( M-"Z#U7[,DN*__UB"V O @U<"2!E F@'35P+Z94#_O3T,RH!!3J:82L[!\Z6_ MF/%TA[ANK=3T1@XSCU;39XF^[K>2J[-,QK/ M2I]% EWZG/OZHGQ"OZ*OMQ[Z^.$3^H!8@E8LBM0U$S-'JA%H'2UL6O9%7 M>L,$K=)$;@0Z2T(:F@*.&GHU?O(\_E-B5?1H<(3(]!=$7#QJ&] [POM8AY-^ M2[CW[G \MLRF7UV-?J[7?T7O*J.:>7*/+E(AT%)=@B>5VSN?AP)]NU"MT;FD ML?BW9:BGA?2@75JO'\W-FR08AZ0F(%T4"$= MV-07GVFHF$8H2'F6*K@42?\1Z8TVAE:MK@P+,>SF:GH!?EBX1P3/G(=].$!= M&G"&%9RA%ZM ZEZRT%)&90&U741E9J7UIIW=&$KEG U-/S+5ZC-E[NJ,&KO=6@K9U=,NGJ.J6=]:JH MF*!O*QK?4=[ZQ+=+=X4%JN9!J9E8]\I:?+A*JM2&X@JIYD&IF5Q)S958;]>: M:TMFT\>,Z;/J<1!2$7"6Z>U6PM9>.A.VCSD?%A5HFT@6J:SJ3UK! @W)!%M7 M_MA:!2\N6,RD*K6L^0Y:XH.J>5!J)KZZRL># ^8[:-D/JN9!J9E<:X. [0ZA M6\UB%^L,@ZJ1Q-/[02PW0JL6,+B;6S/6J 2O80"J>9!J9GX:O^ MQP?,6E#W *KF0:F97&NC@>U.8UF_[.!^:'_E89?JC+%0FYJF=3QLIBU0IR:? MVIA@NS-9^8]OIRVH$P%5\Z#4S%>NM6H>V2;R.(CE.IH]9702?YMC%,W+SXQ M6OG\GB4"172M0MVCL5J%>?'53K$CTRS_CN4NE3*-\\T-59"Y;J#.K]-4/N_H M#JIOIQ;_ 5!+ P04 " "P@&58Q:J]TG\<<^YYS@WUV'!Q8M, 11ZS2B3 RM5 M*C^W;1FGD&%YPG-@>F?!18:5GHJE+7,!."E!&;4]QPGL#!-F16&Y-A%1R%>* M$@83@>0JR[!XNP3*BX'E6N\+4[),E5FPHS#'2YB!>LPG0L_LAB4A&3!).$," M%@/KPCT?!B:^#'@B4,C6&!DG<\Y?S.0F&5B.$0048F48L'ZM80B4&B(MXT_- M:34I#; ]?F>_*KUK+W,L87%-=1^^H8OYE263U34 ML8Z%XI54/*O!6D%&6/7&K_4YM !N[P. 5P.\SP+\&N"71BMEI:T15C@*!2^0 M,-&:S0S*LRG1V@UAYBO.E-"[1.-4-!M>CT>/MV-T?X5N[I[&=P_WTYOQ#!V. M0&%"Y1'ZAAYG(W1X<(0.$&'H(>4KB5DB0UOI_(;%CNM M(\_Q_ [X\/-P;Q-N:]>-=:^Q[I5\_@=\]V*)&?F+33D=HR%GDE.2X*JZ6((F M B0P52WP!;HB#+.88(IF>A%T*2N)?EW,I1*Z&']WG4?>GK_#]$F]:QSKR M7">TUVT'NS'NZ5D3LR&LUPCK[17VK)N$*EK*.F);Z M#67]1EE_K[(I+O2/JD#HBI%E0KB>)YV;KF7.E&6 Y3?56!, %Z?\&Y>I^8;MA&PO=V]R:W-H965T# ]DMY?:8,?3"N]@!7)=+;D:V7V4G!10"L)*Q&$[LQ+W.IUH_\;A M-P)'Q4%8+R8I. MK @*4K;_^*FKPXG #=X0>)W >Z_ [P1^DVA+UJ0UQQ+'4\Z.B&MO%4T_-+5I MU"H;4NI57$FNWA*ED_$JO;^=K[_YGY#F>;Y"G[Y=[K^6VJD=?%*\OBM?$\]^(M^ [7)*_L6ZT MSRAEI6"4Y+CMNS)'2PX"2MD:V!;=D1*7&<$4K9015)-+@?Y,-D)RU:9_F>K1 M @1F +UUKT6%,YA9E9Z+'\"*?_S!'3D_FZKS/P5[52N_KY5_*7I\6U24/0.( MIC+0C50_"$EDK2MD[(H.<-+O(F M6<9KR-$!9_\N*(=,'8'-L,+/)MXVZ.B4-QJ?X0Y]W,G83!OVM.&[:.%)'=L" MC*4,A].Z;GC&-G0*P\#,-NK91A?94F4@F6IZR77K8XV*J8EP-)A\' 1G@$,? MUPLC,^&X)QQ?)JPY5WL1+2K@:G7+':*@CGQ$"=X02B0Q%W1LJ-7Y6@]] G=B MIHUZVN@B[4+N@9MX(D-?.6<\!A_?,?-,>I[)?_4>J_5)ML3/>$.AV2E)N\I" M7P=O\4X&VS9T(O<,>.@4!*Y[1FR?7&SZH^)7S'?J9%'+N%4RYVJL]+R]J-N! M9%5SUVV85#=G\[A7WS; M8-ZOV5,O@ST]=E_+<7_ %!+ P04 " "P@&58 MRP*7E:@# !S$ &0 'AL+W=ONKM [K^_7=LQ&!SK M4EG*E^"U9]Z^>?LP,^D>"/W%-H@4&L]+O)O4?:[Y(=#X,8'RFP711Y]-\!AN30 M4W3EY88;K#=]_I=2@Y 9;1 MDQ>)-DFVJ":(Y3'..!5/ Y''^[/AG3-:3!R8WH#K?'<>%LX,[/G<'0\6Q+S#0,G]M$O JBBJ+PRXZ6R@5&).,+E%9CZ7V!H MAEE":/C_TXT*.F8NM)G@F:_@N;C'>(<,5I1$X#QSI+$7PC Y8J0,A&XP(?'Z MZT3XV@>;,>0,?DP$#HPY1NQGF:KIIHWR3>4[X)IMO27V%/$E9TCWJ/0_?= M M[5N9(C6!%?1IY/HTJM!S?VY-_RAA5IKU5]IK "A5:>876>]C2JE.?FL *^K1R?5I_;,LTTSIQ MG*YWSFUY&=1I:>6N;.>!.,$?]Q@](2T_CTJH-Y]'36C%PH^- MC=Y\%\_6VAC5A5;4Z-@:Z96=1;5GK8MVTS1;%Z_8RRBCTVR'9_("?J9"P\PJ3C^+U'UT',(,25@-2N6H(232?< M=,')-AD2GP@7!D@N-^CY2&6 >+XBA+\LY ;Y_QGZ_P%02P,$% @ L(!E M6%1;V>@3 P &0L !D !X;"]W;W)K&ULM59K M3]LP%/TK5QF:0-K(HP\>:RNU:8!*=%1],$UH'TQSVT8D<6<[+?OWLYTTM! B M0.5+8COWG)QS?>/FR:<+C @_IDN,Y9,991$1 M[:E@+HB-L UWQK M#,K*/:4/:M+SFX:E%&&(4Z$HB+RMT,4P5$Q2Q]^,U,C?J8#;XPW[A38OS=P3 MCBX-?P6^6#2-4P-\G)$D%$.ZOL+,4$WQ36G(]1766:QEP#3A@D896"J(@CB] MD\K?>SXDW@O9X/.QU)F.O"^,;N/1N+H?M MP57/A?;0:X^@\QL&PYONQ!W#81<%"4)^!-]A,NK"X<$1'$ 0PWA!$TYBGS=, M(66JEYG33%(GE>2\(LEVH$]CL>#@Q3[ZNP2F])>;=#8F.TXI8Q>GQU"QOX%C M.94"0>[;X4Z)G$J>\XKFJ[S"-\05Q@G"C-$(O$>!+"8AN'JSD<'=M8R'GL"( M_RG*7DI>+297G_TY7Y(I-@WY77-D*S1:7[_8=>M'D?,]D>WDH9KGH5K&OLE# MD<<46-- =1*M6G7'JC7,U;;VET$U^\3.@W8TU7)-M5)-+EPFA/G@P0!&<-?' MZ!Y9X3:4\KQW&_9$MF.YGENN?V8YUO>9ASV1[>3A),_#R4?+,076R\OQ95#- M5L=-43F>YII.2S7ULW(<,/GO?$-1EK*]=S/V1+9C_"PW?O:917FVSSSLB6PG M#[;U](.V/EJ6Y_O MVKJK>;;>47V?;EZ>:-*FL4_8/(@YA#B3E-;QB13$TCXLG0BZU*W,/16R#O1P M(7M79"I /I]1*C83]8*\&V[]!U!+ P04 " "P@&58_:WI4_H" "_"0 M&0 'AL+W=O*4-XV%$,L;T^3A A/"2W2)J9R94980(;ML;O(E0S+53DEL.I95 M-1,2I4:KH<>&K-6@*Q%'*0X9\%62$/:W@S'=- W;V [XT7PAU(#9:BS)' ,4 MX^60R9Y9H$RC!%,>T108SII&V[YQZ\I>&SQ%N.$[;5!,)I2^J$YOVC0L%1#& M& J%0.1GC2[&L0*28?S),8UB2>6XV]ZBWVKNDLN$<'1I_".:BD73J!LPQ1E9 MQ<*GFWO,^5PKO)#&7/_#)K>U# A77- D=Y81)%&:?#D#LZA M0^6$0SEW*&NB662:5I<(TFHPN@&FK"6::FAMM+=D$Z5J%P/!Y&PD_40K<.^] M[OC!@\$M^-Z3]SCV FB/1GZO,QYY71@-X,X;W/GMX7W/A;;OM0/H_(2AWWMT M>\/V [CC8#3H>WX 7[HH2!3SK_ - A(CA^<^)A-DO^2 JZD@ Y>F(::"$;V+ M?L1?"K.&*20C%9<9YM%WLNB=$]';#O1I*A8@X9Q&[ M&):@;%^!8SGE(P&Y[W=WSH13+K:GK/$J)_ *V=IG53H+HBZ"&[XD(38->=(Y MLC4:K<^?[*KU_1C#"X'M\:T4?"L:O7R"KX]K3%=X!7WRF[*WK'E^D(;0$YCP MHP)4+BG A<#V!+@N!+@^N^%#9.IXR L4Z$Q>DUH.#DNI0:(E"7-)CJF00=N6 MQE;W][IEE>Q*PUSOTCMN52NL]N*N%G%7WY>HG;.)>A;D?_?I0F![?&L%W]J' M)&KMD@)<"&Q/@'HA0/WC$K5^- 6=@T0]:F75K+V??9"WYLY;*%>?ZQ*!0TA7 MJ@6*TJ$+:^O$]&._(ZB0K)MY@LM*F3]@\2CG$.).05JDF3Q3+RH6L(^A2 MO[@3*J0$NKF0%18R92#G9Y2*;4FF'TGDY,8J9T-R=_+^UT*9RW>1 MNQ]].#KJW)U>[L=/&N"4Q$'1\Q>(GG7LA2HW*":?ODS^.7%,^F)7>CW\V&JU MW&.,W ^0-TR4EH5S[B;U]-COZFA0*+G9W(2X@-6G)8ONJ1B2,15\HCFP"EIR ML7+A'@2F2B@=&5M5-F$7(O6#@[NN!P7G=4HNE6YRNPSN>^*'[P'K'ACD0K0& M>\0%1H.*&L.TO+*=9G 3? )%OGV[JJS#F::K;N^<; C-S2:9*)TSW:;IDG5H M-!"L #N:S^9P-ZJ* 31&E;:1U@S?L+)3)L0-/(T_BQWM9;&U8/-AN4RM0&F";1/=.&3[">>V_0\]]=YQF33%.Q;=K6_B&O\JL=^]?7O_#<_%K9=QPTF5PLO*$3^R?+CKX=G[."+H2Y;<$AV;2_LYPORJP==0T+ MX4=MVM]@>MVT/:S:7%SF;,GRL>_JV:1I1K9AL_H+"/O(57.%$8SCL# "&)8' MAX M''0PQM8M3>$GK(9Y P:6!S+]V5KCNXU7R/-U@.WI+>Q/,# =@&K'<@?S@,U%>8D">PJY@U[@G$DRS $:C%1AS!'( '#$F2YCVX]SZ*U^^I>/-_O-$C4$L#!!0 M ( +" 95B7BKL

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end XML 85 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 86 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 88 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 171 298 1 true 81 0 false 6 false false R1.htm 00000001 - Document - Cover Sheet http://inspiremd.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://inspiremd.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://inspiremd.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations Sheet http://inspiremd.com/role/StatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Changes in Equity Sheet http://inspiremd.com/role/StatementsOfChangesInEquity Consolidated Statements of Changes in Equity Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Changes in Equity (Parenthetical) Sheet http://inspiremd.com/role/StatementsOfChangesInEquityParenthetical Consolidated Statements of Changes in Equity (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - Consolidated Statements of Cash Flows Sheet http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 00000008 - Statement - Consolidated Statements of Cash Flows (Parenthetical) Sheet http://inspiremd.com/role/ConsolidatedStatementsOfCashFlowsParenthetical Consolidated Statements of Cash Flows (Parenthetical) Statements 8 false false R9.htm 00000009 - Disclosure - DESCRIPTION OF BUSINESS Sheet http://inspiremd.com/role/DescriptionOfBusiness DESCRIPTION OF BUSINESS Notes 9 false false R10.htm 00000010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://inspiremd.com/role/SignificantAccountingPolicies SIGNIFICANT ACCOUNTING POLICIES Notes 10 false false R11.htm 00000011 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://inspiremd.com/role/FairValueMeasurements FAIR VALUE MEASUREMENTS Notes 11 false false R12.htm 00000012 - Disclosure - MARKETABLE SECURITIES Sheet http://inspiremd.com/role/MarketableSecurities MARKETABLE SECURITIES Notes 12 false false R13.htm 00000013 - Disclosure - PROPERTY, PLANT AND EQUIPMENT Sheet http://inspiremd.com/role/PropertyPlantAndEquipment PROPERTY, PLANT AND EQUIPMENT Notes 13 false false R14.htm 00000014 - Disclosure - LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT Sheet http://inspiremd.com/role/LiabilityForEmployeesRightUponRetirement LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT Notes 14 false false R15.htm 00000015 - Disclosure - LEASE AGREEMENTS Sheet http://inspiremd.com/role/LeaseAgreements LEASE AGREEMENTS Notes 15 false false R16.htm 00000016 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES Sheet http://inspiremd.com/role/CommitmentsAndContingentLiabilities COMMITMENTS AND CONTINGENT LIABILITIES Notes 16 false false R17.htm 00000017 - Disclosure - EQUITY Sheet http://inspiremd.com/role/Equity EQUITY Notes 17 false false R18.htm 00000018 - Disclosure - RELATED PARTIES TRANSACTIONS Sheet http://inspiremd.com/role/RelatedPartiesTransactions RELATED PARTIES TRANSACTIONS Notes 18 false false R19.htm 00000019 - Disclosure - TAXES ON INCOME: Sheet http://inspiremd.com/role/TaxesOnIncome TAXES ON INCOME: Notes 19 false false R20.htm 00000020 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION Sheet http://inspiremd.com/role/SupplementaryFinancialStatementInformation SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION Notes 20 false false R21.htm 00000021 - Disclosure - DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES Sheet http://inspiremd.com/role/DisaggregatedRevenueAndEntityWideDisclosures DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES Notes 21 false false R22.htm 00000022 - Disclosure - SUBSEQUENT EVENTS Sheet http://inspiremd.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 22 false false R23.htm 00000023 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://inspiremd.com/role/SignificantAccountingPoliciesPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 23 false false R24.htm 00000024 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://inspiremd.com/role/FairValueMeasurementsTables FAIR VALUE MEASUREMENTS (Tables) Tables http://inspiremd.com/role/FairValueMeasurements 24 false false R25.htm 00000025 - Disclosure - MARKETABLE SECURITIES (Tables) Sheet http://inspiremd.com/role/MarketableSecuritiesTables MARKETABLE SECURITIES (Tables) Tables http://inspiremd.com/role/MarketableSecurities 25 false false R26.htm 00000026 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables) Sheet http://inspiremd.com/role/PropertyPlantAndEquipmentTables PROPERTY, PLANT AND EQUIPMENT (Tables) Tables http://inspiremd.com/role/PropertyPlantAndEquipment 26 false false R27.htm 00000027 - Disclosure - LEASE AGREEMENTS (Tables) Sheet http://inspiremd.com/role/LeaseAgreementsTables LEASE AGREEMENTS (Tables) Tables http://inspiremd.com/role/LeaseAgreements 27 false false R28.htm 00000028 - Disclosure - EQUITY (Tables) Sheet http://inspiremd.com/role/EquityTables EQUITY (Tables) Tables http://inspiremd.com/role/Equity 28 false false R29.htm 00000029 - Disclosure - TAXES ON INCOME: (Tables) Sheet http://inspiremd.com/role/TaxesOnIncomeTables TAXES ON INCOME: (Tables) Tables http://inspiremd.com/role/TaxesOnIncome 29 false false R30.htm 00000030 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables) Sheet http://inspiremd.com/role/SupplementaryFinancialStatementInformationTables SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables) Tables http://inspiremd.com/role/SupplementaryFinancialStatementInformation 30 false false R31.htm 00000031 - Disclosure - DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES (Tables) Sheet http://inspiremd.com/role/DisaggregatedRevenueAndEntityWideDisclosuresTables DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES (Tables) Tables http://inspiremd.com/role/DisaggregatedRevenueAndEntityWideDisclosures 31 false false R32.htm 00000032 - Disclosure - DESCRIPTION OF BUSINESS (Details Narrative) Sheet http://inspiremd.com/role/DescriptionOfBusinessDetailsNarrative DESCRIPTION OF BUSINESS (Details Narrative) Details http://inspiremd.com/role/DescriptionOfBusiness 32 false false R33.htm 00000033 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://inspiremd.com/role/SignificantAccountingPoliciesDetailsNarrative SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://inspiremd.com/role/SignificantAccountingPoliciesPolicies 33 false false R34.htm 00000034 - Disclosure - SCHEDULE OF FINANCIAL ASSETS SUBJECT TO FAIR VALUE MEASUREMENTS (Details) Sheet http://inspiremd.com/role/ScheduleOfFinancialAssetsSubjectToFairValueMeasurementsDetails SCHEDULE OF FINANCIAL ASSETS SUBJECT TO FAIR VALUE MEASUREMENTS (Details) Details 34 false false R35.htm 00000035 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative) Sheet http://inspiremd.com/role/FairValueMeasurementsDetailsNarrative FAIR VALUE MEASUREMENTS (Details Narrative) Details http://inspiremd.com/role/FairValueMeasurementsTables 35 false false R36.htm 00000036 - Disclosure - SCHEDULE OF MARKETABLE SECURITIES (Details) Sheet http://inspiremd.com/role/ScheduleOfMarketableSecuritiesDetails SCHEDULE OF MARKETABLE SECURITIES (Details) Details 36 false false R37.htm 00000037 - Disclosure - SCHEDULE OF FAIR VALUE OF MARKETABLE SECURITIES CLASSIFIED BY MATURITY (Details) Sheet http://inspiremd.com/role/ScheduleOfFairValueOfMarketableSecuritiesClassifiedByMaturityDetails SCHEDULE OF FAIR VALUE OF MARKETABLE SECURITIES CLASSIFIED BY MATURITY (Details) Details 37 false false R38.htm 00000038 - Disclosure - SCHEDULE OF CHANGES IN FAIR VALUE OF MARKETABLE SECURITIES (Details) Sheet http://inspiremd.com/role/ScheduleOfChangesInFairValueOfMarketableSecuritiesDetails SCHEDULE OF CHANGES IN FAIR VALUE OF MARKETABLE SECURITIES (Details) Details 38 false false R39.htm 00000039 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) Sheet http://inspiremd.com/role/ScheduleOfPropertyPlantAndEquipmentDetails SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) Details 39 false false R40.htm 00000040 - Disclosure - LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT (Details Narrative) Sheet http://inspiremd.com/role/LiabilityForEmployeesRightUponRetirementDetailsNarrative LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT (Details Narrative) Details http://inspiremd.com/role/LiabilityForEmployeesRightUponRetirement 40 false false R41.htm 00000041 - Disclosure - SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES (Details) Sheet http://inspiremd.com/role/ScheduleOfSupplementalInformationRelatedToLeasesDetails SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES (Details) Details 41 false false R42.htm 00000042 - Disclosure - SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details) Sheet http://inspiremd.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details) Details 42 false false R43.htm 00000043 - Disclosure - LEASE AGREEMENTS (Details Narrative) Sheet http://inspiremd.com/role/LeaseAgreementsDetailsNarrative LEASE AGREEMENTS (Details Narrative) Details http://inspiremd.com/role/LeaseAgreementsTables 43 false false R44.htm 00000044 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative) Sheet http://inspiremd.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative) Details http://inspiremd.com/role/CommitmentsAndContingentLiabilities 44 false false R45.htm 00000045 - Disclosure - SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK (Details) Sheet http://inspiremd.com/role/ScheduleOfIssuanceOfWarrantsToPurchaseCommonStockDetails SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK (Details) Details 45 false false R46.htm 00000046 - Disclosure - SCHEDULE OF STOCK OPTIONS GRANTED (Details) Sheet http://inspiremd.com/role/ScheduleOfStockOptionsGrantedDetails SCHEDULE OF STOCK OPTIONS GRANTED (Details) Details 46 false false R47.htm 00000047 - Disclosure - SCHEDULE OF RESTRICTED STOCK GRANTED TO EMPLOYEES (Details) Sheet http://inspiremd.com/role/ScheduleOfRestrictedStockGrantedToEmployeesDetails SCHEDULE OF RESTRICTED STOCK GRANTED TO EMPLOYEES (Details) Details 47 false false R48.htm 00000048 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNIT GRANTED TO EMPLOYEES (Details) Sheet http://inspiremd.com/role/ScheduleOfRestrictedStockUnitGrantedToEmployeesDetails SCHEDULE OF RESTRICTED STOCK UNIT GRANTED TO EMPLOYEES (Details) Details 48 false false R49.htm 00000049 - Disclosure - SCHEDULE OF ADDITIONAL INFORMATION ABOUT ALL OPTIONS OUTSTANDING AND EXERCISABLE (Details) Sheet http://inspiremd.com/role/ScheduleOfAdditionalInformationAboutAllOptionsOutstandingAndExercisableDetails SCHEDULE OF ADDITIONAL INFORMATION ABOUT ALL OPTIONS OUTSTANDING AND EXERCISABLE (Details) Details 49 false false R50.htm 00000050 - Disclosure - SCHEDULE OF FAIR VALUE OF OPTIONS GRANTED TO EMPLOYEES (Details) Sheet http://inspiremd.com/role/ScheduleOfFairValueOfOptionsGrantedToEmployeesDetails SCHEDULE OF FAIR VALUE OF OPTIONS GRANTED TO EMPLOYEES (Details) Details 50 false false R51.htm 00000051 - Disclosure - SCHEDULE OF ALLOCATION OF TOTAL SHARE-BASED COMPENSATION EXPENSE (Details) Sheet http://inspiremd.com/role/ScheduleOfAllocationOfTotalShare-basedCompensationExpenseDetails SCHEDULE OF ALLOCATION OF TOTAL SHARE-BASED COMPENSATION EXPENSE (Details) Details 51 false false R52.htm 00000052 - Disclosure - EQUITY (Details Narrative) Sheet http://inspiremd.com/role/EquityDetailsNarrative EQUITY (Details Narrative) Details http://inspiremd.com/role/EquityTables 52 false false R53.htm 00000053 - Disclosure - RELATED PARTIES TRANSACTIONS (Details Narrative) Sheet http://inspiremd.com/role/RelatedPartiesTransactionsDetailsNarrative RELATED PARTIES TRANSACTIONS (Details Narrative) Details http://inspiremd.com/role/RelatedPartiesTransactions 53 false false R54.htm 00000054 - Disclosure - SCHEDULE OF COMPONENTS OF LOSS BEFORE INCOME TAXES (Details) Sheet http://inspiremd.com/role/ScheduleOfComponentsOfLossBeforeIncomeTaxesDetails SCHEDULE OF COMPONENTS OF LOSS BEFORE INCOME TAXES (Details) Details 54 false false R55.htm 00000055 - Disclosure - SCHEDULE OF CHANGES IN VALUATION ALLOWANCE (Details) Sheet http://inspiremd.com/role/ScheduleOfChangesInValuationAllowanceDetails SCHEDULE OF CHANGES IN VALUATION ALLOWANCE (Details) Details 55 false false R56.htm 00000056 - Disclosure - SCHEDULE OF RECONCILIATION OF UNCERTAIN TAX POSITIONS (Details) Sheet http://inspiremd.com/role/ScheduleOfReconciliationOfUncertainTaxPositionsDetails SCHEDULE OF RECONCILIATION OF UNCERTAIN TAX POSITIONS (Details) Details 56 false false R57.htm 00000057 - Disclosure - SCHEDULE OF OPEN TAX YEARS BY MAJOR JURISDICTION (Details) Sheet http://inspiremd.com/role/ScheduleOfOpenTaxYearsByMajorJurisdictionDetails SCHEDULE OF OPEN TAX YEARS BY MAJOR JURISDICTION (Details) Details 57 false false R58.htm 00000058 - Disclosure - SCHEDULE OF DEFERRED INCOME TAX (Details) Sheet http://inspiremd.com/role/ScheduleOfDeferredIncomeTaxDetails SCHEDULE OF DEFERRED INCOME TAX (Details) Details 58 false false R59.htm 00000059 - Disclosure - TAXES ON INCOME: (Details Narrative) Sheet http://inspiremd.com/role/TaxesOnIncomeDetailsNarrative TAXES ON INCOME: (Details Narrative) Details http://inspiremd.com/role/TaxesOnIncomeTables 59 false false R60.htm 00000060 - Disclosure - SCHEDULE OF INVENTORIES (Details) Sheet http://inspiremd.com/role/ScheduleOfInventoriesDetails SCHEDULE OF INVENTORIES (Details) Details 60 false false R61.htm 00000061 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER (Details) Sheet http://inspiremd.com/role/ScheduleOfAccountsPayableAndAccruals-OtherDetails SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER (Details) Details 61 false false R62.htm 00000062 - Disclosure - SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS (Details) Sheet http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasDetails SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS (Details) Details 62 false false R63.htm 00000063 - Disclosure - SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRODUCT (Details) Sheet http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasByProductDetails SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRODUCT (Details) Details 63 false false R64.htm 00000064 - Disclosure - SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS (Details) Sheet http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasByPrincipalCustomersDetails SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS (Details) Details 64 false false All Reports Book All Reports form10-k.htm nspr-20231231.xsd nspr-20231231_cal.xml nspr-20231231_def.xml nspr-20231231_lab.xml nspr-20231231_pre.xml form10-k_001.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 90 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-k.htm": { "nsprefix": "NSPR", "nsuri": "http://inspiremd.com/20231231", "dts": { "inline": { "local": [ "form10-k.htm" ] }, "schema": { "local": [ "nspr-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "nspr-20231231_cal.xml" ] }, "definitionLink": { "local": [ "nspr-20231231_def.xml" ] }, "labelLink": { "local": [ "nspr-20231231_lab.xml" ] }, "presentationLink": { "local": [ "nspr-20231231_pre.xml" ] } }, "keyStandard": 256, "keyCustom": 42, "axisStandard": 26, "axisCustom": 0, "memberStandard": 41, "memberCustom": 36, "hidden": { "total": 47, "http://fasb.org/us-gaap/2023": 29, "http://inspiremd.com/20231231": 15, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 171, "entityCount": 1, "segmentCount": 81, "elementCount": 517, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 565, "http://xbrl.sec.gov/dei/2023": 38 }, "report": { "R1": { "role": "http://inspiremd.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R2": { "role": "http://inspiremd.com/role/BalanceSheets", "longName": "00000002 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R3": { "role": "http://inspiremd.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R4": { "role": "http://inspiremd.com/role/StatementsOfOperations", "longName": "00000004 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R5": { "role": "http://inspiremd.com/role/StatementsOfChangesInEquity", "longName": "00000005 - Statement - Consolidated Statements of Changes in Equity", "shortName": "Consolidated Statements of Changes in Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R6": { "role": "http://inspiremd.com/role/StatementsOfChangesInEquityParenthetical", "longName": "00000006 - Statement - Consolidated Statements of Changes in Equity (Parenthetical)", "shortName": "Consolidated Statements of Changes in Equity (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "b", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "b", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R7": { "role": "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows", "longName": "00000007 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R8": { "role": "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlowsParenthetical", "longName": "00000008 - Statement - Consolidated Statements of Cash Flows (Parenthetical)", "shortName": "Consolidated Statements of Cash Flows (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role": "http://inspiremd.com/role/DescriptionOfBusiness", "longName": "00000009 - Disclosure - DESCRIPTION OF BUSINESS", "shortName": "DESCRIPTION OF BUSINESS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R10": { "role": "http://inspiremd.com/role/SignificantAccountingPolicies", "longName": "00000010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R11": { "role": "http://inspiremd.com/role/FairValueMeasurements", "longName": "00000011 - Disclosure - FAIR VALUE MEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R12": { "role": "http://inspiremd.com/role/MarketableSecurities", "longName": "00000012 - Disclosure - MARKETABLE SECURITIES", "shortName": "MARKETABLE SECURITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R13": { "role": "http://inspiremd.com/role/PropertyPlantAndEquipment", "longName": "00000013 - Disclosure - PROPERTY, PLANT AND EQUIPMENT", "shortName": "PROPERTY, PLANT AND EQUIPMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R14": { "role": "http://inspiremd.com/role/LiabilityForEmployeesRightUponRetirement", "longName": "00000014 - Disclosure - LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT", "shortName": "LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R15": { "role": "http://inspiremd.com/role/LeaseAgreements", "longName": "00000015 - Disclosure - LEASE AGREEMENTS", "shortName": "LEASE AGREEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R16": { "role": "http://inspiremd.com/role/CommitmentsAndContingentLiabilities", "longName": "00000016 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES", "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R17": { "role": "http://inspiremd.com/role/Equity", "longName": "00000017 - Disclosure - EQUITY", "shortName": "EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R18": { "role": "http://inspiremd.com/role/RelatedPartiesTransactions", "longName": "00000018 - Disclosure - RELATED PARTIES TRANSACTIONS", "shortName": "RELATED PARTIES TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R19": { "role": "http://inspiremd.com/role/TaxesOnIncome", "longName": "00000019 - Disclosure - TAXES ON INCOME:", "shortName": "TAXES ON INCOME:", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R20": { "role": "http://inspiremd.com/role/SupplementaryFinancialStatementInformation", "longName": "00000020 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION", "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R21": { "role": "http://inspiremd.com/role/DisaggregatedRevenueAndEntityWideDisclosures", "longName": "00000021 - Disclosure - DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES", "shortName": "DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R22": { "role": "http://inspiremd.com/role/SubsequentEvents", "longName": "00000022 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R23": { "role": "http://inspiremd.com/role/SignificantAccountingPoliciesPolicies", "longName": "00000023 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R24": { "role": "http://inspiremd.com/role/FairValueMeasurementsTables", "longName": "00000024 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R25": { "role": "http://inspiremd.com/role/MarketableSecuritiesTables", "longName": "00000025 - Disclosure - MARKETABLE SECURITIES (Tables)", "shortName": "MARKETABLE SECURITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R26": { "role": "http://inspiremd.com/role/PropertyPlantAndEquipmentTables", "longName": "00000026 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)", "shortName": "PROPERTY, PLANT AND EQUIPMENT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R27": { "role": "http://inspiremd.com/role/LeaseAgreementsTables", "longName": "00000027 - Disclosure - LEASE AGREEMENTS (Tables)", "shortName": "LEASE AGREEMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "NSPR:ScheduleOfSupplementalInformationRelatedToLeases", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "NSPR:ScheduleOfSupplementalInformationRelatedToLeases", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R28": { "role": "http://inspiremd.com/role/EquityTables", "longName": "00000028 - Disclosure - EQUITY (Tables)", "shortName": "EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R29": { "role": "http://inspiremd.com/role/TaxesOnIncomeTables", "longName": "00000029 - Disclosure - TAXES ON INCOME: (Tables)", "shortName": "TAXES ON INCOME: (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R30": { "role": "http://inspiremd.com/role/SupplementaryFinancialStatementInformationTables", "longName": "00000030 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)", "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R31": { "role": "http://inspiremd.com/role/DisaggregatedRevenueAndEntityWideDisclosuresTables", "longName": "00000031 - Disclosure - DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES (Tables)", "shortName": "DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R32": { "role": "http://inspiremd.com/role/DescriptionOfBusinessDetailsNarrative", "longName": "00000032 - Disclosure - DESCRIPTION OF BUSINESS (Details Narrative)", "shortName": "DESCRIPTION OF BUSINESS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "From2023-01-012023-12-31_custom_RussiaAndBelarusMember_us-gaap_SalesMember_us-gaap_GeographicConcentrationRiskMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "td", "tr", "table", "us-gaap:NatureOfOperations", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_custom_RussiaAndBelarusMember_us-gaap_SalesMember_us-gaap_GeographicConcentrationRiskMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "td", "tr", "table", "us-gaap:NatureOfOperations", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R33": { "role": "http://inspiremd.com/role/SignificantAccountingPoliciesDetailsNarrative", "longName": "00000033 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "NSPR:ResearchAndDevelopmentExpenseIncludingUSBasedClinicalTrialCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:ResearchAndDevelopmentExpensePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "NSPR:ResearchAndDevelopmentExpenseIncludingUSBasedClinicalTrialCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:ResearchAndDevelopmentExpensePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R34": { "role": "http://inspiremd.com/role/ScheduleOfFinancialAssetsSubjectToFairValueMeasurementsDetails", "longName": "00000034 - Disclosure - SCHEDULE OF FINANCIAL ASSETS SUBJECT TO FAIR VALUE MEASUREMENTS (Details)", "shortName": "SCHEDULE OF FINANCIAL ASSETS SUBJECT TO FAIR VALUE MEASUREMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:SecuritiesBorrowedFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USGovernmentAgenciesDebtSecuritiesMember", "name": "us-gaap:SecuritiesBorrowedFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R35": { "role": "http://inspiremd.com/role/FairValueMeasurementsDetailsNarrative", "longName": "00000035 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)", "shortName": "FAIR VALUE MEASUREMENTS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:SecuritiesBorrowedFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": null }, "R36": { "role": "http://inspiremd.com/role/ScheduleOfMarketableSecuritiesDetails", "longName": "00000036 - Disclosure - SCHEDULE OF MARKETABLE SECURITIES (Details)", "shortName": "SCHEDULE OF MARKETABLE SECURITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_USGovernmentAgenciesDebtSecuritiesMember", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R37": { "role": "http://inspiremd.com/role/ScheduleOfFairValueOfMarketableSecuritiesClassifiedByMaturityDetails", "longName": "00000037 - Disclosure - SCHEDULE OF FAIR VALUE OF MARKETABLE SECURITIES CLASSIFIED BY MATURITY (Details)", "shortName": "SCHEDULE OF FAIR VALUE OF MARKETABLE SECURITIES CLASSIFIED BY MATURITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "NSPR:MarketableSecuritiesMaturitiesWithinOneYearFairValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "NSPR:FairValueOfMarketableSecuritiesClassifiedByMaturityTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "NSPR:MarketableSecuritiesMaturitiesWithinOneYearFairValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "NSPR:FairValueOfMarketableSecuritiesClassifiedByMaturityTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R38": { "role": "http://inspiremd.com/role/ScheduleOfChangesInFairValueOfMarketableSecuritiesDetails", "longName": "00000038 - Disclosure - SCHEDULE OF CHANGES IN FAIR VALUE OF MARKETABLE SECURITIES (Details)", "shortName": "SCHEDULE OF CHANGES IN FAIR VALUE OF MARKETABLE SECURITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PaymentsToAcquireMarketableSecurities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "NSPR:ScheduleOfChangesInFairValueOfMarketableSecuritiesTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R39": { "role": "http://inspiremd.com/role/ScheduleOfPropertyPlantAndEquipmentDetails", "longName": "00000039 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)", "shortName": "SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R40": { "role": "http://inspiremd.com/role/LiabilityForEmployeesRightUponRetirementDetailsNarrative", "longName": "00000040 - Disclosure - LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT (Details Narrative)", "shortName": "LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "NSPR:PercentageOfMonthlyDepositsOnSalary", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "NSPR:PercentageOfMonthlyDepositsOnSalary", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R41": { "role": "http://inspiremd.com/role/ScheduleOfSupplementalInformationRelatedToLeasesDetails", "longName": "00000041 - Disclosure - SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES (Details)", "shortName": "SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "NSPR:ScheduleOfSupplementalInformationRelatedToLeases", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R42": { "role": "http://inspiremd.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails", "longName": "00000042 - Disclosure - SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details)", "shortName": "SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R43": { "role": "http://inspiremd.com/role/LeaseAgreementsDetailsNarrative", "longName": "00000043 - Disclosure - LEASE AGREEMENTS (Details Narrative)", "shortName": "LEASE AGREEMENTS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R44": { "role": "http://inspiremd.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "longName": "00000044 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)", "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "AsOf2021-02-03", "name": "NSPR:DirectDistributionRegulatoryCostPercentage", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2021-02-03", "name": "NSPR:DirectDistributionRegulatoryCostPercentage", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R45": { "role": "http://inspiremd.com/role/ScheduleOfIssuanceOfWarrantsToPurchaseCommonStockDetails", "longName": "00000045 - Disclosure - SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK (Details)", "shortName": "SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_custom_SeriesEWarrantsMember", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R46": { "role": "http://inspiremd.com/role/ScheduleOfStockOptionsGrantedDetails", "longName": "00000046 - Disclosure - SCHEDULE OF STOCK OPTIONS GRANTED (Details)", "shortName": "SCHEDULE OF STOCK OPTIONS GRANTED (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "AsOf2022-12-31_custom_EmployeeMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31_custom_EmployeeMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R47": { "role": "http://inspiremd.com/role/ScheduleOfRestrictedStockGrantedToEmployeesDetails", "longName": "00000047 - Disclosure - SCHEDULE OF RESTRICTED STOCK GRANTED TO EMPLOYEES (Details)", "shortName": "SCHEDULE OF RESTRICTED STOCK GRANTED TO EMPLOYEES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31_custom_EmployeeMember_us-gaap_RestrictedStockMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R48": { "role": "http://inspiremd.com/role/ScheduleOfRestrictedStockUnitGrantedToEmployeesDetails", "longName": "00000048 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNIT GRANTED TO EMPLOYEES (Details)", "shortName": "SCHEDULE OF RESTRICTED STOCK UNIT GRANTED TO EMPLOYEES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31_custom_EmployeeMember_us-gaap_RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R49": { "role": "http://inspiremd.com/role/ScheduleOfAdditionalInformationAboutAllOptionsOutstandingAndExercisableDetails", "longName": "00000049 - Disclosure - SCHEDULE OF ADDITIONAL INFORMATION ABOUT ALL OPTIONS OUTSTANDING AND EXERCISABLE (Details)", "shortName": "SCHEDULE OF ADDITIONAL INFORMATION ABOUT ALL OPTIONS OUTSTANDING AND EXERCISABLE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R50": { "role": "http://inspiremd.com/role/ScheduleOfFairValueOfOptionsGrantedToEmployeesDetails", "longName": "00000050 - Disclosure - SCHEDULE OF FAIR VALUE OF OPTIONS GRANTED TO EMPLOYEES (Details)", "shortName": "SCHEDULE OF FAIR VALUE OF OPTIONS GRANTED TO EMPLOYEES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R51": { "role": "http://inspiremd.com/role/ScheduleOfAllocationOfTotalShare-basedCompensationExpenseDetails", "longName": "00000051 - Disclosure - SCHEDULE OF ALLOCATION OF TOTAL SHARE-BASED COMPENSATION EXPENSE (Details)", "shortName": "SCHEDULE OF ALLOCATION OF TOTAL SHARE-BASED COMPENSATION EXPENSE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R52": { "role": "http://inspiremd.com/role/EquityDetailsNarrative", "longName": "00000052 - Disclosure - EQUITY (Details Narrative)", "shortName": "EQUITY (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "td", "tr", "table", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CapitalUnitsAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R53": { "role": "http://inspiremd.com/role/RelatedPartiesTransactionsDetailsNarrative", "longName": "00000053 - Disclosure - RELATED PARTIES TRANSACTIONS (Details Narrative)", "shortName": "RELATED PARTIES TRANSACTIONS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "td", "tr", "table", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R54": { "role": "http://inspiremd.com/role/ScheduleOfComponentsOfLossBeforeIncomeTaxesDetails", "longName": "00000054 - Disclosure - SCHEDULE OF COMPONENTS OF LOSS BEFORE INCOME TAXES (Details)", "shortName": "SCHEDULE OF COMPONENTS OF LOSS BEFORE INCOME TAXES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_srt_ParentCompanyMember", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R55": { "role": "http://inspiremd.com/role/ScheduleOfChangesInValuationAllowanceDetails", "longName": "00000055 - Disclosure - SCHEDULE OF CHANGES IN VALUATION ALLOWANCE (Details)", "shortName": "SCHEDULE OF CHANGES IN VALUATION ALLOWANCE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:SummaryOfValuationAllowanceTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "NSPR:DeferredTaxAssetsLossesDuringYearIncludingForeignExchangeRateEffect", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:SummaryOfValuationAllowanceTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R56": { "role": "http://inspiremd.com/role/ScheduleOfReconciliationOfUncertainTaxPositionsDetails", "longName": "00000056 - Disclosure - SCHEDULE OF RECONCILIATION OF UNCERTAIN TAX POSITIONS (Details)", "shortName": "SCHEDULE OF RECONCILIATION OF UNCERTAIN TAX POSITIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R57": { "role": "http://inspiremd.com/role/ScheduleOfOpenTaxYearsByMajorJurisdictionDetails", "longName": "00000057 - Disclosure - SCHEDULE OF OPEN TAX YEARS BY MAJOR JURISDICTION (Details)", "shortName": "SCHEDULE OF OPEN TAX YEARS BY MAJOR JURISDICTION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "From2023-01-012023-12-31_country_US_us-gaap_EarliestTaxYearMember", "name": "us-gaap:OpenTaxYear", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_country_US_us-gaap_EarliestTaxYearMember", "name": "us-gaap:OpenTaxYear", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R58": { "role": "http://inspiremd.com/role/ScheduleOfDeferredIncomeTaxDetails", "longName": "00000058 - Disclosure - SCHEDULE OF DEFERRED INCOME TAX (Details)", "shortName": "SCHEDULE OF DEFERRED INCOME TAX (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "NSPR:DeferredTaxAssetsTaxDeferredExpenseProvisionForVacationAndRecreationPay", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "NSPR:DeferredTaxAssetsTaxDeferredExpenseProvisionForVacationAndRecreationPay", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R59": { "role": "http://inspiremd.com/role/TaxesOnIncomeDetailsNarrative", "longName": "00000059 - Disclosure - TAXES ON INCOME: (Details Narrative)", "shortName": "TAXES ON INCOME: (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R60": { "role": "http://inspiremd.com/role/ScheduleOfInventoriesDetails", "longName": "00000060 - Disclosure - SCHEDULE OF INVENTORIES (Details)", "shortName": "SCHEDULE OF INVENTORIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R61": { "role": "http://inspiremd.com/role/ScheduleOfAccountsPayableAndAccruals-OtherDetails", "longName": "00000061 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER (Details)", "shortName": "SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AccruedSalariesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AccruedSalariesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R62": { "role": "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasDetails", "longName": "00000062 - Disclosure - SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS (Details)", "shortName": "SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_country_IT", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R63": { "role": "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasByProductDetails", "longName": "00000063 - Disclosure - SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRODUCT (Details)", "shortName": "SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRODUCT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_custom_CGuardEPSMember", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "NSPR:ScheduleOfRevenuesAttributedToGeographicAreasByProductTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R64": { "role": "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasByPrincipalCustomersDetails", "longName": "00000064 - Disclosure - SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS (Details)", "shortName": "SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "From2023-01-012023-12-31_custom_CustomerAMember_us-gaap_SalesMember_us-gaap_CustomerConcentrationRiskMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_custom_CustomerAMember_us-gaap_SalesMember_us-gaap_CustomerConcentrationRiskMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract", "presentation": [ "http://inspiremd.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accruals:" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableOtherCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableOtherCurrent", "crdr": "credit", "calculation": { "http://inspiremd.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://inspiremd.com/role/ScheduleOfAccountsPayableAndAccruals-OtherDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inspiremd.com/role/BalanceSheets", "http://inspiremd.com/role/ScheduleOfAccountsPayableAndAccruals-OtherDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other", "totalLabel": "Accounts Payable and Accruals - Other", "label": "Accounts Payable, Other, Current", "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r17" ] }, "us-gaap_AccountsPayableTradeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableTradeCurrent", "crdr": "credit", "calculation": { "http://inspiremd.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inspiremd.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Trade", "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r15", "r17" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://inspiremd.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://inspiremd.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Trade, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r240", "r241" ] }, "us-gaap_AccountsReceivableNetCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrentAbstract", "presentation": [ "http://inspiremd.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts receivable:" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ScheduleOfAccountsPayableAndAccruals-OtherDetails": { "parentTag": "us-gaap_AccountsPayableOtherCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inspiremd.com/role/ScheduleOfAccountsPayableAndAccruals-OtherDetails" ], "lang": { "en-us": { "role": { "label": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r19" ] }, "NSPR_AccruedOperatingLeaseLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "AccruedOperatingLeaseLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ScheduleOfAccountsPayableAndAccruals-OtherDetails": { "parentTag": "us-gaap_AccountsPayableOtherCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://inspiremd.com/role/ScheduleOfAccountsPayableAndAccruals-OtherDetails" ], "lang": { "en-us": { "role": { "label": "Current Operating lease liabilities" } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://inspiremd.com/role/RelatedPartiesTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received." } } }, "auth_ref": [ "r70" ] }, "us-gaap_AccruedSalariesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedSalariesCurrent", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ScheduleOfAccountsPayableAndAccruals-OtherDetails": { "parentTag": "us-gaap_AccountsPayableOtherCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inspiremd.com/role/ScheduleOfAccountsPayableAndAccruals-OtherDetails" ], "lang": { "en-us": { "role": { "label": "Employees and employee institutions", "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r19", "r692" ] }, "us-gaap_AccruedVacationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedVacationCurrent", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ScheduleOfAccountsPayableAndAccruals-OtherDetails": { "parentTag": "us-gaap_AccountsPayableOtherCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inspiremd.com/role/ScheduleOfAccountsPayableAndAccruals-OtherDetails" ], "lang": { "en-us": { "role": { "label": "Accrued vacation and recreation pay", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r19", "r49" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://inspiremd.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less - accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r40", "r159", "r541" ] }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalFinancialInformationDisclosureTextBlock", "presentation": [ "http://inspiremd.com/role/SupplementaryFinancialStatementInformation" ], "lang": { "en-us": { "role": { "label": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION", "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://inspiremd.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inspiremd.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r82", "r714", "r854" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://inspiremd.com/role/StatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r399", "r400", "r401", "r575", "r771", "r772", "r773", "r831", "r855" ] }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments required to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": [ "http://inspiremd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Advertising", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": [ "r138" ] }, "us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": [ "http://inspiremd.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Advertising Expense", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": [ "r407" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://inspiremd.com/role/ScheduleOfAllocationOfTotalShare-basedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Total share-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r397", "r406" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "NSPR_AmountsWithdrawnInRespectOfEmployeeRightsUponRetirementNet": { "xbrltype": "monetaryItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "AmountsWithdrawnInRespectOfEmployeeRightsUponRetirementNet", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Amounts funded in respect of employee rights upon retirement", "documentation": "Amounts with drawn in respect of employee rights upon retirement net.", "label": "AmountsWithdrawnInRespectOfEmployeeRightsUponRetirementNet" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r742" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://inspiremd.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r204" ] }, "NSPR_ArisingBeforeJanuaryOneTwoThousandAndEighteenMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "ArisingBeforeJanuaryOneTwoThousandAndEighteenMember", "presentation": [ "http://inspiremd.com/role/TaxesOnIncomeDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Arising Before January One 2018 [Member]", "documentation": "Arising Before January One 2018 [Member]" } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://inspiremd.com/role/RelatedPartiesTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r427" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://inspiremd.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inspiremd.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r128", "r160", "r178", "r213", "r226", "r231", "r274", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r428", "r430", "r452", "r533", "r615", "r714", "r727", "r789", "r790", "r839" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://inspiremd.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://inspiremd.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inspiremd.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL CURRENT ASSETS", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r154", "r167", "r178", "r274", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r428", "r430", "r452", "r714", "r789", "r790", "r839" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://inspiremd.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS:" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://inspiremd.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inspiremd.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL NON-CURRENT ASSETS", "label": "Assets, Noncurrent", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r178", "r274", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r428", "r430", "r452", "r789", "r790", "r839" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://inspiremd.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "NON-CURRENT ASSETS:" } } }, "auth_ref": [] }, "NSPR_AtTheMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "AtTheMarketOfferingMember", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "At The Market Offering [Member]", "documentation": "At The Market Offering [Member]" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r742" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r739", "r741", "r742" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r739", "r741", "r742" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r739", "r741", "r742" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative", "http://inspiremd.com/role/ScheduleOfRestrictedStockGrantedToEmployeesDetails", "http://inspiremd.com/role/ScheduleOfRestrictedStockUnitGrantedToEmployeesDetails" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r368", "r369", "r370", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r392", "r393", "r394", "r395", "r396" ] }, "NSPR_CGuardEPSMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "CGuardEPSMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasByProductDetails" ], "lang": { "en-us": { "role": { "label": "C Guard E P S [Member]" } } }, "auth_ref": [] }, "NSPR_CapitalStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "CapitalStockParOrStatedValuePerShare", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Capital stock par value", "documentation": "Capital stock par value." } } }, "auth_ref": [] }, "us-gaap_CapitalUnitsAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalUnitsAuthorized", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Capital stock shares authorized", "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies." } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "presentation": [ "http://inspiremd.com/role/RelatedPartiesTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash paid", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r135", "r535", "r586", "r609", "r714", "r727", "r759" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://inspiremd.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inspiremd.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r25", "r157", "r689" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://inspiremd.com/role/ScheduleOfFinancialAssetsSubjectToFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r157" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://inspiremd.com/role/ScheduleOfFinancialAssetsSubjectToFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Cash equivalents", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://inspiremd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r26" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR", "periodEndLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r25", "r104", "r175" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r2", "r104" ] }, "NSPR_ChangeInLiabilityForEmployeesRightsUponRetirement": { "xbrltype": "monetaryItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "ChangeInLiabilityForEmployeesRightsUponRetirement", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in liability for employees rights upon retirement", "documentation": "Change in liability for employees rights upon retirement.", "label": "ChangeInLiabilityForEmployeesRightsUponRetirement" } } }, "auth_ref": [] }, "NSPR_ChangeInRightOfUseAssetAndLeasingLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "ChangeInRightOfUseAssetAndLeasingLiability", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in operating right of use asset and operating leasing liability", "documentation": "Change In Operating Lease Assets And Liabilities.", "label": "ChangeInRightOfUseAssetAndLeasingLiability" } } }, "auth_ref": [] }, "NSPR_ChangesInFairValueMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "ChangesInFairValueMarketableSecurities", "crdr": "credit", "presentation": [ "http://inspiremd.com/role/ScheduleOfChangesInFairValueOfMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Changes in fair value", "documentation": "Changes in fair value marketable securities." } } }, "auth_ref": [] }, "NSPR_ChangesInFairValueOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "ChangesInFairValueOfMarketableSecurities", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in fair value of markable securities, net of interest received", "documentation": "Changes in fair value of marketable securities.", "label": "ChangesInFairValueOfMarketableSecurities" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://inspiremd.com/role/BalanceSheetsParenthetical", "http://inspiremd.com/role/EquityDetailsNarrative", "http://inspiremd.com/role/ScheduleOfIssuanceOfWarrantsToPurchaseCommonStockDetails", "http://inspiremd.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://inspiremd.com/role/StatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r150", "r161", "r162", "r163", "r178", "r198", "r199", "r201", "r203", "r207", "r208", "r274", "r304", "r306", "r307", "r308", "r311", "r312", "r316", "r317", "r321", "r324", "r331", "r452", "r566", "r567", "r568", "r569", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r587", "r601", "r624", "r646", "r665", "r666", "r667", "r668", "r669", "r749", "r769", "r774" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://inspiremd.com/role/ScheduleOfIssuanceOfWarrantsToPurchaseCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r161", "r162", "r163", "r207", "r316", "r317", "r319", "r321", "r324", "r329", "r331", "r566", "r567", "r568", "r569", "r704", "r749", "r769" ] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative", "http://inspiremd.com/role/ScheduleOfIssuanceOfWarrantsToPurchaseCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price", "verboseLabel": "Warrant exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r332" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative", "http://inspiremd.com/role/ScheduleOfIssuanceOfWarrantsToPurchaseCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Total Warrants", "verboseLabel": "Warrants to purchase common stock", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r332" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "NSPR_ClinicalTrialAccrualCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "ClinicalTrialAccrualCurrent", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ScheduleOfAccountsPayableAndAccruals-OtherDetails": { "parentTag": "us-gaap_AccountsPayableOtherCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://inspiremd.com/role/ScheduleOfAccountsPayableAndAccruals-OtherDetails" ], "lang": { "en-us": { "role": { "label": "Clinical trial accrual" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://inspiremd.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inspiremd.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENT LIABILITIES (Note 8)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r21", "r71", "r534", "r600" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://inspiremd.com/role/CommitmentsAndContingentLiabilities" ], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENT LIABILITIES", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r113", "r298", "r299", "r673", "r785" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://inspiremd.com/role/StatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r717", "r718", "r719", "r721", "r722", "r723", "r724", "r771", "r772", "r831", "r852", "r855" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://inspiremd.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r81" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://inspiremd.com/role/BalanceSheetsParenthetical", "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "verboseLabel": "Common stock shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r81", "r601" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://inspiremd.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r81" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://inspiremd.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r9", "r81", "r601", "r621", "r855", "r856" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://inspiremd.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inspiremd.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, par value $0.0001 per share; 150,000,000 shares authorized at December 31, 2023 and 2022; 21,841,215 and 8,330,918 shares issued and outstanding at December 31, 2023 and 2022, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r81", "r537", "r714" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://inspiremd.com/role/DescriptionOfBusinessDetailsNarrative", "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasByPrincipalCustomersDetails" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r29", "r32", "r66", "r67", "r239", "r672" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://inspiremd.com/role/DescriptionOfBusinessDetailsNarrative", "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasByPrincipalCustomersDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r29", "r32", "r66", "r67", "r239", "r561", "r672" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://inspiremd.com/role/DescriptionOfBusinessDetailsNarrative", "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasByPrincipalCustomersDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r29", "r32", "r66", "r67", "r239", "r672", "r750" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://inspiremd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentration of credit risk and allowance for doubtful accounts", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r73", "r141" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://inspiremd.com/role/DescriptionOfBusinessDetailsNarrative", "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasByPrincipalCustomersDetails" ], "lang": { "en-us": { "role": { "label": "Sales percentage", "verboseLabel": "Percentage of revenues per major customer", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r29", "r32", "r66", "r67", "r239" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://inspiremd.com/role/DescriptionOfBusinessDetailsNarrative", "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasByPrincipalCustomersDetails" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r29", "r32", "r66", "r67", "r239", "r672" ] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://inspiremd.com/role/ScheduleOfComponentsOfLossBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "auth_ref": [ "r182", "r428", "r429", "r430", "r431", "r481", "r683", "r788", "r791", "r792" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://inspiremd.com/role/ScheduleOfComponentsOfLossBeforeIncomeTaxesDetails" ], "auth_ref": [ "r182", "r428", "r429", "r430", "r431", "r481", "r683", "r788", "r791", "r792" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://inspiremd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Principles of consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r64", "r693" ] }, "NSPR_ConsultancyAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "ConsultancyAgreementMember", "presentation": [ "http://inspiremd.com/role/RelatedPartiesTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consultancy Agreement [Member]", "documentation": "Consultancy Agreement [Member]" } } }, "auth_ref": [] }, "NSPR_ConsultantMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "ConsultantMember", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consultants [Member]", "documentation": "Consultants [Member]" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://inspiremd.com/role/StatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://inspiremd.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "COST OF REVENUES", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r96", "r517" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfAllocationOfTotalShare-basedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpensesRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpensesRelatedParty", "crdr": "debit", "presentation": [ "http://inspiremd.com/role/RelatedPartiesTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Marketing services from related party", "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties." } } }, "auth_ref": [ "r97" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "NSPR_CustomerAMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "CustomerAMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasByPrincipalCustomersDetails" ], "lang": { "en-us": { "role": { "label": "Customer A [Member]" } } }, "auth_ref": [] }, "NSPR_CustomerBMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "CustomerBMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasByPrincipalCustomersDetails" ], "lang": { "en-us": { "role": { "label": "Customer B [Member]", "documentation": "Customer B [Member]" } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasByPrincipalCustomersDetails" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r30", "r239" ] }, "country_DE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "DE", "presentation": [ "http://inspiremd.com/role/ScheduleOfOpenTaxYearsByMajorJurisdictionDetails", "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasDetails" ], "lang": { "en-us": { "role": { "label": "GERMANY" } } }, "auth_ref": [] }, "NSPR_DecreaseInRightofuseAssetsAndLeaseLiabilitiesDueToShorteningLeaseTerm": { "xbrltype": "monetaryItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "DecreaseInRightofuseAssetsAndLeaseLiabilitiesDueToShorteningLeaseTerm", "crdr": "debit", "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Decrease in right-of-use assets and lease liabilities due to shortening lease term", "documentation": "Decrease in right-of-use assets and lease liabilities due to shortening lease term." } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "presentation": [ "http://inspiremd.com/role/ScheduleOfRestrictedStockGrantedToEmployeesDetails", "http://inspiremd.com/role/ScheduleOfRestrictedStockUnitGrantedToEmployeesDetails", "http://inspiremd.com/role/ScheduleOfStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://inspiremd.com/role/ScheduleOfDeferredIncomeTaxDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inspiremd.com/role/ScheduleOfDeferredIncomeTaxDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred tax assets noncurrent", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r417" ] }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "crdr": "debit", "calculation": { "http://inspiremd.com/role/ScheduleOfDeferredIncomeTaxDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inspiremd.com/role/ScheduleOfDeferredIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "R&D expenses", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination." } } }, "auth_ref": [ "r63", "r829" ] }, "NSPR_DeferredTaxAssetsLossesDuringYearIncludingForeignExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "DeferredTaxAssetsLossesDuringYearIncludingForeignExchangeRateEffect", "crdr": "debit", "presentation": [ "http://inspiremd.com/role/ScheduleOfChangesInValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "label": "Changes during the year: Losses during the year (including foreign exchange rate effect)", "documentation": "Deferred Tax Assets Losses During Year Including Foreign Exchange Rate Effect." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://inspiremd.com/role/ScheduleOfDeferredIncomeTaxDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inspiremd.com/role/ScheduleOfDeferredIncomeTaxDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred tax assets", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r828" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://inspiremd.com/role/ScheduleOfDeferredIncomeTaxDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://inspiremd.com/role/ScheduleOfDeferredIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Carry forward tax losses", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r63", "r829" ] }, "NSPR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOperatingLeaseLiabilities", "crdr": "debit", "calculation": { "http://inspiremd.com/role/ScheduleOfDeferredIncomeTaxDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://inspiremd.com/role/ScheduleOfDeferredIncomeTaxDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liabilities", "label": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOperatingLeaseLiabilities" } } }, "auth_ref": [] }, "NSPR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOperatingLeaseRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOperatingLeaseRightOfUseAssets", "crdr": "debit", "calculation": { "http://inspiremd.com/role/ScheduleOfDeferredIncomeTaxDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inspiremd.com/role/ScheduleOfDeferredIncomeTaxDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease right of use assets", "label": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOperatingLeaseRightOfUseAssets" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments", "crdr": "debit", "calculation": { "http://inspiremd.com/role/ScheduleOfDeferredIncomeTaxDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://inspiremd.com/role/ScheduleOfDeferredIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Accrued severance pay, net", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from severance costs." } } }, "auth_ref": [ "r63", "r829" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://inspiremd.com/role/ScheduleOfDeferredIncomeTaxDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://inspiremd.com/role/ScheduleOfDeferredIncomeTaxDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-based compensation", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r63", "r829" ] }, "NSPR_DeferredTaxAssetsTaxDeferredExpenseProvisionForVacationAndRecreationPay": { "xbrltype": "monetaryItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "DeferredTaxAssetsTaxDeferredExpenseProvisionForVacationAndRecreationPay", "crdr": "debit", "calculation": { "http://inspiremd.com/role/ScheduleOfDeferredIncomeTaxDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inspiremd.com/role/ScheduleOfDeferredIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Provision for vacation and recreation pay" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ScheduleOfDeferredIncomeTaxDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://inspiremd.com/role/ScheduleOfChangesInValuationAllowanceDetails", "http://inspiremd.com/role/ScheduleOfDeferredIncomeTaxDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at the beginning of the year", "periodEndLabel": "Balance at the end of the year", "negatedLabel": "Less-valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r418" ] }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "crdr": "debit", "calculation": { "http://inspiremd.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inspiremd.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Fund in respect of employee rights upon retirement", "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans." } } }, "auth_ref": [ "r127", "r345", "r346", "r347", "r614", "r710", "r849" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r5", "r39" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": [ "http://inspiremd.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization expenses", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r5", "r39" ] }, "NSPR_DirectDistributionRegulatoryCostPercentage": { "xbrltype": "percentItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "DirectDistributionRegulatoryCostPercentage", "presentation": [ "http://inspiremd.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Distribution cost rate" } } }, "auth_ref": [] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "DirectorMember", "presentation": [ "http://inspiremd.com/role/RelatedPartiesTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "auth_ref": [ "r777", "r853" ] }, "NSPR_DisclosureLeaseAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "DisclosureLeaseAgreementsAbstract", "lang": { "en-us": { "role": { "label": "Lease Agreements", "verboseLabel": "Schedule Of Supplemental Information Related To Leases", "terseLabel": "Schedule Of Maturities Of Lease Liabilities" } } }, "auth_ref": [] }, "us-gaap_DistributionMadeToLimitedPartnerCashDistributionsDeclared": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DistributionMadeToLimitedPartnerCashDistributionsDeclared", "crdr": "debit", "presentation": [ "http://inspiremd.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Distribution reimbursement", "documentation": "Amount of equity impact of cash distribution declared to unit-holder of limited partnership (LP)." } } }, "auth_ref": [ "r117" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r741" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r739", "r741", "r742" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r739", "r741", "r742", "r744" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r740" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r728" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r741" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r741" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r743" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r731" ] }, "us-gaap_EarliestTaxYearMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarliestTaxYearMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfOpenTaxYearsByMajorJurisdictionDetails" ], "lang": { "en-us": { "role": { "label": "Earliest Tax Year [Member]", "documentation": "Earliest identified tax year." } } }, "auth_ref": [ "r825" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://inspiremd.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "NET LOSS PER SHARE - basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r173", "r188", "r189", "r190", "r191", "r192", "r196", "r198", "r201", "r202", "r203", "r205", "r441", "r442", "r530", "r546", "r696" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://inspiremd.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "NET LOSS PER SHARE - diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r173", "r188", "r189", "r190", "r191", "r192", "r198", "r201", "r202", "r203", "r205", "r441", "r442", "r530", "r546", "r696" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://inspiremd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Net loss per share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r27", "r28" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r833" ] }, "NSPR_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate1": { "xbrltype": "percentItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate1", "presentation": [ "http://inspiremd.com/role/TaxesOnIncomeDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revised tax rate on income of preferred enterprises" } } }, "auth_ref": [] }, "NSPR_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate2": { "xbrltype": "percentItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate2", "presentation": [ "http://inspiremd.com/role/TaxesOnIncomeDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tax rate on income of beneficiary enterprises", "documentation": "Effective income tax rate reconciliation change in enacted tax rate 2" } } }, "auth_ref": [] }, "NSPR_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate3": { "xbrltype": "percentItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate3", "presentation": [ "http://inspiremd.com/role/TaxesOnIncomeDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Tax rate on income of beneficiary enterprises", "label": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate3" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "presentation": [ "http://inspiremd.com/role/TaxesOnIncomeDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Federal corporate tax rate", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile." } } }, "auth_ref": [ "r824", "r830" ] }, "NSPR_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential1": { "xbrltype": "percentItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential1", "presentation": [ "http://inspiremd.com/role/TaxesOnIncomeDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Corporate trade tax rate", "documentation": "Effective income tax rate reconciliation foreign income tax rate differential 1" } } }, "auth_ref": [] }, "NSPR_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRatePreferredIncome": { "xbrltype": "percentItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRatePreferredIncome", "presentation": [ "http://inspiremd.com/role/TaxesOnIncomeDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Corporate trade tax rate", "label": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRatePreferredIncome" } } }, "auth_ref": [] }, "NSPR_EmployeeAndNonEmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "EmployeeAndNonEmployeeStockOptionMember", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Employee And Non Employee Stock Option [Member]" } } }, "auth_ref": [] }, "NSPR_EmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "EmployeeMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfRestrictedStockGrantedToEmployeesDetails", "http://inspiremd.com/role/ScheduleOfRestrictedStockUnitGrantedToEmployeesDetails", "http://inspiremd.com/role/ScheduleOfStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Employee [Member]", "documentation": "Employee [Member]" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unvested stock-based compensation", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r398" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unvested stock-based compensation weighted-average period for recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r398" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "NSPR_EmployeesAndDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "EmployeesAndDirectorsMember", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Employees and Directors [Member]", "documentation": "Employees and Directors [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r734" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r730" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r730" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r748" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r730" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r745" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r742" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r730" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r730" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r730" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r730" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r746" ] }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "presentation": [ "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasByProductDetails" ], "lang": { "en-us": { "role": { "label": "Revenue from External Customer [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EntityWideRevenueMajorCustomerLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EntityWideRevenueMajorCustomerLineItems", "presentation": [ "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasByPrincipalCustomersDetails" ], "lang": { "en-us": { "role": { "label": "Revenue, Major Customer [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative", "http://inspiremd.com/role/StatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r9", "r152", "r170", "r171", "r172", "r183", "r184", "r185", "r187", "r193", "r195", "r206", "r275", "r276", "r333", "r399", "r400", "r401", "r420", "r421", "r432", "r433", "r434", "r435", "r436", "r437", "r440", "r454", "r455", "r456", "r457", "r458", "r459", "r472", "r556", "r557", "r558", "r575", "r646" ] }, "NSPR_ExercisePriceFourMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "ExercisePriceFourMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfAdditionalInformationAboutAllOptionsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price Four [Member]", "documentation": "Exercise Price Four [Member]" } } }, "auth_ref": [] }, "NSPR_ExercisePriceOneMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "ExercisePriceOneMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfAdditionalInformationAboutAllOptionsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price One [Member]", "documentation": "Exercise Price One [Member]" } } }, "auth_ref": [] }, "NSPR_ExercisePriceThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "ExercisePriceThreeMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfAdditionalInformationAboutAllOptionsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price Three [Member]", "documentation": "Exercise Price Three [Member]" } } }, "auth_ref": [] }, "NSPR_ExercisePriceTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "ExercisePriceTwoMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfAdditionalInformationAboutAllOptionsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price Two [Member]", "documentation": "Exercise Price Two [Member]" } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://inspiremd.com/role/ScheduleOfFinancialAssetsSubjectToFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r444", "r445", "r448" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://inspiremd.com/role/ScheduleOfFinancialAssetsSubjectToFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r444", "r445", "r448" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://inspiremd.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF FINANCIAL ASSETS SUBJECT TO FAIR VALUE MEASUREMENTS", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r65", "r125" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://inspiremd.com/role/ScheduleOfFinancialAssetsSubjectToFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r313", "r350", "r351", "r352", "r353", "r354", "r355", "r445", "r488", "r489", "r490", "r702", "r703", "r708", "r709", "r710" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://inspiremd.com/role/ScheduleOfFinancialAssetsSubjectToFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r444", "r445", "r446", "r447", "r449" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://inspiremd.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "label": "FAIR VALUE MEASUREMENTS", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r443" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://inspiremd.com/role/ScheduleOfFinancialAssetsSubjectToFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r313", "r350", "r355", "r445", "r488", "r708", "r709", "r710" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://inspiremd.com/role/ScheduleOfFinancialAssetsSubjectToFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r313", "r350", "r355", "r445", "r489", "r702", "r703", "r708", "r709", "r710" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://inspiremd.com/role/ScheduleOfFinancialAssetsSubjectToFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r313", "r350", "r351", "r352", "r353", "r354", "r355", "r445", "r490", "r702", "r703", "r708", "r709", "r710" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://inspiremd.com/role/ScheduleOfFinancialAssetsSubjectToFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://inspiremd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair value measurement", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://inspiremd.com/role/ScheduleOfFinancialAssetsSubjectToFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r313", "r350", "r351", "r352", "r353", "r354", "r355", "r488", "r489", "r490", "r702", "r703", "r708", "r709", "r710" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfFinancialAssetsSubjectToFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r443", "r449" ] }, "NSPR_FairValueOfMarketableSecuritiesClassifiedByMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "FairValueOfMarketableSecuritiesClassifiedByMaturityTableTextBlock", "presentation": [ "http://inspiremd.com/role/MarketableSecuritiesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF FAIR VALUE OF MARKETABLE SECURITIES CLASSIFIED BY MATURITY", "documentation": "Fair Value Of Marketable Securities Classified By Maturity [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://inspiremd.com/role/ScheduleOfFinancialAssetsSubjectToFairValueMeasurementsDetails", "http://inspiremd.com/role/ScheduleOfMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r314", "r329", "r438", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r545", "r701", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r779", "r780", "r781", "r782" ] }, "NSPR_FixedHourlyConsultingFee": { "xbrltype": "monetaryItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "FixedHourlyConsultingFee", "crdr": "debit", "presentation": [ "http://inspiremd.com/role/RelatedPartiesTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fixed hourly consulting fee", "documentation": "Fixed hourly consulting fee." } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://inspiremd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Functional currency", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r453" ] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Gain from sale of property, plant and equipment", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r5" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://inspiremd.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inspiremd.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r98", "r626" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfAllocationOfTotalShare-basedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r93" ] }, "us-gaap_GeographicConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeographicConcentrationRiskMember", "presentation": [ "http://inspiremd.com/role/DescriptionOfBusinessDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Geographic Concentration Risk [Member]", "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)." } } }, "auth_ref": [ "r31", "r672" ] }, "NSPR_GermanyMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "GermanyMember", "presentation": [ "http://inspiremd.com/role/TaxesOnIncomeDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Germany [Member]", "documentation": "Germany [Member]" } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://inspiremd.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inspiremd.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "GROSS PROFIT", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r95", "r178", "r213", "r225", "r230", "r233", "r274", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r452", "r698", "r789" ] }, "country_IL": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "IL", "presentation": [ "http://inspiremd.com/role/ScheduleOfOpenTaxYearsByMajorJurisdictionDetails" ], "lang": { "en-us": { "role": { "label": "ISRAEL" } } }, "auth_ref": [] }, "country_IT": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "IT", "presentation": [ "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasDetails" ], "lang": { "en-us": { "role": { "label": "ITALY" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r739", "r741", "r742" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://inspiremd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Impairment in value of long-lived assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r112" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://inspiremd.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inspiremd.com/role/ScheduleOfComponentsOfLossBeforeIncomeTaxesDetails", "http://inspiremd.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "LOSS BEFORE TAX EXPENSES", "label": "Loss before taxes on income", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r1", "r91", "r130", "r213", "r225", "r230", "r233", "r531", "r543", "r698" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://inspiremd.com/role/ScheduleOfAllocationOfTotalShare-basedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r290", "r293", "r631" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://inspiremd.com/role/ScheduleOfAllocationOfTotalShare-basedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "auth_ref": [ "r293", "r631" ] }, "us-gaap_IncomeTaxAuthorityNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityNameAxis", "presentation": [ "http://inspiremd.com/role/TaxesOnIncomeDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Axis]", "documentation": "Information by name of taxing authority." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncomeTaxAuthorityNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityNameDomain", "presentation": [ "http://inspiremd.com/role/TaxesOnIncomeDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://inspiremd.com/role/TaxesOnIncome" ], "lang": { "en-us": { "role": { "label": "TAXES ON INCOME:", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r179", "r410", "r413", "r416", "r419", "r422", "r424", "r425", "r426", "r571" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://inspiremd.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://inspiremd.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "TAX EXPENSES", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r134", "r147", "r194", "r195", "r216", "r412", "r423", "r548" ] }, "us-gaap_IncomeTaxUncertaintiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxUncertaintiesPolicy", "presentation": [ "http://inspiremd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Deferred income taxes", "documentation": "Disclosure of accounting policy for tax positions taken in the tax return filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other types of contingencies related to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in trade payables", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Decrease (increase) in trade receivables", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Increase in inventory", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating asset and liability items:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherAccountsPayable", "crdr": "debit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase in other payables", "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherReceivables", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Increase in other receivables", "label": "Increase (Decrease) in Other Receivables", "documentation": "Amount of increase (decrease) in receivables classified as other." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Decrease in prepaid expenses", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r4" ] }, "NSPR_InterestIncomeFromShorttermBankDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "InterestIncomeFromShorttermBankDeposits", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Decrease (increase) in interest receivable on short term deposits", "documentation": "Interest income from short term bank deposits.", "label": "InterestIncomeFromShorttermBankDeposits" } } }, "auth_ref": [] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://inspiremd.com/role/ScheduleOfInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inspiremd.com/role/ScheduleOfInventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r764" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://inspiremd.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 7.0 }, "http://inspiremd.com/role/ScheduleOfInventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inspiremd.com/role/BalanceSheets", "http://inspiremd.com/role/ScheduleOfInventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Inventory", "totalLabel": "Total inventory", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r165", "r690", "r714" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://inspiremd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventory", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r136", "r156", "r164", "r285", "r286", "r287", "r516", "r694" ] }, "us-gaap_InventoryRawMaterialsAndSupplies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsAndSupplies", "crdr": "debit", "calculation": { "http://inspiremd.com/role/ScheduleOfInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inspiremd.com/role/ScheduleOfInventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Raw materials and supplies", "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed." } } }, "auth_ref": [ "r766" ] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcess", "crdr": "debit", "calculation": { "http://inspiremd.com/role/ScheduleOfInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inspiremd.com/role/ScheduleOfInventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Work in process", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r765" ] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://inspiremd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Short-term bank deposits", "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r547", "r562", "r563", "r564", "r565", "r656", "r657" ] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://inspiremd.com/role/MarketableSecurities" ], "lang": { "en-us": { "role": { "label": "MARKETABLE SECURITIES", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r126", "r132", "r133", "r151", "r242", "r243", "r450", "r451" ] }, "us-gaap_IsraelTaxAuthorityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IsraelTaxAuthorityMember", "presentation": [ "http://inspiremd.com/role/TaxesOnIncomeDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Israel Tax Authority [Member]", "documentation": "Designated tax department of the government of Israel." } } }, "auth_ref": [] }, "NSPR_IssuanceCostsOfAtMarketOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "IssuanceCostsOfAtMarketOffering", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Issuance costs of At The Market offering", "documentation": "Issuance costs of at market offering.", "label": "IssuanceCostsOfAtMarketOffering" } } }, "auth_ref": [] }, "us-gaap_LatestTaxYearMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LatestTaxYearMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfOpenTaxYearsByMajorJurisdictionDetails" ], "lang": { "en-us": { "role": { "label": "Latest Tax Year [Member]", "documentation": "Latest identified tax year." } } }, "auth_ref": [ "r825" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r111" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://inspiremd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r466" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://inspiremd.com/role/LeaseAgreementsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF MATURITIES OF LEASE LIABILITIES", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r834" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inspiremd.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r471" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inspiremd.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r471" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inspiremd.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r471" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inspiremd.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r471" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://inspiremd.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r471" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://inspiremd.com/role/LeaseAgreements" ], "lang": { "en-us": { "role": { "label": "LEASE AGREEMENTS", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r461" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://inspiremd.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inspiremd.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r18", "r178", "r274", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r429", "r430", "r431", "r452", "r599", "r697", "r727", "r789", "r839", "r840" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://inspiremd.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inspiremd.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r86", "r129", "r539", "r714", "r770", "r783", "r832" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://inspiremd.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://inspiremd.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inspiremd.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL CURRENT LIABILITIES", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r20", "r155", "r178", "r274", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r429", "r430", "r431", "r452", "r714", "r789", "r839", "r840" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://inspiremd.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://inspiremd.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inspiremd.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LONG-TERM LIABILITIES", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r14", "r75", "r76", "r77", "r78", "r178", "r274", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r429", "r430", "r431", "r452", "r789", "r839", "r840" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://inspiremd.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "LONG-TERM LIABILITIES:" } } }, "auth_ref": [] }, "NSPR_LimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "LimitedMember", "presentation": [ "http://inspiremd.com/role/TaxesOnIncomeDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Limited [Member]", "documentation": "Limited [Member]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "NSPR_LossGainOnAmountsFundedInRespectOfEmployeeRightsUponRetirementNet": { "xbrltype": "monetaryItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "LossGainOnAmountsFundedInRespectOfEmployeeRightsUponRetirementNet", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss (gain) on amounts funded in respect of employee rights upon retirement, net", "documentation": "Loss gain on amounts funded in respect of employee rights upon retirement net", "label": "LossGainOnAmountsFundedInRespectOfEmployeeRightsUponRetirementNet" } } }, "auth_ref": [] }, "NSPR_MGuardPrimeEPSMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "MGuardPrimeEPSMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasByProductDetails" ], "lang": { "en-us": { "role": { "label": "M Guard Prime E P S [Member]" } } }, "auth_ref": [] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasByPrincipalCustomersDetails" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": [ "r239", "r707", "r795", "r850", "r851" ] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "calculation": { "http://inspiremd.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inspiremd.com/role/BalanceSheets", "http://inspiremd.com/role/ScheduleOfChangesInFairValueOfMarketableSecuritiesDetails", "http://inspiremd.com/role/ScheduleOfFairValueOfMarketableSecuritiesClassifiedByMaturityDetails", "http://inspiremd.com/role/ScheduleOfMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Marketable securities", "periodStartLabel": "Balance at beginning of the period", "periodEndLabel": "Balance at end of the period", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": [ "r760" ] }, "us-gaap_MarketableSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesLineItems", "presentation": [ "http://inspiremd.com/role/ScheduleOfMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Marketable Securities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "NSPR_MarketableSecuritiesMaturitiesAfterOneYearThroughTwoYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "MarketableSecuritiesMaturitiesAfterOneYearThroughTwoYearsFairValue", "crdr": "debit", "presentation": [ "http://inspiremd.com/role/ScheduleOfFairValueOfMarketableSecuritiesClassifiedByMaturityDetails" ], "lang": { "en-us": { "role": { "label": "Amounts maturing after one year through two years", "documentation": "Marketable securities maturities after one year through two years fair value." } } }, "auth_ref": [] }, "NSPR_MarketableSecuritiesMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "MarketableSecuritiesMaturitiesWithinOneYearFairValue", "crdr": "debit", "presentation": [ "http://inspiremd.com/role/ScheduleOfFairValueOfMarketableSecuritiesClassifiedByMaturityDetails" ], "lang": { "en-us": { "role": { "label": "Amounts maturing within one year", "documentation": "Marketable securities maturities within one year fair value." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesPolicy", "presentation": [ "http://inspiremd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Marketable securities", "label": "Marketable Securities, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": [ "r72" ] }, "us-gaap_MarketableSecuritiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesTable", "presentation": [ "http://inspiremd.com/role/ScheduleOfMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Marketable Securities [Table]", "documentation": "Disclosure of information about investment in marketable security." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesTextBlock", "presentation": [ "http://inspiremd.com/role/MarketableSecuritiesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF MARKETABLE SECURITIES", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfFairValueOfOptionsGrantedToEmployeesDetails", "http://inspiremd.com/role/TaxesOnIncomeDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r300", "r301", "r302", "r303", "r366", "r515", "r555", "r591", "r592", "r654", "r658", "r660", "r661", "r663", "r684", "r685", "r700", "r704", "r711", "r716", "r793", "r841", "r842", "r843", "r844", "r845", "r846" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfFairValueOfOptionsGrantedToEmployeesDetails", "http://inspiremd.com/role/TaxesOnIncomeDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r300", "r301", "r302", "r303", "r366", "r515", "r555", "r591", "r592", "r654", "r658", "r660", "r661", "r663", "r684", "r685", "r700", "r704", "r711", "r716", "r793", "r841", "r842", "r843", "r844", "r845", "r846" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfFinancialAssetsSubjectToFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r796" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasByPrincipalCustomersDetails" ], "auth_ref": [ "r239", "r707", "r795", "r850", "r851" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfOperations", "presentation": [ "http://inspiremd.com/role/DescriptionOfBusiness" ], "lang": { "en-us": { "role": { "label": "DESCRIPTION OF BUSINESS", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r137", "r148" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r174" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r174" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r104", "r105", "r106" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://inspiremd.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows", "http://inspiremd.com/role/StatementsOfChangesInEquity", "http://inspiremd.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "NET LOSS", "label": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r92", "r106", "r131", "r153", "r168", "r169", "r172", "r178", "r186", "r188", "r189", "r190", "r191", "r194", "r195", "r200", "r213", "r225", "r230", "r233", "r274", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r442", "r452", "r544", "r623", "r644", "r645", "r698", "r725", "r789" ] }, "NSPR_NetLossCarryforwardsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "NetLossCarryforwardsPercentage", "presentation": [ "http://inspiremd.com/role/TaxesOnIncomeDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net loss carryforwards percentage" } } }, "auth_ref": [] }, "NSPR_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock", "presentation": [ "http://inspiremd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recently issued accounting pronouncement, not yet adopted" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://inspiremd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recently adopted accounting pronouncement", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "NSPR_NonEmployeeDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "NonEmployeeDirectorsMember", "presentation": [ "http://inspiremd.com/role/RelatedPartiesTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Non Employee Directors [Member]", "documentation": "Non Employee Directors [Member]" } } }, "auth_ref": [] }, "NSPR_NonEmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "NonEmployeeMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Non Employee [Member]", "documentation": "Non Employee [Member]" } } }, "auth_ref": [] }, "NSPR_NoncashAcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "NoncashAcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities", "crdr": "credit", "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Acquisition of right-of-use assets by means of lease liabilities", "documentation": "Non cash acquisition of right of use assets by means of lease liabilities." } } }, "auth_ref": [] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "NSPR_NoncashLeaseIncentive": { "xbrltype": "monetaryItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "NoncashLeaseIncentive", "crdr": "debit", "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Non-cash lease incentive", "documentation": "Non-cash lease incentive." } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://inspiremd.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inspiremd.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "FINANCIAL INCOME , net:", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r100" ] }, "us-gaap_NontradeReceivablesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NontradeReceivablesCurrent", "crdr": "debit", "calculation": { "http://inspiremd.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://inspiremd.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other", "documentation": "The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r763" ] }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": [ "http://inspiremd.com/role/EquityTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF RESTRICTED STOCK GRANTED TO EMPLOYEES", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares." } } }, "auth_ref": [ "r13" ] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://inspiremd.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r776" ] }, "NSPR_OfficeFurnitureAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "OfficeFurnitureAndEquipmentMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Office Furniture And Equipment [Member]", "documentation": "Office Furniture And Equipment [Member]" } } }, "auth_ref": [] }, "us-gaap_OpenTaxYear": { "xbrltype": "gYearListItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OpenTaxYear", "presentation": [ "http://inspiremd.com/role/ScheduleOfOpenTaxYearsByMajorJurisdictionDetails" ], "lang": { "en-us": { "role": { "label": "Open Tax Year", "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format." } } }, "auth_ref": [ "r414" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://inspiremd.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://inspiremd.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://inspiremd.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "OPERATING EXPENSES:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://inspiremd.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inspiremd.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "LOSS FROM OPERATIONS", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r213", "r225", "r230", "r233", "r698" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://inspiremd.com/role/LeaseAgreementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating lease expense", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r467", "r713" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://inspiremd.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Total", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r463" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [ "http://inspiremd.com/role/ScheduleOfSupplementalInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Current Operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r463" ] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://inspiremd.com/role/ScheduleOfSupplementalInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": [ "r464" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://inspiremd.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inspiremd.com/role/BalanceSheets", "http://inspiremd.com/role/ScheduleOfSupplementalInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating lease liabilities", "negatedLabel": "Non-current operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r463" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://inspiremd.com/role/ScheduleOfSupplementalInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Operating cash flows from operating leases (cash paid in thousands)", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r465", "r468" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://inspiremd.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inspiremd.com/role/BalanceSheets", "http://inspiremd.com/role/ScheduleOfSupplementalInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating lease right of use assets", "verboseLabel": "Operating lease right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r462" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://inspiremd.com/role/ScheduleOfSupplementalInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r470", "r713" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://inspiremd.com/role/ScheduleOfSupplementalInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining lease", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r469", "r713" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://inspiremd.com/role/TaxesOnIncomeDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net carry forward tax loss", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r62" ] }, "NSPR_OperatingLossCarryforwardsExpirationDescription": { "xbrltype": "stringItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "OperatingLossCarryforwardsExpirationDescription", "presentation": [ "http://inspiremd.com/role/TaxesOnIncomeDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating loss carryforwards expiration description", "documentation": "Operating Loss Carry forwards Expiration Description." } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsLineItems", "presentation": [ "http://inspiremd.com/role/ScheduleOfOpenTaxYearsByMajorJurisdictionDetails", "http://inspiremd.com/role/TaxesOnIncomeDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsTable", "presentation": [ "http://inspiremd.com/role/ScheduleOfOpenTaxYearsByMajorJurisdictionDetails", "http://inspiremd.com/role/TaxesOnIncomeDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Table]", "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization." } } }, "auth_ref": [ "r61" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ScheduleOfAccountsPayableAndAccruals-OtherDetails": { "parentTag": "us-gaap_AccountsPayableOtherCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://inspiremd.com/role/ScheduleOfAccountsPayableAndAccruals-OtherDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r19" ] }, "NSPR_OtherCountriesMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "OtherCountriesMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasDetails" ], "lang": { "en-us": { "role": { "label": "Other Countries [Member]" } } }, "auth_ref": [] }, "us-gaap_OtherExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherExpenses", "crdr": "debit", "presentation": [ "http://inspiremd.com/role/RelatedPartiesTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consulting expenses", "documentation": "Amount of expense classified as other." } } }, "auth_ref": [ "r99" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other financial expense", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r106" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r741" ] }, "srt_ParentCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ParentCompanyMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfComponentsOfLossBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Parent Company [Member]" } } }, "auth_ref": [ "r182" ] }, "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentOfFinancingAndStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fees payable and other offering expenses", "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities." } } }, "auth_ref": [ "r24" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlowsParenthetical", "http://inspiremd.com/role/StatementsOfChangesInEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Payments of stock issuance costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r24" ] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows", "http://inspiremd.com/role/ScheduleOfChangesInFairValueOfMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Investments in marketable securities", "label": "Additions", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r778" ] }, "us-gaap_PaymentsToAcquireOtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireOtherInvestments", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Investment in short-term bank deposits", "label": "Payments to Acquire Other Investments", "documentation": "Amount of cash outflow to acquire investments classified as other." } } }, "auth_ref": [ "r102" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property, plant and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r103" ] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://inspiremd.com/role/LiabilityForEmployeesRightUponRetirement" ], "lang": { "en-us": { "role": { "label": "LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r344", "r348", "r349", "r355", "r356", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r710" ] }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://inspiremd.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inspiremd.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liability for employee rights upon retirement", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent." } } }, "auth_ref": [ "r79", "r345", "r346", "r347", "r710" ] }, "NSPR_PercentageOfMonthlyDepositsOnSalary": { "xbrltype": "percentItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "PercentageOfMonthlyDepositsOnSalary", "presentation": [ "http://inspiremd.com/role/LiabilityForEmployeesRightUponRetirementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Percentage of monthly deposits on salary", "documentation": "Percentage of monthly deposits on salary." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://inspiremd.com/role/RelatedPartiesTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://inspiremd.com/role/RelatedPartiesTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r735" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r736" ] }, "NSPR_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "PreFundedWarrantsMember", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Pre-Funded Warrants [Member]", "documentation": "Pre-Funded Warrants [Member]" } } }, "auth_ref": [] }, "NSPR_PreferredStockBlankCheckMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "PreferredStockBlankCheckMember", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred Stock Blank Check [Member]", "documentation": "Preferred Stock Blank Check [Member]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockConvertibleConversionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockConvertibleConversionPrice", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock conversion price", "documentation": "Per share conversion price of preferred stock." } } }, "auth_ref": [ "r318" ] }, "us-gaap_PreferredStockConvertibleSharesIssuable": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockConvertibleSharesIssuable", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock convertible shares issuable", "documentation": "Number of common shares issuable upon conversion of preferred stock." } } }, "auth_ref": [ "r318" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://inspiremd.com/role/StatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r717", "r718", "r721", "r722", "r723", "r724", "r852", "r855" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://inspiremd.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r80", "r316" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://inspiremd.com/role/BalanceSheetsParenthetical", "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "verboseLabel": "Preferred stock shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r80", "r601" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://inspiremd.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r80", "r316" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://inspiremd.com/role/BalanceSheetsParenthetical", "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "verboseLabel": "Preferred stock outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r80", "r601", "r621", "r855", "r856" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://inspiremd.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inspiremd.com/role/BalanceSheets", "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred C shares, par value $0.0001 per share; 1,172,000 shares authorized at December 31, 2023 and 2022; 1,718 shares issued and outstanding at December 31, 2023 and 2022;", "verboseLabel": "Preferred stock stated value", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r80", "r536", "r714" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://inspiremd.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://inspiremd.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r166", "r288", "r289", "r691" ] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrivatePlacementMember", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromInterestReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromInterestReceived", "crdr": "debit", "presentation": [ "http://inspiremd.com/role/ScheduleOfChangesInFairValueOfMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest Received", "label": "Proceeds from Interest Received", "documentation": "Interest received on loans and other debt instruments during the current period." } } }, "auth_ref": [ "r768" ] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Private placement", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of shares and warrants net of $4,635 issuance costs,", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r3", "r566" ] }, "NSPR_ProceedsFromMaturedMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "ProceedsFromMaturedMarketableSecurities", "crdr": "debit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from matured marketable securities" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "presentation": [ "http://inspiremd.com/role/ScheduleOfChangesInFairValueOfMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Sale or maturity", "label": "Proceeds from Sale and Maturity of Marketable Securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "crdr": "debit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Withdrawal from short-term bank deposits", "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period." } } }, "auth_ref": [ "r23" ] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from sale of property, plant and equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r101" ] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gross proceeds from warrant exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r767" ] }, "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductInformationLineItems", "presentation": [ "http://inspiremd.com/role/DescriptionOfBusinessDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasByProductDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r235", "r517", "r549", "r550", "r551", "r552", "r553", "r554", "r687", "r705", "r715", "r751", "r786", "r787", "r795", "r850" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasByProductDetails" ], "auth_ref": [ "r235", "r517", "r549", "r550", "r551", "r552", "r553", "r554", "r687", "r705", "r715", "r751", "r786", "r787", "r795", "r850" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://inspiremd.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r6" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://inspiremd.com/role/PropertyPlantAndEquipment" ], "lang": { "en-us": { "role": { "label": "PROPERTY, PLANT AND EQUIPMENT", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r110", "r142", "r145", "r146" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://inspiremd.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inspiremd.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property plant and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r111", "r158", "r542" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://inspiremd.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://inspiremd.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 }, "http://inspiremd.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inspiremd.com/role/BalanceSheets", "http://inspiremd.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment, net", "totalLabel": "Net carrying amount", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r532", "r542", "r714" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://inspiremd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r6", "r142", "r145", "r540" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://inspiremd.com/role/PropertyPlantAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF PROPERTY PLANT AND EQUIPMENT", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://inspiremd.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r111" ] }, "country_RU": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "RU", "presentation": [ "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasDetails" ], "lang": { "en-us": { "role": { "label": "RUSSIAN FEDERATION" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://inspiremd.com/role/ScheduleOfFairValueOfOptionsGrantedToEmployeesDetails", "http://inspiremd.com/role/TaxesOnIncomeDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r300", "r301", "r302", "r303", "r348", "r366", "r393", "r394", "r395", "r491", "r515", "r555", "r591", "r592", "r654", "r658", "r660", "r661", "r663", "r684", "r685", "r700", "r704", "r711", "r716", "r719", "r784", "r793", "r842", "r843", "r844", "r845", "r846" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfFairValueOfOptionsGrantedToEmployeesDetails", "http://inspiremd.com/role/TaxesOnIncomeDetailsNarrative" ], "auth_ref": [ "r300", "r301", "r302", "r303", "r348", "r366", "r393", "r394", "r395", "r491", "r515", "r555", "r591", "r592", "r654", "r658", "r660", "r661", "r663", "r684", "r685", "r700", "r704", "r711", "r716", "r719", "r784", "r793", "r842", "r843", "r844", "r845", "r846" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://inspiremd.com/role/RelatedPartiesTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r357", "r476", "r477", "r594", "r595", "r596", "r597", "r598", "r620", "r622", "r653" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://inspiremd.com/role/RelatedPartiesTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r180", "r181", "r476", "r477", "r478", "r479", "r594", "r595", "r596", "r597", "r598", "r620", "r622", "r653" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://inspiremd.com/role/RelatedPartiesTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r627", "r628", "r631" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://inspiremd.com/role/RelatedPartiesTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r357", "r476", "r477", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r594", "r595", "r596", "r597", "r598", "r620", "r622", "r653", "r838" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://inspiremd.com/role/RelatedPartiesTransactions" ], "lang": { "en-us": { "role": { "label": "RELATED PARTIES TRANSACTIONS", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r473", "r474", "r475", "r477", "r480", "r572", "r573", "r574", "r629", "r630", "r631", "r650", "r652" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://inspiremd.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inspiremd.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r74", "r409", "r847" ] }, "NSPR_ResearchAndDevelopmentExpenseIncludingUSBasedClinicalTrialCost": { "xbrltype": "monetaryItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "ResearchAndDevelopmentExpenseIncludingUSBasedClinicalTrialCost", "crdr": "debit", "presentation": [ "http://inspiremd.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "[custom:ResearchAndDevelopmentExpenseIncludingUSBasedClinicalTrialCost]" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfAllocationOfTotalShare-basedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://inspiremd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and development costs", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r408" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfFinancialAssetsSubjectToFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r157" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative", "http://inspiremd.com/role/ScheduleOfRestrictedStockGrantedToEmployeesDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r27" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative", "http://inspiremd.com/role/ScheduleOfRestrictedStockUnitGrantedToEmployeesDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://inspiremd.com/role/LiabilityForEmployeesRightUponRetirementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r291", "r292", "r295", "r296" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://inspiremd.com/role/LiabilityForEmployeesRightUponRetirementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r291", "r292", "r293", "r294", "r295", "r296", "r297" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://inspiremd.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://inspiremd.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r83", "r117", "r538", "r559", "r560", "r570", "r602", "r714" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://inspiremd.com/role/StatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r152", "r183", "r184", "r185", "r187", "r193", "r195", "r275", "r276", "r399", "r400", "r401", "r420", "r421", "r432", "r434", "r435", "r437", "r440", "r556", "r558", "r575", "r855" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://inspiremd.com/role/StatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasByProductDetails", "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasDetails", "http://inspiremd.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "REVENUES", "verboseLabel": "Revenues", "terseLabel": "Revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r214", "r215", "r224", "r228", "r229", "r235", "r237", "r239", "r342", "r343", "r517" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://inspiremd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r149", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r686" ] }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "presentation": [ "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasDetails" ], "lang": { "en-us": { "role": { "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "NSPR_RussiaAndBelarusMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "RussiaAndBelarusMember", "presentation": [ "http://inspiremd.com/role/DescriptionOfBusinessDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Russia and Belarus [Member]", "documentation": "Russia and Belarus [Member]" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesMember", "presentation": [ "http://inspiremd.com/role/DescriptionOfBusinessDetailsNarrative", "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasByPrincipalCustomersDetails" ], "lang": { "en-us": { "role": { "label": "Sales [Member]", "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business." } } }, "auth_ref": [ "r12" ] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [ "http://inspiremd.com/role/SupplementaryFinancialStatementInformationTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "NSPR_ScheduleOfChangesInFairValueOfMarketableSecuritiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "ScheduleOfChangesInFairValueOfMarketableSecuritiesTableTextBlock", "presentation": [ "http://inspiremd.com/role/MarketableSecuritiesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF CHANGES IN FAIR VALUE OF MARKETABLE SECURITIES", "documentation": "Schedule Of Changes In Fair Value Of Marketable Securities [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "presentation": [ "http://inspiremd.com/role/EquityTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF ALLOCATION OF TOTAL SHARE-BASED COMPENSATION EXPENSE", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit." } } }, "auth_ref": [ "r58" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://inspiremd.com/role/TaxesOnIncomeTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF COMPONENTS OF LOSS BEFORE INCOME TAXES", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r122" ] }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "presentation": [ "http://inspiremd.com/role/ScheduleOfRestrictedStockGrantedToEmployeesDetails", "http://inspiremd.com/role/ScheduleOfRestrictedStockUnitGrantedToEmployeesDetails", "http://inspiremd.com/role/ScheduleOfStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]", "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability." } } }, "auth_ref": [ "r48", "r118" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://inspiremd.com/role/TaxesOnIncomeTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF DEFERRED INCOME TAX", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r121" ] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "presentation": [ "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasByProductDetails" ], "lang": { "en-us": { "role": { "label": "Revenue from External Customers by Products and Services [Table]", "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information." } } }, "auth_ref": [ "r36" ] }, "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable", "presentation": [ "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasByPrincipalCustomersDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]", "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers." } } }, "auth_ref": [ "r108" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://inspiremd.com/role/SupplementaryFinancialStatementInformationTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF INVENTORIES", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r16", "r87", "r88", "r89" ] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://inspiremd.com/role/EquityTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF RESTRICTED STOCK UNIT GRANTED TO EMPLOYEES", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": [ "r54" ] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfProductInformationTable", "presentation": [ "http://inspiremd.com/role/DescriptionOfBusinessDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Product Information [Table]", "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://inspiremd.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://inspiremd.com/role/RelatedPartiesTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r68", "r69", "r627", "r628", "r631" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://inspiremd.com/role/LiabilityForEmployeesRightUponRetirementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring." } } }, "auth_ref": [ "r291", "r292", "r293", "r294", "r295", "r296", "r297" ] }, "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "presentation": [ "http://inspiremd.com/role/DisaggregatedRevenueAndEntityWideDisclosuresTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS", "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "presentation": [ "http://inspiremd.com/role/DisaggregatedRevenueAndEntityWideDisclosuresTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS", "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": [ "r38", "r94" ] }, "NSPR_ScheduleOfRevenuesAttributedToGeographicAreasByProductTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "ScheduleOfRevenuesAttributedToGeographicAreasByProductTableTextBlock", "presentation": [ "http://inspiremd.com/role/DisaggregatedRevenueAndEntityWideDisclosuresTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRODUCT" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": [ "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": [ "r37", "r90" ] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "presentation": [ "http://inspiremd.com/role/ScheduleOfAdditionalInformationAboutAllOptionsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]", "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": [ "r51" ] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "presentation": [ "http://inspiremd.com/role/EquityTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF ADDITIONAL INFORMATION ABOUT ALL OPTIONS OUTSTANDING AND EXERCISABLE", "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms." } } }, "auth_ref": [ "r51" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://inspiremd.com/role/EquityTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF STOCK OPTIONS GRANTED", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r10", "r11", "r52" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://inspiremd.com/role/EquityTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF FAIR VALUE OF OPTIONS GRANTED TO EMPLOYEES", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r120" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://inspiremd.com/role/ScheduleOfIssuanceOfWarrantsToPurchaseCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r41", "r42", "r43", "r44", "r45", "r46", "r47", "r115", "r116", "r117", "r161", "r162", "r163", "r207", "r316", "r317", "r319", "r321", "r324", "r329", "r331", "r566", "r567", "r568", "r569", "r704", "r749", "r769" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://inspiremd.com/role/EquityTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r50" ] }, "NSPR_ScheduleOfSupplementalInformationRelatedToLeases": { "xbrltype": "textBlockItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "ScheduleOfSupplementalInformationRelatedToLeases", "presentation": [ "http://inspiremd.com/role/LeaseAgreementsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES", "documentation": "Schedule of supplemental information related to leases." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": [ "http://inspiremd.com/role/TaxesOnIncomeTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF RECONCILIATION OF UNCERTAIN TAX POSITIONS", "documentation": "Tabular disclosure of the change in unrecognized tax benefits." } } }, "auth_ref": [ "r712", "r826" ] }, "us-gaap_SecuritiesBorrowedFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuritiesBorrowedFairValueDisclosure", "crdr": "debit", "presentation": [ "http://inspiremd.com/role/FairValueMeasurementsDetailsNarrative", "http://inspiremd.com/role/ScheduleOfFinancialAssetsSubjectToFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Marketable securities", "label": "Cost of marketable securities", "documentation": "Fair value portion of securities borrowed from other entities." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r729" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r733" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r732" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r737" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://inspiremd.com/role/DescriptionOfBusinessDetailsNarrative", "http://inspiremd.com/role/ScheduleOfOpenTaxYearsByMajorJurisdictionDetails", "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasDetails" ], "auth_ref": [ "r237", "r238", "r588", "r589", "r590", "r655", "r659", "r662", "r664", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r688", "r706", "r719", "r795", "r850" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://inspiremd.com/role/DisaggregatedRevenueAndEntityWideDisclosures" ], "lang": { "en-us": { "role": { "label": "DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r209", "r210", "r211", "r212", "r213", "r217", "r227", "r231", "r232", "r233", "r234", "r235", "r236", "r239" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://inspiremd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment reporting", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r218", "r219", "r220", "r221", "r222", "r223", "r237", "r699" ] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://inspiremd.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inspiremd.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Selling and marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpenseMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfAllocationOfTotalShare-basedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": [ "r93" ] }, "NSPR_SeriesCConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "SeriesCConvertiblePreferredStockMember", "presentation": [ "http://inspiremd.com/role/StatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Series C Convertible Preferred Stock [Member]", "documentation": "Series C Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_SeriesCPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesCPreferredStockMember", "presentation": [ "http://inspiremd.com/role/BalanceSheetsParenthetical", "http://inspiremd.com/role/EquityDetailsNarrative", "http://inspiremd.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series C Preferred Stock [Member]", "documentation": "Series C preferred stock." } } }, "auth_ref": [ "r761", "r762", "r794" ] }, "NSPR_SeriesEWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "SeriesEWarrantsMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfIssuanceOfWarrantsToPurchaseCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Series E Warrants [Member]", "documentation": "Series E Warrants [Member]" } } }, "auth_ref": [] }, "NSPR_SeriesFWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "SeriesFWarrantsMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfIssuanceOfWarrantsToPurchaseCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Series F Warrants [Member]", "documentation": "Series F Warrants [Member]" } } }, "auth_ref": [] }, "NSPR_SeriesGWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "SeriesGWarrantsMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfIssuanceOfWarrantsToPurchaseCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Series G Warrants [Member]", "documentation": "Series G Warrants [Member]" } } }, "auth_ref": [] }, "NSPR_SeriesHWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "SeriesHWarrantsMember", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative", "http://inspiremd.com/role/ScheduleOfIssuanceOfWarrantsToPurchaseCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Series H Warrants [Member]", "documentation": "Series H Warrants [Member]" } } }, "auth_ref": [] }, "NSPR_SeriesIWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "SeriesIWarrantsMember", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative", "http://inspiremd.com/role/ScheduleOfIssuanceOfWarrantsToPurchaseCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Series I Warrants [Member]", "documentation": "Series I Warrants [Member]" } } }, "auth_ref": [] }, "NSPR_SeriesJWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "SeriesJWarrantsMember", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative", "http://inspiremd.com/role/ScheduleOfIssuanceOfWarrantsToPurchaseCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Series J Warrants [Member]", "documentation": "Series J Warrants [Member]" } } }, "auth_ref": [] }, "NSPR_SeriesKWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "SeriesKWarrantsMember", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative", "http://inspiremd.com/role/ScheduleOfIssuanceOfWarrantsToPurchaseCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Series K Warrants [Member]", "documentation": "Series K Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeveranceCosts1", "crdr": "debit", "presentation": [ "http://inspiremd.com/role/LiabilityForEmployeesRightUponRetirementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Severance expenses", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r5" ] }, "NSPR_SeveranceTypeOneMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "SeveranceTypeOneMember", "presentation": [ "http://inspiremd.com/role/LiabilityForEmployeesRightUponRetirementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Severance Type One [Member]", "documentation": "Severance Type One [Member]" } } }, "auth_ref": [] }, "NSPR_SeveranceTypeTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "SeveranceTypeTwoMember", "presentation": [ "http://inspiremd.com/role/LiabilityForEmployeesRightUponRetirementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Severance Type Two [Member]", "documentation": "Severance Type Two [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://inspiremd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share-based compensation expenses", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://inspiremd.com/role/ScheduleOfRestrictedStockGrantedToEmployeesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of restricted stock, Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r385" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://inspiremd.com/role/ScheduleOfRestrictedStockGrantedToEmployeesDetails", "http://inspiremd.com/role/ScheduleOfRestrictedStockUnitGrantedToEmployeesDetails" ], "lang": { "en-us": { "role": { "label": "Number of restricted stock, Granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r383" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://inspiremd.com/role/ScheduleOfRestrictedStockGrantedToEmployeesDetails", "http://inspiremd.com/role/ScheduleOfRestrictedStockUnitGrantedToEmployeesDetails", "http://inspiremd.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodStartLabel": "Number of restricted stock, Outstanding - beginning of period", "periodEndLabel": "Number of restricted stock, Outstanding - end of period", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r380", "r381" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://inspiremd.com/role/ScheduleOfRestrictedStockGrantedToEmployeesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of restricted stock, Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r384" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://inspiremd.com/role/ScheduleOfFairValueOfOptionsGrantedToEmployeesDetails" ], "lang": { "en-us": { "role": { "label": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r394" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": [ "http://inspiremd.com/role/ScheduleOfFairValueOfOptionsGrantedToEmployeesDetails" ], "lang": { "en-us": { "role": { "label": "Volatility, maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": [ "http://inspiremd.com/role/ScheduleOfFairValueOfOptionsGrantedToEmployeesDetails" ], "lang": { "en-us": { "role": { "label": "Volatility, minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": [ "http://inspiremd.com/role/ScheduleOfFairValueOfOptionsGrantedToEmployeesDetails" ], "lang": { "en-us": { "role": { "label": "Risk-free interest rate, maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": [ "http://inspiremd.com/role/ScheduleOfFairValueOfOptionsGrantedToEmployeesDetails" ], "lang": { "en-us": { "role": { "label": "Risk-free interest rate, minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://inspiremd.com/role/ScheduleOfStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Number of options Outstanding, Exercisable at the end of the period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r374" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://inspiremd.com/role/ScheduleOfStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted average exercise price, Exercisable at the end of the period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r374" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://inspiremd.com/role/ScheduleOfStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of options Outstanding, Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r378" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://inspiremd.com/role/ScheduleOfStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Number of options Outstanding, Granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r376" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://inspiremd.com/role/ScheduleOfStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of options Outstanding - beginning of period", "periodEndLabel": "Number of options Outstanding, Outstanding -end of period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r372", "r373" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://inspiremd.com/role/ScheduleOfStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price Outstanding - beginning of period", "periodEndLabel": "Weighted average exercise price, Outstanding -end of period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r372", "r373" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value of exercisable options", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r389" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative", "http://inspiremd.com/role/ScheduleOfRestrictedStockGrantedToEmployeesDetails", "http://inspiremd.com/role/ScheduleOfRestrictedStockUnitGrantedToEmployeesDetails" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r368", "r369", "r370", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r392", "r393", "r394", "r395", "r396" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://inspiremd.com/role/ScheduleOfStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, Forfeited", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r378" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative", "http://inspiremd.com/role/ScheduleOfStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, Granted", "verboseLabel": "Stock option exercise price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r376" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://inspiremd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Share-based compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r367", "r371", "r390", "r391", "r392", "r393", "r396", "r402", "r403", "r404", "r405" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "presentation": [ "http://inspiremd.com/role/ScheduleOfAdditionalInformationAboutAllOptionsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price Range [Axis]", "documentation": "Information by range of option prices pertaining to options granted." } } }, "auth_ref": [ "r56" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "presentation": [ "http://inspiremd.com/role/ScheduleOfAdditionalInformationAboutAllOptionsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": [ "r57" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "presentation": [ "http://inspiremd.com/role/ScheduleOfAdditionalInformationAboutAllOptionsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "presentation": [ "http://inspiremd.com/role/ScheduleOfAdditionalInformationAboutAllOptionsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "label": "Exercise price lower range", "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": [ "r57" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "presentation": [ "http://inspiremd.com/role/ScheduleOfAdditionalInformationAboutAllOptionsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "label": "Options exercisable", "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied." } } }, "auth_ref": [ "r55" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "presentation": [ "http://inspiremd.com/role/ScheduleOfAdditionalInformationAboutAllOptionsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "label": "Options outstanding", "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices." } } }, "auth_ref": [ "r53" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "presentation": [ "http://inspiremd.com/role/ScheduleOfAdditionalInformationAboutAllOptionsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "label": "Exercise price", "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": [ "r57" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://inspiremd.com/role/ScheduleOfFairValueOfOptionsGrantedToEmployeesDetails" ], "lang": { "en-us": { "role": { "label": "Expected life", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r392" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted average of the remaining contractual life of vested and exercisable options", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r388" ] }, "NSPR_SharebasedCompensationRelatedToRestrictedStockRestrictedStockUnitsAndStockOptionsAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "SharebasedCompensationRelatedToRestrictedStockRestrictedStockUnitsAndStockOptionsAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://inspiremd.com/role/StatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures", "documentation": "Share based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures." } } }, "auth_ref": [] }, "NSPR_SharebasedCompensationRelatedToRestrictedStockRestrictedStockUnitsAndStockOptionsAwardNetOfForfeituresShares": { "xbrltype": "sharesItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "SharebasedCompensationRelatedToRestrictedStockRestrictedStockUnitsAndStockOptionsAwardNetOfForfeituresShares", "presentation": [ "http://inspiremd.com/role/StatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures, shares", "documentation": "Share based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures, shares." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "presentation": [ "http://inspiremd.com/role/ScheduleOfAdditionalInformationAboutAllOptionsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life (years)", "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r119" ] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Offering price per share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://inspiremd.com/role/StatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "NSPR_ShorttermBankDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "ShorttermBankDeposits", "crdr": "debit", "calculation": { "http://inspiremd.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inspiremd.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Short-term bank deposits", "documentation": "Short term bank deposits." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://inspiremd.com/role/SignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r107", "r176" ] }, "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsNatureOfEvent": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantChangeInUnrecognizedTaxBenefitsNatureOfEvent", "presentation": [ "http://inspiremd.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Significant Change in Unrecognized Tax Benefits, Nature of Event", "documentation": "This element provides a description of the nature of the event that could occur within twelve months of the reporting date that would cause a significant increase or decrease in the related unrecognized tax benefit." } } }, "auth_ref": [ "r59" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r738" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://inspiremd.com/role/BalanceSheetsParenthetical", "http://inspiremd.com/role/EquityDetailsNarrative", "http://inspiremd.com/role/ScheduleOfIssuanceOfWarrantsToPurchaseCommonStockDetails", "http://inspiremd.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://inspiremd.com/role/StatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r150", "r161", "r162", "r163", "r178", "r198", "r199", "r201", "r203", "r207", "r208", "r274", "r304", "r306", "r307", "r308", "r311", "r312", "r316", "r317", "r321", "r324", "r331", "r452", "r566", "r567", "r568", "r569", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r587", "r601", "r624", "r646", "r665", "r666", "r667", "r668", "r669", "r749", "r769", "r774" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative", "http://inspiremd.com/role/StatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r9", "r22", "r152", "r170", "r171", "r172", "r183", "r184", "r185", "r187", "r193", "r195", "r206", "r275", "r276", "r333", "r399", "r400", "r401", "r420", "r421", "r432", "r433", "r434", "r435", "r436", "r437", "r440", "r454", "r455", "r456", "r457", "r458", "r459", "r472", "r556", "r557", "r558", "r575", "r646" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://inspiremd.com/role/DescriptionOfBusinessDetailsNarrative", "http://inspiremd.com/role/ScheduleOfOpenTaxYearsByMajorJurisdictionDetails", "http://inspiremd.com/role/ScheduleOfRevenuesAttributedToGeographicAreasDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r237", "r238", "r588", "r589", "r590", "r655", "r659", "r662", "r664", "r671", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r688", "r706", "r719", "r795", "r850" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://inspiremd.com/role/BalanceSheetsParenthetical", "http://inspiremd.com/role/ScheduleOfAllocationOfTotalShare-basedCompensationExpenseDetails", "http://inspiremd.com/role/ScheduleOfComponentsOfLossBeforeIncomeTaxesDetails", "http://inspiremd.com/role/ScheduleOfFairValueOfOptionsGrantedToEmployeesDetails", "http://inspiremd.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://inspiremd.com/role/StatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r183", "r184", "r185", "r206", "r517", "r562", "r587", "r593", "r594", "r595", "r596", "r597", "r598", "r601", "r604", "r605", "r606", "r607", "r608", "r610", "r611", "r612", "r613", "r616", "r617", "r618", "r619", "r620", "r622", "r625", "r626", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r646", "r720" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://inspiremd.com/role/BalanceSheetsParenthetical", "http://inspiremd.com/role/ScheduleOfAllocationOfTotalShare-basedCompensationExpenseDetails", "http://inspiremd.com/role/ScheduleOfComponentsOfLossBeforeIncomeTaxesDetails", "http://inspiremd.com/role/ScheduleOfFairValueOfOptionsGrantedToEmployeesDetails", "http://inspiremd.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://inspiremd.com/role/StatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r183", "r184", "r185", "r206", "r517", "r562", "r587", "r593", "r594", "r595", "r596", "r597", "r598", "r601", "r604", "r605", "r606", "r607", "r608", "r610", "r611", "r612", "r613", "r616", "r617", "r618", "r619", "r620", "r622", "r625", "r626", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r646", "r720" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative", "http://inspiremd.com/role/RelatedPartiesTransactionsDetailsNarrative", "http://inspiremd.com/role/StatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of common shares, pre-funded warrants and warrants, net of $4,635 issuance costs, shares", "verboseLabel": "Issuance of shares", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r9", "r80", "r81", "r117", "r566", "r646", "r666" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "presentation": [ "http://inspiremd.com/role/StatementsOfChangesInEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Shares, restricted stock award, forfeited", "documentation": "Number of shares related to Restricted Stock Award forfeited during the period." } } }, "auth_ref": [ "r9", "r80", "r81", "r117" ] }, "NSPR_StockIssuedDuringPeriodSharesStockWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "StockIssuedDuringPeriodSharesStockWarrantsExercised", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative", "http://inspiremd.com/role/StatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Exercise of pre-funded warrants, shares", "verboseLabel": "Exercise of prefunded warrants" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://inspiremd.com/role/StatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of common shares, pre-funded warrants and warrants, net of $4,635 issuance costs", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r9", "r80", "r81", "r117", "r575", "r646", "r666", "r726" ] }, "NSPR_StockIssuedDuringPeriodValueStockWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "StockIssuedDuringPeriodValueStockWarrantsExercised", "crdr": "credit", "presentation": [ "http://inspiremd.com/role/StatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Exercise of pre-funded warrants" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://inspiremd.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inspiremd.com/role/BalanceSheets", "http://inspiremd.com/role/StatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Beginning balance, value", "periodEndLabel": "Ending balance, value", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r81", "r84", "r85", "r109", "r603", "r621", "r647", "r648", "r714", "r727", "r770", "r783", "r832", "r855" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://inspiremd.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "EQUITY:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://inspiremd.com/role/Equity" ], "lang": { "en-us": { "role": { "label": "EQUITY", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r114", "r177", "r315", "r317", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r330", "r333", "r439", "r649", "r651", "r670" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://inspiremd.com/role/RelatedPartiesTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r460", "r483" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://inspiremd.com/role/RelatedPartiesTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r460", "r483" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://inspiremd.com/role/RelatedPartiesTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r460", "r483" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://inspiremd.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r482", "r484" ] }, "srt_SubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SubsidiariesMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfComponentsOfLossBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiaries [Member]" } } }, "auth_ref": [ "r797", "r835", "r836", "r838" ] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "documentation": "Different names of stock transactions and the different attributes of each transaction." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockLineItems", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsidiary, Sale of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SummaryOfIncomeTaxContingenciesTextBlock", "presentation": [ "http://inspiremd.com/role/TaxesOnIncomeTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF OPEN TAX YEARS BY MAJOR JURISDICTION", "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months." } } }, "auth_ref": [ "r8", "r123", "r124" ] }, "us-gaap_SummaryOfValuationAllowanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SummaryOfValuationAllowanceTextBlock", "presentation": [ "http://inspiremd.com/role/TaxesOnIncomeTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF CHANGES IN VALUATION ALLOWANCE", "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance." } } }, "auth_ref": [ "r60" ] }, "us-gaap_TaxPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxPeriodAxis", "presentation": [ "http://inspiremd.com/role/ScheduleOfOpenTaxYearsByMajorJurisdictionDetails", "http://inspiremd.com/role/TaxesOnIncomeDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tax Period [Axis]", "documentation": "Information about the period subject to enacted tax laws." } } }, "auth_ref": [] }, "us-gaap_TaxPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxPeriodDomain", "presentation": [ "http://inspiremd.com/role/ScheduleOfOpenTaxYearsByMajorJurisdictionDetails", "http://inspiremd.com/role/TaxesOnIncomeDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Identified tax period." } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative", "http://inspiremd.com/role/RelatedPartiesTransactionsDetailsNarrative", "http://inspiremd.com/role/ScheduleOfRestrictedStockGrantedToEmployeesDetails", "http://inspiremd.com/role/ScheduleOfRestrictedStockUnitGrantedToEmployeesDetails", "http://inspiremd.com/role/ScheduleOfStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r777", "r837" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative", "http://inspiremd.com/role/RelatedPartiesTransactionsDetailsNarrative", "http://inspiremd.com/role/ScheduleOfRestrictedStockGrantedToEmployeesDetails", "http://inspiremd.com/role/ScheduleOfRestrictedStockUnitGrantedToEmployeesDetails", "http://inspiremd.com/role/ScheduleOfStockOptionsGrantedDetails" ], "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://inspiremd.com/role/ScheduleOfFinancialAssetsSubjectToFairValueMeasurementsDetails", "http://inspiremd.com/role/ScheduleOfMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r314", "r329", "r438", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r545", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r779", "r780", "r781", "r782" ] }, "NSPR_TwoThousandTwentyOneEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "TwoThousandTwentyOneEquityIncentivePlanMember", "presentation": [ "http://inspiremd.com/role/RelatedPartiesTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2021 Equity Incentive Plan [Member]", "documentation": "2021 Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://inspiremd.com/role/RelatedPartiesTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r427" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://inspiremd.com/role/LiabilityForEmployeesRightUponRetirementDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r291", "r292", "r295", "r296" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://inspiremd.com/role/ScheduleOfOpenTaxYearsByMajorJurisdictionDetails" ], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfFinancialAssetsSubjectToFairValueMeasurementsDetails", "http://inspiremd.com/role/ScheduleOfMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r695", "r708", "r848" ] }, "NSPR_UnderwriterWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://inspiremd.com/20231231", "localname": "UnderwriterWarrantsMember", "presentation": [ "http://inspiremd.com/role/ScheduleOfIssuanceOfWarrantsToPurchaseCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Underwriter Warrants [Member]", "documentation": "Underwriter Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://inspiremd.com/role/ScheduleOfReconciliationOfUncertainTaxPositionsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Uncertain tax positions balance at beginning of period", "periodEndLabel": "Uncertain tax positions balance at end of period", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r411", "r415" ] }, "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease", "presentation": [ "http://inspiremd.com/role/ScheduleOfReconciliationOfUncertainTaxPositionsDetails" ], "lang": { "en-us": { "role": { "label": "Increase in uncertain tax positions because of tax positions taken during the year", "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns." } } }, "auth_ref": [ "r827" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://inspiremd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r33", "r34", "r35", "r139", "r140", "r143", "r144" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://inspiremd.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r717", "r718", "r721", "r722", "r723", "r724" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "presentation": [ "http://inspiremd.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r775" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://inspiremd.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING NET LOSS PER SHARE - diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r197", "r203" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://inspiremd.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING NET LOSS PER SHARE - basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r196", "r203" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://inspiremd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r747" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "710", "SubTopic": "10", "Section": "25", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-11" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "710", "SubTopic": "10", "Section": "25", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-3" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)-(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "320", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4,6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//940-320/tableOfContent" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//942-320/tableOfContent" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//946-320/tableOfContent" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "(b)", "Publisher": "SEC" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//715/tableOfContent" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r749": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-16" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 91 0001493152-24-008850-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-008850-xbrl.zip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�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